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7A B B R E VIAT IO NS
The following are the common ly app earing abbrevia ti ons in the 
t h e s i s .
BBT Basal body temperature
CL Corpus luteum
E2 1 7-B e s tradiol
FD Fo ll ic ular diameter
FSH Follicle stimulating hormone
GIFT Gamete int ra- fa llopian  tube transfer
GnRH Go n a d o t r o p h i n  releasing hormone
hMG Hu ma n meno pausal g o nadot ro phin
hCG Hum an  chorionic g o n a d o tro ph in
IU/1 Interna ti onal units per litre
IV F In-vitro fertilisatio n
LFP Long follicular phase
LH Luteini si ng hormone
LPD Luteal phase defect
LUF Luteini se d unruptured follicle
MHz Megahe r t z
ng/ml Nanograms per millilitre
n m o l /1 Nanomoles per litre
P Pr oge sterone
PF Peritoneal fluid
PFD Poor follicular development
PFM Poor follicular matur ation
PG Pr os t a g l a n d i n
pg/ml Picograms per millilitre
PPS Poor progeste rone surge
PPS-N Poor progester one surge to normal levels
PPS-S Poor progesterone surge to subnormal levels
PRL Pr ola ctin
SD Standard deviati on
SEM Standard error of the mean
SFP Short follicular phase
SLP Short luteal phase
UI U n e x p lain ed  infertility
U/S Ultrasound
SUMMARY
F e r t i l i t y  ass es sment is founded firstly on the documenta ti on of 
egg and sperm av ai l a b i l i t y  and second ly on a determi na tion that the 
gametes can meet. If these criteria are met, then continued 
i n f e r tili ty  is deemed to be unex plained, a situation found in 20-30% 
of the couples att ending most inf erti li ty clinics.
Conv en tional tests of ovulatio n are, in the absence of 
pregnancy, indirect barometers of ovar ian function, and tell us 
little of the dynamics of fol licular growth, oocyte release and 
corpus luteum function. Since g o n a d o t r o p h i n  and ovarian steroid 
secretion is dynamic, and the e n d o me trium is sensitive to hormonal 
fluctuations during the cycle, it is clear that if reproductive 
function is to. be assessed sa t i s f a c t o r i l y  then the maximum 
informat ion possible must be obtained.
The concept of luteal phase de fi c i e n c y  (LPD) has aroused 
considerable debate over the years, and dis ag reeme nts over the 
nature, definition, diagnosis and clinical implications of the 
condition abound in the literature. A number of studies on patients 
with unex pl ained in fertility  have demo nstra te d subtle deviations from 
normal in the plasma co nce ntrations  of go nad otr ophins and ovarian 
steroids, but none have, in substantial numbers, related these 
features to ul t r a s o n i c a l l y  observed fol licular growth patterns.
The present study was designed to explore ovarian function in 
women with un expla ined inf ertility using the combined resources of 
ovarian ultrasound and sim ultaneous daily plasma bio chem istry to 
elaborate follicular growth patterns and go nadotro phin and ovarian
steroid hormone profiles in blood. These ultrasonic and endocrine 
profiles were then related to those obtained from norma l l y  cycling, 
pre sumably fertile, voluntee rs  and from spontaneous co nc eptio n 
cycles .
Daily blood samples were taken throughout complete menstrual  
cycles and frequent ultras ou nd scans were performed during the 
pe ri ov ulator y and luteal phases. The normal cycle data (43 cycles) 
were compared with that from 11 sp on taneous conception cycles, and in 
terms of follicular growth and corpus luteum function, showed no 
differences, thus j u s t ify in g the use of the control data as the 
yardstick of normality.
175 cycles from patients with un explain ed infertility were 
studied in detail. 98 (56%) of these cycles demonstrated apparentl y 
abnormal ovarian function. The analysis of these "abnormal" cycles 
provides the core of the thesis.
Luteal cyst formation was seen in 41 cycles (23.4%); reference 
to the U/S and biochemical data d i sc riminat ed  two distinct subgroups 
- those where the dominant follicle was seen to shrink prior to 
luteal cyst formation, often asso ci ated with normal ovarian steroid 
profiles, and those cycles where no shrinkage of the follicle was 
seen following the LH peak, very often associated with markedly 
deficient luteal phase plasma P concentrations. The former, it is 
hypothesised, represent cystic corpora lutea and the latter, may be 
luteinised unruptured follicles (LUF's). Cyst size alone was not a 
sensitive indicator of the nature of the luteal cysts seen.
51 cycles (29.1%) were found to exhibit abnormal patterns of P
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pro d u c t i o n  in the early luteal phase. Many such PPS cycles exhibited 
mi d- lu teal P con cent ra tions in excess of "normal ovulatory" criteria, 
indicating that infrequ ent sampling will miss a high pr oportion of 
abnormal cycles. 45.1% of the PPS cycles also demonstra ted luteal 
cyst formation, the m a j o r i t y  of which were LUF's. Thus in these 
cycles it is likely that impairment of oocyte release and sub-optimal 
endometrial r e c e pt iv ity render the cycle infertile. Abnorma lities  
were seen in the g o n a d o t r o p h i n  profiles in some cycles, suggesting 
that in these cases follicle recr uitment might have been abnormal.
The therapeuti c implicatio ns of these findings are discussed.
23 cycles (13.1%) demo nstra ted abnormall y high basal LH profiles 
and almost 70% of those had u l t r a s o n i c a l l y  observed abn ormal ities of 
follicular function. Commonest of these was luteal cyst formation.
2/3 of the remai nde r elaborated subnormal luteal P production. These 
data are the first reported d e monstra ti ng an as sociati on  between LUF 
cycles and distur ba nces of g o nadotro ph in secretion. The 
pathop h y s i o l o g y  behind these observat ions and the possible 
therapeutic implicat ions are discussed.
Subnormal follicular development, both biochemical (16 cycles) 
and ult rason ic  (12 cycles), was associated with variable 
gonadot ro phin concentrations. Reference to these profiles would 
suggest that in some cases the follicular de ficiency is a consequence 
of pituitary d ysfunc ti on and in others the problem lies at the 
follicular level.
Abnorm al ities of cycle phase length constituted a small 
proportion of the cycles under study and the data would suggest that 
such disturb an ces are of minor importance in the genesis of
11
in fertili ty in the une xplain ed  infertile population.
Two related studies were performed, to examine further any 
clinical implicat ions of cycle a bn or maliti es  such as those described 
in this thesis.
1) The repr od u c i b i l i t y  of cycle abn or maliti es  was examined when 26 
of the main study group, were evaluated in detail, over two cycles 
within a year of one another. All of the prel im inary cycles had been 
found to be abnormal. 61% of the second cycles demonstrated 
abnormalities, a similar incidence to the overall incidence in the 
main study. R ecid iv is m rates were similar for all the main 
abnor mal ity sub-groups encoun ter ed in the prelim inary cycles, though 
iji those cases the second cycle a b n o r ma lity was not always the same 
as that of the first cycle. Only 1 (16.7%) of 6 LUF cycles was found 
to recur. These results indicate that treatment prescribed in cases 
of unexplained infertility, on the basis of the findings in a single 
cycle of investigation, is pro ba bl y un justified  and is un lik ely to be 
successful.
2) The relationships between ult ra sonic  and biochemical 
abn orm alities of ovarian function in unexplained  infertility, in 
particular luteal cyst formation, and luteal phase laparoscopic 
findings and PF steroid conce ntrat io ns were examined. 24 patients 
with relatively short durations of infertility, in whom a diagnosis 
of unexplained in fe rt ili ty was expected prior to the performance of 
laparoscopy, were shown to exhibit a lower incidence of cycle phase 
ab nor mality compared to the main study group. Neither luteal phase 
laparoscopic findings nor PF steroid concentrations were of 
diagnostic value, and it is suggested that such intensive
12
i n v e s t i g a t i o n  should not be the first line approach in the managem ent  
of patients with potentia l primary une xplaine d infertility.
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De spi te many technical advances in our unde rs tanding  of the 
processes involved in human rep roduction, a core of couples still 
exist in whom, despite intensive investigations, over many years in 
some cases, infe rtility  is unexplained. Conv entional diagnostic tests 
will have had little therapeuti c impact in such cases, yet some will 
conceive sp o n t a n e o u s l y  as time goes by, in spite of, rather than 
because of, the minis t r a t i o n s  of clinicians. Clarif ic ation of the 
disturb an ces in reproductive function in such couples is sought, not 
only by the patients, but also by the physicians responsible for 
their c a r e .
1.1 Defi n i t i o n  of un explai ne d in fertility
Un e x plaine d i n f e r t i 1 ity (idiopathic infertility; normal 
infertile couples; inferti li ty cause unknown;) should be reserved as 
a dia gnosis only for couples who have been trying to conceive for at 
least two years and where inves tigations  have shown the male to have 
normal semen analyses, usua lly  greater than 20m/ml sperm, with >40% 
motile and >50% with normal morphology. The female should have been 
shown to ovulate nor mally and reg ularly and an assessment of the 
pelvis should have revealed normal anatomy with no evidence of tubal 
disease, fibroids or endometriosis. A sexual history should have 
failed to reveal any coital problem. Many couples will present at 
clinics before two years of attempt ing to conceive and, although 
distress at their inability to conceive may be considerable, they 
should be counselled that the chances of spontaneous conception over 
the succeeding year will be high (Barnea, Holford & Mclnnes 1985).
The prognosis is undo u b t e d l y  related to the age of the female 
(Pepperell & McBain 1985, Hull et al 1985).
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1.2 Inc idence of u n e x plaine d infe rtility
Po p u lation  based studies assessing the incidence of unexplained 
i n f e r ti lity are lacking and clinic based incidences will inevitably 
give biased figures dependen t on the parti cular interests of the 
individual clinic and its resources, the population from which it 
receives its referrals, the protocols of investi gation of the clinic 
and its criteria for the diagnos is  of unexpl ained infertility. 
T em pl eton and Penney (1982) reviewed 17 papers between 1944 and 1980 
and found reported incidences of between 5.8% and 58% for unexplained 
infertility. In their own clinic group the incidence was 23.5%, 
similar in both the subgroups of patients with primary and secondary 
infertility. This figure is slightly less than the 28% subsequentl y 
quoted by Hull et al (1985) and the 30% of Haxfron et al (1987).
While it is accepted that such patients maintain a potential for 
spontaneous conception (Verkauf 1983, Taylor, Leader & Pattinson 
1985), influenced in degree by the number of years of trying as well 
as the age of the female partner (Hull et al 1985), the knowledge 
that 36% of those with prim ary infe rtility  and 21% of those with 
secondary inf ertility will remain childless after 9 years of trying 
(Templeton & Penney 1982) has spurred investigators to try to 
elaborate more clearly the nature of the defi ciency in reproduction. 
Avenues of research have been exc el lently reviewed by Moghissi &
Wallach (1983) and McBain & Pepperell (1987).
1.3 Putative "causes" of u ne xplaine d inf ertility
Abnormalities of the anatomical structure of the genital tract,
in particular retrovers ion of the uterus, have been cited as being
16
important causative  factors of i nf ertilit y (McBain & Pepperell 1987) 
though ev idence  that these are of any relevance appears to be lacking 
except in the unusual circumstance of a congeni tally abnormal uterus 
as soc iated with recurrent early miscarriage.
Im mun o l o g i c a l  factors are implicated in some couples' 
inf er ti lity (Shulman 1986), with suspicion  usually aroused at the 
finding of a poor post-coi tal test. Not all authorities rely on this 
somewhat imprecise technique to evaluate sperm cervical mucus 
in teract ion and with newer methods now developed  to define sperm 
antibody pr ese nce (Clarke et al 1984) insight is being gained into a 
previo usl y vague imp res sion of a relation ship in the human between 
sperm function and fertility.
Male factors in the genesis of infertility remain difficult to 
evaluate and reliance is usually placed on the semen analysis in 
isolation to formulate an assessment. This represents a quantitative 
rather than qu al itative method and more emphasis should be placed on 
•the eval uatio n of the fertilising capacity of sperm. Available tests 
in this area are, in the main, limited to couples undergoing IVF, 
while int er- species methods of assessment, such as the zona-free 
hamster egg p ene tr at ion test, are both costly and of debatable value. 
The rela tionshi p of varic oceles to male infertility is controversial 
and evidence seems to be accu mul ating that these commonly occurring 
phenomena are of little relevance to human reproduction (Baker et al
1985).
Occult infections of the genital tract may in some cases be 
linked with in fe rtility but conclusive proof that they have an 
important role in unexplained infertility is lacking. The main
17
org anisms whi ch  have been implicated are ure aplasma  ur ea l y t i c u m  and 
chl amydia trachomatis, the latter now being a well recognised cause 
of pelvic inflammatory disease. Since both organisms are found in 
r el ati vel y high perce ntages of both fertile and infertile couples, 
and treatment of carriers or empirical therapy in groups with 
u n e x plain ed  infertility seems to confer no conclusive benefit to 
those rec eiving antibiotics, it seems unproven whether such organisms 
can be considered a cause of une xp lained infert ility (McBain & 
Pepperell 1987).
The possible a s s o ci at ion of mild end ometriosis with infertility 
is another continuing c o n t r o v e r s y  in the field and to date there have 
been few controlled trials o b j e c ti vely assessing its impact. The 
subject was critically reviewed by Olive & Haney (1986) who concluded 
that many of the assertions in relation to the disease and its 
treatment were based on anecdote and that prospective randomised 
controlled trials were u r g en tly required in order to clarify a very 
confused situation. Thomas and Cooke (1987) in a pl ac ebo-c ontrol 
double-blind trial has suggested that eradicat io n of mild 
as ymptomat ic disease confers no benefit in terms of cumulative chance 
of concept ion and these data cast con siderable doubt on the clinical 
signific anc e of commonly enco untered mild endometriosis. The 
rel ationship between mild end ometr iosis and failure of oocyte release 
at ovulation (Brosens, Ko n i n c k x  & Corveleyn 1978) remains unproven 
(see b e l o w ) .
1 .4 Luteal Phase D efici en cy (LPD)
The concept of the inadequate or deficient luteal phase has been 
espoused by numerous au th orities over the years, although there has
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been con si derab le  d i v ersi ty  of opinion as to the nature and 
rep rod ucti ve  consequences of the abnormality.
It is common practice to regard LPD as a lack in amount and/or 
du rat io n of secretion of P by the corpus luteum.
1 .4.1_______Incidence of luteal phase deficie nc y
The incidence of the phe nom en on depends to a large extent on the 
group of patients under scrutiny, the m e t h o d o l o g y  of diagnosis and 
the number of cycles in wh ic h the a bnorma li ty must be seen in a 
single patient to be considered significant. Jones (1976) claimed 
that the LPD, characteri se d by either a defect of P secretion by the 
corpus luteu m or a failure on the part of the en domet rium to respond 
to the given level of P, was the cause of inferti lity in only 3.5% of 
her clinic population. Others have cited higher rates (Israel et al
1972) though criteria of diagnosis  differed in these studies. A 
quarter to a third of patients with a hist ory  of recurrent abortion 
demonstrate the abnorm al ity (Jones & Delfs 1951, Soules et al 1977, 
Tho , Byrd & McDonou gh  1 97 9) and it seems likely that the inadequacy 
of P production leads to impl antat ion failure of the blastocyst 
(Jones 1976, Kusuda et al 1983) though it is possible that 
alterations in either tubal function, leading to abnormalities of 
gamete transport or sec retion of fluid essential for nourishment of 
the conceptus , or uterine contr ac tility secondary to the lack of P 
also be of importance.
Other reported clues in the history that a patient is at risk of 
dem ons trating LPD include a history of infertility,
hy p e r p r o 1a c t i n a e m i a , weigh t loss, high level exercising and athletic
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training, and evidence of a long follicular phase (Balasch, Creus & 
Vanr ell  1986) or short luteal phase. An occasional hist ory of delayed 
menses (1-2 weeks) with a heavy flow when the period arrives may also 
suggest the p o s s ibi li ty of LPD.
1.4.2______Impact of LPD
The reproducti ve impact of the ab normalit y remains controversial 
since perhaps with the exce pt ion of the data on patients with  a 
history of recurrent ab ortion there have been few statistica ly  
controlled studies demon s t r a t i n g  a signi ficant effect on fertility 
(Wen t z 1982 ) .
Few studies have addressed the question of recurrence of this 
phenomenon since any clinic al sig nificance will depend as much  on the 
frequency of occ urence as on the effect on fertility exerted in a 
single cycle.
1.5 Assessme nt of ov u l a t i o n  and corpus luteum function
Biophysical, bio log ic al and biochemical assays have been used, 
sometimes ind ep endentl y though often in combination, to characterise 
the abnormal luteal phase.
1.5.1______ Endome t r ium
The classical studies of Noyes, Herti g & Rock (1950) inspired 
many to adopt the d e m o n s t r a t i o n  of features of secretory endometrium 
appropriate to the stage in the cycle to define normality of luteal 
function. In general where the endome trium was found to be two or
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more days out of phase with expected h i s t ol og ical development then 
the diag nosis  of LPD could be made (Jones & Delfs 1951, Jones et al 
1970). This bioa ssay of luteal function was, apart from the use of 
thermogenic records of shifting basal body temperature, the main 
method of qua li tat ive  ass essment of o v u lat or y performance for many 
years. Ho w e v e r  accurate timing of the endom etr ial biopsy relative to 
ovulation  is crucial for correct in t e r p r e t a t i o n  of the histology and 
this, perhaps, is a severe limitation of the technique (Koninckx et 
al 1977).
Ga utray  et al (1981) used endom etr ial patterns as the basis for 
their as sessme nt  of the luteal phase of the patients under study and 
found it to be best performed around day 21 ie 7 days post ovulation. 
The a b nor ma li ties found were su b-classi fied in to two main 
categories. Firstly those cycles where the en do metrium was more than 
two days out of phase and secondly, those cycles where, in addition 
to evidence of retarded endometrium, there were stigmata of excessive 
estrogenic influence concurrent with, in most cases, particul arl y low 
plasma P concentrations. These data provided additional insight into 
LPD, and endome trial biopsy, they claimed, was an essential part of 
the work-up of the infertile patient. Abno rma litie s in the production 
of ovarian steroids were described in their patients as well as basal 
body temperature evidence of disturbed ovulation.
Some authors (e.g. Jac ob sen & Marshal l 1980) have cautioned that 
there may be a danger of reducing the potential for pregnancy in 
cycles in which an endometrial biopsy is taken. These data related to 
patients und ergoing induction of ovula tio n with gon adotrophins and 
may not n ecessa ri ly apply to the unstimula ted situation. They found 
no difference in the abortion rate as a consequence of biopsy.
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Ga utray  et al (1981) also evaluated the levels of estrogen and P 
receptors in patients with abnormal luteal function and found the 
concentrat io ns to be lower than those in the normal cycle, accounted 
for in part by the observed dimini shed levels of steroid hormones in 
these women since Bayard et al (1978) had earlier demo nstra ted that 
changes in total E2 and P receptors depend on plasma levels of the 
ho r m o n e s .
Others have hypot he si sed that a lack of appropriate E2 and P 
receptors in the endometr ium may result in a situation where the 
endometrial stroma fails to undergo normal secretory changes despite 
normal plasma P levels (Keller et al 1979). This has been termed 
"pseudo-corpus luteum deficiency". McRae, fiasco & Lyttle (1984) 
found a wide range of receptor concentrat ions in the normal cycles 
they studied and co ns equ ently a cons ide rable overlap with the values 
they found in patients with LPD. At present there seems to be 
insufficient data to draw definiti ve conclusions with respect to the 
significance of these receptor findings.
DiZerega & Hodge n (1981) suggested that the cause of the 
observed deficie ncies in P output in patients with LPD was a lack of 
functional LH receptors on the surface of luteal cells, sec ondary to 
inadequate FSH stimulation in the follicular phase of the cycle. This 
hypothesis was supported by work carried out in primates (Stouffer & 
Hodgen 1980, Stouffer et al 1984) where the ad ministration of porcine 
follicular fluid selectively suppressed FSH levels, resulting in a 
delay in f o l 1 iculogenesis and ovulation and a disturbance in luteal 
function.
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Furt her  eviden ce that local endometrial factors are important in 
patients with SLP is the observati on that some patients exhibiting 
short luteal phase length may men struate prior to the fall in P 
co nce n t r a t i o n  that n o r ma ll y precedes endometria l shedding (Smith, 
Lenton & Cooke 1983, Smith et al 1984). The SLP probably only occurs 
with a fre que nc y of around 5% in ovu latory women and it is probable 
that not all such cycles represent a bar to conc eption (Lenton et al 
1 984)
Ba lasch et al (1985) in a series of patients where sequential 
cycles were studied through repeat endometrial sampling found that in 
almost 40% of the patients they studied there was inc onsistenc y of 
result, fuelling spec ulatio n regarding the impact on fer tility of LPD 
as diagnosed by endometria l studies, and the likely efficacy of 
corrective therapy.
1.5.2 Basal Body Temp eratur e (BBT)
The use of tempe ratur e charts to time ovulation has been shown 
to be imprecise (Lenton, Westo n & Cooke 1977, Qu ag lia rello & Arny
1986) and it is possible that calculati on of incidences of luteal 
abnormalities, based on a technique which can be mis int er preted in as 
many as a third of cases, may be inaccurate.
Perez, Plurad & Palladino (1981) also demonstrated that the 
temperature chart is not always a good index of ovulation and that a 
good plasma P level served better, with a positive predictive value 
in excess of 90%.
Despite this many have relied on the temperature chart as the
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basis for their evaluat ion  of the processes of ovulation (Soules et 
al 1977). This is not surprising since taking one's temperature is a 
n on -i n v a s i v e  , inexpensive and simple technique easily applicable 
within  the context of modern o verbu rd ened infertility services. 
Perhaps its best a pp li catio n might be as a general screening test to 
indicate the patients for whom the more complex and expensive tests 
might be applied. Def ini tive co nclusions  are best avoided with the 
use, in isolation, of temperature charts to assess ovulation.
1.5.3_______Biochemical ev al uatio n
De velopm ent of specific r a d i oim mu noassay s for E2 and P, both in 
urine and plasma, has led to more precise quantitative evaluation  of 
ovarian function. The normal patt ern  of hormone production has been 
cha rac terised  and comparisons can be made with the apparently 
abno r m a l .
Consider abl e debate in the literature has taken place as to an 
acceptable plasma level of P indicative of ovu lation and adequate 
corpus luteum function, and wheth er a single blood sample in the
luteal phase is sufficient to comment on the whole of the post­
ov ulatory period, or whether more than one sample should be taken. If 
reliance is made on a single sample then timing of sampling is 
important and, as with the endometr ial biopsy, careless atten tion to 
this detail may result in inaccuracies.
Israel et al (1972) reported that a serum concentration of P 
>3ng/ml between 11 and 4 days prior to the onset of menstruation was 
always accompanied by secretory e n d o metr iu m and could therefore be 
taken as presumptive evidence of ovulation. Abraham, Maroulis &
24
Marshall (1974) how ever found that Israel's criteria failed to be met 
in almost 20% of their study group and suggested that the if the sura 
of P co ncentrat ions in 3 separate blood samples taken within the same 
time period as Israel's sampling was greater than 15ng/ml then this 
was a better d e t e rmin an t of ovulation.
Ross et al (1970) suggested that 5ng/ml was a better cut off 
point while Radwansk a & Swyer (1974) suggested that >10ng/ml serum P 
level repres ented adequa te function.
Shepard & Senturia (1977) compared the use of endometrial biopsy 
and serum P in co nf irmin g ovula tion and evaluating luteal function 
and asserted that the 5ng/ml level suggested by Ross seemed to be 
s at isf act ory making the comment that histology of the en dometrium  
seemed to correlate poorl y with P levels. Of interest was the 
observation that in 75% of the patients studied who subsequent ly  
conceived and had normal pregnancies the endo me trium showed a 
retarded pattern, implying that the isolated finding of such a 
histological feature had little bearing on future fertility.
A n n o s , Th om pson & Tayraor (1980) evaluated the consiste ncy of 
parameters including BBT charts, endometrial biopsies and plasma P 
measurements used in dia gno si ng LPD in 14 patients where 2 samples of 
blood were taken for P levels in the luteal phase. It was found that 
discrepancy between the endome trial biopsy and the P level occured in 
over 50% of the cycles studied.
Rosenfeld & Garcia (1976) found a 93% correlation between 
endometrial biopsies and sim ultaneous P estimations in patients 
undergoing infertility evalua tions to confirm the occurence of
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ovulation. They found this combined ap proach to be more useful, 
clinically, than a more precise asse ssmen t of the day on which 
ovulation occured.
Hull et al (1982) suggested that a mid-luteal level in excess of 
9.4ng/ml (30nmol/l) was acceptable as a sat isfa ctory  ovul atory 
indicator though higher levels than this might be expected in cycles 
where patients received drugs to stimulate follicular development. 
This study suggested that there was a relat ively narrow range of mid- 
luteal values in unt reated cycles and that one sample was adequate to 
define the ov ulato ry  status of a patient. This finding highlighted 
the need to attend ca ref ully to the detail of timing the sample.
Other studies with a wider spread of values may not have been so 
rigorous in this detail. Hull et al found the prognostic value for 
future ferti lity of a single sample to be good.
Jones et al (1974) showed that in the m id -portio n of the luteal 
phase there was a reliable plateau of P concentra tions and, as 
Shangold, Berke le y & Gray (1983) subsequen tl y concurred, favoured a 
single raidluteal P determinati on, timed with the BBT, as a 
sufficiently precise gauge of corpus luteum function.
More recently, evidence has accrued that, in common with the 
pulsatile pat tern of release of gonadotrophin s, P itself is secreted 
in an episodic fashion and that an individual pulse may result in 
fluctuations in P conc ent ratio n in excess of lng/ml (Healy et al 
1984) .
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1.5.4_______The devel opment of ova rian ultrasound
In 1 973 the first reports emerged that TJ/S could visualize the 
ovaries sufficiently  clearly to permit ide nt ificati on  of the 
develop in g Graafian follicle (Kratochwil, J e n t s c h  & Bresina
1973).This opened up an exciting avenue of inv es tigati on  of ovarian 
function and since 1979 the li terature on the subject has expanded 
e n o r m o u s l y .
Initial work was carried out using the full bladder technique 
(Donald 1963) with B-mode static scanners, but real-time scanning, 
although perhaps not giving pictures of as clear resolution, is 
simple to use and quicker (O'Herlihy, De Cresp igny & Robins on 1980).
Follicular growth was chara cterised in numerous studies 
(Hackeloer et al 1979, Ylostalo, Ronnberg & Jou pp ila 1979, Renaud et 
al 1980, Queenan et al 1980, O'Her lihy et al 1980a, Kerin et al 1981, 
Bryce et al 1982, Sallam et al 1982, F u n d u k- Ku rjak & Kurjak  1982) 
with in general 2 - 3  mm daily increase in FD in the unstimulated 
cycle. Usua lly  the follicle was visuali zed with certainty from about 
8 - 1 0  mm diameter until it reached its maxi mu m diameter. The range 
of maximum FD prior to ov ulation  varied con sidera bl y but in most 
studies was found to lie between 20 and 25 mm. The par tic ularl y small 
values reported by Ylostalo et al (1979) may be a reflection of the 
velocity setting of their ult rasound machine rather than a true 
extreme of biological variation. FD correlates well with follicular 
fluid volume thus validat ing the use of this simpler measu rement as a 
yardstick of Graafian follicle size (O'Herlihy et al 1980a, Kerin et 
al 1981). This variatio n in m a x imum follicular size exposed the 
problem that mere me asure ment of FD alone is not of predictive value
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in terms of imminence of ovulation. The v i s u a lisati on  of the cumulus 
(Hackeloer et al 1979) might be thought to be a useful predictor of 
imminent ov ulation  but this is not always seen (O'Herlihy, Robinson & 
De Cresp ig ny  1980, Kerin et al 1981). Picker et al (1983) have 
described cre nella ti on of the follicular wall as an accurate sign of 
impending ovu la ti on but this was not seen in a study on nine 
patients, scanned int en sivel y following the LH surge (De Crespigny et 
al 1981).
There are no rigid criteria for normal corpus luteura formation; 
Ha cke loer et al (1979) desc ribing  rapid shrinkage of the follicle 
followed by the appe arance of low amplitude echoes within it over the 
succeeding few days. Qu eenan et al (1980) described a similar 
profile, but also observed variants of this, including main tenance of 
the cystic app earance of the follicle following luteinisation. They 
asserted that a single scan was unable to to d is tingui sh  between an 
ovulatory follicle, functional cyst and o ccas io nally a corpus luteura, 
unless repeated scans were being performed, prefe rably by a single 
observer.
1.6 Pat h o p h y s i o l o g y  of LPD
1.6.1 Go nadotroph ins
Wh ate ver method is used as proof of ovulation it is essential 
that adequa cy of luteal function in main taining a pregnancy be 
established (Annos et al 1980). Jones et al (1970) in an attempt to 
explain the poor pregnancy  rates in patients with ovu latory disorders 
undergoing treatment with clomiphene citrate demo nstra ted 
histological abn ormal it y in the form of defective granulosa cell
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lute iniza tio n and pos tula te d that the process of l u teiniza ti on itself 
need not always equate with ovu lation and that perhaps entrapment of 
the ovum might be the result of the ab no rmality  i.e. the hormonal 
requirem ent s for ovu la tion might not be the same as those for 
subsequ ent  normal luteal function. They  postulated that the 
un de rlyi ng  cause of the abnorm al ity was a defective pat tern of 
g o n a d o t r o p h i n  release.
Cook, Rao & Yuss man (1983) also implicated def icienci es  in FSH 
resulting in LPD finding LH levels to be normal with a resultant low 
FSH : LH ratio. These patients also had normal plasma concentra tions
of PRL representing  a pote nt ially different sub-group of defective 
luteal function compared to those patients de monstrati ng 
h y p e r p r ol ac tinaem ic  associate d deficienc ies (Lenton et al 1979). Some 
authors (Seppala, Hi rvon en  & Ranta 1976, Bahamondes et al 1979) have 
hypothe sis ed that a luteal phase abn or ma lity associated with 
h y p e rprol ac ti naemi a represents only a point in a spectrum of 
increasing ova rian disturbance, cul minating in o 1 igome norrhoea and 
amenorrhoea. An al te rnative hyp othesis might be that not all women 
respond in the same way to h y p e r p r ol actinae mi a with some reacting 
with short luteal phases and others with amenorrhoea.
Sherman & Ko re nman (1974a&b) also found subnormal P production 
in as soc iation with subnormal FSH levels prior to the LH peak both in 
patients with irregular cycles and those with luteal phase length of 
less than 10 days and suggested that this might be the mec h a n i s m  of 
the "inadequate" luteal phase they described, This theory was 
supported by others in more recent studies in relation to the 
deficient luteal phase (DiZerega & H o dgen  1981, Stouffer et al 1984). 
Sherman also proposed that in some cases 1uteini zation without
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rupture of a follicle might occur as Jones et al (1970) and later 
J e w e l e w i c z  (1975) suggested.
Decreas e in the FSH : LH ratio might be explained through
re du ct ion in FSH values, but al t e r n a t i v e l y  elevation in LH 
concentr at ions in the face of normal FSH levels will also reduce the 
ratio. It has been shown in some patients that tonically high plasma 
LH c o n c e n tration s may be associated with LPD (Fleming et al 1981). 
Not all patients in this study de mon s t r a t i n g  deficient luteal 
funct ion  had abnormal LH secretion. Some showed transient elevations 
of PRL while others had no dist ur bance of pitui tary hormones.
Se creti on  by the corpus luteura modu la tes the pulsatile release 
of LH by the pi tui tary gland during the luteal phase in normal women 
(Soules et al 1984). Studies on women demon st ra ting LPD have shown 
increased follicular phase fre quency of pulses, of lower amplitude 
than in the normal cycle, associated with abn or malit ies of P 
pro du ct ion by the corpus luteum (Soules et al 1984). It is not clear 
whether these var iat ions in go na d o t r o p h i n  secretion relate to events 
in the previous cycle i.e. low P secretio n leading to compensatory 
increased pulse fre quency with spillage over of abnormal pulsatility 
into the next cycle, or whether this represents a problem at source
i.e. in the hyp o t h a l a m o - p i t u i t a r y  axis itself, leading to decreased 
baseline FSH values.
1.6.2 Prola ctin
The role PRL plays in relation to follicular development, 
ovulation and corpus luteum function remains unclear. A cyclical
pattern of secretion has been reported with, paralleling LH and FSH
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concentrations, a rise in PRL at the mid-cycle. Mc Ne illy et al (1982) 
observed that high levels of PRL may be associated with deficient 
luteal function, though this effect was not observed in 
ph ar macolog ical studies where h y p e r p r o 1 actinaemia was induced in the 
luteal phase alone. It has been postulated (McNatty 1979, McNatty et 
al 1979) that high plasma and follicu lar  fluid PRL concentrations 
interfered with gr anu losa cell p ro li feratio n with resultant 
dimi nu tion of plasma E2 levels though others (Garcea et al 1983) have 
found E2 levels to be normal. Inhibi tion of FSH product ion by the 
pituitary may also be involved (Corenblum, Pairaudeau & Sch ewchuck 
1976). The associat ion of raised PRL levels and the SLP (Kauppila et
al 1982) is not univ ersally  accepted (Sarris et al 1978) but several
workers have shown that through correction of this biochemical 
ab normal ity the luteal phase can be lengthened to normal (Del Pozo et 
al 1979, Seppala et al 1976).
Evide nce  exists that, even in women with normal menstru al rhythm 
and ov ulatory levels of P, transient elevatio'ns in PRL may well
affect fertility (Lenton et al 1979, Fleming et al 1978).
1.6.3 Oxytocin
It has been suggested, on the basis of in vitro studies, that 
oxytocin may be important as an agent of luteolysis (Tan, Tweedale & 
Biggs 1982) but this has not been demon strated in vivo and no 
association with LPD has been found, although there is evidence that 
levels of this hormone are raised in the luteal phase of the cycle.
It is possible that the source of the oxytocin is in the ovary 
(Wathes & Swann 1982).
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1.6 . 4______Pro sta gl andins
PGF2a may also to some degree exert a luteolytic effect and be 
involved in disturbed luteal function, though su bstanti ve evidence 
for this is lacking in the literature which is based m a inly on in 
vitro stu dies on dis persed luteal cells (Baird 1985). PG's are 
thought to be involved in the process of oocyte release at ovulation 
(Craft et al 1980) and it is possible that distu rbance in PG 
m e t a bo li sm could be involved in ov ula tory disorders. Recent evidence 
suggests that inhibition of PG prod uct ion may interfere with the 
processes of ov ulation both in primates (Jaszczak 1983) and humans 
(Killick & Elstein 1987).
1.6. 5______En dom etriosi s
The ass oci at ion between endometriosis and infe rti lity is well 
known and theories abound as to the nature of the link. An increased 
incidence of LPD has been reported (Grant 1981). Others have 
confirmed this finding (Cheesman et al 1983) and it has been 
speculated that a link may exist between the presence of 
endometriosis and failure of the mature follicle to rupture, a 
phenomenon which has also been linked with LPD (Brosens et al 1978).
1.6.  6_______Lut ein ised unr uptured follicle syndrome (LUF)
Assum pti ons that ovulation is an inevitable consequenc e of an LH 
peak (Aksel et al 1976), or definit iv ely associated with the 
biochemical ob servatio n of a rise in plasma P co ncentrati ons (Laborde 
et al 1975), have been questioned.
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Sherman & Korenb lu m (1974), Jewelewicz (1975) and Jones (1976) 
alluded to the pos sib il ity that in some cases where biochemical 
evidence of ovula tion was found the follicle failed to rupture 
leading to entrapment of the oocyte within the ovary. This, it was 
speculated, might be the cause of failure to conceive, both in the 
un stimulat ed cycle and in the patient on cloraiphene, who, despite 
biochemical evidence of a "sa tis facto ry " response to therapy, remains 
i n f e r t i l e .
Koninckx, DeMoor & Brosens (1978) examined this further by 
performing lap aro scopies in patients with unexplained in ferti lity in 
the days following the mi d-cyc le  LH peak. In addition to finding a 
high incidence of ovaries with no stigmata to suggest follicular 
rupture, many of these patients exhibited a slow rise in P 
conc ent rations  similar to that seen in patients with endometriosis 
(Brosens et al 1978). They postulated that, perhaps due to intra- 
ovarian factors or external influences, such as low FSH in the 
follicular phase of the cycle or an elevated prolactin level, since 
the oocyte fails to be released after the LH peak, the onset of 
lutein iza tion is delayed, linking their obs er vatio n with LPD. Marik & 
Hulka (1978) in a pop ulation  of "ovulatory" but infertile women found 
similar features of d y s o v u l a t i o n  in a high proportion of patients and 
suggested that follicular st imula tion with clomiphene or 
gonadotrophin s was likely to give a good chance of conception. Not 
all studies however supported the hyp othesis that absence of an 
ovulation punctum is ass ociated with LPD (Abdulla et al 1983).
Craft et al (1980) described the finding of oocytes within 
follicular structures in patients who had shown indirect evidence of 
ovulation suggesting that PG imbalance might account for this.
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Failure to reproduce a similar picture in patients receiving aspirin 
was disap poi nting . More recently, Killick  and Elstein (1987) have 
produced u ltras on ic evidence of LUF induced by the ad mi nistration  of 
another PG sy nt het ase inhibitor, i n d o m e t h a c i n . Portuondo et al (1981) 
found an absence of stigmata of ov ula tio n in over 57% of patients 
studied and sug gested that it was important at which stage in the
cycle a l a p a r o s c o p y  was performed, since re -epi t h e l i a l i s a t i o n  of the
stigma may occur di sg uisin g the fact that rupture has in fact 
o c cur e d .
Van rel l et al (1982) evaluated the presence of an ovulation 
stigma in fertile patients and found that, in almost half, no clear
sign of foll icula r rupture could be seen. In another study a
lap ar osco pi ca lly diagnosed LUF was seen in a cycle of con ception 
(Portuondo et al 1983) indicating that the presence of a stigma of 
ovulation, as assessed, la paros c o p i c a l l y  was subject to a great deal 
of observer bias. Conseq ue nt ly other methods of diagnosing LUF 
required eva lua ti on  (Mudge 1982).
De Cr esp ign y et al (1981) described the ultr as onica lly observed 
processes of ovulation, including 3 cases in their IVF programme 
where an egg was retrieved from a parti all y collapsed follicle 
suggesting that oocyte release is not neces sar ily an immediate 
consequence of the rupture and release of follicular fluid but may 
involve a gradual extr usi on of the egg following the initial release 
of fluid. The processes of ovu lation were also described by Nitschke- 
Dabelstein, Hacke lo er  & Sturm (1981) where the authors differentiated 
between luteal cyst formation (a small cystic structure seen within 
the ovary, not exceeding 18mm in size, in patients und ergoing 
induction of ovulation) and LUF where there appeared to be no
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evidenc e of follicula r collapse together with an increase in solid 
structures w i t h i n  an enlarging follicle in the luteal phase of the 
cycle. This latter was associa ted with an inadequate rise in the BBT 
and termed an ultraso und detectable LUF. Queenan et al (1980) had 
observed a similar appearance in some of their patients but did not 
ascribe the pattern to LUF. The fact that multiple fol licular 
developme nt  in induced cycles is not associa ted with multiple 
conception  in an equivalent number of cases fuelled the belief that 
perhaps ov u l a t i o n  is not an inevitable consequence of matur e follicle 
developm en t (Sallam, White head & Collins 1983, Stanger & Yovich 
1984). The use of ultraso und to define the LUF syndrome both in 
stimulated (Coulam, Hill & Breckle 1982, Coulara, Hill & Breckle 1983, 
Gibbons, Bu ttr am  & Rossavik 1984, Ha mi lt on et al 1985, Sir et al 
1987) and u ns ti mulated  cycles (Coutts, Adam & Fleming 1982, Kerin et 
al 1983, Li u k k o n e n  et al 1984, Daly et al 1985) became widely 
accepted. In these studies there was no uniformity of opinion as to 
what the ultraso ni c criteria for defining LUF were. Delayed 
di sap pear an ce  of the follicle (Gibbons et al 1984), a biopsy of an 
u l t r a soni ca ll y observed cyst seen in the luteal phase (Coulam et al
1983), infilling but failure to shrink of a dominant follicle (Coulam 
et al 1982, L i u k ko ne n et al 1984), persi stence of the cystic 
appearance of the follicle 36 hours after the LH peak (Kerin et al 
1983, Coutts et al 1982) together with thickening of the cyst wall 
(Daly et al 1985), rapid exp ansion of follicular size following the 
LH peak (Hamilton et al 1985) have all been cited as the ultrasonic 
criteria for diagnosis of the LUF syndrome.
48% of the patients with ultrasound detected LUF in Hamilton's 
study were underg oi ng  ovu lation induction, most with clomiphene and
thus may provide insight into the reason why, as Jones (1976)
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observed, con ce ption rates do not match bioc hemical response rates in 
many series of ovulation induction therapy. 37% also were found to 
have PID whi ch is an interesting association. In total, of the 
patients with proven PID, over 80% demonstrat ed  the LUF phenomenon.
In this group it was postulated that subclinical oophoritis might be 
the cause of the dist urbance in ovulation. Only 1 of 27 patients with 
LUF had endometri osi s, not dissimil ar to the findings of Holtz et al 
(1985) but in contrast to the findings of Ko nninckx  & Brosens (1982) 
using per itoneal fluid as the dia gnostic  tool to define LUF. It is 
likely therefore that LUF is not the only patho phys iologic al  
mechanism at play in the case of LPD in ass oc ia tion with 
endometriosis .
Others have also evaluated the peritoneal fluid concentra tions 
of ovarian steroids in patients exh ibiting features suggestive of LUF 
(Devroey et al 1983, Dhont et al 1 984 , Bernardus et al 1983). Where 
rupture of the follicle fails to occur it is held that the 
concentrations of the peritoneal fluid steroids and the plasma 
concentrations are much the same, whereas when rupture occurs with 
release of the steroid rich follicular fluid from the ovary then the 
concentrations are much higher in the peritoneal cavity. This aspect 
of LUF will be discussed in greater detail in Chapter 7 of the 
the s i s . ,
1.7 Current therapeutic moda litie s in LPD
Many approaches have been employed to tackle the problem of LPD, 
with the logic behind each treatment dependent on the proponents 
belief as to the cause of the abnormality.
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1 .7.1_______ Proges terone
P s u p p l e m e n t a t i o n  is the most co mmonly employed approa ch to 
therapy of LPD and is given, either as a vaginal suppositor y or an 
in tr amu scu lar injection, from about 3 days after the estimated time 
of ovulation. Studies in the lite ratur e suffer from lack of numbers 
and suitable controls but good results are claimed by some (Soules et 
al 1977, Rosenberg, Luciano & R i d di ck  1980, Soules et al 1981).
Others (Lenton, Adams & Cooke 1978) remain sceptical. Natural 
progesto gen s should be used since the oral synthetic formulations 
tend to be lu te os uppre ss ive (Andrews 1979) and most authors advocate 
the use of an endometrial biopsy in the luteal phase to assess 
adequacy of dose. Newer vehicles for a d m i n i strat io n of P are being 
explored (Glazener, Bailey & Hull 1985, Dalton et al 1987) and it is 
likely that this method of treatment will remain popular. There 
remains a need though for large pr osp ective controlled trials to 
adequately assess the usefulness of therapy.
1.7.2 Clomiphene citrate
Follic ula r phase d ysfunc ti on with con sequent di stu rbance in CL 
function has been alluded to and clomiphene citrate has been employed 
to redress the imbalance in FSH secretion proposed as important in 
the pathogenesis of LPD in some cases (DiZerega & Hodgen 1981). 
Clomiphene citrate might be expected to increase the g o na do trophi n 
output in the early part of the cycle with consequent improvement in 
the "quality" of the follicle, higher plasma E2 levels and ultimat ely 
improved CL function. Hammond & Talbert (1982) found a significant 
improvement in con ce pt ion rate with clomiphene citrate in patients 
with biochemical evidence of LPD coincidental to an elevation of the
mi d- luteal P c o nc entra ti on to target levels in excess of 20ng/ml. 
Interestingly, their inclusion criteria for diagn osis as deficient 
luteal fun ction was a single plasma conce ntration of between 4- 
14ng/ml w h ic h therefore may have meant that some of the study group 
may have been normal, if other workers' criteria are used. The study 
also was not controlled making conclusions difficult to derive. Downs 
& Gibson (1983) claimed that the response to clomiphene citrate was 
more likely to result in con cep tion the greater the degree to which 
the en do m e t r i u m  was found to be out of phase. Milder degrees of 
ab nor mality responded less well in terms of ultimate conce ption and 
it was proposed that such patients might benefit more from P therapy. 
A troublesome paradox remains the obs ervation that clomiphene therapy 
itself may not always be ass ociated with normal follicular 
development (Fleming & Coutjis 1 982 ) and can result in LPD (Van Hall & 
Mastboom 1969, Jones et al 1976). Indeed it was these observations 
that provided the foundations of the assertion that the entity 
existed at all. Others too (Dodson, Mac naugh to n & Coutts 1975, Soules 
et al 1977, Annos et al 1980, Hattori et al 1982) have used 
clomiphene citrate with success but none of the studies were 
randomised controlled trials sufficientl y large to be conclusive.
1.7.3 Exogenous go nadotro phins
Another approach to therapy, based on the premise that aberrant 
FSH production precedes LPD, is the use of exogenous gonadot ro phin 
preparations in the follicular phase of the cycle. Initial work on 
primates suggested that P prod uctio n could be improved (DiZerega & 
Hodgen 1981) and clinical studies have suggested that chances of 
conception may be improved. Huang, Muechler & Bonfiglio (1984) have 
used a purified form of menop ausal gonadotro phins giving a greater
38
yield of FSH with some pregnanc ies resulting, and the use of this 
form of therapy is recommended by some for treatment of polycystic 
ovarian syndrome.
1 .7.4_______Com bi na tion therapy
C o m b i nati on  therapy to approach the problem has been used and 
Kemm ann  & Jones (1983) reported sequential clomiph ene citrate and hMG 
in a no vulato ry  and. "dysovulatory " patients. Howeve r problems with 
poor cervical mucus and ovarian h y p e r s t i m u l a t i o n  were encountered 
indicating that this kind of treatment has to be monitored very 
carefully. The use of GnRH analogues to suppress the pituitary and 
then to supplement the patient's hormonal envir onment with hMG to 
induce ovulation has aroused cons iderable interest and has been used 
successfully in patients with LPD and normal menstrual rhythm 
(Fleming et al 1982) and o l i g o m en orrhoea  (Fleming et al 1985). This 
has resulted in a higher pr egnancy rate than in patients undergoing 
hMG therapy alone, with a lower incidence of ovarian
h y p e r s t i m u 1a t i o n . The chance of premature lute ini zatio n is reduced, 
through abo lition of endogenous pitui ta ry function, which enhances 
the efficacy of therapy. Similar attempts to treat patients with 
normal steroid pro duc tion in the luteal phase have failed to achieve 
the same success (Fleming et al 1987).
In a small study premature lu te inization has also been 
controlled by the com bin at ion of sulpiride (inducing a state of 
hyperprolactinaemia) and hMG since it was observed that patients with 
amenorrhoea and hype rp rol a c t i n a e m i a  had a better response rate in 
terms of pregnancies to hMG /hCG treatment than those patients with 
luteal insufficiency unde rgoing similar therapy (Zimmermann et al
1984). It is possible that the high prolactin mi li eu damps endogenous 
pituitary act iv ity in a similar way to long acting GnRH agonists.
1.7 . 5_______hCG
A d m i n i s t r a t i o n  of hCG at the perio vulatory period, and at 
intervals thereafter, has been proposed, combined in some instances 
with clomiphene citrate therapy, to stimulate the corpus luteum 
(Soules et al 1977) though this and other studies (Jones et al 1976) 
dealt with small numbers and conclusions are difficult to make. Jones
(1976) suggested that it was likely that some corpora lutea would not
be able to be rescued by hCG adminis tr ation and it is probable that
this therapy would be of little use in patients where the underlying
abnormality was a lack of appropriate ovarian receptors or those 
where follicular deve lopment was suboptimal. P response in these 
situations would be poor (Gerhard & Runnebaum 1982). Perhaps it may 
have a role where the suspi cio n of LUF exists (Gibbons et al 1984) or 
where the LH surge is thought to be attenuated.
1.7.6 Bromoc ripti ne
Treatment of hy p e r p r o l a c t i n a e m i a  associated ovulatory disorders 
with bromocrip tine (Corenblum et al 1976, Del Pozo et al 1979) has 
been reported with improvement in luteal function as assessed through 
P estimation and pregn anc y rates. It remains unclear as to whether 
this effect is mediated by an alteration in endocrine function at the 
level of the pitui tary and hypothalamus, or at the ovarian level 
(McNatty, Sawers & McN eilly 1974, McNeilly et al 1982). P 
concentrations are increased and the length of the previously 
curtailed luteal phase is normalised. Experience of treating LPD with
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b r omoc ri pt ine in the presence of normal PRL is mixed (Saunders et al 
19 7 9) • Pa dill a et al ( 1 985 ) have reported the use of bromocriptine in 
patients with luteal defects, ga lac t o r r h o e a  and normoprolactinaemia. 
The p h y s i o l o g y  of PRL continues to be inc omp letel y understood and 
the b i o l ogic al  activity  of the various isomeric forms of PRL, as 
elaborated through gel chr om atograp hy  (Andino et al 1985), may have 
roles in the abnormality, as yet not understood. Many take the view 
that elevat ed PRL concentrati ons in the presence of normal menstrual 
rhythm has little influence on future fertili ty (Vanrell & Balasch 
1983, Glaz en er  et al 1987).
1.8 Aim of thesis
The aim of the work presented in this thesis was to examine in detail 
ovarian fun ction in the female partners of couples with unexplained 
infertility.
The combined resources of ovarian ultrasound and sequential 
bi oc he mistry  were employed to elaborate in detail the nature of 
follicular dev el opment  and corpus luteum formation, and to relate U/S 
profiles to changes in ovarian steroid and pi tuitary gonadotro phin 
concentr ati ons throughout the menstrual cycle, both in normal and 
infertile women.
Previous work in this area of reproductive biology has been 
limited and substant ive data relating to large numbers of subjects 
with unif ormity of bac kground is lacking. Gl asgow Royal Infirmary 
has for many years enjoyed the privilege of being a referral centre 
for the West of Scotland, and beyond, in matters related to
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fertility, and the Uni v e r s i t y  Departme nt of Obst etric s and 
Gynaecolo gy's interest in un explaine d infert ili ty is well known 
throughout the region. For this reason it was not unduly difficult to 
gain access to a pool of patients with problems of unexplained 
infertility who could take part in the studies descr ibed in the 
t h e s i s .
The work was carried out over a three year period between 1983 
and 1985 and was based at the Uni v e r s i t y  Departm ent of Obstetrics and 
Gynaecology, Gla sgo w Royal Infirm ar y and the Departmen t of Midwifery, 
the Queen Mother's Hospital, Glasgow.
The thrust of the research was initially to define normal 
ovarian function, and generate data suitable for com parison with the 
infertile population. This section of work, based on 43 volunteers, 
is described in Chapter 2.
Since large numbers of patients were investigated it was hoped 
to generate information from patients who conceived during the study 
cycle. Few studies to date have been able to provide detailed 
biochemical and ultrasonic  inform ati on in relation to spontaneous 
conception cycles and some debate exists in the literature as to the 
"normality" of such cycles. These data on 11 subjects are presented 
and discussed in Chapter 3.
The infertile subjects under study, 175 in number, were drawn 
from the infertility clinics of both the Royal Infirmary and the 
Western Infirmary in Glasgow. They are described, together with the 
methodology used in the study, in Chapter 4 of the thesis.
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Patients with un ex plaine d infertility were investigated using a 
fixed protocol  to attempt to define abnorma lit ies of ovarian function 
which were hitherto uns uspec te d from con ventional techniques of 
investigation. Ult ra sonic  and biochemical di stu rba nces of ovarian 
function were identified, defined and postulates made as to the 
possible pat ho ph ys i o l o g i c a l  processes seen and their likely role in 
the aetiolog y of the patient's infertility. These data are described 
in Chapter 5.
Most studies in the literature restrict investi gation of 
infertile patients to a single cycle and doubt may be expressed as to 
the clinical signific an ce of subtle abn ormalities of ovarian function 
seen in these patients. To determine whether such phenomena were of a 
recurrent nature, and of consequent increased clinical importance, 
patients were recruited for investi gat ion in two complete cycles. 
Comparisons were to be made between cycles to determine the nature of 
any abno rm al ities  identified and their likely recurrence risks. 26 
such patients were studied and their data is presented in Chapter 6.
The significance, if any, that the LUF syndrome plays in 
infertility remains uncertain. The diagnosis is difficult to make and 
the rel ati onships  betw een the different modalities of assessment 
which have been used in the literature are far from clear. A 
prospective study was therefore designed and carried out which 
enabled, in an unique way, the processes of ovulation and corpus 
luteum formation  and function to be examined using plasma 
biochemistry, ovarian ultrasound, luteal phase lapar oscopy with 
aspiration and biochemica l analysis of peritoneal fluid. Four 
different avenues of inv estiga ti on were thus combined to build an 
exceptionally detailed picture of ovarian function in 22 patients
w it h  u n e x p l a i n e d  i 
C h a p t e r  7.
G e n e r a l  c o n c l u s i o n s  and t ho u g ht s  on the i m p l i c a t i o n s  of this 
work for the future are made in Chapter 8 of the thesis.
3
This aspect of study is descr ibe d in
CHAPTER 2 ESTABLISH MENT OF NORMAL RANGES
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2 .1 I n t r o d u c t i o n
Consider ab le debate over the years has taken place as to what 
should be taken as an acceptable standard of norm ality in relation to 
ovarian function. The nature of norm ality is fundamental to our 
u n d e r stan di ng of what is, or may be, abnormal (Wentz 1982, Moghissi & 
Wallach 1983). Many workers have used for comparison data obtained 
from studies on young women, mostly volunteers, in whom normal 
fertility status is inferred through a history of regular 
menstruation, absence of menstru al dis turbance and lack of use of 
oral contraceptive s. Not all control pop ulations are stated to be 
avoiding exposure to pregn anc y but this would be desirable since 
subclinical pr egnancy might adversely affect in te rpretation  of data. 
Some studies in demonstra ting abnormal ities of ovarian function in 
small numbers of patients sometimes use even fewer "normal" patients 
for comparison.
Previous data from the Glasgow group, initially on small numbers 
(Dodson, Coutts & Mac nau gh ton 1975a), and later enlarged upon (Coutts 
et al 1981, Fleming et al 1981), defined the control population as 
women with regular menstrual rhythm (27-32 days), no history of 
pelvic disease or contraceptive use, a biphasic basal body 
temperature record and a luteal phase of at least 13 days, defined as 
the day of max imu m LH secretion to the onset of the following 
menstruation. Their data were in general agreement with similar other 
studies at the time but it was observed that if individual hormone 
profiles were analysed then, even within this fairly narrowly defined 
group, deviations from the mean values occurred. Thus it was noted
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that avera ging of results might mask more detailed i n ter­
relationships between the pitui tary and ovarian hormones. To 
establish no rm ality daily blood sampling was felt to be required 
because of the rapid fluctuati ons observed in hormone levels from day 
to day.
Sobowale et al (1978) attempted to establish nor ma lity using the
premise that, for a cycle to be a true expression of normal function,
conception must arise. 23 cycles in 18 women, 8 of whom were trying 
to conceive and 10 of whom were not exposed to pregnancy were 
compared. The cycles in which conception occurred, those cycles which 
failed to result in conception and the voluntee r cycles with no 
chance of concepti on were analysed. They found that, although there 
were slight differences in P concentrati ons in the non-f ertile 
compared with the conception cycles in the mid-luteal phase, no 
st ati sticall y significant differe nce  in the hormonal profiles could 
be found between the volu nte ers and the conception group. These data 
suggested therefore that it was valid to use such non -conce pt ion
cycles to estab lish the hormone profiles of the normal menstrual
cycle .
Dodson, M a c n au gh ton & Coutts (1975b & c) had made the 
observation that in patients with ovulato ry but infertile cycles, 
when compared to their controls, P produ ction was sometimes found to 
be reduced. Lenton et al (1978) using a similar populat ion of 
controls, selected on the basis of regular menstrual rhythm, 
unremarkable gyn ae col ogi cal history and in whom biochemical analysis 
revealed a mid -cycle LH surge, a luteal phase of more than 12 days 
and elevations of P in the mid-luteal phase greater than 5 ng/ml for 
at least 4 days (Abraham et al 1974), confirmed these findings.
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L e n t o n  and Cooke (1981) reported findings from an exhaustive 
study on the nature of the "normal'' menstrual cycle. They compared 
three types of control pop ulations namely : a) a group, similar to
previous studies, of "normal" volunte ers ; b) a group of patients 
awaiting AID due to an isolated male abnormal ity ; c) a number of 
women who were infertile because of bilateral tubal occlusion. No 
differences were found between the groups, particularly  in relation 
to P p r o d u c t i o n  in the mid-luteal phase. This they assessed through 
the use of a P index, being the average of the sum of P values from 
days +5 to +8 relative to the day of the LH peak (day 0). Their use 
of the index was because P levels in the blood are subject to 
instability over 24 hour periods and it is unlikely that a single 
sample in a day would give an accurate reflection of mean circulating 
P. When comp ar is on was made with women who conceived during the 
course of a similar invest iga tion cycle sig nif icantly increased P 
indices were found in the conceiving women, both in spontaneous and 
induced cycles. They made the point that it is inevitable that any 
population of controls must contain a theoretical distrib ut ion of 
potentially fertile and infertile cycles. Using the P index as a 
guide to potential for conception then 75% of the control cycles were 
potentially fertile. Similar data were published in 1982 (Lenton et 
al), the conc eptio n cycles being a mixture of spontaneous and induced 
cycles. Only minor endocrine differences of limited durat io n were 
noted between the different groups of conception cycles, suggesting 
that P pr od uction in a con ception cycle is a reproducible and 
quantifiable phenomenon with a narrow range of values. No differences 
were found with respect to E2 or gonadotrop hin profiles. Another 
consideration raised was the possibility that a conception cycle 
within an infertile population might not have been representative of
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a "normal" conception cycle. Since the other hormones apart from P 
were similar to the controls Lenton et al concluded that their data 
probably represented normal conception. It is possible that the 
differences between their groups might be explained through their 
controls having a higher than expected incidence of infertile cycles 
with low P production. Even after exclu sion of cycles with clearly 
abnormal P pro duc tion from the control group median P levels did not 
approach the conception levels.
Although some workers have also found higher P levels in 
con ception cycles compared to controls (Kato et al 1982) this has not 
been univ e r s a l l y  the case (Laufer, Navot & Schenker 1982, Hull et al 
1982, Abdu lla et al 1983). Much of the published data deals with 
patients und ergoing induction of ovulation or IVF, or is limited 
through sampling deficiencies (Dlugi et al 1984, Yovich et al 1985a, 
Yovich et al 1985b).
Healy et al (1984) have shown, in studies on monkeys, that P is 
released in a pulsatile fashion mediated through GnRH and that 
fluctuations of more than 1 ng/ml can be seen over periods of 2 
hours. This lends further weight to the argument that it is better to 
take into account more than a single est im ation of P to achieve a
more accurate reflection of the adequacy of luteal function.
It would seem logical, therefore, in defining the normal
biochemical profile of the menstrual cycle to restrict one's 
admission criteria to data in women who are unlikely to have abnormal 
ovarian function, on the basis of careful gynaecological history, and 
who are not exposed to the possibility of pregnancy.
Similar constraints should apply in defining the normal 
population when assessing  follicular growth profiles using 
ultrasound, and most studies in the literature have adopted that 
attitude. The range of maxi mum FD varies consider ably with most 
values lying in the 20-25 mm range. (Hackeloer et al 1978, Renaud et 
al 1980, O'H er lihy et al 1980a, Queenan et al 1980, O'Herlihy et al 
1980b, Kerin et al 1981 and Bryce et al 1982). FD seems to correlate 
well with fol licular fluid volume thus vali dating the use of this 
simpler method of assessing follicular size. Conception cycle data in 
some studies have shown differences from non-co nceptio n data, and so 
one should be cautious in the use of such cycles as controls (Zegers- 
Hochschild et al 1984). Polan et al (1982) described a popu latio n of 
women with tubal disease, using 9 of these patients as controls. Such 
criteria are inadequate since patients with pelvic abnormali ties can 
hardly be representat ive of the normal population and there is a 
suggestion in the literature that pelvic inflammatory disease may 
predispose patients to abnormal follicular growth profiles (Hamilton 
et al 1985). Unco ntrol led studies, while anecdota lly interesting are 
not valuable scient ificall y in det ermining the significance of 
observed follicular profiles (Eissa et al 1986).
The construction  of normal biochemical and ultrasonic profiles 
for the studies to be described hereafter therefore took into account 
the considerations discussed above.
2.2 Materials and Methods
The control pop ulation was obtained through recruitment of 
volunteers, mainly hospital personnel such as nursing staff, doctors 
and medical students, though some members of the general public were
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included.
Criteria for inclusion as "normal" controls were :-
1. A his tory of having normal menstrual rhythm (cycle 
length 24-42 days over the preceed ing 6 months.
2. No past history of gyn aecolo gi cal disease.
3. No hi story of oral contraceptive use over the previous 
6 months.
4. At the time of study not engaging  in sexual 
intercourse.
Over the period of study, 43 volunte ers with similar 
characteristics were recruited. The protocol for inv estigation 
followed the same lines as that used for the main study (Chapter 4).
1. Blood samples
These were taken daily at approximate ly the same time each day,
(0900-1O O O h r s ) from the first day of m enstru at ion throughout the 
cycle until the onset of the next period. The samples were 
centrifuged wi thi n 2 hours of collection and the supernatants removed 
and stored at — 20 degrees Celsius for subsequent analysis. Thus all 
samples for a cycle were analysed in the same batch (Coutts et al 
1981)
2. Ultrasound scans
Ovarian ultrasound was performed using the full bladder
technique (Donald 1963). A B—mode static scanner (Nuclear Enterprises 
4201, Fischer (Edinburgh)) with a 3.5 MHz probe, calibrated to 1540 
metres per second, was employed to image the deve lopin g Graafian 
follicle. The follicles were measured in 3 dimensions. The maximum 
diameter in the lon gitudinal axis was defined and noted. The diameter 
at right angles to this was next ascertained. In this manner one had 
record of the longitudinal and antero -poste ri or diameters of the 
follicle. In transverse scanning the final dimen sion was taken by 
measuring the ma xi mum  transverse diameter. Follicular diameter (FD) 
was expressed as a mean of these three measurements. Scans were 
performed from the eighth day of the cycle onwards. Once the 
developing follicle was identified scans were performed daily, as far 
as possible, until the characteristic infilling of the follicle as it 
became a corpus luteum was observed. Ther eafte r scans were performed 
every 48 hours until the end of the cycle. Not all volunteers could 
attend as fre quently as this ideal schedule demanded, but in practice 
no fewer than four scans in the per i- ovulatory period and three in 
the luteal phase (after the day of the LH peak) were performed.
3. Hormone assays
The levels of E 2 , P, FSH and LH were assayed in all plasma 
samples at the end of each cycle using sensitive, specific and 
precise ra dio immun oassays (Coutts et al 1981). The details of the 
assays for each hormone are shown in table 2.1.
4. I n te rpret at io n of results
Analysis of the results was orientated around the day of the LH 
peak (day 0) and days prior to this (follicular phase) were denoted 
negative and days after this (luteal phase) were denoted positive. In 
this way cycles of differing lengths could be compared and data
51
c o m b i n e d .
5. V o l u nt eers
These fell, on the basis of the data obtained in to 3 broad 
groups :-
1. In the early part of the study, before patients were being
ac tiv el y recruited for investigation, different biochemical 
methods were used, and though the day of the LH peak could 
be identified for cycle orientation, absolute values of 
hormone levels could not be combined with the data from the 
new methods. R eg rettabl y sufficient plasma was not retained 
from these volunteers for re-assay of the hormone levels. 
Thus only the ult rasound data is included from these 15 
c y c l e s .
2. 16 cycles in which complete ultrasonic and biochemical data
using the new methods were obtained.
3. Certain volunteers, for a variety of logistical reasons, were
unable to attend for sufficient ultrasoni c examinations to 
meet the criteria for inclusion of their follicular 
diamet er data in the control figures. Blood samples however 
were obtained on almost all days, and the ultrasound scans 
which were performed failed to demonstrate any 
abnor mal ities worthy of remark. This subgroup comprised 12 
cycles and only their biochemical data is included.
The data from these sub-groups were compared using both non- 
parametric (Wilcoxon rank sum test) and parametric methods (Student's
52
t— test, unpaired samples) to ensure that there was no difference 
between them, permitting combination of the data.
Thus the control data consisted, in total, of observations from 
43 cycles in 43 volunte ers :
31 cycles - U/S data
28 cycles - hormone data.
2.3 R e s u l t s
The age of the volunteer s ranged from 18 to 36 years (median 26 
years). Follicular phase length was defined as the number of days 
from the first day of menstrual bleeding up to, and including, the 
day of the LH peak (day 0). Luteal length was the number of days 
following, but not including, the day of maxi mum  LH concentrations 
until the day prior to to the start of the next menstrual period. 
Cycle length was the sum of these figures. The median length of the
follicular phase was 14 days with a range of 10 to 21 days. Luteal
phase length ranged from 13 to 17 days (median 15 days). Total cycle 
length lay between 24 and 35 days (median 29 days) (Table 2.2). These 
data are similar to those of previous studies (Smith et al 1983, 
Lenton et al 1984).
The different sub-groups within the control population were 
compared to evaluate and confirm their similarity, val idating their 
amalgamation into a larger data pool. Using the student's t-test for 
unpaired samples and the non -p arametric Wil coxon rank sum test the 
following comparisons were made
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A. Group 1 vs Group 2 (U/S vs Bioch + IJ/S)
1. Follicular Diameters Days -5 to Day 0
B. Group 2 vs Group 3 (Bioch + U/S vs Bioch)
1. E2 levels - Days -8,-4 to +2, and +8
2. E2 Index - Calculated for each patient on the basis
of total E2 productio n over the peri- 
ovulatory period (days -2 to +1) and 
expressed as the mean of the sum of the 4 
values on these days in pg/ml.
3. P levels - Days 0 to +6.
4. P Index - This was calculated for each patient on
the basis of total P production in the 
early luteal phase and expressed as the 
total of all P values for each patient 
between days +2 and +6 in ng/ml. (Coutts 
et al 1982)
5. FSH levels - Days -5, -2 to +2, and +8.
6. LH levels - Days -5, -2 to +2, and +8.
As table 2.3 shows, no significant dif ference was found between 
groups 1 and 2 in FD values. Between groups 2 and 3 minor differences 
were found in the values of E2 on days — 4 and +2, but these were 
found not to be significant when subjected to n on— parametrie 
a n a l y s i s (table 2.4). P levels were found to be comparable in the 
groups except on day +2 but as table 2.5 shows this minor difference 
was not reinforced by a significant overall reduction in P production 
in the e'arly luteal phase as assessed by the P index. Gonadotrop hin 
values in the mid — f o l 1 icular , periovulator y and m i d — luteal phases 
were similar for both groups (tables 2.6 & 2.7).
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On this basis the 3 sub-groups were combined to achieve an 
ultimate data pool from 43 cycles.
DE SCRIPT ION OF CONTROLS
Biochemical data
1. 17B-estradiol (E2)
Table 2.8 shows the media n values for plasma E2 levels in 
pg/ml from day -10 to day +14 together with the mean values, 
standard deviations, standard errors of the means and the 95% 
confidence limits of the mean. The 95% confidence limits are 
gr aph ically represented in figure 2.1.
From a median basal value of 75.0 pg/ml the level of E2 rose, 
gradually at first, but more steeply from day -5 onwards to reach 
a peak median of 220.0 pg/ml on day -1. The level dropped to 210.0 
pg/ml on day 0, the day of the LH peak, and continued to fall 
until day +3 when the ch aract eristic secondary rise of E2 in the 
luteal phase was observed, reaching a peak of 168.0 pg/ml on day 
+9. E2 levels fell the reafter to basal levels and menstrua tion 
e n s u e d .
An estradiol index was calculated for E2 over the peri- 
ovulatory period (days -2, -1, 0 and +1). The mean total value was
186.9 (SD 29.4) and the 95% confidence intervals limits are shown 
in table 2.9. These values were standardised such that the mean 
value was translated to be 100. Thus a periovulatory E2 profile 
equivalent to the mean of the normal cycle data had an E2 index of
55
100. The 95% confidence limits lay between 93.9 and 106.1.
2. P r o g e s t e r o n e  (P)
Tabl e 2.10 shows the median and mean plasma P levels in 
ng/ml, standard deviation, standard error of the mean and 95% 
confidence limits of the control population from day 0 to day +14. 
In all cases P levels prior to this were steady below 0.9 ng/ml, 
their being no evidence of 1uteinisation prior to the LH surge.
The P levels rose steadily until a peak was reached on days +6 and 
+7 of about 19.0 ng/ml. The graph (figure 2.2) shows that between 
days +5 and +9 the levels were consistently over 14.8 ng/ml. In 
all cases a mid-lutea l P level of greater than 10 ng/ml was found 
between days +5 and +9.
In order to obtain a P index of luteal function, the sum of P 
values between  days +2 and +6 inclusive were calculated for each 
cycle. This total gave an impression of overall P production 
during the early luteal phase. The mean P index was 63.7 ng/ml 
(standard deviation 17.2 ng/ml) and the 95% confidence limits lay 
between 56.9 ng/ml and 70.5 ng/ml. Expanding the confidence limits 
to the 99% level gave a range of 54.8 ng/ml to 72.6 ng/ml. For 
future comparisons these values were converted to percentage 
points. In other words, a luteal phase profile equivalent to the 
mean of the normal cycle data would therefore have a progesterone 
index of 100 and the 95% confidence limits of the normal data 
would be converted to 89.5 and 110.5 ng/ml. The 99% confidence 
limits were 85.9 and 114.1 ng/ml (table 2.11).
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3. FSH levels.
Table 2.12 shows the median, mean, standard deviation, 
standard error of the mean and the 95% confidence limits of the 
plasma FSH levels from days -10 to +14 inclusive. Figure 2.3 
portrays the 95% confidence limits graphically. In the early part 
of the follicular phase the levels were rather higher than in the 
later part, in keeping with current theory regarding the role of 
FSH in follicle recruitment. Peak levels (11.5 IU/1) were reached 
on day 0, coincidental to the LH peak, with a gradual fall in the 
luteal phase to a basal value of 1.8 IU/1 on day +9. In the few 
days prior to menses FSH levels started to rise again, preparatory 
to follicle recruitment in the next cycle.
4 . LH l e v e l s .
All cycles showed a classical mid-cycle peak of L H . Table
2.13 and figure 2.4 reveal the data. The median level in the early 
and m i d- follicu la r phase remained fairly stable, 8.1 IU/1 on day 
-5. The level increased on day -2 and the maximum level on day 0 
was 73.5 IU/1. Occasional ly  some cycles showed a broad peak, where 
LH levels were high on more than one day. The higher value was 
therefore taken as depicting day 0 or, if the two values were 
similar, then the day on which the E2 level was found to be lower 
was taken as the reference day. In only two of the 28 cycles with 
biochemical data was reference to the E2 levels necessary in order 
to define day 0. Levels of LH fell sharply following the LH peak 
to 11.6 IU/1 by day +2 and in the mid/late luteal phase were 
fairly stable at between 5 and 7 IU/l.In the 15 cycles where old 
standards were used the day of the LH peak was unequivocally  clear
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in all.
The L H :FSH ratio was calculated for each day and, as table
2.14 shows, the median ratio was equal to or less than 2:1 until 
day — 3, when it rose to 2.8, reflecting the propor tionate ly  
greater increase in LH in the per i- o v u l a t o r y  period. On day 0 the 
mean ratio was 6.1:1, falling to 3.9 on day +1 and 2.9 on day +2. 
The ratio fluctuated thereafter, never being greater than 3.1:1, 
save on day +9 (3.7:1). By day +14 the ratio had fallen to below 
2:1, similar to the early follicular phase level (figure 2.5)
Ul tr asound data
In all cases a single Graaffian follicle was seen to develop 
and, following the LH peak, disappear. Table 2.15 shows the median, 
mean, standard deviation, standard error of the mean and 95% 
confidence limits of FD's in mm, in the 31 volunte ers who underwent 
ultrasound examinations. These are grap hi cally represented in figure
2.6. The smallest diameter at which a follicle could confidently be 
seen was 8 m m . The follicle enlarged in a linear fashion from day -5 
until the day of maximum F D , usually day 0. In 7 cases maximum FD was
reached on either day -1 (2 cycles), day +1 (4 cycles) or day +2 (1
cycle). In all cases shrinkage of the follicle was observed following 
the LH surge and in 29 of the 31 cycles the corpus luteum had become 
indistinguishable from the surrounding ovarian tissue by day +5.
Median maximum FD on day 0 was 21.0 mm.
Mean values of FD were correlated with mean levels of plasma E2 
between day -5 and day 0. These were found to be highly significantly 
correlated (r = 0.97, p <0.01). The regression line is shown in
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figure 2.7 ( y = 4.49 + 0.07x). This cor relation was even more
pronounced when the values were compared between day -5 and day -1 (r
= 0.998, p <0.001). The regression line is shown in figure 2.8 (y =
5.9 + 0 . 0 6 x ).
There was no corr el ation  between FD and plasma P levels.
Of the 5 patients where follicular shrinkage was delayed until 
day +2 and +3, in only 1 case was this found to be associated with a
broad LH peak. In this case the profiles were as follows
Day LH (IU/1) FD (mm)
-1 14.0 no measurement
0 72 . 0 18.0
+ 1 61 . 0 21.0
+ 2 2 7.0 23.5
The other 4 cycles, and the 2 cycles where maximum FD was reached 
prior to the LH peak, showed no unusual gonadotr ophin patterns.
In conclusion, the temporal relationship between the circulating 
levels of gonadotroph ins and ovarian steroids was confirmed in the 
volunteer group. The circulating levels of the hormones seemed to be 
similar to those reported previ ously in the literature (Dodson et al 
1975, Kle tzky et al 1975, Sobowale et al 1978, Coutts et al 1981, 
Lenton et al 1982), though not quite as high as those reported by
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Pauerstein et al (1978). Results from differing studies are of course 
not directly  comparable since it is unl ik ely that uniform radio­
immunoassays will be used in all centres.
The u l t r ason ic  data are in keeping with other reports, in 
particular those already published from the same department 
(Hackeloer et al 1978) using identical ultr aso und equipment. None of 
the control group revealed any of the ultr asoni c abnormalities which 
are to be dis cussed in later chapters.
These 43 cycles provide the data for normal ranges for the 
biochemical and U/S parameters. These "normal" ranges are used for 
comparison with the hormone and U/S profiles observed in individual 
women with unexplai ned infertility.
CHAPTER 3 CONCEPTION  CYCLES
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3 .1 Intro duction
The d e t ec ti on of ovula tio n remains something of an enigma in the 
investigation of infertility. Reliance is placed on the use of tests 
which reflect, on the whole, only ind irectly the events which 
transpire following  lute inisation of the gra nulosa cells of the 
presumed mature Graaffian follicle. However, ovulation need not 
necessarily follo w an LH rise (Laborde et al 1976), the use of the 
temperature chart has been criticised (Lenton et al 1977,
Quagliarello & Arny 1986), controversy exists as to what should be 
considered an acceptable level of plasma P consistent with ovulation 
(Israel et al 1972, Abraham et al 1974, Hull et al 1982) and even the 
observation that follicular rupture has occurred has not been shown 
to be conclusive evidence that ovum release has occurred (Craft et al 
1980, Stanger & Yovich 1984).
Unequivocal evidence that ovulation has taken place exists when 
conception occurs and, as referred to in Chapter 2, some authorities 
claim that only conception cycles can reflect true adequacy of 
ovarian function. This view is not un iversall y held, though there can 
be no doubt that such a cycle's dec la ratio n of normality is powerful, 
since the reproductive goal of ovulation resulting in pregnancy has 
been achieved.
Claims have been made that, both en do crinologic ally (Sobowale et 
al 1978, Lenton et al 1981, Lenton et al 1982, Kato et al 1982) and 
ultrasonically (Zegers-Hochschi ld et al 1984), differences exist
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between the spontaneous conception cycle and the n on— fertile 
"ovulatory" cycle, though others (Laufer et al 1982, Hull et al 1982, 
Abdulla et al 1983, Eissa et al 1986) dispute this. Unfortu nately  
many of the studies are limited in the amount of data presented 
through sampli ng and timing deficiences. In attempting comparison 
with control cycles where men st ruatio n ensues, great care must be 
taken that blood samples are taken from patients at the identical 
phase of the cycle, a difficult task when the anticipated next period 
fails to occur.
During the main study on unexplained infertility presented in 
this thesis patients were referred for detailed cycle analysis. Some 
of these did not meet the strict criteria for inclusion in the main 
analysis largely because the duration of their "infertility" was less 
than 3 years. During such investigations 11 patients spontaneously 
conceived thus providing a data pool permitting detailed and accurate 
analysis ul tra s o n i c a l l y  and biochem ically of ovarian function in 
cycles of conception. These conception cycle "controls" could 
therefore be compared and contrasted with the "normal control cycle 
data".
3.2 Materials  and Methods
11 patients were investigated using an identical protocol, 
involving daily blood sampling and detailed ultrasonic moni to ring of 
follicular development, to that described for the main study 
(Chapters 2 & 4). 10 of the 11 patients had essentially unexplained
subferti1 i t y , with normal biochemistry, a normal pelvis, as assessed 
through lap ar oscopy within the previous 18 months, and whose male 
partner had demonstra ted a normal semen analysis on at least two
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occasions. The duration of their involuntary infertility was less 
than 3 years. One patient had previously been found to have a 
modestly elevated serum prolactin concentra tion of 1200 IU/1 and was 
being treated with bromocriptine, 2 . 5mg per day. Three months after 
initiating therapy her prolactin level was 280 IU/1, well within the 
lower limit of normal for the laborat ory  of 500 IU/1. Six months 
after starting therapy conception had still not occurred and she was 
referred for detailed cycle investigation. Her overall du rat ion of 
involuntary in fertility  was 5 years.
These patients all conceived during their investigation cycles, 
as evidenced by delay in menses associated with elevations in B-hCG 
(>50 IU/1).
The resulting biochemical (daily estimations of E 2 , P, LH & FSH) 
and ultrasonic  data (frequent scans in the pe ri-ovula tory and early 
luteal period) were compared to the control data obtained from the 43 
volunteers described in chapter 2 , none of whom were exposed to the 
possibility of pregnancy.
Statistical analysis was performed using both parametric 
(Student's t-test for unpaired samples) and non-pararaetric (Wilcoxon 
rank sum test) methods.
3 . 3 Results
Table 3.1 shows the E2 data of the conception cycles from day -9 
to day +14 inclusive. The median values are plotted g r a p h ic al ly in 
figure 3.1 with the median concentrations of the normal cycle data 
(Chapter 2). The pattern in the conception cycles was very similar to
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that of the controls with an exponential rise of E2 being observed 
until day — 1. Following the LH peak E2 levels dropped, as for the 
control cycles, followed by a secondary rise again characteristically 
seen in the normal cycle volunteers. Divergence  from the conventional 
pattern was seen only from day +10 with this becoming statistically 
significant from day +11 (p < 0 .0 0 1 ).
The P profile of the conception cycle group is shown in table
3.2 together with the P index. Graphicall y portrayed in figure 3.2 it 
is seen that this profile is comparable to the control cycle data.
The influence of conception on the profile is again not strikingly 
obvious until day +10 when the levels are seen to rise (p <0.02 on 
day +10). The mean P index was 105.0, similar to the control mean of 
100. (t = 0.486, p >0.2). However there was a wide range of values in 
the con ception  group (50 to 170), incorporati ng 1 cycle with markedly 
deficient luteal function (P index 50) and 2 other cycles with 
borderline P indices, 72 and 76 respectively. Two cycles exhibited 
very high levels of P (P indices 140 and 170) and in both of these 
multiple follicular dev elopment was observed on ultrasound.
FSH conce ntr ations parallelled the non — concept ion cycle data and 
although minor differences were observed, pa rticularly  in the luteal 
phase where levels were slightly lower, these did not reach 
statistical significance (table 3.3, Figure 3.3).
LH profiles are doc umented in table 3.4 and figure 3.4.
Deviation from the normal was likewise not seen until beyond the time 
of embryonic imp lantation with statistical significance being 
achieved on day +12 (p <0.001). These elevations would be due to
cross reaction of B-hCG of the pregnancy in the LH assay.
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Despite small numbers, ultrasonic data was obtained on more 
than half the group during the pe riovulato ry period. With the 
exception of the two patients with elevated P levels described above, 
a single domin ant follicle was seen to develop and, following the LH 
peak, shrink and disappear. In no case was the cystic nature of the 
follicle retained beyond day +2. A scan was performed on day 0 in 8 
of the patients, with a median diameter of the dominant follicle of 
20.8mm being observed on that day (table 3.5). This was statis tical ly 
similar to the control cycle data (figure 3.5). In the two patients 
where sec ondar y follicles were observed the maximum diameters of the 
smaller follicles were 17.0mm and 1 2 .0mm respectively.
3.4_______D is cu ssion
The data presented above relates to patients where diagnosis of 
pregnancy was based on the clinical observat ion of delay in menses 
associated with elevations in B-hCG. It has been estimated that in a 
fertile po pulation the exp ectation of conception in a cycle is almost 
60% (Edmonds et al 1982). In over half of these cases the woman may 
be unaware of the pregnancy, which results in a sub-clinical 
abortion, manifest, perhaps, as a heavy period, delayed by a few 
days. Em bry oni c loss, except in a research context, is currently 
difficult to quantify but Whittaker, Taylor & Lind (1983) suggested 
that Edmond's figure might be rather high. They found that in 
monitoring 226 ovulatory cycles, 85 clinical pregnancies occurred. In 
addition, 7 women, despite experiencing menstrua tion when expected, 
were found to have elevated B-hCG in the luteal phase. These sub- 
clinical pregnancies amounted to 7.6% of all conceptions. It is 
unlikely that other patients, in the series described in this thesis,
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conceived , since, although B — h C G was not assayed as a routine in the 
protocol of investigation, cross reactivity of LH with B-hCG would 
have been expected to detect these conceptions, as in the cycles 
described h e r e .
Some previous reports suggested that P concentrations in the 
mid-luteal phase of the conception cycle are higher than in the 
ovulatory non-f ertil e cycle. Lenton et al (1981 & 1982) found this to 
be the case in both unsti mul ated and stimulated cycles. They 
speculated that the early pre-i mplan ta tion embryo might, through 
el abo ration of an as yet unknown factor, influence the steroidogenic 
potential of the corpus luteum. It has been suggested through studies 
on rats that the non-gravid part of the uterus may have some 
influence on corpus luteum function leading to increased P production 
(Kato et al 1982). Few studies' protocols have dictated blood 
sampling of patients as frequently as the Sheffield group's but since 
it is established in the non-human primate that P levels are subject 
to fluctuation (Healy et al 1984) it is des irable that as detailed 
information as possible be obtained (Dodson et al 1975b). Comparison 
with studies opposing the view that the conception cycle exhibits 
greater P prod uction is hindered by paucity of sampling during the 
luteal phase. Thus the contention that no difference exists between 
cycles of concept ion and the no n-conceptio n cycle (Laufer et al 1982, 
Hull et al 1982) requires confirmation through more detailed 
analysis. The literature also contains reference to cycles of 
conception in IVF programmes and, although the evidence seems 
persuasive that P concentrations are higher in successful treatment 
cycles (Garcia et al 1984, Dlugi et al 1984, Yovich et al 1985a,
1985b) these data are unlikel y to be relevant to the physiological 
processes of the normal fertile cycle and spontaneous conception.
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The data of the present study meet the requirements of frequency 
of sampling. No difference was found between the conception cycles 
and the controls. Wide variations in CL function were observed and 
defic ien t P indices were obvio usly not a bar to conception. The 
higher P indices were accounted for by multiple follicular growth and 
pr esuma bl y luteinisation.
Three of the group (27.3%) aborted prior to ultrasonic 
co nfirmatio n of a viable intra-uterine pregnancy. These patients had 
P indices of 50, 87 and 140 respectively; thus only one of them 
exhibited a markedly deficient luteal phase, using the P index as the 
criteria of efficiency. This patient, and indeed all the other 
patients, met the criteria of ovulation set by various authorities on 
the basis of P levels in the mid-luteal phase i.e. Israel et al 
(1972) - >3ng/ml; Abraham et al (1974) - >15ng/ml sum of P values on 
3 days in the mid-lut eal phase; Hull et al (1982) - >9.4ng/ml. 
Abnormal ovarian function was thus not a barrier to conception but 
the observed abnormality might have prejudiced the outcome of the 
pregnancy. The patient aborted on day +35 and diagnostic curettage 
confirmed the presence of chorionic villi. Kusuda et al (1983) have 
suggested that corpus luteum insufficiency may cause infertility 
mediated through a defect in nidation. This is in agreement with the 
observations that the luteal phase defect has an association with 
recurrent abortion (Jones 1976, Tho et al 1979). The patient with the 
markedly reduced P index had regular periods prior to her cycle of 
conception but it is possible that she might have had prior sub- 
clinical pregnancies, perhaps related to a recurrent defective luteal 
phase. Soules et al (1981) has observed that corpus luteum function 
in cases of luteal deficiency may be enhanced through treatment with
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clomiphene citrate compared with P supplementation, although 
pre gnancy rates seem to be better with the latter. This patient was 
undergoing treatment for modest hyperpr olact in aemia with 
bromocriptine but did not receive P supplementation. Her PRL levels 
in the concept ion cycle were checked retr ospec tively and found tobe 
within the normal range. PRL levels in conception cyles have been 
reported as no dif ferent from the no n-conception cycle (Lenton et al 
1979, Ade juwon et al 1984).
The other cases of spontaneous abortion were not found in 
association with defic ient P production. They occurred at day +37 and 
+47 respectively. Embry onic abnormalities may have been the cause of 
pregnancy loss but the products of conception were not subjected to 
genetic analysis to confirm this.
Pap iernik et al (1979) suggested that delayed ovulation through 
pr olongation of the follicular phase in cycles of conception might 
predispose to embryonic mo rtality  and fetal growth retardation. The 
length of the fol licular phase was 13, 14 and 14 days in the patients 
described above.
Two other patients with lowish P indices, 72 and 76 
respectively, had un rem ark able normal pregnancies.
The finding of normal E2 profiles is in agreement with the 
previously published data of Smith et al (1980) and Lenton et al 
(1982) though the former study had limited data.
Follicular growth patterns in the patients studied followed the
normal pattern with secondary follicles observed in two of the
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patients. In all cases, except one of the aborters, follicular 
collapse was observed within 48 hours of the LH peak. The 
"sta bil isation " of follicular development des cribed by Zegers— 
Hoc hschild et al (1984) in the 24 hours prior to rupture was not a 
feature in these patients and the pattern of events was no different 
between the controls and the study group. The present study agrees 
with the data of Eissa et al (1986) but in addition provides a needed 
comparison with normal non-co nception data. In no case was there 
evidence of u l t r a s o n i c a l 1y defined luteal cyst formation (Chapter 5). 
Although foll icu lar rupture need not nece ssaril y lead to release of 
an ovum (Craft et al 1980, Stanger & Yovich 1984), this obviously 
occurred in the present series. De Crespigny et al (1981) described 
several variants  of follicular collapse, as observed u l t r a s o n i c a l l y , 
including initial rapid reduction in size with subsequent shrinkage 
lasting from five to thirty-five minutes. Ovum release need not 
coincide with the initial rapid release of fluid and the egg may be 
extruded with the subsequent slow follicular collapse.
Se co ndar y follicular growth is not an unusual phenomenon 
(Breitenecker , Friedrich & Kemeter 1 978 , O'H erlihy et al 1980a, 
Queenan et al 1981, Kerin et al 1981, Sallam et al 1983). In the 
patients described, although multiple ovu lation was possible in the 
patient with the 17mm secondary follicle and improbable in the 
patient with the 12mra follicle, both cycles were associated with high 
P indices and ensuing singleton pregnancies. The role of secondary 
follicles remains unclear.
In conclusio n these data would suggest that the human conception 
cycle does not differ in terms of follicular growth and corpus luteum 
function from the normal non— fertile cycle thus justifying the use of
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n o n - c o n c e p t i o n  data as a p h y s i o l o g i c a l  y a r d s t i c k  of n o r m al i t y.  
D e f i c i e n t  lu te al  f u n c t i o n ,  as m e a s u r e d  by p l a s m a  P c o n c e n t r a t i o n s ,  
not a bar to c o n c e p t i o n  but ma y be a s s o c i a t e d  wi th  e m b r y o n i c  loss, 
the p r e c i s e  ca u se  of w h i c h  is uncle ar .
CHAPTER 4
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INVESTIGA TION OF U N E X P LAINED INFERTILITY
4.1 Ma teria ls
The patients under study attended the infertility clinics of 
Glasgow Royal Infirmary and the Western Infirmary, Glasgow. For all 
patients, no ex pl anation had been found for their failure to 
conceive. Their unexplained infertility was defined as follows :
1 . All patients had a history of regular menstrual rhythm with 
cycle length, in the 6 months prior to investigation, of 
between 24 and 42 days duration.
2. All had had a pelvic assessment with laparoscopy in the 
previous, two years. In all cases this had revealed normal 
pelvic organs with no evidence of endometriosis or pelvic 
i nf lam mat ory disease.
3. All male partners had provided at least two semen samples 
wh ich  fulfilled the laboratory's criteria of nor mality - 
volume 2 - 6 m l , sperm density >20M/ml, motility >40%, normal 
m o r p holog y >60%.
4. All patients had undertaken a post-coital test which had 
revealed active sperm in the cervical mucus.
5. All couples denied any sexual problems, and had been having 
regular unprotected intercourse for a minimum of 3 years.
The bulk of the patients were recruited from the infertility 
clinic of the Royal Infirmary which for some years has enjoyed a 
reputation as a centre with a particular interest and expertise in 
the investigation and management of patients with unexplained 
infertility. Referrals from all over the West of Scotland and beyond
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are received by the clinic and largely as a result of this, during 
the period of study (October 1982 to September 1985), it was possible 
to recruit 175 patients who fulfilled the above criteria.
4.2 Methods
All patients gave their informed consent to the investigations 
which were standardised for all.
1. Blood Samples
Commencing on the first day of the cycle, all patients provided 
a blood sample (10ml) which was collected in to a lithium heparin 
tube. Samples were^obtain ed each day at about the same time (0900- 
lOOOhrs), wherev er possible, and spun down in a centrifuge to 
separate the plasmas, which were then labelled and stored at -20 
degrees Celsius until assayed. Patients provided blood samples every 
day throughout their entire menstrual cycle. Most attended the 
relevant hospital for this to be carried out, but where long 
distances were involved the patients' general practitioners were 
asked to assist in the collection of specimens. These were then 
posted in except when the patient was attending the hospital for 
ultrasound scans.
2. Ultraso und Scans
These were performed by a single operator (the author) in the 
ultrasound department of the Queen Mother s Hospital, Glasgow. The 
methodology was exactly the same as that employed in the 
establishment of the normal ranges (Chapter 2)..The same ultrasound
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machine was used (Nuclear Enterprises 4201, Fischer (Edinburgh), B— 
mode static scanner with a 3.5MHz probe, calib ration 1540m/s) and the 
timing of scans was similar.
Patients were asked to phone the author with the onset of menses 
in the cycle under investigation. The first ultrasound scan was then 
arranged for the eighth day of the cycle. The full bladder technique 
(Donald 1963) provided excellent imaging of the ovaries. Scans were 
performed every 48 hours from day 8 until the developing Graafian 
follicle could be visualised, whereupon scans were carried out daily, 
until the cha rac teri st ic infilling of the follicle as it became a 
corpus luteum  was observed. Thereafter, scans were performed every 
48-72 hours throughout the luteal phase, until the beginning of the 
next menses .
Fo llicula r diameter was calculated as in section 2.2.
L o g i s t i c a l l y  (due to travel problems etc.) not all patients were 
able to attend as frequently as this ideal protocol dictated, but in 
practice no fewer than four scans in the follicular phase and three 
in the luteal phase (after the day of the LH peak) were performed on 
each p a t i e n t .
3. Hormone Assays
The plasma concentrations of E 2 , P, FSH and LH for all samples 
from the cycle under study were assayed retrospectively, using 
sensitive, specific and precise radioimmunoassays. These were 
processed in a single batch to eliminate between assay variations.
The details of these assays are described in table 2.1.
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4. I n te rp re tatio n of Results
This followed the schedule laid out in section 2.2 with
or ie nt ati on of each cycle around the day of the LH peak (day 0) in
order to permit com parison of cycles of differing length.
No assump tions were made regarding the distribution  of the data
in respect of these cycles and, except where indicated, non-
parametric methods of statistical analysis (Wilcoxon Rank Sum Test) 
were employed to determine differences between groups. Differences in 
frequencies were assessed using the Chi-square test or Fisher's exact 
test where appropriate.
4.3 Safety of U/S mo ni toring of follicular development
Concern has been expressed in the literature regarding the 
safety of diag nosti c ultrasound, principally in the context of fetal 
exposure during antenatal scanning. A report by Testart et al (1982) 
suggested that ovulation might occur prematurely in patients 
undergoing follicular mo nitoring with frequent ultrasound scans 
during the p e r i — ovulatory period but others (Fleischer et al 1984) 
have been unable to reproduce this observation.
Most studies on the biological effect of ultrasound have been 
conducted at cellular levels under laboratory conditions, and it is 
difficult to extrapolate data obtained in such an environment to the 
clinical realities of an in— vivo situation. Bomsel—Helroreich (1985) 
observed that fertilizat ion rates and the characteristics of 
blastocyst formation in IVF programmes based on ultrasound seem
similar to those in the few programmes where ultrasound is not used. 
Post-imp 1 antation effects are possible but diffi cul t to evaluate, and 
with so many variables surrounding success or failure in 1VF 
programmes, it is doubtful if an effect, exclusive to ultrasound 
could be demon strated  conclusively.
Statements from ultrasound related societies such as the 
European Fed er at ion of Societies for Ultrasound in Medicine and 
Biology (EFSUMB) (1984) and the Bioeffects Committee of the American 
Institute of Ult rasou nd  in Medicine (AIUM) (1984) have emphasised the 
lack of convincing evidence that ultrasound causes any ill effects on 
the develop ing fetus at the intensities used in diagnostic imaging. 
McNay and Fleming (1984) concurred that there appeared to be no 
evidence suggest that the benefits of diagnos tic ultrasound should be 
witheld from patients und ergoing fertility investigations, ovulation 
induction or in-vitro fertilization.
The average rate at which tissue receives ultrasonic energy is 
usually expressed as the temporal average of the most intense region 
in the beam (McNay and Fleming 1984). This intensity (I) is referred 
to as the spatial peak, temporal average (spta). The statement from 
the AIUM affirmed that, in the low MHz frequency range, there have 
been no, ind epe ndent ly  confirmed, significant biological effects in 
mammalian tissues exposed to I(spta) below 100mW/cm2.
For the ultrasonic equipment used in this study (NE4201,
3.5 M H z ), I(spta) has been calculated as 61mW/cm2 (Duck et al 1985). 
The output of the equipment was attenuated by 20db i.e. by a factor 
of 100, and co nsequently  the actual I(spta) in this study was 
0.61m W /cm2, over 160 times lower than the maximum recommended by
AIUM. The statement also affirmed that ult rasou nd exposure times up 
to 500 seconds were not associated with signi ficant biological 
effects, even at intensities higher than 100mW/cra2. Average scanning 
time per patient in the present study was in the region of 300 
seconds, thus it would seem to be highly un l i k e l y  that the 
investigation  posed any risks to the patients or their putative 
c o n c e p t u s e s .
CHAPTER 5 RESULTS
98 of the 175 cycles investigated (56.0%) demonstra te d distu rbed  
ovarian function, in the form of either bi ochemical  or ultr asonic 
deviations from the normal patterns described above.
These abnormal cycles are defined and des cribed in relatio n to 
their frequency of occurrence, in the following sections of the 
thesis :
5.1 Luteal cyst formation (41 c y c l e s )
5.2 Poor proge st erone surge (51 c y c l e s )
5.3 High LH concen trati on s (23 c y c l e s )
5.4 Poor fqlli cular mat ur at ion (16 cycles)
Poor follic ular development (12 cycles)
5.5 Short luteal phase (6 c y c l e s )
Long follicu lar  phase (9 c y c l e s )
Short fo ll icula r phase (6 c y c l e s )
The abn ormalities to be descr ibed were not mutuall y exclusive* 
77 cycles (44.0%) ful filled the criteria of norma lity set out in 
Chapter 2.
SECTION 5.1 LUTEAL CYST F O R M AT IO N
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5 .1. 1______ De f i n i t i o n
Normal fol lic ular dev elopment and corpus luteum formation have 
been di scuss ed  in chapter 2. In a high prop ortion  of the cycles under 
study the normal ult ra s o n i c a l l y  observed process of collapse, 
infilling and eventual disappea rance of the dominant follicle 
following the LH peak did not occur. Instead the follicle retained 
its cystic appearance, in some cases continuing to enlarge throughout 
the luteal phase.
Luteal cyst for ma tion was diagnosed on the basis of ultrasonic  
examinations, betw een days +5 and +8 relative to the LH peak, of the 
ovary ipselat eral to that which contained the dominant follicle. If 
the cystic nature of the follicle was found to have persisted between 
these days then the structures were termed luteal cysts. The 
diameters of the cysts were calculated on the basis of the mean of
all diameters measured between days +5 and + 8 .
5.1. 2______ Int roduc ti on
Previous studies have described similar structures in the luteal 
phase and much discus si on has taken place as to whether they 
represent the LUF syndrome. As alluded to in chapter 1, data in this
area has suffered from lack of numbers (Coutts et al 1982, Coulam et
al 1982, Coulam et al 1983), failure to evaluate the relations hi p of 
observed abn orma li ti es to biochemical indices of luteal function 
(Nitschke-Dabelstein et al 1981, Gibbons et al 1984, Daly et al 
1985), and failure to discriminate between cycles where induction of
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ovulation was being carried out and unstimul ated cycles (Nitschke- 
Dabelstein et al 1981, Gibbons et al 1984, Hamilton et al 1985). The 
ultrasonic criteria for defini ng the LUF syndrome have varied 
considerably in the studies cited.
Kerin et al (1983) used sequential ultrasound to det ermine the 
incidence of LUF, defined as failure of the dominant follicle to lose 
its cystic appeara nce  within 36 hours of the peak LH concent ra tion in 
blood, in a mixture of patients, some with tubal disease, some 
awaiting artificial insem in at ion with donor sperm (AID), a small 
number with end om etrio sis and only a small number with unexplai ned 
infertility. The incidence of "LUF" was 4.9%. One of the six patients 
with un ex plained infert ility demo nstrated the LUF phenomenon. The 
biochemical data in this study were limited to steroid assays only at 
three to five day intervals in the luteal phase, and thus the 
conclusion that P concentr ations in the LUF cycles were normal must 
be viewed with caution. In some cases the diagnosis of LUF was made 
on the basis of scans performed only two days after the LH peak and 
it is possible that these data represent a variant of normal : one of
the conception cycles described in chapter 3 demonstrated this 
periovulatory pattern of follicular growth. No data were supplied of 
the dynamics of these phenomena beyond day +4, nor was any 
discrimination ipade between the cycles where the follicle was seen to 
shrink and the cycles where the follicle retained its periovul at ory 
dimensions or expanded. No data were provided regarding the 
follicular phase biochemical profiles of the gonadotrophins, nor of 
E2 prior to day 11 of the cycle, and thus it is difficult to 
speculate on the likely pathogenetic mechanisms at play in these 
cycles. In addition the cycles are drawn from such a het erogeneous 
Population that one cannot draw a firm conclusion with respect to
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incidence of the phenomenon in unexplained infertility. The fact that 
it was seen in the AID patients suggests that, on occasion, LUF may 
occur in p o t e n t i a l l y  fertile women since, as a group, when treated, 
these women exhibit only slightly reduced fecundity compared to 
normal (Mathews and Peek 1987).
Li u k konen et al (1984) restricted analysis to patients with 
presumed unexp la in ed infertility. However, when lapar oscopy was 
performed, in close temporal proximity to the cycles of 
investigation, significant pelvic pathology was discovered in 36.0% 
of the series, suggesting that the patients studied did not represent 
an homog eneous group. The definitio n of LUF was based on the 
observation of i n t r a f o 1 1 icular echoes in the absence of shrinkage 
within the dominant follicle. No comment was made with respect to the 
follicular dynamics prior to presumed ovulation in the study group 
and the data were not compared to suitable controls. In addition, 
biochemical data were not provided in the study. It is difficult, 
therefore, to draw conclusions on the nature of the structures 
observed in the absence of these important points of information.
Ha mil to n et al (1985) provided more substantial data in respect 
of ultrasound diagnosed LUF syndrome in that follicular profiles were 
analysed and biochemical data were provided, albeit on a limited 
basis, since blood samples were taken only on the days of ultrasound 
scans, and in frequently  in the luteal phase. Comparison was made with 
suitable controls but the strength of the analysis was somewhat 
diluted by the h et er ogeneit y of patients under study. 11 of the 27 
Patients d em onstra ti ng LUF, defined as failure of the follicle to 
rupture despite signs of luteinisation (elevation in basal body 
temperature and a rise in plasma P), were undergoing ovulation
induction. 11 of the patients had been demonstrated to have 
significant pelvic patho logy (pelvic inflammatory disease or 
endometriosis) and only 10 had unexplained infertility. In the study 
mention was made of patients with "cystic corpora lutea" where 
decrease in the mean follicular diameter of the pre-existing follicle 
was seen several days prior to the luteal cyst. No data was supplied 
on the number, the follicular profiles or the biochemical patterns of 
these cycles. The higher con centrations of E2 observed in the 
follicular phase of the "LUF" cycles could be explained by the 
relatively high number of patients undergoing ovulation induction.
5.1.3______ Anal y s is
Description of analysis
41 (23.4%) of the 175 cycles under study were found to
demonstrate luteal cyst formation.
Analysis of the biochemic al and ultrasonic profiles of these 
cycles is structure d as follows :
Normal P index
Low P index
Shrinkers
Non-shrinkers
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10 21 S hr inke rs
31 20 Non-shrinkers
LUTEAL CYSTS 41
Large 30 11 Small
10 23 Low P index
20 7 Normal P index
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A. Size
An ar b i t r a r y  d i s t i nct io n was made between large and small cysts 
on the basis of the mean di amete r of the dominant follicle in the 
control cycles on day 0, i.e. 20mm. Large luteal cysts (>20mm) were 
found in 30 of the 41 cycles (73.2%) while small cysts were seen in 
11 (26.8%).
B. Shrinkage
Frequent scanning over the p e ri-o vu latory period permitted 
discrimination to be made between those cycles where the dominant 
follicle was seen to reduce in size following the LH peak (21 cycles 
(51.2%)), and those where the dominant follicle did not show evidence 
of shrinkage after day 0 (20 cycles (48.8%)).
C. P index
Comparison was made bet ween those cycles where luteal cyst 
formation was ass oci ated with deficient P product ion  in the early 
luteal phase (P index <89.5, i.e. <95% confidence limit of the mean 
of the normal range) and those cycles associated with normal P 
production. There were 31 cycles with a low P index (73.2%) and 11 
(26.8%) with a normal value.
P« Large cysts & shrinkage
The 30 cycles exhibi ting large luteal cyst formation were 
analysed with respect to the ultrasonic profiles in the immediate 
Period following the LH peak. 10 (33.3%) showed shrinkage, as defined
above, while the remaining 20 (6 6 .6 %) did not.
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E. Large cysts & P index
23 of the 30 cycles with large cyst fo rmation (76.7%) were found 
to have a low P index (<89.5) and these were compared with the 
remaining 7 cycles (23.3%) with normal P indices.
Table 5.1.1 shows the patient and cycle ch ar acteris ti cs (as 
defined in chapter 2 ) of the various sub-groups within the luteal 
cyst formation population. There was no significant dif fer ence 
between any of the groups, and when comparison was made with control 
data, apart from the age of the infertile group being greater, there 
was again no dif f e r e n c e  (Wilcoxon rank sum test).
A. Large (>20mm) & small (<20mm) cysts
Tables 5.1.2 to 5.1.11 detail the biochemical and ultraso nic
data relating to these sub-gro ups of cyst formers. The median, mean,
SD, SEM and 95% confidence limits are shox?n for E2 , P, LH , FSH and FD
measurements together with statistical significance, where found, in 
comparison be twee n the groups and also with the control data 
(Wilcoxon rank sum test). These values are g raphi ca lly ill ustrated in 
figures 5.1.1 to 5.1.5 where the median values for the hormones and 
the follicular diamete rs are plotted against the background control 
cycle medians.
E2 (Tables 5.1.2 & 3, Figure 5.1.1)
There was no signi ficant difference in E2 conc en trati ons between
large and small cyst formers, except for a slightly higher day 0 
level in the small cyst formers (235pg/ml compared with 196pg/ml (p 
<0.05))- Alth ou gh small cyst formers tended to have higher m i d — luteal 
E2 con centrations, these differences did not achieve statistical 
significance when compared with the >20mm group. Neither sub-group 
exhibited any si gnifican t difference compared to the control data.
P (Tables 5.1.4 & 5, Figure 5.1.2)
Both large and small cyst formers demonstr at ed s i gn if icantl y 
reduced P pr o d u c t i o n  in the early luteal phase compared with the
controls. More pro found reduction occurred in the group with cysts
>20mm diameter, reflected in their mar ke dl y reduced P index (median
66.0, control 100.0, p <0.001). Small cyst formers' P index was 84.0,
reduced compared to the controls' (p <0.05), though the difference 
between the cyst sub-gro ups did not achieve statistical significance. 
P production in the late luteal phase was similar in both groups 
though di ffere nces were observed between both groups of cyst formers
and the controls on days +11 and +12 (and +13 in the case of the
large cyst group).
LH (Tables 5.1.6 & 7, Figure 5.1.3)
Apart from a slight ly reduced peak value (median 42.5IU/1) in
the small cyst formers as compared to the large cyst formers 
(66.0IU/1, p <0.05), there were no differences seen between the 
groups. Day 0 levels were comparable in the control population and 
the small cyst group.
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F SH (Tables 5.1.8 & 9 , Figure 5.1.4)
Both  large and small cyst formers exh ibited minor differences in 
FSH co nc en t r a t i o n s  compared with controls, with FSH sec retion 
signi f i c a n t l y  higher in the raid/late-luteal phase (days +6 to + 1 0 ) in 
the > 2 0 m m  group. Over a similar period, in co mparison wit h the small 
cyst formers, there was no difference. In the latter's case the 
profile was not s ig ni ficantl y different  from the control profile. 
Minor d i f f erenc es  were seen in both the cyst groups, compared to 
controls, in the early follicu lar phase, with slightly elevated FSH 
concentrations and, altho ugh the levels were higher in the large cyst 
group, both populations of cyst formers were st a t i s t i c a l l y  similar.
FD (Tables 5.1.10 & 11, Figure 5.1.5)
A l t h o u g h  FD mea su rements  tended to be slightly lower in the 
group u l t i m a t e l y  forming luteal cysts > 20ram diameter, the differences 
between this group and the small cyst formers, as well as the 
controls, did not achieve statistical significance. Media n cyst size 
in the large cyst former group was 29.5mm and 16.0mm in the small 
cyst formers (p <0 .0 0 1 ).
Comment
Follicular function as assessed by plasma E2 measurem en ts and 
FD"s would appear to be similar in these two populations of cycles.
The slightly lower day 0 E2 levels seen in the large cyst formers was 
accompanied by a slight ly reduced FD on day 0, but the significan ce 
°f this finding is debatable since peak E2 (day — 1) concentrations 
were virtually the same in both groups.
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The g o n a d o t r o p h i n  differences are interesting in that FSH levels 
tended to be higher in the early follicu lar phase in both the groups. 
This mig ht  indicate a follicular  defect since FSH at this stage in 
the cycle mi ght  have some bearing on the eventual selection of the 
dominant follicle. High levels of FSH may be a c o m p e nsat or y 
ph enomenon  for a functio nal defect of the follicle, perhaps as a 
result of receptor  d e f i c i e n c y  and/or dysf unc tion, or might be 
consequent upon a lack at this stage in the cycle of a g on adotrop hi n 
suppressant compound e.g. inhibin, perhaps produced in normal 
ci rcu mstance s by the dev el oping  follicle, or as recent evidence 
suggests, the corpus luteun of the previous cycle. Impairment of 
inhibin sy nth esi s and or secretion in the luteal phase of the cyst 
formers may also account for the observed elevation in FSH at this 
time. Lu teal cyst formation could thus be int erpreted as a sequel to 
abnormal fo ll icu lar  development, as suggested by DiZerega and Hodgen 
(1981), though  U/S FD profiles were, in the present study, unable to 
discriminate between the normal and abnormal cycle prior to the LH 
peak.
P p r o d u c t i o n  was reduced in both cyst former groups. The lack 
was more profound  in the large cyst formers, though the difference 
between the sub-groups was only significant on day +5. P indices were 
not si gni f i c a n t l y  different. Some of the cycles with large cyst 
formation were associa ted  with normal P product ion and it would 
therefore seem that such a group does not represent a homogeneous 
population.
Current thinking with respect to the me ch anism of 
steroidogenesis in the corpus luteum (Carr et al 1981) suggests that
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granulosa  lutein cells require intimate contact with blood to take up 
the n e c e s s a r y  LDL precursors for luteal phase steroidogenesis. If 
reduction in size of the domina nt follicle represents a breach in the 
"blood fol lic le barrier" then study of cycles where dif fere nc es are 
seen in fol licu la r dynamics as assessed by ovar ian ultrasound at the 
p e r i o vula to ry period might provide va lu able insight into the 
pathogenesis of luteal phase defects.
B. S h r i n k e r s  & n o n - s h r i n k e r s  (all c ys ts)
Ta bl es  5.1.12 to 5.1.21 detail the bio chemi ca l and ultrasonic 
data rel ating to these sub-groups of cyst formers. The median, mean, 
SD , SEM and 95% con fidence limits are shown for E 2 , P, L H , FSH and FD 
measurements together with statistical significance, where found, in 
comparison between the groups and also with the control data 
(Wilcoxon rank sum test). These values are gra phical ly  illustrated in 
figures 5.1.6 to 5.1.10 where the median values for the hormones and 
the foll ic ul ar dia meters are plotted against the background control 
cycle med i a n s .
E2 (Tables 5.1.12 & 13, Figure 5.1.6)
E2 profiles were v i r t ually  identical in both groups and no 
differences were found in comparison with the controls.
P (Tables 5.1.14 & 15, Figure 5.1.7)
P co nc entra ti ons in the cycles where no shrinkage of the 
dominant follicle was seen following the LH peak, were profoundly 
reduced (median P index 53.5) compared to the control cycles (P
<0.001) and to the cycles where shrinkage of the follicle was 
observed (median P index 84.0, p <0.001). Al tho u g h  P concentrations 
were reduced in the cycles with shrinkage this differenc e did not 
achieve s tati st ical significance when c o m p a r i s o n  was made with the 
controls. P c o nc en tr ation s in the late luteal phase were greater in 
the study cycles compared to the controls be tw ee n days +11 and +13, 
but by day +14 basal levels were reached.
LH (Tables 5.1.16 & 17, Figure 5.1.8)
LH p r o d u c t i o n  was similar in the study groups and no differences 
were found in com par ison with the control cycle data.
FSH (Tables 5.1.18 & 19, Figure 5.1.9)
In those cycles where shrinkage of the follicle was observed,
FSH levels were found to be significantly higher in the early 
follicular phase (days -9 to -6) compared to the control data, and, 
in comparison to the non-shrinkage cycles, also tended to be higher, 
though this achiev ed statistical signif icance only on day -7. M i d ­
cycle levels were similar in both groups and the controls. In the 
luteal phase there were minor differ enc es in both groups compared to 
the controls and this was more pronounced in the cycles where no 
shrinkage was seen, with concentra tions  being sig ni ficant ly  elevated 
on days +6 to +10.
FD (Tables 5.1.20 & 21, Figure 5.1.10)
There was no differe nce between the two study groups in FD 
Profiles up to, and including, day 0. Divergence occurred from day +1
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onwards. The follicu lar phase profiles were similar in both groups to 
the control cycles. Me dian cyst size was sig nifi cantly  greater in the 
non-shrink ag e (33.0mm) compared to the shrinkage cycles (18.5mm, p 
<0.001 ) .
Comment
Cycles in which the FD profiles were destined to di ffer could 
not be pr e d i c t e d  on the basis of foll icular mat ura ti on as assessed by 
circulating E2 con cen tr ations or follicular growt h profiles.
C i r c u m s t a n t i a l  evidence that the different U/S profiles observed 
do represent abnormal phenomena derives from the associated subnormal 
P concen tratio ns  in the luteal phase.^ The nature of the differences 
lends support to the concept that follicular rupture is a nec es sity 
for efficien t P pr od uctio n in the luteal phase, and that the 
discrimination seen could perhaps represent two distinct 
pathophysiological events.
The folli cle s where no shrinkage occurs and where P prod uctio n 
is seriously impaired may represent the LUF syndrome. The other sub­
group, where some shrinkage (?rupture) was observed and with less 
impairment of steroid production, could be described as cycles with 
cystic corpus luteum formation. Neither of these phenomena were seen 
in the control cycles (chapter 2) nor in the cycles studied where 
conception occurred (chapter 3). The occurre nce  of a luteal phase 
cyst indicated a sub -fertile cycle, the nature of which could only be 
clarified by detail ed  study of pe ri -ovulat or y events and subsequent 
ovarian steroid biochemistry.
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A l t h o u g h  LH conce ntratio ns in the cyst formers did not differ
overall from the control data some cycles were found to be associated
with tonic al ly  high LH levels and may rep resent a m a n i f e s t a t i o n  of 
the PCO syndrome. This will be disc ussed  further in section 5.3.
The FSH data are interesting with the higher values in the early 
follicular phase in the shrinkage cycles seeming to discrim in ate this 
pop ula tion from the normal cycles. It is not apparent wheth er the 
differences in FSH productio n are a cause, or a conseque nce , of 
abnormal f o l l icular  developmen t in these cycles. Highe r FSH values in 
the luteal phase in the luteal cyst cycles were more pronoun ced in
the n o n - s h r i n k e r  sub-group than in the shrinkers and may represent an
increased res ist ance on the part of these CL"s to the g o nado tr ophin 
output by the pituitary, or a reduction in the synthesis and/or 
secretion of inhibin by the luteinised follicle, as.a consequence of 
cyst formation. Gon ad otrophi n output in both sub-groups during the 
peri-ovulatory period gave no clue to the cause of the striking 
differences seen, ul trason ically, subsequent to the LH peak.
Luteal cyst formation was analysed further to determ in e if the 
cycles where  P conce ntr ation s were found to be normal demonstr ated 
any dif ferences,  as a group, compared to the cycles where P profiles 
(P index) were deficient (<95% confidence limits of the normal 
range ) .
C. Normal P index & low P index (All cysts)
Tables 5.1.22 to 5.1.31 detail the biochemical and ultrasonic 
data relating to these sub-groups of cyst formers. The median, mean, 
SD, SEM and 95% con fidence limits are shown for E 2 , P, L H , FSH and FD
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m e a s u r e m e n t s  together with stati stical sig nificance, where found, in 
c om pa rison between the groups and also with the control data 
(Wilc oxo n rank sum test). These values are gra p h i c a l l y  illustrated in 
figures 5•1•11 to 5.1.15 where the me dian values for the hormones and 
the foll ic ul ar diam eters  are plotted against the backgroun d control 
cycle medians.
E2 (Tables 5.1.22 & 23, Figure 5.1.11)
Mi nor  diff er ences in E2 con cent ra tions were identified between 
the two sub -groups with slightly higher levels found, in the cycles 
associated with def icient P levels in the early luteal phase, on days 
+1 and +2 compared with controls, and on days +2 and +3 compared with 
normal P index cycles. In the remainder^ of the luteal phase, although 
E2 prod uc tion was higher in the low P index cycles, the diffe ren ces 
observed were not significant, and profiles were similar to the 
control data, except on day +13.
J? (Tables 5.1.24 & 25, Figure 5.1.12)
Striking diff erences were observed between the two sub-groups 
from day +2 onwards. Low P index cycles' diminis hed P production, 
compared with the normal P index cycles, was apparent throughout the 
greater part of the luteal phase, but levels were similar from +11 
onward s .
Normal P index cycles were found to have significantly greater 
levels of P pro d u c t i o n  compared to the control cycles from days +6 
until +12. In the late luteal phase (days +11 to +13) the low P index 
cycles were found to have slightly higher P levels compared with
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controls .
The median P index in the low P index group was 62.0 (control
100.0, p <0.001) and 101.0 in the normal P index group (no difference 
from c o n t r o l s ).
LH (Tables 5.1.26 & 27, Figure 5.1.13)
There was no diff erence observed in LH secretion  between the 
sub-groups, and both profiles were similar to the control data.
FSH (Tables 5.1.28 & 29, Figure 5.1.14)
Compared with the controls, the normal P index cycles' FSH 
concentrations were s i g n i fi cantly  higher in the early part of the 
follicular phase (days -10, -9, -7 and -6). Th ereafter, control and 
normal P index profiles were similar.
Low P index cycles were associated with reduced FSH sec retion in 
the early follicula r phase (days -9 and -7), compared to the normal P 
index cycles, but thereafter the two sub-groups had similar profiles.
Low P index cycles, in comparison with controls, were found to 
have slightly higher mid-luteal levels of FSH (days +6 to +10).
FD (Tables 5.1.30 & 31, Figure 5.1.15)
The normal P index cycles had slightly higher FD's on days -1 
and 0 compared with the low P index cycles, but in compariso n with 
the controls there was no difference.
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L a r g e  and small cyst formation was observed in both sub-groups. 
In the low P index cycles the dia met er of the cysts was greater 
(median 27.0mm) than in the normal P index cycles (median 20.5mm). 
This d i f f e r e n c e  was not s ta ti stical ly  significant.
C om ment
L u teal  cyst formation of all pr ev iousl y men tioned types i.e. 
large, small, shrinkers and non-shr inkers were seen in both the sub­
groups under  scrutiny, though the commonest pattern in the low P 
index group was that of a large cyst showing no evidence of 
shrinkage. Foll ic ular dynamics were similar in both groups prior to 
the LH peak  and together with-the similarities observed in E2 
profiles would suggest that discri mi nation between the two types of 
cycle canno t be made with these parameters alone.
The steroid output in the luteal phase, in the low P index 
cycles in particular, is interesting. The role of LDL as a precursor 
of P synth esis in the luteal phase has been alluded to. Di sr uptio n of 
a barrier be tween blood and the granulosa lutein cells seems 
necessary for the initiation and maintenance of corpus luteum 
function. The lag in P product ion observed in the low P index cycles 
could be explained by the failure, in many cases, of the granulosa 
cell layer to undergo neo-v as cu larisa ti on as a consequence of 
follicular rupture, or impairment of basement membrane disr uptio n of 
the gr anu los a and theca cell layers. Availabilit y of steroid 
precursors would thus be diminished. In cycles with a normal P index 
Availability of precursors in the early luteal phase cannot have been 
Affected, despite luteal cyst formation and provides evidence, as in
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the previous section, that limited ultras ound data of per iovulatory 
f ol lic ula r dynamics cannot d i sc ri minate a b s o l u t e l y  between normal and 
abnormal potential for steroid production.
In the mid to late part of the luteal phase P pro du ct ion in the 
normal P index cycles was found to be greater than in the control 
cycles. In the case of E2 the concent ra tions were similar to the 
controls, though i n s i g n ifican tl y lower than in the normal P index 
cycles. Study of g o n a d o troph in  secretion at this time revealed that 
the output of FSH, in the cycles with lower P pro duction, was greater 
than in the control cycles. The principle l u t e ot rophin  is thought to 
be LH but it is possible that FSH may play a sub ordi na te role 
(Hillier & Wicking s 1985). The finding of high FSH secre tio n in the 
low P index cycles could represent an attempt at compe ns ation for 
defective luteal function but the mediator between the ovary and the 
pituitary in this situation is unclear, since E2 levels were no 
different from normal cycle patterns and broadly similar to the 
cycles with normal P indices. The integrity of a barrier between 
blood and the gran ulosa lutein cells would require to be maintained  
throughout the luteal phase if P production was to be kept at a low 
level. Higher  P concentra tions observed in the low P index cycles 
towards the end of the luteal phase may represent an eventual breach 
in this barrier. It is possible that cystic CL"s have increased 
concentrations of steroid precursors stored and available for P 
biosynthesis once the cellular conditions are optimised, late in the 
luteal phase. It is also likely that ageing granulosa and theca cells 
behave d i f f e r e n t l y  from younger cells and may in part account for the 
differences in circulat ing P concentrations.
Higher than normal P productio n in the normal P index cycles is
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more dif fi cu lt to explain. Higher FSH c o n c e ntrat io ns were observed in 
these cycles and perhaps, as a consequence, may have led to an 
alteration  in the number of g o n a d o t r o p h i n  receptors in the follicle. 
Responses to the LH surge and the subse quent g o n a d o t r o p h i n  output by 
the pi t u i t a r y  might be mo difie d as a result. In these cycles it is 
possible that the b l ood— foilicle barrier is overcome in a way that is 
not dete c t a b l e  through ultrasound, and that steroid precursors can be 
metabolised at increased rates given the right pre-, peri- and p o s t ­
ovulatory conditions. The subtle aberr ati ons from normal in 
gonadotrophin secretion seen in these cycles are similar to the 
patterns observed in the analysis of cycles where cyst formation was 
associated with shrinkage of the dominant follicle following the LH 
pea k .
Lo w FSH secre tio n in the early follicular phase was not a 
feature in the profiles of the cyst formers and is in contrast to the 
data impl ic ating  this me c h a n i s m  in the path ogenesis of the deficient 
luteal phase (Jones et al 1970, Sherman & Ko re nman 1974a, DiZerega & 
Hodgen 1981, Cook et al 1983, Stouffer et al 1984).
Large cysts were almost three times as common as small cysts and 
the latter as a matter of course exhibited shrinkage. To determine 
whether the excl usion of the small cyst formers in the analyses might 
provide further insight in to the pathogenesis of disordered luteal 
function in these cycles similar comparisons to the above were made 
in the 30 cycles with large cyst formation alone.
D» Large Cysts ()>20mm) ~ shrinkers & no n— shrinkers
Tables 5.1.32 to 5.1.41 detail the biochemical and ultrasonic
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data re lat ing to these sub-groups of cyst formers. The median, mean, 
SD, SEM and 95% co nfidence limits are shown for E 2 , P, L H , FSH and FD 
m easur em en ts together with statistical si gnificance , where found, in 
com par ison between the groups and also with the control data 
(Wilcoxon rank sum test). These values are g r a p h i c a l l y  ill ustrated in 
figures 5.1.16 to 5.1.20 where the median values for the hormones and 
the fo ll ic ular diameters are plotted against the b a c k ground  control 
cycle medians.
E2 (Tables 5.1.32 & 33, Figure 5.1.16)
Pro fil es were similar in the sub-groups and exhibited no 
significant diff er ences when compared with the control data, although 
the large cyst* formers whic h exhibited shrinkage did demonst ra te a 
tendency to reduced luteal phase E2 production.
jP (Tables 5.1.34 & 35, Figure 5.1.17)
Co mp ar ison of the P profiles revealed profound difference s 
between the sub-groups. As described in analysis B, those cycles 
lacking evidence of follicular shrinkage after the LH peak were 
associated with marked reduction in P concent rations from days +1 to 
+8. As a cons eq uence  the P index was sig nificantl y reduced (median 
53.5) compared to controls (p <0.001) and to cycles where shrinkage 
was observed (median 90.0, p <0.001). The reduction in P productio n 
in the cycles with shrinkage did not achieve statistical significance 
in comparison with controls. In both sub-groups, late luteal P 
production was higher than the control data, significa ntly so on days 
+ 11 to +13.
LH (Tables 5.1.36 & 37, Figure 5.1.18)
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No signi fic ant diff erence was found be twe en the sub-groups, and, 
in c o m p a r i s o n  with the control data, profiles were again similar.
FSH (Tables 5.1.38 & 39, Figure 5.1.19)
As before, in the cycles where shrinkage of the follicle was 
evident and u l t i ma te ly P levels achieved v i r t u a l l y  normal 
proportions, the concentra tions of FSH in the early follicular phase 
were sl ig htly higher than normal; this was only stati st ically 
significant on days -9 and -7. The concen tr ation s were signif icantly 
higher than those in patients with no shrinkage on day -7.
In the mid to late luteal phase, althou gh shrinkage cycles had 
higher m e d i a n  concentration s than the non-shr in kage group, the 
differences observed did not achieve statistical significance. 
Interestingly, alt hough the levels were lower in the non-shrinkage 
cycles, when  com paris on was made with controls it was in these cycles 
only that the el evation in conce ntrations with respect to the control 
data achieved a degree of significance, a reflection of the small 
numbers and wide range of values in the shrinkage sub-group. These 
data present similar findings to section B.
FD (Tables 5.1.40 & 41, Figure 5.1.20)
Prior to the LH peak, FD profiles were similar in each sub­
group , and when  compared to controls no differe nce was observed.
Median cyst size in the shrinkage sub-group was 18.5mm, significantly 
smaller than that of the n o n — shrinkers (33.0mm, p <0.001).
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Commen t
The se data present similar trends to those revealed in section
B.
As befor e the E2 profile s and FD curves gave no clue as to the 
impending abn or ma lity in the u l t r a s o n i c a l l y  observed ovul ati on 
dynamics. P pr od uction by the corpus luteum was profo un dly impaired 
in the non -s h r i n k a g e  cycles suggest ing that follicular shrinkage was 
a prere qu is ite for efficien t steroid bios yn thesis  and release by the 
granulosa lutein cells.
6 of the 10 cycles (60%) showing shrinkage of the dominant 
follicle prior to cyst fo rma tion were associa ted with normal P 
production as opposed to only 2 of the 20 cycles (20%) where no 
shrinkage was observed (p = 0.007, Fisher's exact test).
It is interesting that luteal phase E2 release was normal in 
these cycles, the main site of this steroid's biosynth esi s probably 
being through a ro ma tisat io n of androgens, produced in the theca 
lutein cells, by the adjace nt granulosa lutein cells. Since the 
source of androgen may be within the theca lutein cell itself 
(Macnaughton et al 1981) breakdo wn  of the blood-fol lic le barrier may 
not be a necessi ty for E2 production, in contrast to the biosynt hetic 
pathway of P.
There is no doubt that in the human the lut eotrophic complex 
requires L H , but whethe r this is required alone or in concert with 
other factors is open to doubt. In both the sub-groups, FSH levels
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were found to be slightly higher than in the controls in the mid- 
luteal phase. It is possible that FSH is involved in the luteotrophic 
influence at this point in the cycle, acting on its receptor in the 
g r a n ul os a cell membrane. Inhibin con ce ntrati on s, in blood, have 
recently been found to rise in the luteal phase of the cycle (Baird 
1988) and, as before it is hypothesis ed that luteal cyst formation is 
associated w ith reduced conce ntrations  of inhibin and elevated FSH 
concen tr ations  as a consequence.
D i f f e r e n c e s  in FSH secretion in the early follicular phase were 
not as ma rked as in section B, but the co nc entrati on s in the 
shrinkers did tend to be slightly higher than in the cycles where no 
shrinkage was seen.
E. Large Cysts (>20mm) - Normal P index & Low P index
The cycles where large cyst formation was seen were subdivided 
in to those where normal P production was seen and those where the P 
index was low. These sub-groups were compared.
Tables 5.1.42 to 5.1.51 detail the biochemical and ultrasonic 
data relating  to the 30 cycles in these sub-groups of cyst formers.
The median, mean, SD, SEM and 95% confidence limits are shown for E 2 , 
P, LH, FSH and FD measurements  together with statistical 
significance, where found, in comparison between the groups and also 
with the control data (Wilcoxon rank sum test). These values are 
graphically illustrated in figures 5.1.21 to 5.1.25 where the median 
values for the hormones and the follicular diameters are plotted 
against the background control cycle medians.
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E2 (Tables 5.1.42 & 43, Figure 5.1.21)
C o n c e n t r a t i o n s  of E2 were similar in both sub-groups in the 
fol lic ular phase. Concen tration s were s l i gh tly higher in the luteal 
phase of the low P index cycles, but the dif fe re nces did not achieve 
sta tistical significance. Compared with the control data, apart from 
a minor e l e v a t i o n  on day +1 in the low P index group and a reduction 
on day +6 in the normal P index group, the sub-groups were broadly 
s i m i l a r .
JP (Tables 5.1.44 & 45, Figure 5.1.22)
The me dian P index in the normal P index group was 101.0, 
similar to the control cycles' data.
The low P index cycles' value (median 63.0) (by definition) 
represented a profound reductio n (p <0.001), and P c o nc en tratio ns  in 
this sub -g ro up were s i gn if icantly  reduced from days +1 to +8 compared 
to controls, and days +1 to + 9 compared with the normal P index sub­
group.
As in the previous analyses, P concentrations were found in 
these cyst formers to be higher than the control data in the later 
part of the luteal phase (days +11 to +13 in the case of the low P 
index group, and days +7 and +9 to +12 in the case of the normal P 
index group).
LH (Tables 5.1.46 & 47, Figure 5.1.23)
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Cycles with normal P indices exhibi ted no di fferences when 
compared with the control data, and with the low P index data.
The low P index cycles, when compared with controls, showed 
minor el ev ati ons on days +3, +5 and +9.
The conc entration s, in both sub-groups, were similar to those of 
the control data at the mi d-cycle peak.
FSH (Tables 5.1.48 & 49, Figure 5.1.24)
In _the follicular phase the normal P index cycles tended to have 
higher c o n c e n tr at ions of FSH than the low P index cycles, but the 
differences observed were not st atistically  significant. In 
comparison with the controls the elevation was si gnifica nt only on 
day -10.
Peak values on day 0 did not vary from normal.
In the luteal phase the low P index cycles had higher 
concentrations on days +6 to +10 when compared to controls, but when 
comparison with the normal P index cycles was made no differe nces 
could be found. The normal P index sub-group did not differ from the 
control cycle data.
FD (Tables 5.1.50 & 51, Figure 5.1.25)
In the low P index group the median FD's on days-1 and 0 were
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slightl y smaller than in the normal P index group. Overall cyst size 
was greater in the low P index group (median 32.0mm), though this did 
not achieve signific ance (median cyst size normal P index 24.5mm).
Compare d to the controls, the p r e — ov u l a t o r y  profiles were 
similar in both groups except for a minor red ucti on  in size on day -1 
in the low P index group.
18 of the 23 cycles d e m o n s t r a t i n g  no evidence of shrinkage 
(78.3%) were associa ted with defic ien t P production, while only 2 of 
the 7 cycles where P pro du ct ion was normal (28.6%) demonstrate d this 
ultrasonic pat tern (p = 0.025, Fisher's exact test).
Commeji t
The high pro po rt ion of cycles in the low P index group which 
were asso ciated with lack of evidence of follicular shrinkage is 
reflected in the deficient P profiles observed. This diffe rence is 
similar to that shown in section C where the 11 small cyst formers, 
all of whom  exhibited fol licular shrinkage, were included in the. 
analyses. In cl us ion of their data in the previous section would not 
appear to have biased the results.
5.1.4 General Discuss ion
Luteal cyst formation was found to be the commonest ultrasound 
abnormality de tecte d in this populat ion of patients with unexplained 
infertility, all of whom were investigated in spontaneous cycles. 41 
such cycles, 23.4% of the total investigated, have been described,
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prov idi ng su bstantial  bio chemical and u l t r as on ic data on such 
ab normaliti es, in a un ifo rm patient population, whi ch have, until 
now, been lacking.
The data prese nte d in this section of the study demonstr ate 
that, while there is a close relationship be t w e e n  ultras on ograph ic  
and hormon al assessme nt of luteal function, d e f i n i t i o n  of luteal 
phase a b n o r ma lities  requires consi de ration of b ioc he mical and 
ultrasonic indices together, rather than independ ently. Luteal cyst 
formation cycles do not represent a homoge neous population. The 
ultimate size of the cyst is not a sensitive indic ato r of the nature 
of the structure, or its effect on luteal function, and, while 
shrinkage of the domina nt follicle prior to cyst for mation is a major 
determining factor of the ste roidogenic poten tial of the luteinized 
follicle, it is not the only one.
At least two distinct populations of luteal phase cystic 
structures have been described. The first, where luteal function in 
terms of steroid pr od uctio n was maintained, and the second where 
markedly de ficie nt  proges terone in the periphera l plasma was evident.
In the study by Ham ilton  et al (1985), peak LH values were found 
to be reduced signif ic antly in the LUF patients, compared to the 
controls, and the suggestion was made that this might have played a 
role in the patho ge ne sis of the LUF syndrome. In su ffi cient data on 
spontaneously cycling patients with unexplained infert ility were 
provided in that study to permit comparison with the data in this 
section of the thesis. It would have been useful, as the present 
study has done, to assess gon ado trophin and steroid production 
serially in the early follicular phase, a time when normal ovulatory
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process es  might be determined, and to assess in detail the hormonal 
dynamics following the LH peak. In this way d i sc riminat io n between 
the pot ential sub-groups of luteal cyst formation, some representing 
the LUF syndrome, and some merely cystic corpus luteum formation, 
might be possible.
In a recent publication, Eissa et al (1987) used sequential 
ovarian ul trasound and serial b i o c h e m i s t r y  to study follicular 
functio n in 113 cycles in a heteroge no us group of 45 patients, 22 of 
whom had un explai ned infertility, the remai nde r having endometriosis 
or tubal disease. They described four d y sf un ctional  ultrasonic and 
biochemical patterns, including one group termed " L U F 11 cycles. This 
occurred in 22.1% of the series, and was cha rac terised by shrinkage 
of the domina nt follicle following the LH peak but maintenance of its 
cystic appear ance during the luteal phase. This pattern was 
associated with normal endocrine profiles, between days -8 and +8, 
and would seem to be comparable to the 11 cycles described in the 
present study where cyst size was found to be less than 20mm diameter 
(section A), seen in 6.3% of the 175 cycles studied. The small cyst 
formers in this study did, however, exhibit slight differences in FSH 
concentrations in the early follicular phase and P concentrations in 
the luteal phase in comparison with the controls.
Eissa's paper also described in 16 cycles (14.2%) a second type 
of cyst fo rma tion where a normal pattern of follicular growth was 
observed, though E2 concentr ations were low in the mid-cycle.
Following the LH peak no ultrasonic features of lut einisation were 
seen and the follicle continued to grow. This pattern was termed a 
"dysfunctional ovulation cyst" and was associated with low P 
concentrations up to the final day of sampling (+8). Gonadotrophins
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were normal. The ul tr asoni c pattern described would appear to be 
similar to that of the 20 cycles (11.4%) in the present series where 
no shr in kage of the dominan t follicle was seen following the LH peak 
(sections B & D). No di fferenc e in E2 concen tration s was seen in 
these cycles but P p r o d uctio n was ma r k e d l y  reduced for the reasons 
hypothe si sed above. FSH co ncentr at ions in contrast were found to be 
higher in the mid to late luteal phase. Eissa did not observ e any of 
the sub- group  with large cyst formation, seen in 1/3 of the cycles 
described here, where ex pansio n of the follicular structu re occurred 
following signs of shrinkage at the time of the LH peak.
A strong as soc iation has been shown between the o b s e rva ti on of 
shrinkage of the follicle and efficient P production, while the 
failure to observe follicu lar shrinkage was associated with m a r ke dl y  
deficient luteal function. It might be postulated, therefore, that 
the ultr a s o n i c  patterns represent, in the case of the luteal cyst 
formers wi thout shrinkage, the LUF syndrome, and in the remaining 
cyst formers with some evidence of shrinkage, cystic corpus luteum 
formation. These hypotheses are in contrast to those of Eissa et al , 
as it is tempting to equate u l trasoni ca lly observed follicular 
shrinkage with follicle rupture.
It is possible that the two groups presented here may not be as 
distinct as their ultrasonic and biochemical patterns might suggest. 
The process of ovum release may not always be consequ ent  upon 
ultrasound observed follicular shrinkage (Craft et al 1980, Stanger & 
Yovich 1984) and ovum entrapmen t may have occurred in some of the 
Cycles where shrinkage of the dominant follicle was observed. 
Conversely, in some of the non— shr inking cyst formers, it is possible 
that a di mi nutio n in size of the follicle might have been missed in
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the pe rio ds  between ultr asonic observations. This type of error was 
kept to a mi ni mu m by the endeavour to scan patients evey day over the 
p e r i o v u 1 atory  period, but it is possible, since the processes of 
f o l l ic ul ar rupture, as observed u l t r a s o n i c a l l y , take place over a 
re lativ el y short period of time (de Crespigny et al 1981), that some 
overlap of the two groups of cycles occurred.
Th es e patterns were seen neither in the control cycles (chapter 
2) nor the co nc ept ion cycles (chapter 3), and it could be argued that 
such d i s c r i m i n a t i o n  may only be of academic importance since both 
variants may represent infertile cycles.
D e f i c i e n c y  of FSH secretion was not, as others have suggested 
(Sherman & Kore nm an  1974a & b, Jones et al 1970, di Zerega & Hodgen 
1981, Cook et al 1983, Stouffer et al 1984) found in these cycles. 
Indeed it was found that cycles more often associa ted with normal P 
pr oduction were found to have slightly increased FSH output in the 
early fol licul ar  phase. Those with deficient P prod uction could not 
be disti n g u i s h e d  from the controls. Some have suggested that an 
approach to treatment of the LUF syndrome could be to stimulate 
gonadotrophin secretion in the early part of the cycle through use of 
anti-estrogens, or to administer exogenous gonadotrophins. These data 
would not appear to support this concept.
In summary, luteal cyst formation has been shown not to be 
uniform in its presentation. Study of ul trasonic and plasma P 
profiles can di st i n g u i s h  several distinct groups of abnormalities, 
some of whi ch  may represent the LUF syndrome and others merely cystic 
corpus luteum formation.
SECTION 5.2 POOR PROG E S T E R O N E  SURGE (PPS)
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5.2.1______ Def Ini tion
The normal luteal phase profile of P co nce n t r a t i o n  in plasma has 
b e e n  ou tl ined in chapter 2.1. From very low levels prior to the LH 
peak, there is a steady increase in co nc en tratio ns  until a plateau is 
re ached bet we en  days +5 and +8, with co nc entrati on s at this time 
ijelng betw een 17.0ng/ml and 19.1ng/ral. Ther eafter  co ncentrat ions fall 
s t e a d i l y  until the onset of menstruation.
In a high proportion of the cycles under study the rise in 
pl as m a  P conce ntr ation s was observed to be slower than in the normal 
cyel-es. Where  the co ncentration s in the study cycle between days +1 
and -+5 were found to be more than one standard de viatio n below the 
tnormal mean on two or more days, the cycle was described as 
d e m o n s t r a t i n g  a "poor prog esterone surge (PPS)".
5..2 .2______ Analysis
51 (29.1%) of the 175 cycles under study were found .to 
demonstrate PPS profiles.
The median  age of the PPS patients was 30 years (range 22 to 40 
years) w h ich  was greater than that of the control po pu lation  (p 
<0.001). Follicular phase length ranged from 8 to 27 days (median 15 
days), while median luteal phase length was 15 days (range 11 to 18 
days). (See Table 5.2.1). These cycle c h a r a c t e r i s t i c s ^  as .defined in 
chapter 2, did not differ sig nificantly from the control data.
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Tables 5.2.2 to 5.2.6 detail the bio chemica l and ultrasonic data 
relating to the PPS cycles. The median, mean, SD, SEM and 95% 
confidence limits are shown for E 2 , P, L H , FSH and FD measurements, 
together with  statistical significance, where found, in comparison 
with the control data (Wilcoxon rank sum test). These profiles are 
g r a p h i c a l l y  illustrated in figures 5.2.1 to 5.2.5 where the median 
values for the hormone co ncentrat ions and the follicular diameters 
are pl otted against the background control cycle medians.
E2 (Table 5.2.2, Figure 5.2.1)
In the early follicular phase plasma E2 conc entration s tended to 
the lower end of the normal range, and were s ignif ic antly reduced, 
compared to the control data, between days -5 and -1. The media n peak 
E2 level (day -1) was 205.0 pg/ml.
The E2 c o n c e ntratio n coincident to the day of the LH peak (day 
0) was w i t h i n  the normal range.
The profile in the luteal phase was similar to that of the 
control cycles' and, although median conce ntrat ions were high on days 
+11 to +13, the differ ences observed did not achieve statistical 
signif i c a n c e .
P (Table 5.2.3, Figure 5.2.2)
P c o n c e n tr at ions were dram aticall y reduced for the greater part 
of the early to mid-luteal phase. The differen ces observed achieved 
statistical signifi cance on days +1 to +8. The impairment of steroid 
production by the corpus luteum, which justified the PPS definition,
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was re fle cted in the signifi cant re duc tion in the P index (median
61.0, control 100.0, p <0.001).
On days +11 to +13, P con centra ti ons were slightly higher than 
the normal range, but were comparable by day +14.
LH (Table 5.2.4, Figure 5.2.3)
M e dian  plasma LH co nc entrations tended to be at the upper end of 
the normal range throughout the cycle. This tendency was more 
noticeable in the luteal phase and a sig nificant d i f f er en ce was seen 
on days +5 and +7. Peak LH c o n c e n tration  did not differ from normal. 
As the high SD's indicate, a fairly wide range of c o ncen tr ations was 
observed.
FSH (Table 5.2.5, Figure 5.2.4)
Concentr at ions of FSH were sig nifi cantl y elevated on days -10,
-6 and -3. In the remainder of the follicular phase, values tended to
the upper limit of the normal range.
Median peak concentration (day 0) did not differ from normal 
but, in the luteal phase, the observed tendency to high 
concentrations was significant from days +4 to +10.
FD (Table 5.2.6, Figure 5.2.5)
Until the LH peak (day 0), FD profiles were found to follow a 
linear grow t h  pattern, at the lower end of the normal range. This 
bore a resembla nce to the lowish E2 profile already described.
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Although the observed d iffere nc e in diameter on day -1 was 
st a t i st ically significant (median 18.0mm, control median 20.0mm, p 
<0.01), the m a x imum follicu lar  size seen on day 0 (19.0mm) was 
similar to that of the control population.
Fo ll ow ing the LH peak, 23 (45.1%) of the PPS cycles demonstrated 
luteal cyst fo rmati on (viz. section 5.1). The ma jo rity of these (18 
(78.3%)) followed the pattern, pre viously described, of cyst 
formation without shrinkage of the dominant follicle. The remaining 5 
(21.7%) elabo rated a pe r i o v u l a t o r y  pattern of follicular reduction in 
size followed by luteal cyst formation. 20 of the cysts (87.0%) were 
greater than 20mm. Media n cyst size was 30.0mm (mean 31.5mm, SD 
10.9mm, SEM 2.3mm).
51 PPS cycles
cyst formers 23 (45.1%) 28 (54.9%) no luteal cyst
Shrinkers 3 (13.0%) small
Non-shrinkers 18 (78.3%) 20 (87.0%) large
Ill
5.2.3_______D is cu ssion
The incidence of PPS in the p o p u lati on  of unexplained 
i n f e r t i l i t y  patients under ex am i n a t i o n  is similar to that described 
in p r e l i m i n a r y  work carried out in the same labo rator y (Fleming et al 
19 81). V i r t u a l l y  all the cycles exh ib ited a mid -lut ea l plasma 
c o n c e n t r a t i o n  of P in excess of the "normal" ovu lato ry  criteria 
demanded by previous studies using single (Israel et al 1972, Shepard 
et: al 1 977 , Hull et al 1 982 , Abdu lla et al 1 983 ) and limited multiple 
(Abraham et al 1974) sampling techniques. The data presented would 
suggest that such m e t h o d s  are likely to miss, in a similar 
3>DpuJ.ation, a cons iderable number of abnormal cycles.
l e n t o n  et al (1978) in a small study found similar early luteal 
? p r o f i l e s  in infertile women but did not examine the follicu lar 
dynamics of such patients using ultrasound.
The implica tions for the fertility of the cycle de monstratin g 
? ? S would appear to be considerable. Koninckx et al (1978) observed, 
in a p o p u l a t i o n  of women with une xplained infertility, a high 
Incidence of delay in the onset of lutei ni sation determi ned by 
elevation in BBT, as compared to infertile patients with tubal 
occlusion. It was postulated that this was a ma ni f e s t a t i o n  of the LUF 
syndrome, since a high proportion of the patients de mo nstrating 
delayed lutein i s a t i o n  lacked a punctum on the corpus luteum when 
subjected to laparoscopy. The pattern of a slow rise in P 
'Concentrations seen in the present study would support the concept of 
defective lute in is ation  in the peripd imm ediately following the LH 
peak and the obse rva tion of such a high incidence of luteal cyst 
formation, most of which were of the type suggestive of unruptured
112
follicles, would lend credence to the h y p o t h e s i s  that the process of 
LUF, in a d d itio n to impedence of oocyte release (Aksel 1987), may 
also affect en do metrial receptiveness to the implanting blastocyst 
(Wentz 1982, Ku sud a et al 1983). A d i s t u r b a n c e  such as this might 
have pr of ound im pl ica tions for the suc ces sf ul c ontin ua tion of 
pre gnancy beyond the first few weeks of g e s t a t i o n  (Soules et al 1977, 
Tho et al 1979, Annos et al 1980) (viz. ch apter  2).
F o l l i c u l a r  phase determinants of abnorm al luteal function, in 
particular dimi ni shed gonadotr ophic stimula ti on, have been alluded to 
previously (Sherman & Korenm an 1974a, Sto uf fer & Hodgen 1980, Aksel 
1980, D i Z e r e g a  & Hod ge n 1981, Gautray et al 1981, Cook et al 1983). 
McNatty et al (1975) observed that an absence of an intercycle 
increase in FSH was often associated with luteal inadequacy. This was 
not the case in the cycles under study where the FSH concentrations 
tended to the upper limit of the normal range. It is possible that 
this refle cted an attempt by the h y p o t h a 1a m o - p i t u i t a r y  axis to 
compensate for a defi ci ency within the follicle since E2 production 
in the cycle was slightly low, sig nif icant ly  so in the late 
follicular phase. Previous work suggesting that this abnormality
might be of central origin (Gautray et al 1981) must now be re-
>
evaluated carefully. !
It is well recognised that FSH is the stimulus to the antral 
follicle"s p r o l i f e r a t i o n  of granulosa cells (McNatty et al 1975, 
Breitenecker et al 1978, Marut, Huang & Hodgen  1983) leading to the 
eventual d o m i n a n c e  of a single follicle from which the ma jor it y of 
the cir cula ti ng  E2 is produced (Baird & Fraser 1974). Altho ug h the 
follicular gr owt h profiles in the PPS cycles did not differ markedly 
from normal, save on day — 1, the E2 and FSH data suggest that the
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do minan t follicles recruited in these cycles could have been 
abnormal, accounting for subs equent endoc ri ne dysfunction, in many 
cases associ ated with luteal cyst formation.
Soules et al (1984) reported abnor ma lities of pulsatile LH 
secretion  in patients de mon s t r a t i n g  L P D , associated with slightly 
diminished  secretion of FSH in the early follicu lar phase. The 
pulsatili ty  patterns of LH release were not evaluated in the present 
study, but the fact that FSH co ncentratio ns were higher in the PPS 
group would suggest that these pote nt ially represent a different 
population of cycles from those in the cited studies with low FSH 
output. The LH profiles in the PPS cycles showed a wide variat io n  
with m e d i a n  concentra tions lying in the upper range of normal. In 
some cases the conce ntrations  were quite high and these cycles are 
included in the analysis in the next section.
Marut et al (1983) observed in primate studies that removal of 
the gr a n u l o s a  cells from pre-o v u l a t o r y  follicles produced diminished 
corpora lutea cha racterised by decreased P secretion. The granulosa 
lutein cells would therefore seem to be the predominant source of P 
production. However, they observed that luteal E2 production, despite 
the lack of granulosa cells, seemed adequate, and concluded that E2 
in these cycles emanated pr in cipally from luteinised theca cells.
This would be in accordance with the observ ations of M a c n a u g h t o n  et 
al (1981) who alluded to the likely differi ng  cellular pathways of E2 
and P pr od u c t i o n  in the luteal phase. In respect of the data 
presented here, it would seem to offer an explan ation for the 
normality of luteal E2 concentration s in cycles with markedly  
deficient P production. Taking into account the data presented in the 
previous section, there could be two variants of PPS. The first where
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luteal P pr o d u c t i o n  is dim inish ed  through lack of functional 
g r a n ul os a cells as reflected in the above data where follicular phase 
E2 co nc en t r a t i o n s  are low with compens at ory high FSH secretion. The 
second form of deficient early luteal P p r o d uc tion could be where, 
through failure of the blood follicle barrier to be broken down, as 
in the n o n - s h r i n k i n g  luteal cyst formers, the necessar y precursors 
are not made ava ilable to granulosa lutein cells, present in normal 
amounts as reflected in normal follicular phase E2 concentrations.
These data may have important implications for theraputic 
strategies in these patients. In the cycles where LPD might be due to 
a follicu lar abno rmali ty  then stimulating these abnormal follicles 
with endoge no us  or exogenous gonado tr ophins  is unlikely to meet with 
success. On the other hand if therapy could achieve breakdown  of the 
blood-follicle barrier in the second type of cycle, perhaps with 
exogenous go na do troph in s, as in the Glasgow approa ch (Fleming et al 
1982, Fleming et al 1987), then the chances of success might be 
fairly good.
It was intere sting to note that, of the 51 PPS cycles, only 2 
(3.9%) were ass ociated with a short luteal phase, 11 days in length 
in both cases (SLP = luteal phase length of 11 days or less (Smith et 
al 1984)) .
SECTION 5.3 HIGH LH
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5 . 3 .  1______ Defi ni ti on
The normal cyclical pat tern of LH se cretion  by the pituitary has 
been outlined  in Chapter 2.
Cycles de si gnate d "high LH" were defined on the basis of the 
proportio n of samples in the follicula r phase of the cycle with LH 
concentrati ons greater than normal. Where more than 50% of the values 
in either the follicular phase were more than 2 SD above the normal 
mean, then the cycle was regarded as demon s t r a t i n g  a "high LH" 
p r o f i l e .
5.3. 2______ Analysis
23 (13.1%) of the 175 cycles demonstra ted high LH profiles.
3 of the total demo ns trated biochemical features of anovulation, 
with cycle lengths of 22, 22 and 30 days respectively. Plasma E2 
concentrations remained below 145 pg/ml throughout the period of 
sampling and P concentrations did not rise above basal levels at any 
stage. LH co ncentrat ions were consiste ntly high throughout, with 
virtually all values being in excess of 20mIU/ml. No surge in 
concentration, sufficient to constitute an LH peak, was observed. FSH 
concentrations were in the normal range in these cycles, save that no 
peak was observed. Ultrasound exa mination revealed follicular 
structures in all 3 cycles, from the 8th day of sampling through 
until the onset of menstruation. These, once visualised, usually
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remai ned  static in terms of size and echogenicity,  ranging from 15.0 
to 2 5 . 0 m m  diameter.
The remai nin g 20 high LH cycles con sti tute the basis for the 
bio ch em ical and u lt rasoni c data presented.
T a bl e 5.3.1 shows the age and cycle ch ar ac teristi cs , as defined 
in chapter2, of these 20 patients. The age of the patients was 
similar to that of the control cycles, but the d u r atio n of the cycle 
was ra ther greater in the high LH group, largely due to lengt hening 
of the fol lic ular phase of these cycles. The range of fol licular 
phase leng th was considerable (11-29 days), with 4 patients having a 
follicular length in excess of 20 days.
Ta ble s 5.3.2 to 5.3.6 detail the biochemical and ult ra so nic data 
relating to the high LH cycles. The median, mean, SD, SEM and 95% 
confidence limits are shown for E 2 , P, L H , FSH and FD meas urements  
together with the statistical significance, where found, in 
comparison with the control data (Wilcoxon rank sum test). These 
values are g r a p hi ca lly illustrated in figures 5.3.1 to 5.3.5 where 
the m e dian values for the hormones and the fo ll icular dia meters are 
plotted against the background control cycle medians.
E2 (Table 5.3.2, Figure 5.3.1)
In the follicular phase E2 concentrations were reduced, 
significantly so between days -4 and -1. Median day 0 co nc entration 
did not di ffer sig nifican tl y from the control data althou gh the value 
(192.5 pg/ml) lay at the lower end of the normal range.
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No sign ifi cant deviations from normal were seen in the luteal 
phase, except on days +11 and +13 when the E2 concentrations were 
slightly higher in the high LH cycles.
^  (Table 5.3.3, Figure 5.3.2)
The rise in P concentrat io n in this group of cycles was found to 
be slow, with concentrat ions s i g n i f i c a n t l y  lower on day +4. This 
pattern was reflected in* the sig nificant reduct io n in med ia n P index
(71.5) compared with the controls (100.0, p <0.01).
Late luteal P concentrations were highe r than in the control 
data on days +10 to +13.
Ev id en ce of premature lute.inisation (P concent rations >1.5 ng/ml 
on day 0) was found in 4 cycles (20%). 3 of these cycles had very 
high earl y luteal P concentrations (P indices of 121, 157 and 158). 
None showed ultrasonic evidence of multiple follicular develo pment or 
luteinisation prior to the LH peak, though one of these cycles was 
associated w it h a luteal cyst, 25.0 mm diameter. The cyst showed 
evidence of shrinkage (see section 7.3.1). The other cycle showed 
premature l u t e i n i s a t i o n , with a reduced P index (50), and dev eloped a 
54mm luteal cyst, with no shrinkage.
LH (Table 5.3.4, Figure 5.3.3)
. 18 of the 23 high LH cycles (78.3%) were found to have elevated 
concentrations in both the follicular and the luteal phase of the 
cycle. The remaining 5 cycles (21.7%) exhibited high LH only in the 
follicular phase of the cycle.
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Having excluded the anov ulatory  cycles, all of whom had high LH 
c on ce ntrations throughout the period of blood sampling, it was noted 
that, despite high basal LH conc entration s, the chara c t e r i s t i c  LH 
peak was still ide ntif iable  in the remaining 20 cycles. The peak, as 
evidenced by the medi an LH con ce ntrati on  on day 0 (75.0 IU/1), was 
not attenuated.
The cycles with premature lute ini satio n included 1 cycle with 
elevation only in the follicu lar phase (P index 157), while the 
others dem onst ra ted high LH throughout.
By the end of the luteal phase (+12 to +14), LH co nc entrations 
were indi s t i n g u i s h a b l e  from the control cycles.
FSH (Table 5.3.5, Figure 5.3.4)
Apart from a minor eleva tion on day +9, the c o n c e ntrati on  of FSH 
throughout the cycle, including the day of the FSH peak (day 0), was 
indistinguishable in the high LH group from the control cycle data.
FD (Table 5.3.6, Figure 5.3.5)
As a group, the high LH cycles demonstrated reduced FD's on days 
-2 and -1 but the median diameter on day 0 was 21.0mm, no di fferent 
from the controls.
Looking in more detail at the individual cycles, a high
Percentage demonst ra te d ul tr asonically abnormal ovarian function 
(16/23 (69.6% of all high LH cycles), 13/20 (65% of the "ovulatory"
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cycles)). These are listed below :
a) Ano vula tion, as alr eady alluded to, was observed in 3 
c y c l e s .
b) Luteal cyst formation  was seen in 8 cycles. Cyst size 
ranged from 22-54mm diameter (median 31.0mm).
5 of the cysts failed to show eviden ce  of shrinkage and all 
of these had P indices below the 95% confidence limits
(89.5) of the normal data (range 29-72, me dian 50). The 
remaining 3 cyst formers d e mo ns trated  shrinkage, and had P 
indices of 86, 120 and 157.
8 of the 12 cycles where no luteal cyst format ion was 
evident had low P indices (median 66, range 36-85) while 
the remaining 4 cycles without cyst formation had P indices 
of 94, 96, 121 and 158.
c) Poor follicular devel opment (see section 7.3.4) was 
observed in 3 cycles. 1 of these cycles also demonstrated 
luteal cyst formation (30ram, n o n - s h r i n k e r , P index 60).
d) 1 cycle demonstra ted an unusual follicular diameter profile 
wit h  an FD of 20.5mm on day -4. This represented a 
me a s u r e m e n t  in excess of 3 SD above the normal mean. The FD 
was found to be 24.0mm on day — 1 and 25.0mm on day 0. 
T h e r e a f t e r  normal corpus luteum formation was seen with a 
high P index of 158. P conce ntration on day 0 was 1.8 
ng/ml , indicating that premature 1utei nisatio n had
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o c c u r r e d .
e ) 1 cycle was found to dev elop a d o m inant follicle which
achie ved  ma ximum  f ol li cular d i a m e t e r  2 days prior to the LH 
peak. This d i s s o c i a t i o n  was a s s o ci at ed with a slightly 
reduced P index (86), but not cyst formation.
5.3.3 Dis c u s s i o n
Fl eming  et al (1981) first drew att e n t i o n  to the finding, in a 
small numbe r of women with unex pl ained infertility, in addition to a 
pattern of early luteal P deficiency, an associated el evation in the 
co nc en tratio n of L H , par ti cularly  in the follicular phase. The data 
presented here provide ^an insight in to the frequency of the 
phenomenon, in a large population of patients with unexplai ned 
infertility, and provide original inf ormation on the follicular 
dynamics in these abnormal cycles.
That the pathogenesis of LPD may be linked to ab normalities of 
pituitary sec retion of gonado trophin s has been suggested for some 
time, with the emphasis on defi cienc ies in production of FSH. Jones 
et al (1970) speculated that the cause of reproductive failure in 
some o v u l a t o r y  patients was defective patterns of release of 
gonadotrophins, in particular FSH, but observed that in some cases 
(Jones 1976) the adequacy of the LH surge was an important factor in 
determining luteal function. Sherman .and Korenm an (1974) did not 
find, in the small number of cycles they studied, any evidence of 
abnormal LH secretion but, as others were to confirm later in primate 
studies (Stouffer and Hodgen 1980, Dizerega and Hodgen 1981, Stouffer 
at al 1984) and in infertile women (Aksel 1980, Cook et al 1983),
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reduct ion  in FSH se cretion with a res ultant high LH : FSH ratio, can
often lead to sub se qu ent luteal dys function, reversible with 
a d mini st ra tion of exogenous g o n a d o tro ph ins in the follicu lar phase 
(DiZerega and H o d g e n  1981). These data sug gested that reduction in 
follicular phase FSH lead to an impairment of the e xpress io n of LH 
receptors dur ing f o l l i c u l o g e n e s i s , i r revers ib ly altering ovarian LH 
r e s p o n s i t i v i t y , resul ting in defective luteal function. In these and 
other studies (Lenton et al*, 1 978 , Lenton et al 1982), including 
women with u nexpl ai ned infertility, a bn or mally high LH secretion  has 
not been described.
In the high LH group described here, low E2 produ ct ion was seen 
in the late fol licul ar  phase, with an associate d slight reduction in 
FD prior to the LH peak , ^though day 0 E2 and FD were within the 
normal range. FSH concentr ations were normal. Luteal function in the 
group as a whole was impaired and, since LH co ncentrati ons were 
abnormally high in the follicular phase of these cycles, it might be 
speculated that the imbalance in go nadotroph in secretion may have 
modified the ex pr e s s i o n  of FSH and LH receptors on the granu losa  
cells of the follicle. The response to the LH surge could thus have 
been modif ied with  the induction, as a result, of luteal phase 
deficiency.
As the ultrason ic data reveal, the nature of LPD in these cycles 
was not uniform. Luteal cyst formation was seen in 40% of the cycles, 
most of whi ch were of the type demonstrating no shrinkage of the 
follicle. 66.6% of the cycles with no evidence of cyst formation, 
however, also dem onst rated LPD. Gonadotrophin conc entration s in 
cycles d e m o n s t r a t i n g  the LUF syndrome have not been found, in the 
Past, to be abnormal  (Konninckx et al 1978, Konninckx and Brosens
122
1982). Recen t studies, descri bi ng u l t r a s o n i c a l l y  observed luteal 
phase cysts in patients with u ne xp lained in fer tility (Hamilton et al 
1985, Eis sa et al 1987), possibly ana lagous to the LUF syndrome, have 
not allu ded to abnormalities of LH secre tio n in the, relative to the 
present study, small numbers of patients under examination.
It has been dem onstrated (McNatty et al 1975, Mc Natty & Sawers 
1975) that FSH is a necessary component in the prepar at ion of the 
antral follic le for production of E2 and the p r e - o vulat or y production 
of P u n de r the influence of LH. They suggested that ab nor malities of 
luteal f u n ct ion might arise through the inte rference by LH during the 
growth of these follicles under the influence of FSH. Later work 
(McNatty et al 1979) established a relatio nship between FD and the 
number of gra n u l o s a  cells, and that antral follicular E2 and FSH 
levels were d i r ec tly related to the resumption of oocyte meiosis in 
vitro. If, as is possible, tonically high LH concentr ations alter the 
endocrine mic ro en v i r o n m e n t  of the follicle, then it is possible that 
this could affect the potential fertility of the cycle, irrespecti ve  
of the qu ality of luteal function subsequent to the LH peak. There is 
some evi de nce from IVF studies that patients with raised basal LH 
levels du ring the follicular phase of treatment achieve reduced 
fertilization rates and it is possible therefore that this may be a 
reflection of the disturbances alluded to here (Stanger and Yovich
1985) .
The m e c h a n i s m  whereby high LH concentr ations obtain in these 
cycles remains obscure. In cycles demon strating LPD, signif icantl y  
greater LH pulse frequency has been observed in the early follicular 
phase (Soules et al 1 984 ) but,in the small number of cycles studied, 
the absolute plasma concentrations of LH did not differ from normal.
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Interestin gl y,  FSH conce ntratio ns in these cycles were found to lie 
within the normal range, albeit at the lower end. This is in contrast 
to a study on patients with polycystic ov arian disease where no 
specific ab no r m a l i t y  in the pulsatile release of LH was found (Molloy 
et al 1984). Most of these patients however pre sented with 
o l i g o m e n o r r h o e a  rather than normal menstrual rhythm.
That po lycystic ov arian disease may be associa ted with  high LH 
levels is well known (Duignan 1976). Some patients with the condition 
may, in addition to features of dist urbed gona d o t r o p h i n  secretion, 
manifest u l t r a s o n i c a l l y  demo nstra ble structural ovarian abnormalities 
- multi p l e  small cysts with an increase in ovarian stroma (Adams et 
al 1985). These were not a feature in the patients in this study.
Patients with polycys tic ovarian disease may also have disturbed 
menstrual patterns, often with prolongati on of the follicular phase 
of the cycle. 4 of the high LH series (20%) described here had 
follicular phase lengths in excess of 20 days. In the 175 patients 
studied in total only 9 cycles (5.1%) were found to demons trate a 
prolonged follicular phase (p = 0.03, Fisher's exact test). These 
cycles will be described in section 7.5. The low incidence of long 
follicular phase length in this population of unexp lained infertility 
is similar to the expected distribution  of phase length in the 
normal p o p u lati on  (Lenton et al 1984) but the disturbed endocrine and 
ultrasonic profiles demonstrated in this group of cycles illustrate, 
as others have, the high potential for infertility these 
circumstances create (Sherman and Korenman 1974a, Balasch et al
1986).
The 3 an ov ulatory cycles, all in patients with normal menstrual
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rhythm, com prising only 1.7% of the total popu la tion of unexplained 
in fertility, may, as has been suggested (Aksel et al 1976), represent 
a severe form of LPD. Aksel's series included a d esc ri ption of 5 such 
cycles, 3 of which were found to be ass ocia te d with high LH 
concen tra tions. Laborde et al (1976) observ ed that a significant m i d ­
cycle rise in LH does not guarantee that ov ulatio n or luteinisatio n 
will d e f i n i t e l y  occur. In this series, none of the "aluteal" cycles 
demonst ra ted a rise in plasma L H , at any stage in the cycle, above 
the tonically elevated basal concentrations.
T h e r a p e u t i c  choices in these patients revolve around the need to 
improve the quality of ovu lation and luteal function, avoiding the 
potentially deleterious effects of premature luteini sa tion and 
hyperstimulation. One approach might be to utilise a GnRH analogue to 
suppress the endogenous levels of LH and thereafter to stimulate the 
ovary with  exogenous gonadotrophins. This app ro ac h has already been 
used in Gl a s g o w  in the treatment of patients with unexplained 
infertility and normal menstrual rhythm, who have demonstrated  an 
early luteal pattern of PPS in the presence of normal LH 
concentrations. Experience has also been gained in the use of this 
combination to treat o 1 igomenorrheic women with high LH 
concentrations and polycystic ovarian disease and, compared to the 
use of exo genous go nadotrophi ns in isolation, a good response has 
been achieved, with a reduced incidence of premature luteini sation 
(Fleming et al 1985, Fleming et al 1987). It would be interesting to 
see what the responses to such an approach would be in the patients 
described above, with normal menstrual rhythm but tonically high LH 
concentrations. Since FSH concentrations were normal in these cycles 
it would seem un likely that clomiphene citrate would achieve much, 
but perhaps the use of P (Rosenberg et al 1980), particularl y in the
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cycles whe re no luteal cyst formation is found, would be an option 
for con sid er ation.  However, as alluded to above, it is possible that, 
even if oocyte release occurs, the f e r t i 1 i z a b i 1 ity of the egg may 
have b een j e o p a rdise d early in the foll icular phase, irrevoca bly 
impeding fertility.
SECT ION  5.4 POOR FOLL IC ULAR M A T U R A T I O N
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5 . 4 .  1______ Def initions
In ke ep ing with previous biochemica l observa ti ons in patients 
with u n e x p l a i n e d  infertility (Dodson et al 1975, Fleming et al 1981), 
a small p r o p o r t i o n  of cycles were found to manife st  deficient  ovarian 
function in the follicular phase of the cycle. This took the form of 
reduced f o l l icular phase E2 con centr at ions or, in some cases, FD 
profiles c u l m inat in g in maximum diameters b e lo w the normal range.
Poor f o l l ic ular ma turation refers to those cycles where more 
than 50% of the plasma E2 concentrations, b e t wee n days -5 and -1, 
were b e low the 99.9% confidence limit of the mean of the control 
cycles, for the same period.
Poor folli cu lar develo pment refers to those cycles where 
follicular d i a met er  on day 0 was found to be less than the 99.9% 
confidence limit of the mean of the control cycles on that day i.e. 
<17.1 mm diameter.
5.4.2 Ana ly si s
16 pat ie nts demonstrate d poor follicular mat ur ation (PFM) and 
the patient det ails and cycle charact erist ics are listed in Table 
5.4.1. M e d i a n  follicular phase length was 15.5 days, while median 
luteal lengt h was 16.0 days, both slightly greater than the control 
data. The patients, as in the other infertile groups were slightly 
older than the controls.
127
In 12 cycles, the FD on day 0 ful filled the diagno stic criteria 
of poor fo llicular dev el opment (PFD) and the cycle cha rac teris tics 
for this group of patients are presented in Table 5.4.2. An age 
d iffer en ce  was observed, but the phase lengths were similar to the 
controls .
Ta bles 5.4.3, 5.4.5, 5.4.7, 5.4.9, & 5.4.11 detail the 
bi och emical and ultr asonic data relating to the PFM data, while those 
data re lating  to the PFD subgroup are shown in Tables 5.4.4, 5.4.6, 
5.4.8, 5.4.10, 5.4.12. The median, mean, SD, SEM and 95% confidence 
limits are shown for E 2 , P, FSH, LH and FD measurements, together 
with sta ti st ic al significance, where found, in comparison with 
control data (Wilcoxon rank sum test). These profiles are gra phic al ly 
illustrated in figures 5.4.1, 5.4.3, 5.4.5, 5.4.7 & 5.4.9 for the PFM 
cycles, and figures 5.4.2, 5.4.4, 5.4.6, 5.4.8 & 5.4.10 for the PFD 
cycles. M e d i a n  values for the hormone concentrations and the 
follicular di ameters are plotted against the background control cycle 
medians.
E2 (Tables 5.4.3 & 4, Figures 5.4.1 & 2)
In the PFM sub-group, E2 concentrations were observed to be 
significantly lower than the controls throughout the follicu lar  
phase, and for the greater part of the luteal phase. Peak 
concentrations were achieved on Day 0 (165.0 pg/ml), the day of the 
LH peak, followed by a precipitous fall, rising again, in a similar 
fashion to the m i d — cycle rise in normal cycles, and eve nt ua lly 
achieving levels within the normal range from day +10 onwards.
The "PFD cycles also exhibited a lower than normal E2 profile but
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the o b s erved  dif ferences achieved statistical signi ficance only on 
days -6, +2, and +5 to +9 inclusive. The me di an  concen tr ation of E2 
on day 0 (195.0 pg/ml) was within the normal range.
jp (Tables 5.4.5 & 6, Figures 5.4.3 & 4)
P con ce ntrati on s in the early luteal phase in both groups were 
sub-normal but only in the PFM cycles did this achieve significance 
in terms of the P index (67.0, controls 100.0, p <0.001)
Bot h  the PFD and the PFM cycles de mo n s t r a t e d  supranormal P 
concentrations in the late luteal phase.
FSH (Tables 5.4.7 & 8, Figures 5.4.5 & 6)
The PFM cycles were associated with normal FSH profiles in the
follicular phase, with a mid-cyc le surge similar to that of the
controls. In the mid-luteal phase, concen tr ations  were slightly 
higher (days +5 to +7, +9), but were normal thereafter.
The PFD cycles exhibited slightly higher FSH concentr ations on 
days -6, -5 and -3. Peak concentration s on day 0 were also higher 
than the norm and this elevation was sustained until day +8. In the
late luteal phase concentrations were normal.
LH (Tables 5.4.9 & 10, Figures 5.4.7 & 8)
Apart from minor deviations in the case of the PFM cycles on 
days -4 and +1, LH con centrations were normal throughout in both 
groups •
i
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FD (Tables 5.4.11 & 12, Figures 5.4.9 & 10)
The small numbers of cycles in each sub-group  is reflected in 
the wide confide nce  limits seen. On the whole the FD measurem ent s 
tended to lie below the normal range in the p e r i — ovulatory  period.
Day 0 m e d i a n  FD in the PFM group was 16.0 mm, and 15.0 mm in the PFD 
g r o u p .
Luteal cyst fomation was seen in 1 cycle in the PFD group (size 
30mm, n o n - s h r i n k e r , P index 64) (this cycle also dem onstrated  high LH 
described in section 7.3.3), and 3 cycles in the PFM group (size 20, 
22 & 54mm, shrinker, non- shrinke r & n o n - s h r i n k e r , P indices 94, 33 & 
50 respectively).
5.4.3 Di sc ussion
5 of the PFD sub-group had scans on day +1 wh ic h demonst rat ed 
FD's lying wi thi n the normal range. It could be argued that inclusion 
of these cycles in the analysis would bias the E2 concentrati ons 
upwards in the group, but when these cycles were removed the E2 
profiles remained similar :
Nos Med ian Mean SD SEM Range
Day -3 7 135 155. 6 70.7 26.7 100-308
Day -2 7 150 176.6 69.2 26.1 120-325
Day -1 7 190 220.9 63. 5 24.0 150-313
Day 0 7 200 190.1 37.1 14.0 120-225
Day + 1 7 105 104 . 3 34.0 12.8 45-140
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E2 produc tio n, in the follicular phase of the cycle, is 
dep en de nt on gran ulosa  cell aro matase activity, which has been shown, 
in in— vi tr o studies on human cells, to be greates t in the period 
im me d i a t e l y  prior to ov ulation (Hillier 1981). Since follicular 
dia meters in the PFM group desc ribed here were found to be 
si gni f i c a n t l y  reduced in the days prior to the LH peak, it is 
probable that the observed reduction in aroma tase activity, 
as soc iated with low plasma E2 con centra ti ons in these cycles, is 
consequent upon a reduction in the total pop ula ti on of granulosa  
cells in the dominant follicle.
E2 co n c e n t r a t i o n s  in the PFD group, alt ho ugh a little lower, 
were not sign i f i c a n t l y  different from the control data. Median FD in 
this gro up on day 0 was profou ndly reduced (15mm, p <0.001). These 
data w o ul d therefore suggest that FD and gr anulosa  cell numbers 
cannot be the only de te rminant of aromatase activity at this stage in 
the cycle. Fol lic ular phase FSH concentrations in this group were 
higher than in the controls, in contrast to the cycles with a PFM 
profile. This may indicate in some cases, an attempt, at the level of 
the hyp ot h a l a m u s  and pituitary, perhaps mediated through feedback 
mechanisms, to compensate for sub-optimal follicular development.
Since the reg ul at ion of granulosa cell aromatase activity has been 
shown to be FSH dependent, those cycles with dominant follicles 
which, al t h o u g h  small, are associated with normal plasma E2 
concentrations and elevated FSH concentrations, may well be 
demonstrating a form of granulosa cell "rescue", with normal or even 
enhanced aro ma tase activity. It could be hypothesised  that the 
elevation in FSH might be a consequence of a reduction in the amount, 
or bioactivity, of an inhi bin— like peptide produced by these 
follicles. Conversely, the normal FSH concentrations, observed in
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some cycles with small do min ant follicles, may be conseq uent upon 
normal p r o d u c t i o n  of an inhibin-like peptide by these follicles, and 
the low E2 c o ncentr at ions seen may be the end result of failure, on 
the part of the h y p o t h a l a m o - p i t u i t a r y - o v a r i a n  axis, to compensate for 
abnormal fol li cu lar development. Higher luteal phase FSH 
co n c e n t r a t i o n s ,  seen p ar ticula rl y in the PFD cycles, may also be 
con se qu ent upo n impaired inhibin prod uc tion or se cretion  by the 
granulo sa  lut ei n cells of the corpus luteum in these cycles. As 
specific assays for this peptide become available, further insight 
may be ga ine d into the pat h o p h y s i o l o g y  of these a b n o r maliti es  of 
ovarian function.
E2 c o nce nt rations  in the luteal phase were simil arly depressed 
in both groups, as were P con centrations, though in both cases this 
was mor e m a r k e d  in the PFM group. In some cases this was associated 
with luteal cyst formation (seen in 3 of the PFM and 1 of the PFD
cycles). The possible me ch ani sms for reduced s t e r o i do genesis  in these
circums tan ces have already been discussed (section 5.1). In the 
absence of cyst formation, it is possible that the di minished steroid 
production was a result of reduced populations of gran ul osa cells, 
and de c r e a s e d  expression of LH receptors on the surface of the cells. 
Defective lut einisa ti on would be an inevitable co nsequence  of these 
pre-ovulat ory conditions. In contrast to the data of DiZ erega  and
Hodgen (1981), low FSH concentr ations in the follicular phase were
unusua1.
T o n i c a l l y  elevated LH con centrations were seen in 3 of the PFD 
cycles ( s e ct io n 5.3) and the observed increase in the length of the
follicular phase of the group as a whole may be a con sequence of 
this. Despite this, plasma LH concentrations, in both the follicular
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and the luteal phase, were normal in both groups.
D e f e c t i v e  follicular d evelo pm ent has pr eviously been diagnosed 
on the basis of reduced plasma conce nt rations  of E 2 . As has been 
shown, poor follicular d e v e l op me nt can be asso cia ted with E2 
c o n c e n t r a t i o n s  not s ig nifican tl y dif ferent from normal, and 
c o n s i d e r a t i o n  of the follicu lar phase g o n a d o t r o p h i n  patterns, 
together with the ultrasoni c profiles before and after the LH peak, 
are essent ia l to clarify the pathological processes involved if 
optimal thera peu tic strategies are to be devised. Four circumstances 
bear c o n s i d e r a t i o n  :
i . Small follicle, E2 low, FSH normal
The use of clomiphene citrate to enhance endogenou s production 
of go n a d o t r o p h i n s  might prove efficacious in these cases. As has 
been hypothe sised , inhibin-like activity in these cycles may be 
normal, and the failure of the pituitary to respond to the low 
E2 con cent ra tions in plasma requires to be overcome.
ii. Small follicle, E2 normal, FSH high
Since E2 prod uction by these follicles is normal, probably as a 
cons e q u e n c e  of the elevated FSH secretion by the pituitary, it 
could be argued, that since physiological com pen satio n has taken 
place, no treatment is necessary. Ho wever,the  fact that FD is 
well below  the normal range, and luteal function is depressed in 
these cycles indicates that, despite these adjustments, ovarian 
function is not normal. Further enhancement of g o nadotr op hin  
s e c re ti on  with clomiphene citrate might increase follicular 
phase E2 production but whether the dominant follicle would 
respond in terms of FD, granulosa cell proliferation, and
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s ub se quent improved luteal phase steroid production is less 
certain, since the poor follicular de vel opment in these cases 
may signify an inherent defect within the follicle itself, 
beyo nd rescue by external influences.
i i i . Small follicle, high LH
As alluded to earlier (section 5.3), high LH con centrat io ns may 
interfere with oocyte quality and po ss ibly be associat ed with 
prem at ur e luteinisation. Combined treatment involving down- 
re g u lation  of the pitui tary and subsequen t ovarian stimul ation  
wi t h  exo genous go na do trophin s may lead to improved follicular 
dev elo pmen t,  reduced chance of pr ema tur e lut ei nisati on  and 
improved luteal function. P sup ple mentation, in isolation, might 
not be exp ected to achieve success since, even if ovula tion 
occurs in these cycles, the potential f e r t i 1i z a b i 1 ity of the 
oocyte is in doubt.
iv. Small follicle, luteal cyst formation
Three of the 4 cysts observed were of the category which showed 
no evidence of shrinkage, possibly therefore repr ese nting the 
LUF syndrome (see section 5.1). In these circumstances, in a 
similar fashion to the approach described above, abolitio n of 
en dog enous control of follicular development with long acting 
GnRH analogues and subsequent HMG therapy may well be the best 
approach. The observations that follicular development was sub- 
optimal and, in addition, the LH surge was not attenuated would 
suggest that expressio n of granulosa LH receptors in these 
cycles would be low and, consequently, one could not expect 
a d m i n i s t r a t i o n  of hCG to achieve an improvement in the ovulatory 
mechanism. P therapy would confer no therapeutic benefit in
these c y c l e s .
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SE CTION 5.5 A B N O R MAL IT IES OF CYCLE PHASE LENGTH
5.5.1 D ef initi on s
The cycle c h ar ac teristi cs  of the control population under study 
have been discuss ed earlier (chapter 2), and were found to lie within 
fairly narr o w  limits. The 175 patients with un explain ed infertility 
had simi lar follicul ar and luteal phase lengths : 
follicular - mean  14.4 days, SD 3.5 days, SEM 1.1 days 
luteal - mean 14.6 days, SD 1.6 days, SEM 0.1 days.
The short luteal phase (SLP) has been defined by most 
authorities as a luteal phase (the number of days following, but not 
including, the day of peak LH concent rations until the day of onset 
of s ub se quent menses) of less than 12 days. Lento n et al (1984) in an 
exhaustive analysis of over 300 cycles in ap pa rently ovu lating women 
found the lower 95% probabilit y limit of luteal length in their study 
population to be 11.3 days. In the infertile population under study 
here the lower 95% pr obability limit (1.96 x SD) of luteal length was 
11.4 days and so it would appear that the populations are comparable. 
In this analysis, a cycle was taken as exh ibiting  a SLP if luteal 
length, as defined above, was 11 days or less.
Le nt on  et al (1984) in their studies also examined the variation 
in the lengt h of the follicular phase of the cycle. They defined the 
follicular phase length as the number of days up to, but not 
including the day of peak LH concentrations. The lower 95% pr obabilty
limit of this substantial population was 10.3 days. In the present
study the d ef in ition of follicular length included the day of the LH
Peak, and the lower 95% probability limit of the infertile population
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was 7.6 days. Only 2 cycles in the entire study exhibited a 
fol li cu lar phase length less than this (6 days in both cases). In 
ke eping therefore with the data of Lenton et al (1984) a short 
f ol l i c u l a r  phase (SFP) was desi gnate d if the durat io n of follicular 
length was 10 days or less.
The upper 95% pr ob a b i l i t y  limit in Lent o n  et al^s data for 
fol lic ular phase length was 20.5 days, while the figure in the 
present study was 21.2 days. Few cycles in this study exhibited a 
fol lic ular length greater than 21 days and in order to provide a 
substantial enough group for analysis, an ar bit rary distin ction 
between normal and abnormal was made at 20 days follicular phase 
length. Thus a long foll icular phase (L F P ) cycle was defined as one 
with a follicula r length of 20 days or more.
Of the 175 cycles under study, 6 (3.4%) were found to 
demonstrate a short luteal phase. There were 9 cycles with a long 
follicular phase (5.1%), and 6 (3.4%) d e monstr at ing a short 
follicular phase.
5.5.2 Analysis (short luteal phase)
The patient and cycle characteristi cs of the SLP cycles are 
shown in Table 5.5.1 with  the biochemical (plasma E 2 , P, LH & FSH) 
and u lt ra sonic  data in Tables 5.5.2 to 5.5.7. Since small numbers 
were involved the mean, S D , SEM, median and ranges are shown rather 
than the 95% confidence limits. These data are graphi cal ly 
represented, in a similar fashion to that of previous analyses, in 
figures 5.5.1 to 5.5.5, with the median values plotted against the 
medians of the normal cycles. Significant differences, in com paris on
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with  the controls (Wilcoxon rank sum test), are shown on the relevant 
tables.
The m e d i a n  age of the SLP patients was 33 years, sig ni ficant ly  
older than the control cycles (median 26 years, p <0.001). Luteal 
phase l e n g t h  varied between 9 and 11 days (median 10.5 days, controls 
15.0 days, p <0.001) with an associa ted  reduced me di an overall length 
of the cycle (25.0 days, controls 29.5 days, p <0.01).
E2 (Table 5.5.2, Figure 5.5.1)
T h e r e  were no significant di fference s in E2 concen trations  
throughout the cycle in comparison with the controls, with peak 
con centr at io ns seen on day -1 (median 283.0 p^/ml). Luteal levels 
peaked on +7, similar to the control cycles, but fell sharply 
thereafter. In one cycle the E2 con ce ntrati on  on the day of menses 
was 200 pg/ml (P con cent ratio n on this day was 1.5 ng/ml).
£ (Table 5.5.3, Figure 5.5.2)
The ear ly part of the luteal phase in these cycles was similar 
to that of the control cycles with a steady rise in plasma P 
concentrations up until day +5. The P index, although slightly 
decreased (median 77.5), was not significant ly different from the 
normal range. From day +6 onwards, P concentrations fell, with the 
onset of m e ns tr uatio n,  in all cases, coincident to P concentrati ons 
of 1.5 ng/ ml or less.
LH (Table 5.5.4, Figure 5.5.3)
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No si gnifica nt dif fere nc es were seen with respect to LH 
concen tr ations . Although the me dian day 0 peak c o n c e ntratio n was 
slight ly reduced, the observe d d if ference  did not achieve statistical 
signif i c a n c e .
FSH (Table 5.5.5, Figure 5.5.4)
FSH conce ntrat io ns in the SLP cycles were i n d i s t i ng ui shable  from 
the normal  cycle data.
FJD (Table 5.5.6, Figure 5.5.5)
M e d i a n  FD followed a linear course similar to the control 
cycles. M a x i m u m  FD was seen on day 0 when the me dian FD was 22.0 mm. 
Only one of the cycles d em on strated  luteal cyst forma tion and this 
was a small cyst (16mm diameter, P index 89).
5.5.3 Comment
The low incidence of SLP (3.4%) would suggest that this 
phenomenon is an extremely uncomm on occurence in women with
unexplained infertility. The incidence of cycles with luteal phase
length of less than 11 days in fertile women has been shown to lie
between 5 and 9% (Lenton et al 1984, Smith et al 1984) and
consequently it would appear that this phenomenon is unlike ly  to be a 
major c o n t ri buting  factor to the continuing inf ertility of the 
couples in whom it is identified. The rigid met ho dology  in the 
Present study, incorporating daily blood sampling in all cycles,
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would suggest that the observed incidence of SLP is accurate, since 
cervical mucus assess men ts and m ea sureme nt  of BBT, used in some 
studies, are relativ ely inaccurate methods of pi npointing the onset 
of the luteal phase (Templeton et al 1982, Le nt o n  et al 1977).
Sherman et al (1974) defined the short luteal phase in the 4 
cycles they studied as having a duration of <10 days. In contrast to 
the data pre sen te d above, they found reduced plasma levels of E2 in 
the fo l l i c u l a r  phase with a subnormal peak E2 concentr ation, together 
with reduced con cen tr ations of FSH. P con ce ntrations, in their 
series, were reduced throughout the luteal phase in contrast to the
above data where the pattern in the first five days following the LH
peak was similar to normal profile. E2 concentrat ions, in contrast to 
the present series were found to be sub-normal in the luteal phase.
Smith et al (1983) in a study of 20 cycles with luteal lengths 
of <12 days found similar E2 concentrations to the present study but, 
in contrast to the present data, found a number of cycles of apparent 
short luteal le ngth where P concentrations were high at the time of 
menstruation. All patients described above menstrua ted when P 
concentrations were 1.5 ng/ml or less, so it would appear that none 
complied with the hypothesis that, in some cases of SLP, the
abnormality of luteal length represents endometrial dysf unctio n
manifest as prema tur e menstruation  in the presence of normal plasma P 
concentrations, rather than early demise of the corpus luteum.
Fleming et al (1981) observed subtle abnormalit ies of PRL 
secretion, in the periovu latory period, in 4 out of 5 cycles with 
luteal phases of less than 11 days. PRL was not assayed in the 
Present study and it may be that some of the cycles described may
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have had similar profiles. The role of PRL in LPD remains unclear 
(see chapter 1) and further wor k  is required in this area.
W h e t h e r  these cycles, al t h o u g h  abnormal, were truly infertile is 
debatable , since p r e — ovu lator y follicular dynamics, and luteal 
f u n c t i o n  in the immediate p o s t — ovulatory period, were normal. It is 
not clear what the cause of premature luteolysis is in these cycles. 
Central (hypothal am ic or pituitary), ov ari an or uterine factors could 
be in volved  leading to a distu rb ance in the balance of luteotro phic  
and l u t e ol yt ic factors (Baird 1985). Con cep ti on and consequent 
i n t e r a c t i o n  betwee n the embryo and the corpus luteum might be an 
important, though as yet ill understood, mechanism wher eby infertile 
cycles mig ht be "rescued" and rendered poten tia lly "fertile". The 
fact that SLP cycles are seen with similar frequency in fertile and 
infertile popul ations (Smith et al 1984) is evidence that the 
reproductiv e implicatio ns of this phenomenon are not perhaps as 
serious as have pr ev iou sly been thought.
5.5.4 Ana lysis  (Long fol licul ar  phase)
The patient and cycle cha ract er istics of the 9 LFP cycles are 
shown in Table 5.5.7 with the biochemical (plasma E 2 , P, LH & FSH) 
and ultr a s o n i c  data in Tables 5.5.8 to 5.5.12. The mean, SD, SEM, 
median and 95% confidence limits are shown and these data are 
graphically represented, in a similar fashion to that of previous 
analyses, in figures 5.5.6 to 5.5.10, with the median values plotted 
against the medians of the normal cycles. Significant differen ces , in 
comparison with the controls (Wilcoxon rank sum test), are shown on 
the relevant tables.
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The med i a n  age of the LFP patients was 27 years, similar to that 
of the control cycles (median 26 years). M e di an follicula r phase 
length (25 days) was, by def inition, grea ter than the controls (14 
days, p <0.001) but luteal phase length was similar.
E2 (Table 5.5.8, Figure 5.5.6)
Plasm a E2 con ce ntrat io ns were similar, in both the follicular 
(days — 10 to 0) and luteal phases, to the control data. Median  peak 
concentration on day 0 was 220.0 pg/ml. There was a minor devi ation  
from the norm on day +12 but conce ntratio ns the rea fter were 
indisting uishab le  from the controls.
P (Table 5.5.9, Figure 5.5.7)
P co nc en t r a t i o n s  in the early luteal phase, a l t ho ug h reduced, 
did not differ s i gnifica nt ly from the control cycles. The median P 
index was 83.9.
In the late luteal phase (days +11 to +13) the LFP cycles had 
slightly higher P concentra tions than the controls.
LH (Table 5.5.10, Figure 5.5.8)
LH c o n c e ntra ti ons in the follicular phase were found to be 
significantly elevated on days -9 to -4, -2 and -1. Peak 
concentrations (day 0) were normal, and in the luteal phase no
deviations from the norm were encountered.
FSH (Table 5.5.11, Figure 5.5.9)
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A l t h o u g h  tending to the lower end of the normal range, plasma 
FSH co n c e n t r a t i o n s  were not differen t from the controls throughout 
these c y c l e s .
FD (Table 5.5.12, Figure 5.5.10)
The fol lic ular phase FD profile was in dis ti nguisha bl e from the 
controls wit h media n day 0 FD 21.0mm. In 1 of the 9 cycles (11.1%) 
luteal cyst formation was observed. In this instance the cyst was 
32mm diame ter, showed no evidence of shr inkage following the LH peak, 
and was asso ciated  with marked reduction in P concentrat ions in the 
early luteal phase (P index 29).
5.5.5 Comment
The le ngt h of the follicular phase has been alluded to in the 
context of the cycles with high LH co nce ntr ations (section 5.3). Of 
the 9 cycles with LFP patterns, 4 demonstra ted high LH profiles, 
accounting for observed increase in LH conce ntr ations in the group as 
a whole. FSH concentra tions in the group were at the lower end of the 
normal range and the mechanism  for delay in initiation of follicular 
growth and rise in plasma E2 concentration s in cycles with normal 
gonadotrophin con centrations remains obscure. Central problems, such 
as a b n o r maliti es  in the GnRH pulse regulatory mechanism in the 
hypothalamus, or ovarian disturbances, such as delay in the 
expression of appropriate receptors on the granulosa cell surface 
could be involved. It is possible that circums tances in the luteal 
Phase of the preceding cycle, such as a dim inut io n in gonadotr ophin
143
c o ncen tr at ions,  perhaps se c o n d a r y  to high E2 p r o d uc ti on by the corpus 
luteum of that cycle, might cause a depleti on in the pool of 
dev e l o p i n g  follicles reaching the final stages of g r o w t h  preparatory 
to the last days of ex p a n s i o n  leading to ovu lation (Baird et al 
1975). As a result fol li cular recruitment to ovul at ion might take 
longer than the normal cycle. Study in successive cycles might have 
shed some light in this regard.
B a l as ch et al (1986) observed that de ficient luteal function, as 
assessed through endome tri al biopsy, was found in almost 40% of 
cycles with follicular lengt h in excess of 20 days, four-fifths of 
whom had normal plasma P concentrations. The authors used the BBT in 
order to determine the time of ovulation, and it is possible that 
this may have led to an imprecise assessment of the endometrial 
specimens obtained. Luteal phase length in their study was not 
affected by the p ol on gation  in the follicular phase, and is in 
agreement with the o b s e r vations  in the present study. 3 of the 9 
(33.3%) cycles were found to demonstrate poor progester one surge, and 
one of these cycles d e mo nstrate d luteal cyst formation. Thus, 
although some authors have suggested that fertility bears little 
relation to follicular phase length (Broom et al 1981, Aksel 1981), 
the observe d reduction in P concentrations would appear to be a 
manifestation of abnormal luteal function, with impaired fertility, 
perhaps se con dary to a dis turbed endometrial environment, a probable 
consequence of this. However, the fact that the m a j ority of LFP 
cycles dem on strat ed  normal luteal function, and the group as a whole 
accounted for only 5.1% of the total unexplained infertile 
population, would suggest that this form of disturbed ovarian 
function is of minor importance in the genesis of infertility.
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The o b s e r v a t i o n  that FD profiles, in all but one case, and 
fo l l i c u l a r  phase E2 concen trations were normal in these cycles would 
suggest that, to a signi ficant degree, these patients' continued 
in f e r t i l i t y  is a function of the reduced frequenc y with which 
o v u l a t i o n  occurs, as much as the lik elihood  of any associated 
d i s t u r b a n c e  in the hormonal environment.
5.5.6 Analysi s (short follicular phase)
The patient and cycle ch ar acteristi cs of the SFP cycles are 
shown in Table 5.5.13 with the biochemical (plasma E 2 , P, LH & FSH) 
and u l t r a s o n i c  data in Tables 5.5.14 to 5.5.18. Since small numbers 
were in volved the mean, SD, SEM, median and ranges are shown rather 
than the 95% confide nce limits. These data are grap hically 
represented, in a similar fashion to that of previous analyses, in 
figures 7 . 3 . 5 . 1 1 . to 7.3.5.15, with the m e di an  values plotted against 
the m e d i a n s  of the normal cycles. Signi ficant differences, in 
comparison with the controls (Wilcoxon rank sum test), are shown in 
the relev ant tables.
As with most of the other sub-fertile groups, the age of the SFP 
patients was greater than the controls (median 32 years, controls 26 
years, p <0.01). Follicular phase length, by definition, (median 8 
days) and cycle length (median 23.5 days) were si gn ifi cantly reduced 
(controls 14 days (p <0.001), 29 days (p <0.001)).
E2 (Table 5.5.14, Figure 5.5.11)
Al t h o u g h  E2 concentr ation s were reduced in the luteal phase and 
peak foll icula r phase concentrations were seen on day — 2, the
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d i f f e r e n c e s  from the controls did not achieve statistical 
s i g n i f i c a n c e  .
Jp (Table 5.5.15, Figure 5.5.12)
P concen t r a t i o n s  in the early luteal phase were lower than the 
control cycles, but the di fference only achieved statistical 
sig ni fi cance  on day +4. The P index was also lower than normal 
(median 79.0) but this differe nce was not s tatist ic ally significant. 
On days +11 and +13 the concentra tions were higher than the controls. 
2 of the 6 cycles exhibited a PPS profile.
LH (Table 5.5.16, Figure 5.5.13)
In the follicular phase, LH co ncent ra tions tended to be slightly 
lower than the control cycles with the differe nces observed achieving 
significance on days -7, -4 and -3. The LH peak was signifi ca ntly 
reduced in the group as a whole (median 37.8 IU/1, controls 73.5 
IU/1, p <0.001). In the luteal phase co ncent rations were normal 
throughout.
FSH (Table 5.5.17, Figure 5.5.14)
Co n c e n tra ti ons of FSH were sig nific antly higher in the luteal 
phase (+2 to +11) in the SFP cycles. Peak con centrations (day 0), 
although higher, did not differ signi ficantly from the controls. 
Follicular phase concentrations were normal.
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FD (Table 5.5.18, Figure 5.5.15)
FD's in this small group of patients did not show any 
d i f f er en ces from normal with median m a x i m u m  F D , on day 0, 19.0mm. 
Luteal cyst formati on  was observed in one cycle (23*5ram, n o n — 
shrinker, P index 25).
5.5.7 Comment
As wit h the SLP cycles it is difficult  to make de finitive 
conclusions about the nature of the pa thophy si ologica l processes, if 
any, oc c u r r i n g  in these cycles. Events in the preceding cycle may 
have had an imp ortant influence on the sub sequent bi ochemic al and 
ultrasonic profiles observed, namely the striking ele vation of FSH in 
the days after the LH peak, in assoc iat ion with reduced E2 
concentrations, and re latively normal P concentrations. The principle 
source of E2 in the luteal phase of the cycle is the theca lutein 
cells of the corpus luteum (Baird et al 1975, Mac naugh to n et al 1981) 
while P de rives from the granu losa lutein cells (Carr et al 1981).
The elevated  FSH con centr at ions might reflect an attempt at 
compensation for a pre-d etermined  follicular abnormality resultant in 
quantitative and/or qualita tive alteration in the balance of these 
two types of cell. No evidence for this exists in the literature. 
Alternatively, high FSH concentrations may reflect reduced luteal 
phase in hi bin concentrations,  consequent upon follicular abnormality.
Despite the brevity of the follicular phase, E 2 , FSH and FD 
Profiles were normal. LH concentrations, however, were lower and it 
®ay be that expres si on of receptors in the theca layer of these 
follicles was impaired. Granulosa cell receptor expression, however,
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may have been normal and, as a result, respons ive to the mid-cycle LH 
surge, w h ich in the group as a whole was sub-normal. The abnormality 
in LH sec re ti on could reflect a central d istu rb ance in the pulsatile 
release of GnRH. Further wo r k  in this area would be a fruitful avenue 
of re searc h into the u n d e r s t a n d i n g  of the pat ho ph y s i o l o g y  of these 
subtle a b n o r ma li ti es of ov arian function.
In summary, cycle phase length abn ormali ti es are rare in 
patients with un exp lained infertility, only accounting for between 5 
and 10% of the patients in this study. D istur ba nces in ovarian 
function may be encountered in these sub-groups but the ma jority of 
cycles are found to elaborate almost normal biochemical and 
ultraso nic  profiles. Whether such "abnormalities'' invoke a reduction 
in fer ti li ty potential is uncertain, though und ou bt edly in individual 
cycles profou nd  devi ation s from the normal can be seen, which are 
likely, in these cases, to be a major influence on the chances for 
successful conc eption in that particular cycle. Since only a small 
prportion of patients with  unexplained in ferti lity dem ons tr ate such 
phase le ngth abnormal ities, it is probably unnecessary, unless the 
phenomena recur, to treat these patients on the information gained in 
a single cycle of investigation.
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C HA PTE R 6 CYCLE TO CYCLE V A R I A T I O N  IN O V A R I A N  FUN CT ION
6.1 I n t r o d u c t i o n
A w e a l t h  of data now exists in the l ite ra ture desc ribin g 
a b n o r ma lities  of ovarian function in patien ts wi t h  i n f e rtil it y and 
claims are made that such variations from normal are causal factors 
of the pat ient s"  infertility. Genuine though these o b s e rvat io ns may 
be, few studi es address the crucially import ant quest io n as to 
whether any deviation, usually observed in only  one cycle of study, 
is a rec urr ent, or an isolated phenomenon.
W i t h  respect to the diagnosis of the LPD in infertile 
populations, Jones (1976) demonstrated that to be of qlinical 
significance hi stologic evidence for luteal i n s u f fi ciency  must be 
found c o n s i s t e n t l y  and repetitively. Employing such cons tr aints she 
found an in cidence  of 3.5% in her infertile population, contrasting 
with the data  of Israel (1972) who found, through em ployin g 
endometrial biopsy in a single cycle, a muc h higher incid ence of 19%. 
That such a b norma li ti es do in certain patients recur with high 
frequency is sup ported by data from patients pres enting w i t h  a 
history of recurrent abortion (Jones & Delfs 1951, Tho et al 1979) 
where the rape ut ic  success has been obtained through a d min is tration  of 
exogenous p r o g es to ge ns to supplement endogenous P production. Others 
(Soules et al 1977, Andrews 1979) have also emphasised the need for 
more than one endom etria l biopsy to define the deficient luteal 
phase, whi le Shepard et al (1977) showed that the finding of a luteal 
abnormality in a single cycle had little prognostic importance for 
their study popula tion's future fertility. Others (Aksel 1980, Wentz 
1982) would agree with this observation. Balasch et al (1985), having
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noted a highly  sig nificant tendency in their patients for change in 
endo me tr ial assessment from cycle to cycle , have proposed that three 
samples of e n d o metrium  are required to c o nfirm the diagn osis of 
luteal phase insufficiency.
Conversely, there is a need in the subfertil e population to 
confirm the regu larit y of normality, as much as abn orma li ty (Moghissi 
& W a l l a c h  1983), since normal ovarian fu nction may be an isolated 
occurence in some patients rather than the norm.
Sh er ma n and Ko renman  (1974a) in a study on obese patients with 
prolonged cycles found abnormalities of both FSH and P production 
and, in finding the deficient luteal phase to recur in two of the ten 
patients studied, observed that these cycles might not be 
characteristic of the patients' entire menstrual history. In a 
parallel study the authors (1974b) found the short luteal phase, 
associated with diminished E2 in the follicular phase, to recur in 3 
and 4 cycles withi n a twelve month period re spe ctive ly in two out of 
a study gro up of four volunteers. All such cycles were of normal 
duration. The volunte ers were young nursing students, a group, 
through stressful working conditions, at a potentiall y high risk of 
endocrine d i s t ur ba nce (Editorial 1982), and such data need not 
necessarily apply to infertile populations.
Whe re more than one test is applied to assess luteal function, 
difficulties can arise for, as shown by Annos et al (1980), use of 
the basal body temperature chart, plasma P and endometrial biopsy 
together may only be in agreement in one— third of cases casting doubt 
on the r e l i a b i l i t y  of each individual test in diagnosing the 
abnormality. Others (Rosenfeld and Garcia 1976) are less sceptical
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about these tests and claim a gr eat er  than 90% cor relat io n of P 
m e a s u r e m e n t  and endometrial biopsy in detec ti on of ovulation. As 
Shangold et al (1983) observed there is a need, in the case of the 
LPD, to sta ndar di se criteria for di agnosis in order that incidences 
and re cu rrence  rates of the a b n o r ma li ty can be studied accurately. 
Hull et al (1982) in attemptin g to define an acceptable serum P level 
compatible wit h ovulati on in a large popula tion undergoing basic 
infertil ity screening reported consistent results from cycle to 
cycle, though did not specify the number of patients this observation  
referred to. Their reported cumulative conception  rate of 10% per 
cycle, cons istent  over two years, does suggest that, in most cases, 
the as se s s m e n t  of luteal function in the study cycle was truly 
represent ati ve of cyclical ovarian steroidogenesis.
The LUF has aroused a great deal of interest over the past few 
years. U l t r aso un d might be expected to provide a convenient and 
simple way of studying the per sistence of LUF. Kerin et al (1983) 
found that, in 66 patients studied over 183 cycles, 8 women in a 
total of 9 cycles demonstrated LUF, as the authors defined it, using 
ultrasound as the method of investigation. These 8 women were re­
examined over a total of 35 cycles and in only 1, a patient 
undergoing her fourth study cycle, was the LUF found to recur. 
Liukkonen et al (1984) found LUF in their study of a small number of 
patients u nd ergoi ng  ultrasonic evaluation over 3 cycles to occur 
exclusively in only 34% of the group. Hamilton et al (1985) in a 
large study found 27 patients dem onstrating the LUF phenomenon, 
almost half of whom  were undergoing induction of ovulation, mostly 
with clom ip h e n e . T h e y  found that LUF did not recur in the patients 
with un explaine d infertility but only in those with pelvic 
inflammatory disease or those undergoing induction of ovulation.
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Precise figures for recurrence were not given. These data, together 
with the l a p a r os copic  observations of Vanr ell et al (1982), lend 
further weigh t to the thesis that one cyclical event is un likely to 
be r e p r e s e n t a t i v e  of all cycles in a patient, though Devroey et al 
(1983), using bi ochemic al analyses of periton eal fluid collected by 
cu ld oc entes is  , have taken the opposing view  that in the case of LUF 
the a b n o r m a l i t y  tends to be repetitive.
To examine this question further, the combined resources of 
sequential ul tr asoun d and serial bi ochemistry were employed. 
Spo nt an eously  cycling women with une xplained in fertility  were studied 
over two i n t e n siv el y monitored cycles, in an attempt to ascertain the 
reproduci bi lity of observed ovarian function.
6.2 Mater ia ls and Methods
The study pop ul at ion consisted of 26 patients with unexplained 
infertility of at least 3 years duration, as defined in chapter 4.
All u n d e r w e n t  deta iled investigation over two complete cycles in a 
similar m a n n e r  to that described earlier (section 4.2).
These patients had demonstrated an abn ormality in their first 
cycle of inv est igati on , and are included in the main study's analyses 
(Chapter 5). The study group comprised 26.5% of the 98 cycles, in 175 
patients with un ex plained infertility, in which ovarian function was 
observed to devi ate from the normal control profiles described in 
chapter 2.
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B i o ch em is  try
A r e v i o u s l y  described (chapter 2) the analys is was orienta ted  
around the day of the LH peak and an a ss es sment of the pituitar y and 
ovarian horm one profiles made through c o m p a r i s o n  wit h normal 
controls. Part ic ular atten tion was paid to events in the 
per iovula to ry period. To quantify fo ll icular function at this time an 
E2 index was used, being the average of the sura of the E2 
c o n c e n t r a t i o n s  on days -2, -1, 0 and +1. The P indices (days +2 to 
+6) were also compared for the two cycles to evaluate early luteal 
function.
Ultrasound
The day of the LH peak was again used to ori entate analysis. 
Maximum FD was compared together with the nature of the ultr asoni c  
profile as a whole from one cycle to the next. The r elat io nship of 
the o b s e r v a t i o n  of follicular rupture to the g o n a d o t r o p h i n  and 
ovarian steroid patterns was assessed and any differences from one 
month to the next noted.
Statistics
Statistic al  analyses using Student's t-test (paired samples), 
Pearson's correlation, non— parametrie methods (Wilcoxon rank sum 
test) and Ch i-square test for frequencies were employed where 
appropriate.
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6.3 Re sult s
The age of the patients was in the range 21 to 39 years (median
30.5 years) and their m e dian duration of i n f e rtilit y was 4 years
(range 3 to 10 years).
The mean time span betw een the cycles of invest i g a t i o n  was 3.6 
months (SD 2.4 months) with a median value of 3 months (range 1 to 9 
months). All patients therefore completed their e va lu ation within 1 
year of the initial entry to the study (Table 6.1).
Table 6.2 shows the paired cycle charac terist ic s of the patients 
under study. The den omin ators vary for the fol lowing reasons :
Three of the 26 patients failed to ovulate in the first study 
cycle. It is inappro priat e therefore to consider their paired cycles 
in as s e s s m e n t  of follicular and luteal phase duration. The remaining 
23 cycles provide the data for comparison.
2 pat ie nts conceived during the second cycle and a calculation
of luteal phase length, as with the 3 an ovulatory  patients, is
impossible. 21 paired cycles are therefore compared for luteal phase 
length.
The patients  who conceived are also excuded from the comparison 
of overall cycle length, but the ano vulatory patients are included. 
This c o m p a r i s o n  comprises data from 24 cycles.
In the case of these 3 anovulatory patients neither an E2 nor a 
P index could be calculated and so the denominator for these paired
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data is also 23 (Table 6.3).
T a ble 6.2 also shows the phase length data for the study cycles. 
As can be seen the figures are broadl y similar with  a median total 
cycle l e ngth of 28 days in both cycles. The minor dif feren ce s 
ob se rv ed did not reach st atistical  signifi ca nce (Student's t-test : 
paired samples).
Ta bl e 6.3 shows the data on biochem ical indices for the study 
cycles and again although minor dif fe rence s were noted these were not 
significant. The ranges of values were similar in both groups.
B i o c h e m i c a l  p r o f i l e s
E x a m i n a t i o n  of the bioche mical profiles compar ed to normal data 
(Table 6.4), revealed that, of the 26 patients studied, 25 (96.2%) 
had an a b n o rm al ity in at least 1 cycle. 14 (53.8%) revealed abnormal 
function in both cycles while 11 (47.2%) showed this in their first
cycle only. The remaining patient exhibited normal biochemical 
profiles throughout both cycles.
Table 6.5 shows the nature of the biochemi cal abnormalities, 
cycle by cycle. The commonest observed a bn or mality was that of 
deficient luteal function, manifest as dimini shed P concentra tions in 
the ear ly p o s t - o vul at ory period. This phe nom enon of PPS (section 5.2) 
was seen in 17 (68.0%) of the 25 abnormal first cycles. In the 
majority of cases P levels attained normal values by the mid-luteal 
phase (p p s - N )  , but in some P concentrations remained low throughout 
the luteal phase (PPS— S). Of the 14 abnormal second cycles, 10 
(71.4%) involved PPS, a similar proportion to that found in the first
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cycle. Other a bn or malit ie s observed included PFM (section 5.4), 
in a p p r o p r i a t e l y  high levels of LH (section 5.3) and anovulation.
Other dev ia ti ons from the normal control profiles, including the SLP, 
L F P , SFP (section 5.5), transient h y p e r p r o l a c t i n a e m i a  (P R L ) , and 
pl at ea ued E2 levels in the p eri ov ulatory  period i.e. no convincing E2
peak identifiable,  were seen as isolated o c c u r r e n c e s  in either the
first or second cycles.
Table 6.6 shows the type of bioc hemical  a bn ormali ty  in the 14 
cycles where dual cycle abnor malities were revealed. As can be seen 
not all biochemical  abno rma litie s were m u t u a l l y  exclusive.
These data provide insight into the risk of recurrence specific 
to each abnormality. Table 6.7 summarises this for the main 
abnormality sub-groups.
17 patients demonstrat ed  PPS in the first cycle of whom 9
(52.9%) demonstr at ed abnormal ovarian function in their repeat cycle.
In 8 cases, the PPS profile was repeated.
Of the 7 cycles dem on stratin g PFM, 5 (71.4%) elaborated abnormal 
biochemical profiles again, 4 of which repeated the PFM pattern.
3 (60%) of the 5 patients with the high LH profile and 2 of the 
3 an ovulatory  patients demo nstrated an abnormal biochemical profile 
in cycle 2 and in all cases the defect was similar to that of the 
preliminary cycle.
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U l t r a s o n i c  p r o f i l e s
Tab le 6.8 shows that of the 26 patients studied only 6 (23.1%) 
revealed normal ovarian function in both cycles. 9 (52.9%) of the 17 
patients with abnormal ultr as onic profiles in the first cycle had 
normal pat te rns in the next. Where the first i n ves ti gation cycle had 
de m o n s t r a t e d  normal function (9 cycles), in only 3 cases was the 
second cycle found to be abnormal. Co nsistent no rma lity or 
a b n o r m a l i t y  was found in 14 patients, amounting  to 53.8% of the 
series .
Luteal cyst formation (section 5.1) was the com monest 
a b n o r m a l i t y  seen (table 6.9) compris ing 10 of the 17 abn orm aliti es  in 
the first cycle and 6 of the 11 in the second. Poor follicular 
d ev el opment  (PFD) (section 5.4) was the next most common, followed by 
anovulation. A var iety of other deviations from the control cycles' 
profiles were seen including multiple follicular deve lopmen t with 
associated twin ovulation, and developmen t of a non-f unctional 
follicle prior to normal follicular development with normal 
bio chemical function.
The ultraso nic abn ormalities seen in the 8 patients with dual 
cycle pr ob le ms are listed in table 6.10. These data are summarised in 
Table 6.11. Only 5 of the 10 patients (50%) with luteal cysts in the 
first cycle had atypical ultrasonic profiles in the next. 3 of these 
were again luteal cysts representing a 30.0% chance that the 
abnormality would be the same as that seen in the first cycle. One of 
the 3 patients who revealed PFD and 2 of the 3 anovul atory  patients 
in cycle 1, demo nst rated a second cycle abnormality, in both cases, 
the same ul trasonic phenomenon in the second cycle.
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Tab le 6.12 shows the combined data of recurrence patterns for 
both u l t r a s o n i c  and b i o c he mi cal abnormal iti es. 17 of the patients in 
their first cycle had an ult rason ic  a b n o r m a l i t y  and, al though fewer 
revealed an abnormal profil e in the second cycle, the dif ference  was 
not sig nificant. Bi ochemica l abn ormali ti es were found in nearly all 
the pat ie nts' first cycles but si gnif i c a n t l y  less commonly in the 
second cycles (Chi-square = 10.3, p <0.001).
16 patients in all ex perienced a bn or malitie s in both cycles. 
Eight had U/S evidence of abnormal ovar ian function in both, of whom 
7 d e m o n s t r a t e d  dual bioc hemica l distu rba nce as well. 14 patients had 
biochemical dis turb ances in both cycles. One patient in her first 
cycle exhibited deficien t luteal P pro du ct ion despite a normal 
follicular gr owth pattern. In the second cycle she formed a luteal 
cyst but on this occasi on her biochemical profile was normal (Table 
6.13) .
10 patients had an ultrasound scan performed on day 0 in both 
cycles and, as table 6.14 shows, there was no statistical difference 
observed be tw een  the two paired sets of data (t = 0.32, p = 0.76), 
though FD's did not correlate well from one cycle to the next (r = 
0.45, p = 0.19).
16 patients develop ed follicles on the same side in both 
cycles, 11 on the right and 5 on the left. Of the remainder 4 grew 
their initial follicle on the right while 6 commenced on the left.
The inci den ces of all four possible combinations are shown in table 
6.15. There were no significant differences.
6.4 D i s c u s s i o n
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This study represents a prospective analysis  of ovarian 
function, using a protocol of intensive u l t r as on ic and biochemical 
s u r v e i l l a n c e  over two cycles, closely related in time, on patients 
with UI. All of them, by def inition, were cyclin g regul arly without 
s t imula tio n .
The data show that cycle phase length was consist ent from cycle 
to cycle in these patients. The raethodolgy of the study however 
permitted more detailed eva lu ation of cycle to cycle c onsi st ency of 
ovarian function. It is interesting that FD on day 0 in the paired 
cycles, a l t h o u g h  sta ti sticall y similar did not corrrelat e well from 
one cycle to the next, suggest ing that the ma ximum FD in one cycle 
cannot be relied upon to be predictive of the p e r i o vul at ory FD in 
future c y c l e s .
All 26 patients showed an ultrasonic or bio chemical variati on 
from normal in the first cycle of study. They represent 26.5% of the 
patients d e m o n s t r a t i n g  de vi ant ovarian function in the whole study 
group and mi gh t have been expected to demo ns trate a high rate of 
abnormality in a second cycle of investigation. Only 14 (53.8%) of 
the series elab orated consecutive biochemi ca lly abnormal cycles and 8 
(30.8%) c o n s ecutiv e U/S deviations. Combining U/S and bio chemical 
data, 16 (61.5%) of the 26 patients exhibited aberrant ovarian 
function in the second cycle. This incidence is similar to the 
overall in ci dence of ab no rmality in the main study (Chapter 5) where 
98 (56.0%) of 175 patients exhibited abnormal profiles (Chi-square = 
0.10, p = 0.75). These data suggest that there is a co nsisten cy of 
chance of de v i a t i o n  from normal in patients with UI from cycle to
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cycle. Data are required from a popu latio n of patients with UI who 
d e m o n s t r a t e  normal ovaria n function in a p r e l i m i n a r y  cycle, since 
their chance of deviant ovarian function may be less. This is 
u n l ik ely to be the case since the main study population, selected 
only on the basis of their hi story of U I , was large (175 cycles), and 
co n s e q u e n t l y  is u n l ik el y to represent a biased group, at greater risk 
of re petiti ve  abnormality.
The dif fer en ce  in incidences from one cycle to the next may be 
due to the sporadic nature of the a b nor ma lities observed, but, as 
Moghissi and Wa ll ach (1983) suggested, it is po ssibl e that the stress 
involved in att ending for such inves tigations  was less in the second 
cycle where patients had evolved a famil ia rity with the protocol of 
study. There is a need to carry out studies on the fertile population 
over a series of cycles to determine a m e a n i n g f u l  expectation of 
normal or abnormal function, rather than rely on obse rv ations of 
doubtful si gni fic ance in one cycle in isol at ion (Vanrell et al 1982).
E x a m i n a t i o n  of the paired cycle patterns, in respect of specific 
abn orm alities seen in the prelimin ary cycle, revealed similar risks 
of rec id ivism  in the main sub-groups identified. 50% of the luteal 
cyst formers, 52.9% of the PPS and 60% of the high LH group 
elaborated abnormal patterns in the second cycle. It was interesting 
that not all repeated aberrant profiles were the same as in the 
preliminary cycles. Two of the 5 luteal cyst formers exh ibited a 
different pattern of abn ormality, but in 8 of the 9 cycles with PPS 
and 4 of the 5 cycles with PFM, the phenomena were repeated.
R e p r o d u c i b i l i t y  of ovarian f u n c t i o n  c a n n o t  be d e t e r m i n e d  by 
^sfGrGnc6 to U/S p r o f i l e s  a l one since, as the d a t a  from the p r e s e n t
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study indicate, endo crine abnor malit ie s may be found in the presence 
of a norma l follic ular growth profile. Polan et al (1982) found in a 
small study of 5 patients with u l t r a s o n i c a l l y  observed abnormal 
ovar ian  function in a prel i m i n a r y  cycle that in 4 cases the next 
m e n s t r u a l  cycle was en tire ly  normal. Had intensive b ioc he mical 
ana ly ses been pe rfo rme d on these cycles subtle ab n o r m a l i t i e s  of 
o v a ri an  function might have been found. Accurate e v a l u a t i o n  of 
ov arian  functi on must take both modes of investi ga tion in to 
considera tio n.
Shepard et al (1977) observed that the finding of a single 
a b n o r m a l i t y  in an i n ve stiga ti on cycle may have little prognostic 
i mp ort anc e for fertility. In the present study, two patients, both of 
whom had abnormal ovar ian function in their first cycle, conceived in 
their second cycle. The first developed a luteal cyst in her first 
cycle, 16mm in dia meter between days +5 and +8, as so ciate d with a P 
index of 87 and a short luteal phase of 11 days. She was the only 
patient who dem onst rated a short luteal phase (SLP) in this series. 
The relevance of SLP to infertility remains controversial. Smith et 
al (1984) found a 9% incidence of SLP in a study of 95 patients with 
unexplain ed  inf ertility but found this to be no diff er ent from the 
incidence in a similar number of healthy controls. It w^s suggested 
that in many cases of SLP the m a n i f e s t a t i o n  was due to premature 
menstrual bleeding in the face of normal P levels rather than a 
de ficiency  of P prod uction by the corpus luteum. Al thoug h this 
patient's P index was normal and the ma ximum P value 14.0 ng/m, from 
day +7 onwards her levels dropped d r a m a t i c a l l y  sugg estin g premature 
luteolysis. She exhibited no other bi ochem ical clue as to why this 
might have occurred. In the cycle of conception two follicles were 
seen to develop and rupture, with normal biochemistry. A single fetus
d e v e l o p e d  and the pregnancy  progressed uneventfully.
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The second con ce pt ion occurred in a patient who had transiently 
ele va ted PRL levels in her first cycle as an isolated abnormality, 
but in the second cycle, despite a normal foll icular phase, exhibited 
PPS-N profile w ith a P index of 75. She u n f o r t u n a t e l y  aborted at 7 
weeks gestati on. His t o l o g y  of the aborted mat erial  confirmed the 
pr es en ce of chori oni c villi. It is un ce rtain whet her the cause of 
this patient' s m i s c a r r i a g e  was corpus luteum failure. She did not 
receive P s u p p l e m e n t a t i o n  which has been shown to have some possible 
therapeu tic value in patients who have a hi story of recurrent
ab or ti on (Tho et al 1979) and perhaps this might have been helpful in
her case. The materi al was not sent for gene tic analysis which might 
have clarified  the nature of the miscarriage.
Of the 17 patients with an ultrasonic  ab no rmality in their first 
cycle, 8 (47.1%) exhibited an abnormal it y in the second cycle. In the 
case of luteal cyst formation, 6 of the 10 patients de mon str ated a 
no n - s hr inkage pattern suggestive of LUF (section 5.1). Of these, only 
1 (16.7%) d e monst ra ted a LUF pattern in the second cycle. This 
figure, albeit based on small numbers, is lower than that quoted by 
Liukkonen et al (1984) but rather higher than the findings of Kerin 
et al (1983). Ham il ton et al (1985) found the LUF to recur only in 
patients und erg oi ng induction of ovulation or having pelvic 
in fla mmatory  disease (PID), criteria for exclusion in the present 
study. Of the 4 patients demon strat in g the cystic CL pattern of
luteal cyst formation (section 5.1) in the first cycle, only 1 did so
in the subsequent cycle.
Over half of the cases of PPS in cycle 1 were found to have a
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b i o c h e m i c a l  abnormality in cycle 2, most of which were similar to 
that of the previous cycle. The data would suggest that infertile 
patie nts  have a tendency for abnormal ov arian  function, greater 
p r o b a b l y  than in the general population, the exact nature of which 
may vary from cycle to cycle depen den t on a v a r iety of factors as yet 
not understood. Perhaps d i f f erenc es  relate to receptor status within 
the follicle or p u l s atili ty  patterns of h yp othala mi c hormones in the 
early fo llicular phase or at the time of the LH surge. It is 
i n t e re st ing that the more severe form of PPS recurred e x c l us iv ely to 
the patien ts who had the abno r m a l i t y  in the first cycle, though one 
patient in cycle 2 with  PPS-S had the m i l d e r  P d eficie nc y (PPS-N) in 
the first c y c l e .
A n o v u l a t o r y  cycles are unusual in patients with  normal menstrual 
rhythm. It has been suggested (Aksel et al 1976, Aksel 1980) that 
high PRL levels may be implicated in LPD and that the so-called 
aluteal cycle may represent a severe form of the same phenomenon.
None of the patients with ano vu lation  had abnor malities of PRL 
secretion. Annos et al (1980) likewise found LPD only to be rarely 
associated with elevations in PRL.
In clinical terms, the inferences to be drawn from this study 
are that, although patients with pro longed UI may often exhibit 
abnormal ovarian function, aber rat ion from normal is not ne cessarily  
consistent. Continued in fertility is p r o ba bl y a function of the 
frequency with which such abnormalities occur, and since normal 
ovarian function can occur in these patien ts it is not surprising 
that some conceive spontaneously. (Hull et al 1985). To base 
therapeutic decisions on the information gained in a single cycle of 
investigation is unjustified, and in d e c iding  on therapeutic
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stra te gi es, an approach whi ch attempts to override all potential 
d e v i a t i o n s  from normal would best be employed. Te chniques such as IVF 
and GIFT have already been used suc ce s s f u l l y  in U I , and the approach 
of p i t u i t a r y  d o w n r e g u l a t i o n  with GnRH agonists and subsequent 
o v u l a t i o n  indu cti on with exogenous go n a d o t r o p h i n s  has similar 
po t e n t i a l  (Fleming et al 1982).
CH A P T E R  7 P ER IT ONEAL FLUID STUDY
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7.1__________I n t r o duct io n
In as many  as 10% of cases of female subfertil it y 
a b n o r m a l i t i e s  of the luteal phase are implicated. It has also 
been shown thr ough studies using bioche mis try, lap aros co py and 
u l t r as ou nd that in cases of unexplained infert ilityt he re may be 
an a s s o c i a t i o n  with abn orma lities of the luteal phase.
In 1978, using ap pro p r i a t e l y  timed laparoscopy, Kon inc kx et 
al found that in 58% of patients with unex plained infertility, 
when the corpus luteum was examined carefully, no ovulat ion 
stigma could be found. Mari k and Hulka (1978) also studied a 
similar p o p u l a t i o n  with la parosco py and found a stigmatised 
corpus luteum in only 39% of their patients implying that 
lute ini sa ti on of the Graafia n follicle without rupture, and with 
consequent en trapme nt  of the ovum, might provide an explana ti on 
for many couples' failure to conceive.
Bi o c hemica l charact er isation  of P profiles in the luteal 
phase has also been shown to reveal abnorm ali ties which 
conventional single sample analysis of luteal function would fail 
to elucidate. Thus Koninckx' group suggested that their 
luteinised unru ptured follicle (LUF) patients demonstrated 
biochemical evidence of LPD both in terms of duration and overall 
quantity of P secretion similar to abnormalities demonst rated in 
patients with endometriosis (Brosens et al 1978). Others (Fleming 
et al 1981) have shown that patients with unexplained infert ility  
reveal subtle abnormalities of reproductive function when
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s u b jected to intensive cycle mo ni toring  through daily analysis of 
of p i t u i t a r y  and ovarian hormones throughout the mens tr ual cycle. 
Com m o n e s t  of these is deficie nt  P prod uction in the early luteal 
phase found in over 36% of the patients studied.
Di ag n o s t i c  U/S has provided a further tool for inv esti gation  
of u n e x p l a i n e d  inf erti li ty and several workers have describ ed  
retained folli cular cysts observed throughout the luteal phase 
both in un st i m u l a t e d  and stimulated cycles (Coulam et al 1982, 
Coutts et al 1982, Liukk one n et al 1984). It has been proposed 
that such phe no me na might represent the LUF syndrome.
Per it on eal fluid (PF) is present in varying qua ntity 
thr oug hout the me nstrual cycle and Maathius, Van Look & Michie 
(1978) suggested that changes in the PF volume during the 
menstrual cycle relate to the cyclical act ivi ty of the ovaries. 
They found that the PF E2 and P concentra tio ns were m a r kedl y  
increased following follicular rupture and that this may, in 
part, be due to release of follicular fluid containing  high 
concentrati ons of these hormones. PF steroid levels were also 
much higher than the equivalent plasma steroid levels. Koninc kx  
et al confirmed these findings (1980 JCEM, 1980 BJOGa & b) and 
went on to describ e di ffere nces in the co nst ituen ts of PF between 
cycles where an ovula tion stigma was seen on the corpus luteum at 
laparoscopy and the 43% of their study cycles where no stigma 
could be identified. This led to their hypothesis that steroid 
hormone assays on PF could discriminate between the normal cycle 
and the LUF cycle. Others (Lesorgen et al 1984) have also 
suggested that this more objective evaluation of ovulation,
3. t It. g rr than the more subjective assessment of stigma formation,
p r o vi des a helpful method of diagn osis of LUF.
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Based on these reports other workers have studied the 
r ec u r r e n c e  of these phenomena, avoiding the use of laparoscopy, 
either through meas u r e m e n t  of per ito neal fluid steroids obtained 
at cu ldo c e n t e s i s  (Devroey et al 1983) or through ovarian 
u l t r a s o n o g r a p h y  in repeated cycles (Kerin et al 1983, Li ukkonen 
et al 1984).
The si gn ifi cance of these phenomena is not yet clear in 
re lat io n to un explained  in fe rtility or end ometriosis. The 
pro ce ss es of of o v u l ation and corpus luteum forma tio n and 
fun ct ion have therefore been examined further using the combined 
res ources of sequential plasma biochemistry, ov arian U/S and 
luteal phase l ap ar oscopy  with peritoneal fluid aspiration. This 
detailed study would usually be difficult, in that most patients 
being referred for detailed cycle analysis using ovarian U/S will 
already have undergone diagnostic laparoscopy. Thus, in offering 
such detail ed investig at ion to patients with a likely diagnosis 
of u n e x pl ained infe rti lity at an early stage in the couples' 
infertil ity inves tigations, a unique o pportun it y was presented to 
relate the findings from four different avenues of study.
7 .2_________ M a t e rials  and Methods
The plan of investigation  was for patients with potentia lly 
unexplained infe rti lity to attend for blood sampling throughout 
an entire menst rua l cycle. Ovarian U/S examinations were 
performed freq uently from about the eighth day of the cycle 
onwards. Once a follicle greater than 12mm diameter was observed,
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scans were perfo rmed daily until the c h arac te ristic shrinkage and 
infilling  of the follicle as it became a corpus luteum  was 
observed. T h e r eafte r scans were performed every f o r t y-eight  hours 
until the day of laparoscopy. A NE4201 static scanner w i t h  a 
3.5MHz probe was employed using the full bladder technique to 
visuali se  the ovaries.
La p a r o s c o p y  was timed to coincide with the ea rly/mid luteal 
phase as determ ined by the U/S data. At op eration the ovaries 
were thoroughly  inspected to confirm the presence of the CL with 
or wi t h o u t  stigma formation. Endom etr iosis, if present, was noted 
and cla ssi fied acc ording to the criteria of the Ame rican  
Ferti lit y Society. Hy d r o t u b a t i o n  was performed and peritoneal 
fluid obtained by aspiration.
T we nt y-four  patients were studied, all of whom had normal 
menstrual rhythm and normal initial biochemical test results - 
plasma L H , FSH, Prolactin, testosterone and TSH measur eme nts, 
together with a mid-luteal P con centrat ion of at least lOng/ml, 
suggestive of ovulation. They  had nothing in their past medical 
or surgical his tor y to suggest the likelihood of pelvic disease.
The couples' only abno rm ality was a failure to conceive despite 
unprotected intercourse for a min imum of two years. All patients 
gave informed consent to undergo investigati on and the study 
carried hospital ethical committee approval.
The daily venous blood samples were centrifuged and the 
plasmas stored at — 20 C until analysis was carried out.
Sensitive, specific and precise rad ioimmunoassays were performed 
(Coutts et al 1981) to determine the conce ntrations of FSH, L H ,
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PRL, E2 and P. Each patient s samples for the whole cycle were 
assayed in the same batch, as descr ib ed in Chapter 2.
PF samples were centrifuged and the sup erna tants  stored at 
-20 C until assays for E2 and P were performed.
Sta ti st ical analyses were carried out using linear 
re gr e s s i o n  analysis and the Wi l c o x o n  rank sura test, where 
appropr iat e.
7.3 Resul ts
Two of the twenty-four women were found to have extensive 
pelvic adhesion s at laparos copy due to i nf lammato ry  disease with 
re sul tant tubal occ lu sion and these are therefore excluded from 
further analysis. In the remaining twenty-two women the diagnosis 
of un ex p l a i n e d  infe rt ility was sustained and the data reported 
hereafte r relate to this group of patients.
The age range of the patients was from 22 to 40 years 
(median 30 years) and the median duration of infertility 3 years 
(range 2 to 8 years). Laparosco pi es were performed between days 
+2 and +12 of the cycle with reference to the day of the 
pr eceding LH peak (Day 0).
Plasma b i o c h e m i s t r y  and ultraso nic profiles.
These are summarised in table 7.1.
In 16 cycles (72.7%) the pattern of ovarian function as
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assessed by U/S and sequential blood sampling was normal, 
compared with the est ab lished normal cycle ranges (Chapter 2).
All of these plus the remaining 6 cycles showed g r owth  of a 
single d o m in an t follicle, a classical m i d — cycle surge of LH and 
rise of plasma P co nce n t r a t i o n s  subsequently.
The 6 cycles where an a bnor ma lity was found are summarised 
in table 7.2.
All patients ex hib ite d shrinkage of the do mi nant follicle 
following  the LH surge but in one was the cystic nature of the 
follicle m a i n t a i n e d  during the luteal phase. Her bi ochemic al  
profi les  were normal. 2 patients showed abnormal u l t r aso ni c 
profiles where the ma xi mum pre -ovul atory FD was less than the 
lower 99.9% co nf ide nce limit of the mean of the control data 
( < 1 7 . 1mm). One of these exhibited a defi cient  luteal phase P 
profile (PPS-S) wh ils t the other was bioch e m i c a l l y  normal. One 
patient with normal bio chem is tr y had a large fol licular  gr owth 
pattern, with m a x imum  FD more than two SD's above the control 
mean. One patient with an abnormal biochemical pro file (PPS-N) 
had a normal ultrasou nd profile and one patient wit h normal 
b i o c he mi stry profiles had an apparently inactive c o n t r ala te ral 
ovarian cyst as well as the growing follicle.
L ap ar oscopy  observati on s
At laparoscopy, a "corpus luteum" was seen in all patients
with a def ini tive punctum identifiable in sixteen cases (72.7%) - 
the "punctum" group. In three cases (13.6%) there was equivocal 
evidence of punctum formation and in the remaining three patients
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(13.6%) no stigma of ovul at ion could be identified. These were 
classified  as luteinised unruptured follicles (LUF).
Ten patients were found to have end om etriosi s,  but in all 
cases this was cla ssified as mild disease. Areas involved 
included the ute rosacr al  ligaments, the broad ligaments and the 
ovaries. In none was there any inv olvement of the fallopian 
tubes. Two of the LUF patient s (66.6%) had endometri os is while 8 
of the pu nctum  group (50%) were affected.
The la pa r o s c o p y  procedures were con centra te d in the week
foll owi ng ovu l a t i o n  but extended to day +12 as a result of 
dif ficul ti es  with theatre schedules (table 7.3). Thr oughout the 
full range of lapa ro scopy  timings it was possible  to define 
ovu la tion  puncta. The LUF patients und erwent la paroscop y on days 
+5, +6 and +9. Most of the "punctum" group had undergone 
l ap ar oscopy  by day +8, but in one patient definite stigma of 
ovu lation was observed at laparo scopy on day +12.
Per itoneal fluid (PF) steroids
Pe ri tone al  fluid was obtained in all cases. The amount of 
fluid ava ilabl e for colle ction from the Pouch of Douglas is 
influenced by the presence of loops of bowel or omen tum in the 
pelvis and the degree of Trend el en berg tilt to which the patient 
is subjected. In view of this it is unl ikely  that the volume of
PF aspirated is truly representative of the total amount of fluid
present and cons equentl y these volumes are not reported. It is 
assumed that the hormones measured are evenly distributed 
throughout the peritoneal fluid.
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There was a wide range of PFE2 and PFP co ncentrations but 
only w it h PFP was a signific ant trend appare nt in relation to 
timing of sampling following the LH peak (figures 7.1 & 7.2).
This was more apparent after loga rithmic  tr an sf ormatio n of the 
PFP data (figure 7.3). There was a sign ificant  correla ti on 
be tw ee n the steroid levels in individual patients (r = 0.816; p < 
0.001) (figure 7.4).
Plasma levels bore no relation to PF levels of the ov ar ian 
steroids (figures 7.5 & 7.6) (r = 0.135 & 0.29 7). There was, 
however, a strong c orr el ation between the PF : plasma ratios of 
E2 and P for individual patients (figure 7.7) (r = 0.783; p < 
0 . 0 01 ).fcThe P and E2 ratios correlated signifi cantly with the 
timing of laparoscopy, though this was closer in relation to the 
P ratio than the E2 ratio (figures 7.8 & 7.9) (r = 0.577, p < 
0.01; r = 0.518, p < 0.05).
There was co nsiderable overlap between the punctum group and 
the LUF group in the range of PFE2 and PFP levels (table 7.4) 
with the values in the LUF group being in the lower part of the 
range for the punctum group. Where a punctum had been visu alised 
the PF : plasma ratios of E2 and P tended to be higher than those 
seen in the LUF group but again consid erable overlap was observed 
between the two groups. The differences observed did not achieve 
statistical significance (Wilcoxon Rank Sura Test).
Table 7.5 shows the PF steroid levels and PFiplasma steroid 
ratios in the 10 patients with signs of endometriosis, and the 
remaining 12 patients where no evidence of end ometriosis could be
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seen. Range s of steroid values in both groups overlap ped 
c o n s i d e r a b l y  with both PFE2 and PFP levels in the ’'endometriosis" 
group being m o st ly in the lower part of the range for the "no 
e n d o m e t r i o s i s "  group. Steroid ratios in the " e n d o m et ri osis" group 
were also lower than in the "no endometrio sis" group, but the 
d i f f e r e n c e s  did not achieve statistical signi fi cance (Wilcoxon 
Rank Sum Test).
There was a stronger co rrelation  between the PF steroid 
levels in individual patients in the "end ometriosi s" group (r = 
0.855, p < 0.001) than in the "no endometrio sis" group (r =
0.799, p < 0.01). Similarly steroid ratios were more closely 
c orrel at ed  in individual patients in the " e n dometr io sis" group (r 
= 0.911, p < 0.001) than in the "no end ometriosi s" group (r =
0.739 , p < 0.01).
Since undergo in g laparoscopy, six of the twenty-two patients 
have conceived (27.3%), two of whom have done so twice (table 
7.6). One of these eight pregnancies resulted in a spontaneous 
abortion, the others all being delivered safely of healthy 
babies. These six women had a duration of infe rt ility at the time 
of their l aparo sc op y in the range 24-39 months (median 32 
months). These patients accounted for two of the ten cases with 
en dom etri os is  (20%), four of the twelve without (33.3%), four of 
the sixteen cases with a punctum identified on the corpus luteum 
(25%), one of the three LUF patients (33.3%) and one of the three 
patients where there was equivocal evidence of punctum formation 
(33.3%) .
In only one patient who subsequently conceived was their any
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d e m o n s t r a b l e  bioch emical abnormal ity during  the study cycle. This 
was m a n i f e s t  as a subnormal plasma P rise in the early luteal 
phase (days +1 to +5) but subseque ntly normal pro gest erone  
p roduc t i o n .
U l t r a s o n i c  profiles in all the patients who s ub se quently  
c on ceived were normal (table 7.6).
The pa tient who exhibited the gre atest cycle abn orma li ty 
Nhad a do min a n t  follicle 15.5mm diameter on day -1 (more than two 
standard dev i a t i o n s  below the normal mean) and developed two 
small cysts in the early luteal phase. The luteal phase plasma P 
rise was m a r k e d l y  subnormal (P index 35) and P levels remained 
defi ci en t through out the luteal phase. The lapa roscopi c findings, 
on day +2 were unusual. The ovary contained a corpus luteum with 
a p u n ct um  at the lower pole, an endometrio tic plaque centrally 
and a lcra di am et er cyst at the upper pole, a spi ra tion of which 
produced 0.5ml of fluid. Aspirat ion of the corpus luteum which 
had been cystic on ultrasound on day +1 produced 0.3ml of fluid. 
The patient ovulated from the left ovary in this cycle but, as 
ultrasound had shown, had ovulated from the right side in the 
previous cycle. The steroid concentrations are shown in table 
7.7. It is possi ble that the deficient P prod uction  after day +2 
related to d ist ur bance of the corpus luteum by a spi ra tion or 
possibly the effect of general anaesthaesia (Soules et al 1980).
7.4 D i s cussion
The present literature on the abnormal luteal phase presents 
a conf using  picture in terms of incidence, recurrence and
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s i g n i f i c a n c e  for fertility. This pros pe ctive  study has confined 
itself to the study of patients with unex plain ed  infertility, a 
group wh ic h is often m e n t io ne d in the literature in a s s o ciation  
w i t h  a b n o r m a l i t i e s  of luteal function and more sp ec i f i c a l l y  the 
LUF ph en omenon. Most previous studies in this area have related 
to m i xe d infe rtilit y groups.
In this series of patients, 72.7% of the popu lation 
di s p l a y e d  normal ovarian function  as det er mined by plasma 
b i o c h e m i s t r y  and ovarian U/S. The 13.6% incidence of LUF is 
simi lar  to the low, one in six, incidence found by Kerin et al
(1983) in the small group of patients with unexplained 
i n f e r t i l i t y  in their study. Koninck x et al (1978) found a much 
higher inc idence of LUF (41.6%) in the 32 patients they studied 
with u n e x p l a i n e d  infertility. This compared with the 93.8% 
inci den ce of normal corpus luteum and stigma formation in their 
"e xp lain ed " infertile group.
The three examples of LUF diagnosed l a p a r o sc op ically  showed 
no unus ual  follicular growth patterns and follicular shrinkage 
and in-fil ling was observed in all cases. The ultrasonic 
equipment used was of a high quality with excellent resolu ti on at 
the d e pt h of field required and clear pictures of the ovaries 
were obtained. In terms of the ultrasonic detection of LUF these 
must be regarded as false negative results. No clear d e f i nit io n 
of the LUF syndrome exists using ultrasound. Kerin et al (1983) 
studying unstimu lated cycles suggested the continued obs erv at ion 
of the dominan t follicle two days or more after the LH peak was 
diagnostic. Using these criteria a varied population of LUF's was 
revealed, some with diameters less than the "ovulatory" FD and
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others with d i a m et ers greater than the "ov u l a t o r y "  FD. Gibbons et 
al (1984) used a similar defini tion in studying a mixed 
p o p u l a t i o n  of both uns timu lated  and st im ulated patients. Coulam 
et al (1982) des cr ibed the ultrasonic d e v e l o p m e n t  of 
i n t r a f o 1 1 i c u 1 ar echoes with failure of foll ic ular shrinkage in 
st imulated  cycles in four patients and suggest ed  that this might 
repr ese nt the LUF syndrome. Some of the LUF's desc ribed expanded 
and reached quite sizeable dimensions. L i u k k o n e n  et al (1984) 
de scribed the LUF p h e n o m e n o n  as the pe rs i s t e n c e  of the dominant 
follicle follow ing de velopmen t of i n t r a f o l l i c u l a r  echoes but 
wit hout ensu ing shrinkage. Thus defined, in their unexplained 
i nf er tility  pop u l a t i o n  of 37 patients, a 57% incidence of LUF was 
suspected. L a p a r o s c o p y  was performed on twenty-two patients whose 
ult ras ound profil es suggested the LUF p h e n o m e n o n  and in eighteen 
of these no ov ulati on  stigma was found. Thus there were four 
false positive  diagnos es of LUF using ultr asound and no false 
negatives. Bi oc hemical data on follicular funct ion were lacking 
in these two studies. The present study's failure to detect LUF 
using ult ras ound in all the three cases dia gn osed at lapa ro scopy 
may be due to the LUF structures having i n t r a f o 1 1 icular contents 
of suffici ent de ns ity to mimic the natural processes of 
l ut ei nis ation observed in the normal cycle. Thus it would appear 
that while ul tr asound would seem to be an attractive prop os ition 
for the study of the incidence and recurrence of the LUF syndrome 
its findings should be interpreted with caution in view of the 
po ssibili ty of false negatives.
Recent work also suggests that the ultras onic ob servatio n of 
follicular shrinkage both in unstimulated (Craft et al 1980) and 
stimulated cycles (Stanger & Yovich 1984) need not ne cessarily
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equate with ovum release. The incidence of retained oocytes in 
s t i m ul at ed cycles may be as high as 60%.
It is d i s a p p o i n t i n g  that no u l t r a s o n i c a l l y  observed luteal 
cysts were ob serve d in this study and thus it is not possible to 
address the q u e st io n as to whether such p h e n omen a re present the 
LUF syndrome.
C a u t i o n  is also appropriate in the use of PF steroid levels 
in the d i a g nosis of LUF without laparoscopy. Following ovulation 
PFE2 and PFP c o n c e n tr ations  rise rapidly (Bernardus et al 1983, 
Ko ninck x et al 1980a, Koninckx et al 1980b) to levels where the 
PFr pl asma  c o n c e n t r a t i o n  ratios of these hormon es are high 
(Leso rge n et al 1984) partic ul arly in the early luteal phase 
(Donnez, L a n g e r o c k  & Thomas 1982). The source of this fluid in 
part relates to spillage of intra-fo llicular fluid, rich in 
steroids (Mcnat ty et al 1975, Zorn et al 1982, L o u m a y e , Donnez & 
Thomas 1985), and also to subsequent al teratio ns in ovarian 
ca pillary pe rm e a b i l i t y  (Koninckx et al 1980a&b, Donnez et al 
1982). In the LUF syndrome, it has been suggested that PF and 
plasma steroid concent rations tend to be similar. However, a very 
wide range of of PF steroid concentrations occur in women who 
exhibit ov u l a t i o n  stigmata. In this study the steroid ratios 
tended to be higher when a punctum was observed as compared with 
the small group of LUF patients, but there was considerable 
overlap b e t ween  the two groups. Lesorgen et al (1984) suggested 
that b i o c h e m i s t r y  alone might discriminate between these two 
groups of patients but their criteria of diagnos is of stigma 
formation using a PF:plasma steroid ratio >3:1 would result in a 
very high false positive diagnosis of the LUF syndrome if applied
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to the patients in this study. A similar overlap between LUF and 
normal cycles was also observed in the original p u b l ic at ion by 
K o n i n c k x  et al (1980a) and in the report by Dhont et al (1984). 
This ov erlap implies that an attempt to dia gn ose LUF by low PF 
st eroid levels alone may have high sensi tiv ity (if an app ropriate 
cu t-off point is chosen) but will have poor specificity. The 
s i g n i fi cant chance of false positive diagnoses will be 
p a r t i c u l a r l y  high in groups where LUF has a low prevalence. 
R e s t r i c t i n g  PF fluid sampling to the early part of the luteal 
phase mi gh t improve the speci ficity of the test since in this 
study group, as in others (Donnez et al 1982), the ratio tends to 
fall as the luteal phase progresses, but Dhont et al (1984) 
indicate from their data that considerabl e overlap in PFP 
conce n t r a t i o n s  between LUF and stigma cases occurs even in the 
first few days after ovulation.
The patients who were found to have endometrios is at 
l a p a r o s c o p y  tended to have lower PF steroid levels and ratios 
than those with no evidence of endometriosis. Brosens et al 
(1978) suggested the incidence of LUF in patients with 
endometriosis  was high, and this would be an attractive theory to 
explain the observed diff erences  in PF steroid levels in the two 
groups. How ever only two of the three LUF patients had 
en do met rio sis and the range of conce ntrations in the two groups 
was similar. Dhont et al (1984) failed to show a significant 
relationship between low PF steroid values and endometriosis.
Since this is testing the correlation of values in a chronic 
condition with the single values obtained in an invest iga tion  
cycle of what is poten tially a cyclical variable it is not 
surprising that one might find conflicting results between
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studies.
The f i n din gs  by some workers of increased volumes of PF and 
el ev at ed co n c e n t r a t i o n s  of PF pros tanoids (Drake et al 1980,
1981, 1982 & 1983, Ylik orkala et al 1984, Badawy, Marshall & 
Cuenca 1985) in patients with endo me triosis  and unexp lai ned 
infertil it y, w h i c h  others (Koninckx et al 1980a, Rock et al 1982, 
Mudge et al 1985) have been unable to confirm, have fuelled the 
c o n t i n u i n g  co nt r o v e r s y  over the possible relat ionship  between 
these clinical  problems.
It has been suggested that failure to identify the stigma 
within the corpus luteum under la pa ros copic study is not of 
immediate or pro gnostic importance. Marik and Hulka (1978) made 
the o b s e r v a t i o n  that r e - e p i t h elia li sation of the stigma can occur 
within a few days of follicular rupture thus implying that the 
l a p a r o s c o p i c  diagnosis  of the LUF syndrome could only be made 
reliab ly in the early luteal phase. Others (Portuondo et al 1981) 
have bi op si ed the corpus luteum in patients with absent stigmata 
and failed to de monst rate an entrapped oocyte. Portuondo et al
(1983) de s c r i b e d  four patients where conception occurred during 
the cycle of lapar os copy at which the corpus luteum was found 
bearing no sign of stigmatisation. Vanrell et al (1982) studied a 
population of women of proven fertility in the early luteal phase 
and found the ovulation stigma to be present in only 53% of the 
study group. On the basis of these data it has been suggested 
that the LUF syndrome may not be a primary cause of infertility, 
as one cyclical event may not be truly represent ati ve of all 
cycles. Ul t r a s o n i c  studies on the recurrence of this phenomenon 
suggest that the LUF syndrome may be less prevalent than was
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o r i g i n a l l y  suspected. Ker in et al (1983) observed in their study 
p o p u la ti on, most of whom did not have un explained inf ertility, 
that LUF syndrome did not tend to recur with greater fr equ enc y 
than in the general population. Liukkon en  et al (1984) in their 
u n e x p l a i n e d  i nf er ti lity population  found the abnormal ultrasound 
prof ile  they des cr ib ed  to occur in three consec utive cycles in 
only 34% of patients. Further work is required in this field for, 
if these ovarian events do cause infertility, is it by virtue of 
their undue frequ ency of occurrence, cycle by cycle?
In conclusion, this study, in a p op ulatio n of patients 
with r e l a t i v e l y  short duratio ns of unexplained infertility, 
showed a lower inciden ce of cycle abn or mality than pre v i o u s l y  
reported figures in series involving patients with much longer 
dur at io ns of i nfer ti lity (Coutts 1985). This method of study 
cannot therefore be rec ommended as a d i a g n o stica ll y def i n i t i v e  or 
ec ono m i c a l l y  j u s t if iable technique of primary in v e s t i g a t i o n  in 
pa tie nts where the dur at ion of infertility in most cases is 
likely to be co mpa r a t i v e l y  low.
C H A P T E R  8 CONCLUSI ONS
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In this thesis ovar ian function in women with unexp lai ned 
i n f e r t i l i t y  has been explored using the combined resources of ovarian 
u l t r a s o u n d  and sequent ial plasma biochemist ry , compa ring the findings 
in w o m e n  wi t h  u n e x pla in ed inf er ti lity with ultr as onic and endocrine 
data from normal fertile women.
The fo llowing concl usions can be d r awn :
1. The r e la ti onshi ps  between the changes in circula ting 
c o n c e n t r a t i o n s  of gonado trophi ns  and ovar ian steroids during the 
m e n s t r u a l  cycle were established in 43 cycles from normally 
c y c li ng volunteers. Previously reported patterns of follicular 
growth, using identical ultrasound equipment, were confirmed.
All vo l u n t e e r s  developed a single dominant follicle which, 
f ol lo wing the mid-cyc le LH peak, was seen to collapse and in­
fill as the corpus luteum formed and P secretion increased.
2. Data gener ated in concept ion cycles suggested that, in terms of
f o l l ic ul ar growt h and corpus luteum function, such cycles did
not differ  from the normal no n-ferti le cycle, jus tif ying the 
use of no n - c o n c e p t i o n  data as a normal control. A sub-normal P 
pr ofile was not a barrier to conception, althoug h it may be 
a s s o ci at ed with early embryonic loss, the cause of whi ch is 
u n c l e a r .
3. In a po pu la tion of patients (175) with unexplained infertility
more than half (56%) demonstrated ab normalities  of ovarian
function.
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4. The most commonl y found ultra sonic ab normalit y was the formation 
of ret ained luteal phase cysts, seen in 23.4% of the cycles. Two 
di st in ct pop ul at ions of luteal cyst cycles were id entified on 
the basis of presence or absence of ul trasonic evi dence of 
foll icula r shr inkage following the LH peak. Shrinkage of the 
dominan t follicle prior to luteal cyst formation was ge n e r a l l y  
as so ciated with normal P pr oducti on  by the corpus luteum. These 
cysts were termed cystic corpora lutea. In the abs ence of 
ult r a s o n i c  evidence of shrinkage of the dominant fol licle after 
the LH peak circulating P conce ntrat ions tended to be reduced. 
These cysts were termed luteinised unruptured follicles (LUF's). 
D i s c r i m i n a t i o n  betwee n these 2 sub-groups of cyst formers, on 
the basis of ult rasonic  profiles, ^could not be made in the 
fo ll icul ar  phase of the cycle. Detailed ult rasonic  data of 
fo lli cular dynamics  im mediately  follwing the LH peak were 
required if the nature of the luteal cysts was to be determine d 
a c c u r a t e l y .
5. The associa ted hormone data could be interpreted in acc ord ance 
wit h the 2 cell hy po thesi s of steroid productio n in the luteal 
phase of the cycle, with the ultrasonic differences observed 
p o s s i b l y  repre sen ting difference s in v a s c u l ar isatio n of the 
cysts. LUF cycles possibly represent a failure of the blood- 
folli cle  barrier to be broken down, decre asing a v a i l a b i l i t y  to 
the g r a n ulosa  lutein cells of precursors for steroid production, 
with  a consequ ent reduction in secretion of products. Low 
fo ll icul ar  phase plasma FSH concentrations were not seen in the 
luteal cyst cycles, in contrast to previous reports in the 
li terat ur e in respect of luteal phase defects. Cycles associated
with normal P p r o d u c t i o n  in the early luteal phase (up to day 
+6) tended to have sligh tl y higher than normal early follicular 
phase FSH concen tr ations.  FSH concen tratio ns  in the raid-luteal 
phase of the cycle, in both types of cyst formers, tended to be 
elevated. This may be a co nsequen ce of diff er ences in the 
se cretion of i n h i b i n — like products by the corpus luteum, or 
d ev ia tions from the normal in hyp othalamic  pulsatile control of 
g o n a d o t r o p h i n  se cr etion by the pituitary. This would be an 
in ter esting avenue of research  for the future.
De fic ie nt P p r o d uc tion in the early luteal phase (PPS) was 
identified in 51 (29.1%) of the patients under study, a similar
p ro po rtion to that describ ed previous ly (Fleming et al 1981). 
Elevated follicula r phase FSH conce ntratio ns in PPS cycles 
suggested that the dominan t follicles recruited may be abnormal, 
and do not derive from sub-normal follicular phase FSH profiles 
at any stage. It was hyp othesised  that low P prod uction may be a 
c ons equence  of one of two possible pat hogenic pathways : the
first where granu lo sa cell populations may be small, leading to 
decre ase d aromatase activ it y (low E2) and low inhibin-like 
a cti vity (high FSH) in the follicular phase; and the second 
where LUF occurs, the integrity of the blood -foil ic le barrier 
failing to be breached.
Ton i c a l l y  elevated LH secretion was identified in 23 (13.1%) of 
the un explained  infertile patients. High LH profiles were 
ass ociated with ab no rmalities of follicular dynamics in more 
than 2/3 of cases. Luteal cyst formation was commonly seen, with 
luteal phase defects seen in a high proportion of the remainder. 
Studies of LHRH puls at ility  patterns may provide insight into
the p a t h o p h y s i o l o g y  of this disorder.
Su b-opt im al  follicular de ve lopment was seen in ass oc iation with 
reduced pla sm a conce ntrat io ns of E 2 , but in some cases steroid 
c o n c e n t r a t i o n s  were normal. Consi d e r a t i o n  of the follicular 
phase g o n a d o t r o p h i n  profiles was esse ntial to clarify the 
pa th o l o g i c a l  processes involved.
Ab n o r m a l i t i e s  of cycle phase length, na mel y the short luteal 
phase, the long follicular phase and the short follicu lar phase, 
were rare in patients with unexplained infertility. The majority 
of such cycles showed normal biochemical and ultrasonic 
prof iles .
A b n o r m a l i t i e s  of ova rian function occurred with reduced 
fr e q u e n c y  in women with relatively short (<3yrs) durations of 
unex p l a i n e d  infertility. Intensive cycle inv esti gation  could not 
be r e c o m men de d as a dia gno st ically de fin itive, or eco nomi cally 
j u s t i f i a b l e  technique of primary i n vest ig ation in such patients.
The dia gn os is of LUF by luteal phase l a p a ro sc opy i.e. absence of 
stigma of ov ula tion on the corpus luteum, did not correlate well 
with ul tr a s o n i c  desc rip tions of the phenomenon. Ult rasound may 
have too high a false negative rate to permit its use as a tool 
of study of the incidence and recurrence of the LUF syndrome. 
Alternativ el y, subjective assessment of the presence or absence 
of an ov ul ation  stigma was also imprecise when compared to the 
ultrasoni c features of LUF described above.
Pe ri toneal fluid steroid concentrations in women who exhibited
14.
15.
16.
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o v u l a t i o n  stigmata varied enormously, and considerable overlap 
b e t w e e n  normal and l a p a r o s c o p i c a l l y  di agnosed LUF cycles 
existed.
Ne it he r ultr asoun d nor bio che mistry, in isolation, was ideal to 
evaluat e ovarian function. When ul tr a s o n i c  follicular dynamics 
appeare d to be normal, in a single cycle of investigation, it 
was likely that in a repeated exam i n a t i o n  the pattern would 
again be normal. This was not the case with the hormone 
profiles, since, in some cases, abnor m a l i t i e s  of steroid 
pr o d u c t i o n  were identified in the absence of ultrasonic 
de v i a t i o n s  from normal.
Ov a r i a n  function, as assessed by detailed bio chem is try and 
u l t r a s o n i c  examinations, may change from cycle to cycle, and 
thus the imp lications for long term ferti lit y of finding an 
isolated abn ormal it y remain unsolved. T he rapeuti c decision 
ma k i n g  in une xplained infertility remains difficult, and must 
only be considered after observing recidivism  of an abnormality.
Since v a r ia tion in the abnormalities described could occur from 
cycle to cycle, des igning therapy to correct a single pattern of 
ab no r m a l i t y  is unjustified. The different abnormalities may be a 
m a n i f e s t a t i o n  of a fundamental di sturbance  in ovarian function, 
best approached through a strategy which attempts to override 
all pot ential deviations from normal. In vitro f e rt ilizati on  or 
GIFT might be suitable, or the approach of pituitary down- 
re g u lation  with GnRH agonists and subsequent ovulation induction 
with exogenous gonadotrophins.
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Table 2.1
Radio-im mu no assay technical details
Hormone 17-B es tradiol Progesterone FSH LH
Antigen es tradiol-6-Cl­
ear boxyme thy 1 
oxirae
Proges terone 
-11 alpha- 
hemisuccinate
FSH hCG
Major cross 
reactions
Oestriol (11%) 
Oestrone (1.2%)
De oxyco r t ico- 
sterone (11%)
20 alpha di­
hydro proge s t- 
erone (1.2%)
None hCG
(100%)
Precision 
of inter- 
Assay intra-
11.3%
10.2%
11.8%
9.2%
8.1%
3.8%
7.4%
4.2%
Minimura
Sensitivity
1Opg/ml 2 Opg/ml 1IU/1 2 IU/1
(Coutts et al 1981)
Table 2.2 
Controls 
Patient/cycle characteristics
Nos Mean SD SEM Median Range
*
AGE (Years)
43 26.4 4.2 0.6 26 18-36
FOL LIC ULAR PHASE (Days)
43 14.3 2.9 0.4 14 10-21
LUTEAL PHASE (Days)
43 15.1 1.0 0.2 15 13-17
CYCLE LENGTH (Days)
43 29.5 3.1 0.5 29 24-35
Table 2.3
Group 1 (U/S) vs Group 2 (U/S + Bioch) 
Follicular diameters (mm)
Gp. Mean SD
1 11.5 2.15 4
Day -5 1•09 >0.1
2 13.0 2.3 10
1 13.1 1.9 8
Day -4 1.93 >0.05
2 14.8 1.6 8
1 16.1 3.7 11
Day -3 0.46 >0.1
2 15.4 2.0 7
1 17.5 3.4 12
Day -2 0 . 6 0 > 0 . 5
2 18.3 2.3 9
1 19.6 2.9 11
Day -1 0.58 >0.5
2 20.2 2.0 12
1 19.9 5.2 11
D a y O  0.42 >0.5
2 20.6 1.7 11
Table 2.4
Group 2 (Biochemi st ry & U/S) vs. Group 3 (Biochemistry)
Plasma E2 concentrations (pg/ml)
Group me an SD N o s . t P
2 85 10.3 13
Day -8 0.78 >0.1
3 92 30. 1 11
2 122 21.9 15
Day -4 2.61 >0. 01
3 148 29.7 12
2 153 35.4 15
Day -3 1 .53 >0.1
3 176 42 . 8 12
2 192 46.3 15
Day -2 1 .03 >0.1
3 215 67.6 11
2 216 48.7 15
Day ~1 1.34 >0.1
3 244 62.4 12
2 189 42.9 14
Day 0 1.60 >0.1
3 223 64 .2 12
2 130 32.8 16
Day +1 1 .70 >0.1
3 107 40.4 12
2 137 32 . 8 16
Day +2 2.24 >0. 02
3 112 23.7 12
2 171 53.2 16
Day +8 0.58 >0.5
3 160 46. 2 11
2 182 21.8 1 6
E2 Index 1.10 >0.1
3 194 37 . 1 12
Table 2.5
Group 2 (Bioch & U/S) vs Group 3 (Bioch)
Plasma P concentrations (ng/ml)
Group mean SD Nos t P
2 0.8 0.5 10
Day 0 2.00 >0.05
3 1 .2 0.3 1 1
2 1.7 0. 9 16
Day +1 2 . 00 >0. 05
3 2.3 0.7 12
2 3 . 3 0. 9 15
Day +2 5.35 <0.001
3 5.7 1 . 5 12
2 7 . 6 3.8 16 -
Day +3 1 .40 >0.1
3 9.4 2.7 12
2 12.1 5.2 15
Day +4 1 .62 >0.1
3 15.1 4.2 12
2 17.0 4.9 16
Day +5 0.45 >0.5
3 17.9 5.6 12
2 18.1 5.9 1 6 j
Day +6 0.86 >0.1
3 20.0 5.7 12
P Index 2 58.5 16.5 16
(Sum +2- + 6) 1 .94 >0. 05
3 70.6 16.1 12
Table 2.6
Group 2 (Bioch & U/S) vs Group 3 (Bioch)
Plasma FSH con centrations (IU/1)
Group me an SD Nos t P
2 4.7 2.3 15
Day -5 0.32 >0.5
3 4.4 2 . 4 12
2 4.6 3.6 16
Day -2 1.40 >0.1
3 3.3 1 . 5 11
2 6.2 5.1 15
Day -1 0.93 >0.1
3 4.6 3.4 12
2 10.4 4.4 14
Day 0 0.42 >0.5 ‘
3 11.2 5.2 12
2 8.2 5.9 16
Day +1 1.47 >0.1
3 5.2 1.9 9
2 4.5 2 . 3 15
Day +2 0.45 >0.5
3 5.1 4.5 12
2 2.4 1.2 13
Day +8 0.43 >0.5
3 2.2 1. 1 12
Table 2.7
Group 2 (Bioch & U/S) vs Group 3 (Bioch)
Plasma LH concentrations (IU/1)
Group mean SD Nos . t P
2 8.7 3.3 15
Day -5 0.98 >0.1
3 7.5 3.1 12
2 10.9 4.6 16
Day -2 0.51 >0.5
3 10.1 2.1 11
2 19.5 11.9 15
Day -1 0.70 >0.1
3 16.9 5.3 12
2 62.9 21.6 14
Day 0 0. 03 >0.5
3 63.2 29.7 12
2 27.7 16.4 16
Day +1 0.62 >0.5
3 23.5 17.1 10
2 13.4 6.1 15
Day +2 1.45 >0.1
3 10.6 3.2 12
2 6.4 3.1 13
Day +8 0.20 >0.5
3 6.1 4.5 12
Table 2.8
Controls
Plasma E2 con centrations (pg/ml)
Day No s Median Mean SD SEM 95% low 95% hi,
-10 23 75 . 0 79.7 2 1.3 4.4 70.5 88 . 8
-9 24 90.0 87 . 9 17.0 3 . 5 80. 7 95. 1
-8 26 88.0 87.2 23.9 4 . 7 77.6 96.8
-7 27 95.0 92 . 5 22.0 4.2 83 . 8 101 .2
-6 24 100.0 1 00. 3 2 1.1 4.3 91.4 109.2
-5 28 115.0 114.5 27.6 5.2 103 . 8 125.2
-4 27 130.0 133.2 28.3 5.4 122.0 144.4
-3 27 150.0 162.9 39.8 7 . 7 147.2 178.6
-2 26 202 . 5 201.6 56.3 11.0 178.9 224 . 3
-1 2 7 220.0 228 .4 55.8 10.7 206 . 4 250. 4
0 26 210.0 204 . 6 55.4 10.9 182.2 227.0
+ 1 28 124.0 120.4 37.5 7 . 1 105.9 134.9
+ 2 28 107 . 5 109.5 28.8 5.4 98. 4 120.6
+ 3 28 125.0 129.2 44.5 8.4 112.0 146.4
+ 4 28 135.0 139.5 42 . 3 8 . 0 123.1 155.9
+ 5 27 150.0 150.3 43 . 3 8 . 3 133.2 167.4
+ 6 28 145.0 159.1 46.7 8 . 8 141.0 177.2
+ 7 27 160.0 159.6 41 .2 7 . 9 143.3 175.9
+ 8 27 155.0 16 6.6 49.9 9.6 146.9 186.3
+ 9 26 168.0 165.6 50.3 9.9 145.3 185.9
+ 10 20 134.0 138.2 53. 6 11.9 113.3 163. 1
+ 11 1 6 102 . 5 116.2 53.0 13.3 88.0 144.4
+ 12 1 6 105. 0 108. 1 36.9 9.2 88.4 127.8
+ 13 14 79.0 85.5 33 . 3 9.0 6 6.1 1 04 . 9
+ 14 6 80.0 89 . 7 31.3 13.0 56.2 123.2
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Table 2.9 
Controls 
E2 Index (pg/ml)
Actual Corrected (%)
Mean 186.9 100.0
SD 29.4 15.7
SEM 5.6 3.0
95% low 
high
175.5
198.3
93. 9 
106.1
Nos
21
28
27
28
27
28
28
28
28
26
19
17
1 6
13
8
Table 2.10
Controls
Plasma P concentrati ons (ng/ral)
Median Mean SD SEM 95% low 95% high
0.9 1 . 0 0.4 0 . 1 0.8 1.2
1. 9 2 . 0 0.8 0.2 1 . 7 2 . 3
4.0 4.3 1 . 7 0.3 3.6 5.0
8.4 8.4 3.4 0.7 7.1 9.7
14.0 13.4 4.9 1.0 11.4 15.4
17.0 17.4 5.2 1 . 0 15.4 19.4
18.9 18.9 5.8 1 . 1 16.7 21.1
19.1 19.0 5.2 1.0 17.0 21.0
18.5 18.3 6.0 1 . 1 16.0 20.6
14.8 15.6 6 . 6 1.3 12.9 18.3
12.2 11.6 6.9 1 . 6 8.3 14.9
5.4 6.0 3.9 0. 9 4.0 8.0
1.9 3 . 5 3.9 1.0 1.4 5.6
1.2 2.3 2.5 0.7 0.8 3.8
0.9 1 . 5 1 .4 0.5 0.4 2.6
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Table 2.11 
Controls 
P Index (ng/ml)
Actual Corrected
Nos 28 28
Mean 63. 7 100.0
SD 17.2 27.0
SEM 3 . 3 5.1
95% 1 ow 56.9 89.5
high 70. 5 110.5
99% low 54.8 85.9
high 72.6 114.1
Day
- 1 0
-9
-8
-7
-6
-5
-4
-3
- 2
-1
0
+1
+ 2
+ 3
+ 4
+ 5
+ 6
+ 7
+ 8
+ 9
+ 10
+ 11
+ 12
+ 13
+ 14
Table 2.12
Controls
Plasma FSH concentrations (IU/1)
Nos Median Mean
24 5.2 5.4
25 5.0 5.7
25 5.5 6.0
27 4.7 5.4
26 4.1 4 . 7
27 4.2 4.6
26 3.6 4.2
.2 5 3.3 3.5
27 3.4 4 . 1
27 3 . 8 5.5
26 11.5 10.8
25 4.5 7 . 1
27 4.3 4.8
28 3.6 4.4
26 3.3 3.8
26 2.7 3.2
26 2 . 1 2 . 7
24 2 . 0 2 . 3
25 2.1 2 . 3
25 1. 8 2 . 0
20 1 . 9 2 . 0
17 1 . 9 2.1
17 2.3 2 . 6
13 2.9 3.2
9 3.5 3.9
SD SEM 95% low
2 . 1 0.4 4.5
1 . 9 0.4 4.9
2.6 0.5 4.9
2.2 0.4 4.5
2 . 0 0.4 3.9
2.3 0.4 3.7
2 . 1 0.4 3.3
1 . 8 0.4 2 . 8
2.9 0.6 2.9
4.4 0.9 3.7
4.7 0.9 8.9
5.0 1 . 0 4.9
3.4 0.7 3.5
3.3 0.6 3.1
1 .9 0.4 3.0
1 . 7 0.3 2.5
1 . 3 0.3 2.2
1.2 0.2 1.8
1 .1 0.2 1.8
1 . 1 0.2 1.6
1. 1 0.2 1.5
1.2 0.3 1.5
1.8 0.4 1.7
2.2 0.6 1 . 9
2.6 0.9 1 .9
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Table 2.13
Controls
Plasma LH concentrations (IU/1)
Nos Median Mean
24 7.3 8.2
25 8.0 8.3
25 8.4 8.9
27 8.3 8.7
26 7 . 7 8.2
27 8.1 8.1
26 7 . 7 7 . 7
25 8.6 8.9
27 10.0 10.6
27 16.5 18.3
26 73.5 63 . 0
26 18.7 26.1
27 11.6 12.1
2 8 11.1 11.3
2 6 9 . 8 10.8
26 8 . 1 8.5
26 6.7 8 . 7
24 5.3 6.2
25 5 . 7 6 . 2
25 6 . 3 6.8
19 5.4 6.0
18 4.6 5.4
17 5.7 6.8
13 7 . 0 9.4
8 6.6 6.7
SD SEM 95% low
3.9 0.8 6.6
3 . 0 0.6 7.0
3.5 0.7 7.5
3 . 3 0.6 7.4
3 .1 0.6 6.9
3 . 2 0.6 6.8
2 . 5 0.5 6.7
3 . 7 0.8 7.4
3 . 7 0.7 9.1
9.5 1 . 8 14.6
25.1 4.9 52.9
16.5 3.2 19.4
5. 1 0.9 10.2
4 . 9 1 . 0 9.2
5.4 1 . 0 8.6
4.1 0.8 6.8
5.6 1 . 1 6.4
4.4 0.9 4.3
3 . 8 0.8 4.6
4.2 0.8 5.1
3.5 0.8 4.3
2.9 0.7 4 . 0
4.0 1 . 0 4.7
7.0 2 .0 5.1
2.6 0.9 4.5
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Table 2.14
Controls
Plasma LH : FSH ratio
Day Nos Med i an Mean SD SEM 95% low 95% hi]
-10 24 1.4 1 . 6 0.8 0.2 1.2 2 . 0
-9 25 1 . 5 1 . 6 0.9 0.2 1. 2 2 . 0
-8 25 1.6 1 . 7 0.7 0.1 1. 5 1 . 9
-7 27 1 . 7 1 . 8 0.8 0.2 1.4 2.2
-6 26 1.8 2 . 0 1 . 1 0 . 2 1.6 2.4
-5 27 1 . 9 2 . 2 1 . 3 0.3 1.6 2.8
-4 26 1.9 2 . 3 1 . 5 0.3 1 . 7 2.9
-3 25 2 . 8 2 . 9 1 . 6 0.3 2.3 3.5
-2 27 3 . 0 3 . 3 1 . 6 0.3 2 . 7 3.9
-1 27 4 . 5 4.4 2.4 0.5 3.4 5.4
0 26 6.1 6.6 3 . 8 0.7 5.2 8.0
+ 1 25 3.9 4 . 2 2 . 5 0.5 3.2 5.2
+ 2 27 2.9 3.2 1 . 8 0.3 2 . 6 3.8
+ 3 2 8 2 . 9 3 . 2 1 . 5 0.3 2 . 6 3.8
+ 4 26 3 . 0 3.2 1 . 7 0.3 2.6 3.8
+ 5 26 2 . 8 2.9 1.4 0.3 2.3 3.5
+ 6 26 3 .1 3 . 3 1 . 9 0.4 2 . 5 4.1
+ 7 24 2.9 2.9 1 . 4 0.3 2.3 3.5
+ 8 25 3.2 2 . 9 1 .2 0.2 2 . 5 3.3
+ 9 25 3.7 3 . 8 2 . 0 0.4 3.0 4.6
+ 10 18 3 . 0 3.3 1 . 9 0.4 2.5 4.1
+ 1 1 1 6 2.5 2 . 7 1.6 0.4 1. 9 3.5
+ 12 16 2.3 2.9 1 . 9 0.5 1.9 3.9
+ 13 12 2 . 0 3 . 1 3 . 1 0.9 1 . 1 5.1
+ 14 8 1 . 5 1 . 9 1 .0 0.4 1 . 0 2.8
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Table 2.15
Controls
Follicular diameters (mm)
Median Mean SD SEM 95% low 95% high
10.0 10.5 1 . 0 0.5 8.9 12.1
10.0 9.8 1 . 1 0.5 8.4 11.2
12.0 12.3 2 . 3 1 . 0 9.9 14.7
13.0 12.5 2.4 0.6 11.2 13.8
14.3 13.9 1 . 9 0.5 12.9 14.9
15.5 15.8 3 . 1 0.7 14.3 17.3
18.0 17.8 3 . 0 0.6 16.5 19.1
20.0 19.9 2 . 4 0.5 18.8 21.0
21.0 20.2 3 . 8 0.8 18.5 21 . 9
19.0 18.0 5.2 1.4 15.1 20.9
16.5 16.1 4.3 1 .4 13.0 19.2
12.0 13.0 1 . 7 1 .0 8.7 17.3
9.0 9.0 1 . 0 0.6 6.5 11.5
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Table 3.1
Conceptions
Plasma E2 concentrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-9 8 85.0 86 . 3 8.3 2 .95 79.5 93 . 1
-8 10 87 . 5 87 . 8 18.3 5.79 74.7 100.9
-7 10 105.0 96 . 3 24 . 1 7 .62 79.1 113.5
-6 10 97 . 5 99 . 3 25.1 7 . 94 81 . 3 117.3
-5 11 120.0 110.7 28.7 8.65 91 .4 130.0
-4 10 119.0 129.6 40. 9 12 . 90 100.4 158.8
-3 10 167.5 163.0 40.8 12.90 133.8 192.2
-2 10 217.5 240.3 86.2 27.23 178.7 301 . 9
-1 1 1 220.0 238 . 0 62 . 8 18.93 195.8 280.2
0 1 1 220.0 230. 9 31.4 9.47 209.8 252 . 0
+ 1 1 1 1 53 . 0 1 53 . 0 27.6 8.32 134.7 171.5
+ 2 “ 11 120.0 113.6 39.4 11.88 87 . 1 140.1
+ 3 11 105.0 116.4 34 . 7 10.46 93 . 1 139.7
+ 4 1 1 140.0 142.1 47 . 3 14.26 110.3 173.9
+ 5 1 0 142.5 155.0 55.3 17.49 115.4 194.6
+ 6 1 1 155.0 159.0 30.7 9.26 138.4 179.6
+ 7 11 160.0 162.5 27.5 8.29 143.7 181.3
+ 8 1 1 170.0 181.8 37.9 13.43 151.9 211.7
+ 9 1 1 170.0 165.9 24 . 3 7.33 149.6 182.2
+ 10 9 195.0 186.4 45 . 6 15.20 151.3 221.5 a
+ 11 8 185.0 199.4 72.9 25.77 138.5 260.3 b
+ 12 5 200. 0 220.0 60.4 27 . 01 145.0 295.0 c
+ 13 3 210.0 216.7 11.4 6.58 188.4 245.0 c
+ 14 2 266.5 266.5 47.4 33.52
Significance (Wilcoxon Rank Sum Test) in comparison with controls
a = p <0.05 
b = p <0.01 
c = p <0.001
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Table 3.2
Conceptions
Plasma P concentrations (ng/ml)
Day Nos Median. Mean SD SEM 95% low 95% high
0 10 1.0 0.9 0.2 0. 06 0.8 1.0
+ 1 1 1 1 . 6 1 . 9 0.7 0.21 1 . 4 2 . 4
+ 2 11 3.9 4 . 0 1 . 5 0.44 3.0 5.0
+ 3 11 8.4 9.2 3 . 5 1 . 06 6.8 11.6
+ 4 10 13.7 13.2 3 . 1 0.99 11.0 15.4
+ 5 11 17.0 19.0 7.0 2.10 14.3 23 . 7
+ 6 1 1 20.6 20.5 8.1 2.45 15.0 26.0
+ 7 10 21.8 21.3 7 . 3 2.31 16.1 26.5
+ 8 11 18.4 20.0 6.9 2 . 07 15.4 24.6
+ 9 10 16.7 16.1 6.7 2.10 11.3 20.9
+ 10 9 18.3 20.2 9.4 3.14 13.0 27.2 a
+ 11 8 17.8 20.8 10.0 3.53 12.5 29.1 b
+ 12 7 “ 20.0 24.7 11.0 4.17 14.5 34.9 b
+ 13 6 29.5 29.9 8.2 3.36 21.3 38.5 b
P
index
11 105. 5 105. 0 33.6 10.13 82.4 127.6
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.02 
b = p <0.001
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Table 3.3 
Conceptions 
Plasma FSH concentrations (IU/1)
Day Nos Median Mean SD SEM 95% low 95% high
-9 8 5.0 6 . 0 3 . 0 1 .06 3 . 5 8.5
-8 9 5.5 5.8 2 . 6 0.85 3 . 8 7 . 8
-7 8 5.3 4.9 1 . 8 0.63 3.4 6.4
-6 9 4.2 4.4 1 . 3 0.43 3 . 4 5.4
-5 10 3.7 4.1 2 . 0 0. 62 2 . 7 5.5
-4 9 3 . 1 3.3 1 . 2 0.41 2 . 4 4.2
-3 8 2.9 3 . 0 1 . 1 0.40 2 . 1 3.9
-2 10 2 . 6 2 . 9 1 . 1 0.36 2 . 1 3.7
-1 10 3.1 3.1 0.9 0.30 2.4 3 . 8
0 10 9.6 9.8 3.1 0.99 7.6 12 . 0
+ 1 10 8.0 8.9 6 . 0 1.91 4.6 13.2
+ 2 10 4.4 4.3 1 . 4 0.43 3.3 5.3
+ 3 10 “ 3 . 1 3.1 1 . 4 0.44 2 . 1 4.1
+ 4 9 2 . 7 2. 9 1 . 4 0.47 1 . 8 4.0
+ 5 9 2.4 2 . 5 1 . 1 0.36 1 . 7 3 . 3
+ 6 9 1 . 8 2 . 0 1 . 0 0.35 1 . 2 2 . 8
+7 8 1.7 1 . 9 1 . 0 0.37 1.0 2 . 8
+ 8 8 1.6 1 . 9 1 . 1 0.39 1 . 0 2 . 8
+ 9 8 1.3 1 . 5 0.9 0.32 0.7 2.3
+ 10 3 1.3 1 . 4 0.2 0.13 0.8 2 . 0
+ 11 2 1 . 1 1 . 1 0.7 0.50 - -
+ 12 3 1 . 3 1 . 3 0.5 0.26 0.2 2.4
+ 13 3 1 . 6 1 . 4 0. 5 0.27 0.2 2 . 6
+ 14 2 1 .4 1.4 0.8 0.59
No significant differences in comparison with controls 
(Wilcoxon rank sum test)
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Table 3.4 
Concep tions 
Plasma LH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-9 8 7 . 1 7 . 9 5.1 1 .82 3 . 6 12.2
-8 9 8.4 7 . 8 4.2 1.40 4.6 11.0
-7 9 7 . 9 8.3 4.3 1 .43 5.0 11.6
-6 8 8.6 9.0 5.2 1 .54 5.4 12.6
-5 10 8.3 8.9 5.3 1 .89 4.6 13.2
-4 9 7.9 6.6 3.2 1 . 06 4.2 9.0
-3 7 7.2 6.8 4.4 1 .68 2 . 7 10.9
-2 10 10.0 9.6 4.4 1 .40 6.4 12.8
-1 10 13 . 7 13.8 5.0 1.57 10.2 17.4
0 10 73.5 65.4 28.6 9.03 45.0 85.4
+ 1 10 43.6 36.3 17.0 5.37 24 . 2 48.4
+2 10 15.7 14.1 7.0 2.23 9 . 1 19.1
+ 3 10 “ 12.5 11.0 6 . 3 1 .98 6.5 15.5
+ 4 9 8.0 8.4 3.5 1.16 5.7 11.1
+ 5 9 7 . 9 8.9 4.0 1.35 5.8 12 . 0
+ 6 9 8.3 9.4 6.3 ■ 2 . 09 4.6 14.2
+ 7 9 4.7 7.4 5.3 1.77 3 . 3 11.5
+ 8 9 7 . 2 8.1 5.3 1.76 4.0 12.2
+ 9 < r 6.4 7.2 4 . 6 1 . 52 3.7 10.7
+ 10 4 7 . 7 6.4 2 . 7 1 .34 2 .1 10.7
+ 11 4 8.7 8 . 0 2.3 1.18 4.2 11.8
+ 12 3 18.0 17.0 1 . 7 1 .00 12.7 21.3 a
+ 13 4 23.5 21.2 6.6 3.28 10.8 • 31.6 a
Significance (Wilcoxon rank sum test) in comparison with controls 
a = p <0.001
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Table 3.5
Conceptions
Follicular Diameters (mm)
Day Nos Med ian Mean SD SEM 95% low 95% high
-4 4 14.8 14.6 0.48 0.24 13.8 15.4
-3 2 14.8 14.8 3.18 2.25 - -
-2 6 16.0 15.8 0.75 0.31 15.0 16.6
-1 6 18.5 18.8 1.86 1.32 15.4 22.2
0 8 20.8 20.8 1.46 0. 52 19.6 22.0
+ 1 7 20.5 20.2 2.91 1 .10 17.5 22 . 9
+ 2 3 16.0 16.5 6.76 3 .90 —
No significant differences in comparison with controls 
(Wilcoxon Rank Sum Test)
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Table 5.1.1 
Luteal Cyst Formers 
Patient/cycle characteristics
Nos Mean SD SEM Med i an Range
AGE (Years) 
All cysts 41 29.7 4.2 0.7 29 22-39 a
Shrinkers 21 30.3 4.6 1 .0 30 22-39 a
Non-shrinkers 20 29.1 3.8 0.8 29 24-38 a
> 2 Omm 30 29.2 3 . 9 0.7 29 22-38 a
<2 Omm 11 31.3 4.8 1 .4 30 23-39 a
Normal PI 1 0 30.8 4.9 1 . 5 31 23-39 a
Low PI 31 29.4 4.0 0.7 29 22-38 a
FOLLICULAR PHASE (Days) 
All cys ts 41 14.6 3.4 0.5 14 8-27
Shrinkers 21 14.3 3.1 0.7 14 11-25
Non-shrinkers 20 14.9 3.8 0.9 14.5 8-27
> 2 Omm 30 14.8 3 . 2 0.6 15 8-27
<2 Omm 1 1 13.9 4 . 0 1.2 13 11-25
Normal PI 10 13.5 2 . 1 0.7 13 11-17
Low PI 31 14.5 3.7 0.7 1 5 8-27
LUTEAL PHASE 
All cysts
(D a y s ) 
41 15.0 1 . 6 0.3 15 11-18
Shrinkers 21 14.9 1 . 8 0.4 1 5 11-17
Non-shrinkers 20 15.2 1 . 5 0.3 15 12-18
> 2 Omm 30 15.1 1 . 6 0.3 1 5 12-18
<2 Omm 1 1 14.9 1 . 6 0.5 15 11-17
Normal PI 10 14.7 0. 9 0.3 15 14-16
Low PI 31 15.2 1 . 8 0.3 15 11-18
CYCLE LENGTH 
All cysts
(D a y s ) 
41 29.6 3 . 9 0.6 30 22-44
Shrinkers 21 29.2 3 . 8 0.8 29 22-41
Non-shrinkers 20 30. 1 4 . 0 0. 9 30 25-44
>2 Omm 30 29 . 9 3 . 5 0. 6 30 25-44
<2 Omm 1 1 28 . 8 4.9 1 . 5 27 22-41
Normal PI 10 28.2 2 . 1 0.7 27 26-32
Low PI 31 30. 1 4 . 2 0.8 30 22-44
No significant inter-group differences.
Significance in comparison with controls : a = p <0.001
(Wilcoxon Rank Sum Test)
Table 5.1.2
Large Cysts (>20rom)
Plasma E2 concentrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 20 75.0 77.0 16.7 3.7 6 9.6 84.4
-9 21 80.0 77 . 0 17.9 3.9 69.2 84 . 8 a
-8 24 80.0 79.0 17.9 3 . 7 71.6 86.4 i
-7 25 85.0 86.2 17.2 3.4 79.4 93.0
-6 25 85.0 89.5 20.8 4.2 81 . 1 97.9 i
-5 26 107. 5 109.5 22.4 4.4 100. 6 118.2
-4 28 107.5 123.4 38.8 7.3 108.8 138.0
-3 28 140.0 144. 6 43.0 8.1 128.4 160.8
-2 28 166.5 181.3 50.2 9.5 162 .3 200.3
-1 27 230.0 216.0 51.2 9.9 196.2 235 .8
0 30 191.5 196.2 54.3 9.9 176.4 216.0 i
+1 28 140.0 . 139.1 42 . 7 8 . 1 122.9 155.3
+ 2 30 121.5 121.2 30.4 5.6 110.0 132.4
+ 3 30 135.0 136.2 28.7 5.2 125.8 14 6.6
+ 4 29 140.0 145.7 44 . 6 8.3 129.1 152 .8
+ 5 30 135.0 151.4 52 . 1 9.5 132.4 170.4
+ 6 28 140.0 148.9 49.2 9.3 130.3 167.5
+ 7 29 147.5 1 54 . 2 45.0 8.4 137.4 171.0
+8 28 142. 5 153.7 47.2 8.9 135.9 171.5
+ 9 26 137.5 158.3 70.8 13.9 130.5 186.1
+ 10 25 135.0 147.3 55.4 11.1 125.1 169.5
+ 11 2 7 133.0 143.4 57 . 1 11.0 121.4 165.4
+ 12 26 125.0 127.2 51.9 10.2 1 06 . 8 147.6
+ 13 24 115.0 108 . 6 41 . 0 8.4 91. 8 125.4
+ 14 22 97.5 97 . 1 30.9 6 . 6 83.9 110.3
Significance (Wilcoxon Rank Sum Test) in comparison with
Controls Small Cysts
p < 0.05 a i
Table 5.1.3
Small Cysts (<20mm)
Plasma E2 concentrations (pg/ml)
Day No s Median Mean SD SEM 95% low 95% high
-10 9 75.0 73.3 12.5 4.2 63 . 7 82 . 9
-9 10 77 . 5 80.5 21.8 6.9 64 . 9 96 .1
-8 10 87 . 5 96 . 0 27.8 8.8 86 . 1 115.9
-7 10 80.0 90.8 24.9 7.9 82 . 9 108. 7
-6 11 1 05 . 0 110.3 31.6 9.5 88.8 131.8
-5 1 1 115.0 119.6 32.0 9.6 97 . 9 141 .3
-4 11 133.0 140.3 36.9 11.1 115.2 165.4
-3 11 153.0 167.4 47.7 14.4 134.9 199.9
-2 11 195.0 199.5 59.6 18.0 158.8 240.2
-1 10 245.0 246 . 0 53. 7 17.0 207 . 6 284 . 4
0 11 235.0 236.2 38.2 11.5 220.2 252 .2
+ 1 1 1 130.0 143.6 39 . 8 12.0 116.9 170.3
+ 2 1 1 120.0 118.0 36.7 11.1 93 . 3 142.7
+ 3 11 120.0 131.5 33.8 10.2 108.8 154 . 2
+ 4 11 130.0 159.6 56.6 17.1 121.5 197.7
+ 5 11 148.0 162.1 48.5 14 . 6 129.6 194.6
+ 6 145.0 160.3 53 .2 17.7 119.5 201 . 1
+ 7 1 1 155.0 165.5 36.6 11.0 141.0 190.0
+ 8 11 165.0 175.7 45.7 13.8 145.0 206.4
+ 9 11 165.0 172.1 51.4 15.5 137.6 2 0 6 .6
+ 10 11 163.0 164.2 44.1 13.3 134.6 193 .8
+ 11 11 145.0 149.4 36.6 11.0 124.9 173.9
+ 12 9 135.0 144.8 61.2 20.4 98.7 190.9
+ 13 9 125.0 134.4 54. 6 18.2 93 .2 175.6
+ 14 9 93 . 0 125.7 75.6 25.2 68.7 182.7
No significant differences with controls (Wilcoxon Rank Sum Test)
FIGURE 5.1.1
CO
O
E
o
CM
CO X
i  * aE  ECO
O  O S
•«- ECO c
< §
O A
CD
E?
ce
too
O
CO
C
O
c5
o
£3
CD
C D
CD2?
05
L O
CZ> CZ> O
<Z> CO CD
o o o o o o o o
S ^  C V I O O O C D ^ C V J  
CM CM CM CM *1— — •t— **—
Day
 r
elat
ive 
to 
LH 
pe
ak
Table 5.1.4
Large Cysts (>20mm)
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 19 1 . 0 1 . 0 0.7 0.2 0.6 1.4
+ 1 27 1 . 3 1 . 6 1.3 0.3 1 . 0 2.2
+2 29 3.1 3.4 2 . 9 0.5 2.4 4.4
+ 3 30 4.9 5.4 3.7 0.7 4 . 0 6.8 b
+4 29 6.6 7.6 4.3 0.8 6.0 9.2 c
+ 5 30 11.1 11.2 5.7 1 .0 9.2 11.2 c i
+ 6 28 15.7 15.1 7.0 1.3 12.4 17.8 a
+ 7 29 17.2 17.8 7.5 1 . 4 14.9 20.7
+ 8 29 16.6 15.9 6.9 1 .3 13.2 18.6
+ 9 26 14.6 15.9 7.4 1 . 5 12.3 19.0
+ 10 25 16.4 14.8 6.9 1 .4 11.9 17.7
+ 11 27 13.4 12 . 9 7 . 2 1.4 10.0 15.8 c
+ 12 26 8.9 9.5 6.0 1.2 7 . 0 12 . 0 b
+ 13 24 5.4 5.7 4.9 1.0 3 . 6 7 . 8 a
+ 14 22 2.4 3.3 3.3 0.7 1.8 4.8
P
index 30 6 6.0 67.4 31.3 5.7 55.7 79.1 c
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls Small Cysts
p <0.05 a i
p <0.01 b
p <0.001 c
Table 5.1.5
Small Cysts (<20mm)
Plasma P concentrations (ng/ml)
Day Nos Median Mean SD SEM 95% low 95% high
0 7 0.8 0.8 0.4 0.2 0.3 1.3
+1 10 1 . 1 1 . 5 0.8 0.3 0.8 2.2
+2 11 2.7 3.0 1 . 6 0.5 1 . 9 4.1 a
+ 3 11 4.2 5.1 2 . 0 0.6 4.8 6.4 b
+4 11 9.2 9.7 3.9 1 . 2 7.0 12.4 a
+ 5 11 13 . 4 15.4 6.1 1 . 8 11.4 19.4
+ 6 18.0 18.2 7.5 2 . 5 12.4 24 . 0
+ 7 11 17.6 19.1 5.2 1.6 15.6 22. 7
+8 11 18.0 18.5 5.7 1 . 7 14.7 22.3
+ 9 11 19.2 16.9 5.4 1 . 6 13.3 20.2
+ 10 11 15.0 13.9 5.9 1 .8 9.9 17.7
+ 11 11 11.6 12 . 7 7 . 5 2.3 7 . 6 17.8 b
+ 12 9 8.4 8.4 3". 7 1 . 2 5.6 11.2 b
+ 13 9 5.0 4.5 2.5 0.8 .2.7 6.3
+ 14 9 1.6 2 .1 1.4 0.9 0.9 3.3
P
index 11 84.0 80.0 26.7 8.1 62 .1 97.9
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05 
P <0.01
a
b
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Table 5.1.6
Large Cysts (>20mm)
Plasma LH concentrations (IU/1)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 18 8.8 8.9 4.0 0.9 6.9 10.9
-9 21 7.6 8.8 5.8 1 . 3 6.2 11.4
-8 24 7.3 8.9 5.6 1 . 1 6 . 5 11.3
-7 24 7 . 6 9.4 5.4 1 . 1 7 . 1 11.7
-6 25 9.4 9.5 4.4 0.9 7 . 7 11.3
-5 27 9 . 1 8.9 4.2 0.8 7 . 2 10.6
-4 27 6.9 7 . 6 3.7 0.7 6.1 9.1
-3 27 8.7 10.7 4.7 0.9 8 . 8 12 . 6
-2 27 9.8 10.7 4.7 0.9 8.8 12.6
-1 26 18.5 21.9 13.0 2 . 6 7.7 18.3
0 29 66.0 61.7 18.0 3.3 54.9 68.5 i
+ 1 28 19.0 24.2 14.6. 2 . 8 18.5 29.9
+2 29 13.0 13.5 7.1 1 .3 10.8 16.2
+ 3 30 14.0 14.1 6.4 1 . 2 11.7 16.5
+ 4 28 9.6 14.7 10. 5 2 . 0 6.4 14.6
+ 5 30 9.9 12.1 7.0 1 . 3 9.5 14.7
+ 6 27 9.0 9.7 6.2 1 .2 7.2 12.2
+ 7 30 7.9 9 . 1 6.0 1 . 1 6.9 11.3
+ 8 26 5.8 7.4 4.6 0. 9 5.5 9.3
+ 9 25 8 . 8 9 . 7 7 . 7 1 . 5 6.5 12 . 9
+ 10 25 6.7 7.4 5.0 1 . 0 2.9 7 . 1
+ 11 26 6 . 0 7 . 6 5.2 1 .0 5.6 9.6
+ 12 23 7.6 7.8 4.5 0.9 5 . 9 9.7
+ 13 23 . 7.1 6.7 2.9 0.6 5.5 7 . 9
+ 14 1 9 7.2 7 . 6 2.6 0.5 6.5 8.7
Significance (Wilcoxon Rank Sum Test) in comparison with :
Small Cysts 
p <0.05 i
No significant differences from controls.
Table 5.1.7
Small Cysts (<20mm)
Plasma LH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 8 8.1 9.4 6.1 2.2 4.2 14.6
-9 9 6.3 8.0 5.1 1 . 7 4.1 11.9
-8 9 9.5 10.0 7.6 2.5 4 . 3 15.7
-7 9 9.1 8.4 5.4 1 . 8 4.0 12.8
-6 10 8.0 9.8 6.5 2 . 1 5.0 14.6
-5 10 7.4 9.0 6.2 2 . 0 4.5 13.5
-4 10 8.6 9.0 5.7 1 . 8 4 . 9 13.1
-3 9 7.8 8.2 5.2 1 . 7 4.3 12 . 1
-2 10 10.0 10.2 6.0 1 . 9 5.9 14.5
-1 10 18.5 21.1 12 . 7 4.0 12 .1 30.1
0 10 42.5 45.7 22.7 7.2 29.4 62 . 0
+ 1 10 28.5 27 . 7 12.8 4rf0 18.7 36 . 7
+2 10 11.5 12.1 5.1 1.6 8.5 15.7
+ 3 10 8.3 10.2 7 . 1 2.2 5.2 15.2
+ 4 10 9.4 12.5 7.0 2.2 7.5 17.5
+ 5 10 7.0 8.9 5.7 3 . 2 1 . 7 16.1
+ 6 8 11.2 12.2 7.3 2 . 6 6.1 18.3
+ 7 10 6.5 8.3 6.3 2.0 3.8 12.8
+ 8 10 5.3 8.4 7.8 2.5 2.7 14.1
+ 9 10 3.7 6.1 6.2 2 . 0 1 . 6 10.6
+ 10 10 6.4 6.9 6.0 1.9 2.6 11.2
+ 11 10 4.3 5.0 4.2 1.3 2 .1 7 . 9
+ 12 8 5.0 6.1 4.8 1.7 2 .1 10.1
+ 13 8 8.1 7.2 5.1 1 .8 2.9 11.5
+ 14 8 7.1 6.7 4.6 1.6 2.9 10. 5
No significant differences from controls.
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Table 5.1.8
Large Cysts (>20mm)
Plasma FSH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 18 6 . 8 7.3 2 . 5 0.6 6 . 0 8.6 b
-9 21 6.9 7.2 2.7 0.6 5.9 8.5 a
-8 24 6.2 6.7 3.5 0.7 5.3 8.1
-7 24 5.5 5.9 2 . 6 0.5 4.9 6.9
-6 25 5.3 5.9 2.2 0.4 5.1 6.7 a
-5 27 5.6 5.0 1 . 5 0.3 4.4 5.6
-4 28 4 . 3 4.2 1 .1 0.2 3.8 4.6
-3 28 3 . 8 3.8 1.3 0.2 3.4 4.2
-2 28 4 . 0 3.8 1 .1 0.2 3.4 4.2
-1 27 4.6 5.0 2 . 1 0.4 4.2 5.8
0 30 14.0 13.5 6.0 1 . 1 11.3 15.7
+1 29 7 . 6 7 . 9 4.3 0.8 6.3 9.5
+ 2 28 5.3 6 .1 3 . 9 o.r 4.7 7 . 5
+ 3 30 4.4 5.1 3 . 0 0.5 4 . 1 6.1
+ 4 28 4.6 4.9 3.2 0.6 3 . 7 6.1
+ 5 30 4 . 0 4.4 3 . 1 0.6 3.2 5 . 6
+ 6 27 3 . 6 4 . 0 2 . 6 0.5 3.0 5.0 a
+ 7 30 3 . 5 3.7 2 . 9 0.5 2.7 4.7 a
+ 8 28 3 . 2 3.4 2.5 0.5 2.4 4.4 a
+ 9 24 3 . 0 3 . 7 2 . 7 0.6 2 . 5 4.9 c
+ 10 25 2 . 6 3 . 6 3.0 0.6 2.4 4.8 a
+ 11 27 2 . 7 3 . 2 2 . 4 0.5 2 . 2 4.2
+ 12 26 2.8 3.3 2.3 0.5 2.3 4.3
+ 13 24 2 . 8 3 . 7 2.7 0.6 2 . 5 4.9
+ 14 19 4.2 4.9 3.2 0.7 3.5 6.3
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05 a
p <0.02 b
p <0.01 c
No significant differences from small cysts.
Table 5.1.9
Small Cysts (<20mm)
Plasma FSH concentrations (IU/1)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 8 7 .1 7.6 4.4 1 . 6 3.8 11.4
-9 9 8.3 8.4 4.4 1 . 5 4.9 11.9 b
-8 9 6 . 8 7.7 4.0 1.3 4.7 10.7
-7 9 5.5 8.1 4.3 1 . 4 4.9 11.3 b
-6 10 7 . 1 7.7 4.4 1 . 4 4.5 10.9 c
-5 10 6.6 6 . 8 3 . 6 1 . 1 4.3 9.3 a
-4 1 0 5.4 5.5 2 . 3 0.7 3.9 7 . 1
-3 9 4 . 0 4.6 1 . 9 0.6 3.2 6.0
-2 10 4.0 4.5 1.8 0.6 3 .1 5.9
-1 10 5.7 6.0 3 . 0 0.9 4.0 8 . 0
0 10 13.5 10.5 5.8 1.8 6.4 14.6
+ 1 10 10.7 11.1 4.6 1 . 5 - 7 . 7 14.5 a
+ 2 10 7.5 7.3 3 . 0 0.9 5.3 9.3 a
+ 3 10 5.4 5.2 2 . 0 0.6 3 . 8 6.6
+ 4 1 0 4.6 4.7 1 . 5 0.5 3 . 6 5.8
+ 5 10 3 . 4 3 . 8 1 . 4 0.4 2.9 4.7
+ 6 8 3.4 3.6 0.9 1.3 0.5 6.7
+ 7 10 2 . 8 2 . 9 1 . 0 0.3 2.2 3 . 6
+ 8 10 2 . 8 2.9 1.2 0.4 2 . 0 3 . 8
+ 9 10 2 . 5 2 . 5 1 . 0 0.3 1 . 8 3 . 2
+ 10 10 2.5 2 . 6 0.8 0 . 3 1.9 3.3
+ 11 10 2.3 2.3 0.8 0.3 1 . 6 3 . 0
+ 12 8 2.5 2 . 7 1.2 0.4 1.8 3 . 6
+ 13 8 2 . 7 3.3 2 . 0 0.7 1.6 5.0
+ 14 8 3.7 4.4 3 . 0 1 . 1 1.9 6.9
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05
p <0.02 
p <0.01
a
b
c
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Table 5.1.10
Large Cysts (>20mm)
Follicular Diameters (mm)
Day Nos Med ian Me an SD SEM 95% low 95% high
-5 7 11.0 11.1 2.8 1 . 1 8.4 13.8
-4 11 13.8 14.1 2 . 6 0.8 12.3 15.9
-3 1 1 13.5 14.8 3.7 1 . 1 12.3 17.3
-2 12 16.0 17.1 3 . 8 1 . 1 14.7 19.5
-1 13 18.2 18.2 2.8 0.8 16.5 19.9
0 20 20.3 20.3 3.3 0.7 18.8 21.8
+ 1 19 20.0 21 . 1 5.6 1 . 2 18.4 23.8
+ 2 17 24 .0 23.7 4 . 0 1 . 0 21.6 25.8
+ 3 21 26.0 25.7 5.3 1.2 23.2 28.2
+ 4 15 27.0 26.7 6 .1 1 . 6 23.3 30. 1
+ 5 1 8 26.0 26.9 6.0 1.4 23.9 29.9
+ 6 12 28.5 29.5 8.6 2 . 5 24*0 35.0
+ 7 13 28 . 0 29.1 6.4 1 . 8 25.2 33.0
+ 8 13 30.0 31.8 10.8 3 . 0 25.3 38.3
Cys t 
size
31 29.5 30.4 8.4 1 . 5 27.3 33.5 a
Significance (Wilcoxon Rank Sum Test) in comparison with :
Small Cysts
p <0.001 a
No significant differences in FD's in comparison with controls or 
small cyst formers.
Table 5.1.11
Small Cysts (<20mm)
Follicular Diameters (mm)
Day Nos Med ian Mean SD SEM 95% low 95% high
-5 3 16.0 15.0 3.6 2 . 1 6.0 24.0
-4 5 12 . 0 13.9 3.2 1 . 4 10.0 17.8
-3 4 15.0 15.5 1.4 0.7 13.3 17.7
-2 7 17.0 16.8 2.2 0.8 14.8 18.8
-1 7 21.0 20.6 1.7 0.6 19.1 22.1
0 10 21.0 21. 6 3.4 1 . 1 19.1 24.1
+ 1 6 18.0 17.8 3.2 1 . 3 14.5 21 .1
+ 2 7 16.5 17.7 3.8 1.4 14.3 21.1
+ 3 5 16.5 15.9 3.4 1 . 5 11.7 20.1
+ 4 7 17.0 16.3 2 . 1 0.8 14.3 . 18.3
+ 5 2 16.5 16.5 0.7 0.5 10.1 22.6
+ 6 9 15.0 15.3 1 .4 0.5 14.1 16.5
+ 7 3 17.0 17.2 1.3 0.8 13.8 20.6
+ 8 4 17.5 18.0 1 .4 0.7 15.8 20.2
Cyst
size
11 16.0 16.2 1.4 0.4 15.3 17.1
No significant differences in comparison with controls 
(Wilcoxon Rank Sum Test)
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Table 5.1.12
All Cysts (shrinkers)
Plasma E2 concentrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 16 72 . 5 73 . 1 15.7 3.9 64.8 81 . 4
“ 9 17 80.0 77 . 9 23 .1 5.6 6 6.0 89.8
-8 18 80.0 84.2 19.8 4.7 74.3 94 .1
-7 18 85 . 0 87 . 9 21.9 5.2 76.9 98.9
-6 19 95 . 0 102 .8 28.8 6.6 88.9 116.7
-5 20 105. 0 119.3 27.4 6. 1 106. 5 132 .1
“4 19 120.0 133.5 37.3 8.6 115.4 151.6
-3 20 150.0 155.8 40.5 9.1 136.8 174. 8
-2 19 195.0 193.4 53 .6 12.3 167.6 219.2
-1 18 230.0 227 .2 51 . 5 12 . 1 201 . 7 252 . 7
0 21 220.0 218.1 42 .7 9.3 198.7 237 .5
+1 20 135.0 139.3 34 . 3 7 . 7 123.2 1 55.4
+2 21 123.0 118.6 29.1 6.3 105. 5 131.7
+ 3 21 125.0 130.9 28.9 6.3 117.8 144.0
+ 4 21 130.0 154.3 48.4 10.6 132.2 176.4
+ 5 21 135.0 151.2 42 . 0 9.2 132.0 170.4
+ 6 18 137.5 150. 7 45.7 10.8 127.9 173.5
+ 7 21 155.0 159.0 41.9 9.1 140.0 178.0
+ 8 21 155.0 163.0 44.8 9.8 142.6 183 .4
+ 9 1 9 1 50.0 155.9 47 . 7 10.9 133.0 178.8
+ 10 20 145.0 155.3 52.6 11.8 130.6 180.0
+ 11 20 140.0 137.9 38.1 8.5 120.1 155.7
+ 12 1 6 127.5 130.2 55.5 13.9 101 . 1 159.3
+ 13 1 6 112.5 116.3 49.7 . 12.4 86.1 142 . 7
+ 14 15 91 .5 111.4 62 .5 16.1 76.9 145.9
No significant differences from controls and non- shrinkers.
(Wilcoxon Rank Sum Test)
Table 5.1.13
All Cysts ( n o n - s h r i n k e r s )
Plasma E2 concentrations (pg/ral)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 13 80.0 79.2 14.8 4.1 70.2 88.2
-9 14 77 . 5 78.3 13.0 3 . 5 70.8 85 . 8
-8 1 6 87.5 83 . 8 15.8 3 . 9 75.4 92 .2
-7 1 7 85.0 87 . 1 17.1 4.1 78.3 95.9
-6 17 85 . 0 88.1 20.5 5.0 77.5 98.7
-5 1 7 105.0 104.4 21.3 5.2 93. 5 115.3
-4 20 115.0 123.2 39.9 8.9 104. 5 141.9
-3 1 9 140.0 145.9 49.8 11.4 121.9 169.9
-2 20 168.0 179.6 52 . 7 11.8 154.9 2 04.3
-1 1 9 235 .0 221.1 55.5 12 . 7 194.3 247 .9
0 20 191.5 195.2 61.2 13.7 166.6 223.8
+ 1 1 9 145.0 141.6 48.8 11.2 118.1 1 6l5 • 1
+2 20 116.5 122.2 35.0 7 . 8 105.8 138.6
+ 3 20 137.5 139.2 30. 9 6.9 124.7 1 53 . 7
+ 4 19 140.0 144.2 47.9 11.0 121.1 167.3
+ 5 20 135.0 157.5 59.7 13.3 129.6 185.4
+ 6 1 9 150.0 152.6 54.4 12.5 136.8 168.4
+ 7 1 9 1 55 . 0 155.3 44.7 10.3 133.8 176.8
+ 8 18 142.5 156.3 51 . 1 12.0 130.9 181.7
+ 9 1 8 155.0 169.2 80.6 19.0 129.1 209.3
+ 10 16 140.0 148.9 53 . 1 13.3 120.6 177.2
+ 11 1 8 136.5 153.2 63.6 15.0 121.6 184.8
+ 12 19 130.0 133.1 54.3 12.5 106.9 159.3
+ 13 17 115.0 115.1 43 .0 10.4 93.0 137.2
+ 14 16 97.5 99.7 31 .9 8.0 82.7 116.7
No significant differences from controls.
(Wilcoxon Rank Sum Test)
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Table 5.1.14
All Cysts (shrinkers)
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 14 0.9 0.9 0.7 0.2 0.5 1.3
+ 1 1 9 1 . 4 1 . 7 1 . 4 0.3 1 . 1 2.3
+2 2 1 3.1 3 . 8 3.3 0.7 2.3 5.3
+ 3 21 5.3 6 . 2 3 . 8 0.8 4.5 7 . 9
+4 21 10.6 10.3 3 . 8 0.8 8.6 12.0 a
+ 5 21 14.2 15.8 5.6 1 . 2 13.3 18.3 a iii
+ 6 18 18.0 19.5 6.6 1.6 16.1 22 . 9 iii
+ 7 21 19.2 20.4 5.1 1 . 1 18.1 22 . 7 i i
+ 8 21 18.0 18.9 5.6 1.3 16.2 21.6 i
+ 9 1 9 19.2 18.0 6.3 1.4 15.1 20.9 i
+ 1 0 20 16.4 15.5 7.0 1.6 12.2 18.8
+ 11 20 14.7 14.0 7.7 1 . 7 10.4 17.6 c
+ 12 1 6 10.4 9.6 4.5 1 . 1 7‘.3 11.9 c
+ 13 1 6 5.3 5 . 0 3 . 1 0.8 3.3 6.7 b
+ 14 1 5 2 .1 2 . 9 2.6 0.7 1 .4 4.4
p 21 84.0 86.0 28.1 6.1 73.2 98.8 iii
index
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls Non-shrinkers
P <0.05 a i
P <0.02 b
P <0.01 ii
P <0.001 c iii
Table 5.1.15
All Cysts (n o n - s h r i n k e r s )
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 12 1.0 1 .0 0.6 0.2 0.6 1.4
+ 1 1 8 1 . 2 1 .4 0.7 0.2 1 . 0 1 . 8 b
+2 19 2 . 8 2 . 7 1 .3 0.3 2.1 3.3 c
+ 3 20 4 . 1 4.4 2.4 0.5 3.3 5.5 d
+4 19 5.6 5.8 3.4 0.8 4.2 7.4 d
+ 5 20 8.2 8.8 4.1 0.9 6.9 10.7 d
+ 6 19 10.4 12.5 5.9 1 .4 9.7 15.3 d
+ 7 19 14.4 15.6 7 . 8 1 . 8 11.8 19.4
+ 8 19 10.8 14.2 6.9 1 . 6 10.9 17.5 a
+ 9 1 8 13.2 14.3 7.0 1 . 6 10.8 17.8
+ 10 16 13.4 13.2 6.0 1.5 10.0 16.4
+ 11 1 8 11.1 11.6 6.5 1 . 5 8.4 14.8 c
+ 12 19 8.2 8.9 6.3 1 . 4 5.9 11.9 c
+ 13 17 4 . 0 5.7 5.3 1.3 3 . 0 8.4 a
+ 14 16 1 . 1 3.0 3.2 0.8 1.3 4.7
P
index
20 53.5 Ln • 00 24 .1 5.4 43.5 66.1 d
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls
a 
b 
c 
d
t
p <0.05
p <0.02 
p <0.01 
p <0.001
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Table 5.1.16
All Cysts (shrinkers)
Plasma LH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 14 7.0 8.9 5.2 1 . 4 5.9 11.9
-9 16 6.5 8.2 5.7 1 . 4 5.2 11.2
-8 17 7 . 4 9 . 1 6.2 1 . 5 5.9 12.3
-7 17 7.4 9.2 6.4 1 . 5 6 .0 12 . 4
-6 18 7.0 9 . 6 5.9 1.4 5.2 14.0
-5 19 6.2 8.2 5.5 1 .3 5.5 10.9
-4 1 7 6.6 7 . 5 4.7 1 . 1 5 . 2 9.8
-3 17 7.0 7.4 4.0 1 . 0 5.3 9.5
-2 1 7 8 . 1 9.8 4.9 1.2 7 . 3 12.3
-1 17 19.0 20.7 13.4 3.2 13.9 27.5
0 19 50. 0 54. 7 21.6 4.9 44.4 65.0
+ 1 18 25.5 28.4 14.0 3.2 21.6 35.2
+ 2 1 9 12.0 12 . 2 5.6 1.3 9.5 14.9
+ 3 20 12.5 12.5 7 . 1 1.6 9.2 15.8
+ 4 20 10.0 14.2 11.3 2 . 5 9 . 0 19.4
+ 5 20 8.1 9.6 6 . 0 1.3 6 . 9 12.3
+ 6 1 6 11.0 10.2 6.7 1 . 7 6.6 13.8
+ 7 20 5.9 7 . 7 5.6 1 .3 5.0 10.4
+ 8 18 4 . 1 7.4 6.6 1 . 6 4 . 0 10.8
+ 9 1 7 3 . 8 7.2 7.2 1.7 3.6 10.8
+ 10 1 9 4.5 5.7 4.8 1 . 1 3.4 8 . 0
+ 11 18 4.4 5.8 5.2 1.2 3.3 8.3
+ 12 13 4.9 5.7 4.2 1.2 3 . 1 8.3
+ 13 15 7.6 7.4 4.0 1.0 5.3 9.5
+ 14 13 7.2 7.4 3 . 9 1.1 5.0 9.8
No significant differences from controls and n o n - s h r i n k e r s .
(Wilcoxon Rank Sum Test)
Table 5.1.17
All Cysts ( n o n - s h r i n k e r s )
Plasma LH concentrations (IU/1)
Day Nos Med i an Mean SD SEM 95% low 95% high
-10 12 9.9 9.3 4.0 1.2 6.8 11.8
-9 14 8.3 9 . 0 5.4 1 . 4 5.9 12.1
-8 16 7.4 9.4 6.2 1 . 5 6.1 12.7
-7 16 8.7 9.1 4 . 0 1 . 0 7.0 11.2
-6 1 7 9.7 9.5 4.1 1.0 7.4 11.6
-5 18 9.7 9.7 3.6 0.9 7.9 11.5
-4 20 7.0 8.3 3.9 0.9 6.5 10.1
-3 19 9.4 10.8 6.2 1.4 7.8 13.8
-2 20 10.0 11.2 5.1 1 . 1 8.8 13.6
-1 19 19.0 22 . 5 12.4 2 . 9 16.5 28.5
0 20 63 . 0 60.4 19.2 4.3 51.5 69.3
+ 1 20 18.0 22 . 3 14.0 3.1 15.8 28 . 8
+ 2 20 14.5 14.0 7.6 1.7 10.5 1 7 "5
+ 3 20 13.0 12.7 6.0 1.3 9.9 15.5
+ 4 18 11.0 14.1 7.7 1.8 10.3 17.9
+ 5 20 10.5 13.0 7.2 1.6 9.6 16.4
+ 6 19 9 . 0 10.3 6.4 1 . 5 7.2 13.4
+ 7 20 8.4 10. 1 6.3 1.4 7 . 2 13.0
+ 8 18 5.8 7.9 4.4 1 .0 5.7 10. 1
+ 9 18 8.9 10.1 7.5 1. 8 6.4 13.8
+ 10 16 8.7 9.1 5.3 1.3 6.3 11.9
+ 11 18 6. 0 7 . 9 4.8 1 . 1 5.5 10.3
+ 12 18 7.8 8.5 4.6 1.1 6.2 10.8
+ 13 16 7.0 6.3 3.0 0.8 4.7 7 . 8
+ 14 14 7.2 7.3 2.6 0.7 5.8 8.8
No significant differences from controls.
(Wilcoxon Rank Sum Test)
FIGURE 5.1.8
LO
CO
■ S lCO c  
CDZ L  CO
O o
d
o a
CO  co 
5 ^  <x>o  ^
CO
Table 5.1.18
All Cysts (shrinkers)
Plasma FSH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 14 7.4 7.3 3.8 1 . 0 5.1 9.5
-9 1 6 8.6 8 . 3 4.0 1 . 0 6.2 10.4 c
-8 1 7 6.8 7 . 6 4.3 1 . 0 5.5 9.7
-7 17 7 . 5 7 . 8 3.9 0. 9 5.9 9.7 b i
-6 18 6.9 7.3 3.5 0.8 5.6 9.0 c
-5 1 9 6.4 6 . 0 2.8 0.7 4.5 7.5
-4 18 5.4 5.1 1 . 9 0.5 4.0 6.2 i
-3 18 3 . 8 4.1 1. 6 0.4 3.3 4.9
-2 18 4.3 4.2 1 . 5 0.3 3.6 4.8
-1 1 8 5.4 5.6 2.6 0. 6 4.3 6.9
0 20 13.0 11.4 5.1 1 . 1 9.1 13.7
+ 1 19 9.3 9 . 8 4 . 3 1 . 0 7 . 7 11.9
+ 2 1 9 6.4 6.3 2 . 9 0.7 4.8 7.8
+ 3 20 5 . 0 5.2 2 . 7 0. 6 3.9 6.5
+ 4 20 4 . 9 4.7 2.1 0.5 3.7 5.7
+ 5 20 3.4 3.9 1 . 8 0.4 3 .1 4.7
+ 6 1 6 3.4 3 . 8 1 . 6 0.4 2.9 4 . 7 a
+ 7 20 3 . 0 2 . 8 1 . 2 0.3 2.2 3.4
+ 8 20 2.8 2 . 9 1.3 0.3 2.3 3.5
+ 9 1 6 2 . 6 2 . 8 1 . 2 0.3 2 . 2 3.4 a
+ 10 19 2 . 7 2 . 9 2 . 1 0.5 1.8 4 . 0
+ 11 1 9 2 . 3 2 . 7 1 . 3 0.3 2.1 3 . 3
+ 12 14 2 . 5 2 . 9 1 . 6 0.7 1.4 4.4
+ 13 1 5 2 . 8 3.5 2 . 1 0.5 2.4 4.6
+ 14 13 4.2 4 . 8 3.2 0.9 2.8 6.8
Significance (Wilcoxon Rank Sum Test) in comparison wi th :
Controls Non-shrinkers
p < 0 . 0 5  a i
p <0.02 b
p <0.01 c
Table 5.1.19
All Cysts (n o n - s h r i n k e r s )
Plasma FSH concentrations (IU/1)
Day Nos Median Mean SD SEM 95% low 95% high
-10 12 7.2 7.5 2 . 2 0.6 6.1 8.9 c
-9 14 6.3 6.7 2 . 0 0.5 5.6 7.8
-8 16 6.0 6.3 2.7 0.7 4 . 8 7.8
-7 16 5.3 5.2 1 . 7 0.4 4.3 6.1
-6 17 5.2 5.4 2 . 1 0.5 4.3 6.5
-5 18 5.5 4.9 1 . 5 0.4 4 .1 5.7
-4 20 4.2 4.1 0.7 0.2 3 . 8 4.4
-3 19 3 . 9 3 . 8 1 . 3 0.3 3.2 4.4
-2 20 3.8 3.7 1.2 0.3 3.1 4.3
-1 1 9 4.5 5.0 2 . 2 0.5 4.0 6 .0
0 20 14.0 14.2 6.7 1.5 11.1 17.3 a
+ 1 20 7 . 0 7 . 8 4.7 1 . 0 5.6 10.0
+ 2 19 4.7 6.4 4.4 1 . 0 4.3 8.5
+ 3 20 4 . 1 5. 1 2 . 9 0. 7 3 . 7 6.5
+ 4 18 3 . 9 5.0 3.6 0.8 3.2 6.8
+ 5 20 4.0 4.6 3.6 0.8 2.9 6 . 3
+ 6 1 9 3 . 3 4.1 2 . 8 0.6 2 . 7 5.5 a
+ 7 20 3 . 6 4 . 2 3.3 0.7 2 . 7 5.7 b
+8 18 3 . 0 3.7 2 . 9 0.7 2.3 5.1 a
+ 9 1 8 2 . 9 3 . 8 3 . 1 0.7 2.3 5.3 b
+ 10 16 3 . 0 3 . 8 3.0 0.8 2.2 5.4 b
+ 11 18 2 . 7 3.3 2 . 8 0.7 1 . 9 4.7
+ 12 19 2 . 6 3.2 2.5 0.6 2.0 4.4
+ 13 1 7 2 . 7 3.7 2.9 0.7 2.2 5.2
+ 14 14 3.7 4.8 3.2 0.8 3.0 6.6
Significanc e (Wilcoxon Rank Sum Test) in comparison wi t h :
Controls
p <0.05
p <0.02 
p <0.01
a
b
c
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Table 5.1.20
All Cysts (shrinkers)
Follicular Diameters (mm)
Day Nos Med ian Mean SD SEM 95% low 95% high
-5 6 11.8 12.6 3.8 1 . 5 8.7 16.5
-4 8 14.0 14.8 3.5 1.2 12.0 17.6
-3 6 14.8 14.6 1.8 0.7 12.8 16.4
-2 11 16.5 16.8 3.4 1 .0 14.6 19.0
-1 9 19.5 20.0 2 . 1 0.7 18.4 21.6
0 19 20.5 21.4 3 . 0 0. 7 19.9 22.9
+ 1 15 19.0 18.7 3.6 0.9 16.8 20.6 i
+ 2 13 19.3 19.4 3.7 1.0 17.2 21.6 iii
+ 3 13 18.5 2 1.0 6.0 1.7 16.3 24.7 i i
+ 4 13 19.0 19.6 4.7 1.3 16.8 22.4 iv
+ 5 8 2 1.0 21.6 4 . 0 1 . 1 19.0 24.2 i i
+ 6 12 15.5 17.3 4 . 1 1 . 2 14.7 . 19.9 iv
+ 7 7 18.5 20.7 4.8 1.8 16.3 25.1 iv
+ 8 10 19.0 22 . 5 7 . 2 2 . 3 17.3 27.7 iii
Cyst 21 
size
18.5 20.4 5.7 1.2 17.8 23.0 iv
S ignif icance (Wilcoxon Rank Sum Test) in comparison with :
Non-shrinkers
p <0.05 i
p <0.02 ii
p <0.01 iii
p <0.001 iv
No significant differences from controls.
Table 5.1.21
All Cysts (n o n - s h r i n k e r s )
Follicular Diameters (mm)
Day Nos Median Mean SD SEM 95% low 95% high
-5 4 9.5 11.8 3.3 1.7 6.5 17.1
-4 8 13.8 13.3 1 . 4 0.5 12 .1 14.5
-3 9 14.0 15.2 3.9 1 . 3 12.2 18.2
-2 8 16.3 17.3 3 . 1 1 .1 14.7 19.6
-1 11 18.0 18.2 2.9 0.9 16.2 20.2
0 11 19.5 19.6 3.5 1 .1 17.2 23.0
+ 1 10 21.0 22.9 6.5 2 .1 18.2 27.6
+ 2 1 1 25.5 24.9 4 . 1 1.2 22.2 27.6
+ 3 13 26.0 2 6.6 5.4 1.5 23.4 29.8
+ 4 9 28.0 28.9 6.5 2.2 23.9 33 . 9
+ 5 12 31.0 28 . 8 6.4 1.9 24.7 32 . 9
+ 6 9 31 .0 31 . 7 8.7 2.9 25.0 - 38.4
+ 7 9 33 . 0 31.6 5.4 1.8 27.4 35.8
+ 8 7 37.0 37 . 2 10.2 3.9 27.7 46.7
Cyst
size
20 33.0 33.1 8.4 1.9 29.1 37.1
No significant differences from controls. 
(Wilcoxon Rank Sum Test)
FIGURE 5.1.10
o o
r  CO
CCS
CD
CM Q_
n=
p
CD CD
>
*co
CM CD
I 1—1
>■*
00
Q
CO
CO
U L - Q
E
E
Table 5.1.22
All Cysts (low P index)
Plasma E2 conce ntrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 22 75.0 77 . 0 15.9 3.4 69.9 84.1
-9 23 80.0 80.0 19.1 4.0 71.7 88. 3
-8 24 82.5 87 . 9 21.7 4.4 78.8 97.0
-7 26 90.0 89 . 1 20.9 4 .1 80. 7 97 . 5
-6 26 95.0 96.8 26.4 5.2 86.1 107 . 5
-5 28 110.0 112.5 26.9 5.1 102 .0 123.0
-4 29 120.0 127.9 39.1 7 . 3 112.9 142.9
-3 29 140.0 147.3 45.6 8.5 129.9 164.7
-2 29 168.0 176.9 47.7 8.9 158.7 195.1
-1 27 235 .0 220.4 51 . 6 9 . 9 200. 0 240.8
0 31 208.0 205.5 45.3 8.1 189.0 222 .0
+ 1 29 140. 0 143.8 42 . 5 7 . 9 127.6 160.0 a
+ 2 30 125.0 128.1 30.8 5.6 116.6 13 9/6 a i
+ 3 31 135.0 140.3 31.2 5.6 128.9 151.7 i
+4 31 145.0 156.7 50.9 9.1 138.1 175.3
+ 5 31 135.0 159.2 55.5 10.0 138.8 179.6
+ 6 27 150.0 159.6 52 . 0 10.0 139.0 180.2
+ 7 29 150.0 162.1 45.4 8.4 144. 9 179.3
+ 8 30 157.5 163.1 50.5 9.2 144.3 181.9
+ 9 28 150.0 169.8 71.2 13.5 142.1 197.5
+ 10 27 145.0 156.2 55.3 10.6 134.4 178.0
+ 11 29 140.0 148.9 54. 6 10.1 128.2 169.6
+ 12 25 135.0 139.1 57.2 11.4 115.6 162.6
+ 13 24 112.5 121.2 42.3 8.6 94. 7 139.0 b
+ 14 22 107.5 108.4 42.7 9.1 89.5 127.3
Significance (Wilcoxon Rank Sum Test) in comparison with : 
Controls Normal P Index
p <0.05
p <0.02
a
b
i
ii
Table 5.1.23
All Cysts (normal P index)
Plasma E2 concentrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0»—l1 8 72.5 75.6 16.4 5.8 61 . 9 89.3
-9 9 75.0 75.6 19.6 6.5 70.6 90.6
-8 10 82 . 5 74 . 5 21.8 6.9 58.9 90.1
-7 9 83.0 83 . 1 14.1 4.7 72.3 93 . 9
-6 10 90.0 93 .3 26.0 8.2 74.8 111.8
-5 10 107 . 5 111.5 21.5 6.8 96.1 126.9
-4 10 131.5 129.1 38.8 12.3 101 .3 156.9
-3 10 154.0 161.6 43. 6 13 . 8 130.4 1 92 . 8
-2 10 212.5 214.0 59.8 18.9 171.2 256 .8
-1 10 230.0 234 . 0 54. 9 17.4 194. 6 2 73 .4
O' 10 215.0 211.6 75.2 23 . 8 157.8 265.4
+1 10 135.0 130.0 37 . 6 11.9 103 .1 156.9
+ 2 10 105.0 1 01 . 6 24.5 7 . 8 84 .0 119.2 -
+ 3 1 0 115.0 118.4 17.2 5.5 106.0 130.8
+ 4 9 122.5 125.0 22 . 6 7 . 5 107.7 142.3
+ 5 10 135.0 139.1 29.2 9.2 118.3 159.9
+ 6 10 125.0 130.3 36.9 11.7 103.8 156.8
+ 7 9 140.0 143 . 9 35.4 11.8 116.7 171.1
+ 8 10 150.0 145.8 34.6 10.9 121 . 1 170.5
+ 9 9 125.0 139.2 35.0 11.7 112.2 166.2
+ 10 9 128.0 141 .2 42.2 13.4 110.3 172.1
+ 11 9 120.0 133.1 41 .0 13.7 101 . 5 164. 7
+ 12 10 110.0 113.3 42.6 13.4 83.0 143.6
+ 13 9 90.0 100. 9 53. 5 17.8 59.9 141.9
+ 14 9 80.0 97.9 63.2 21.1 49.2 146.6
No siginificant differences in comparison with controls.
(Wilcoxon Rank Sum Test)
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Table 5.1.24
All Cysts (low P index)
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 17 0.9 0.9 0.5 0.1 0.7 1 .1
+ 1 27 1.2 1 .4 0.7 0.1 1.2 1 . 6 b
+2 30 2.6 2.6 1.2 0.2 2.2 3 . 0 c i i
+ 3 31 3.8 4.2 1 . 8 0.3 3.6 4.8 c iii
+ 4 31 6.2 6.7 3.1 0.6 5.5 7.9 c iii
+ 5 30 11.6 9.7 3.7 0.7 8.3 11.1 c iii
+ 6 27 13.1 12.8 5.0 1.0 10.7 14.9 c iii
+ 7 30 16.1 15.6 5.8 1 . 1 13 . 4 17.8 a iii
+ 8 30 15.5 14.6 5.8 1 . 1 12.4 16.8 a iii
+ 9 28 14.6 13.9 5.9 1 . 1 11.7 16.1 iii
+ 10 27 13.2 13.2 6.4 1.2 10.7 15.7 i
+ 11 29 11.6 11.7 7.0 1.3 9.0 14.4 b
+ 12 25 8.4 8.6 4.8 1 . 0 6.5 10.7 b
+ 13 24 4.7 5 . 8 4.8 1 . 0 3.7 7 . 9 a
+ 14 22 1.6 3.2 3.3 1 . 6 -0.3 6.7
P 31 62 . 0 57 . 5 19.5 3.5 50.4 64.6 c iii
index
Significance (Wilcoxon Rank Sum Test) in comparison with : 
Controls Normal P index
p <0.05 a
p <0.01 b
p <0.001 c
i
ii
iii
Table 5.1.25
All Cysts (normal P i n d e x )
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 9 0.9 1.0 0.8 0.3 0.3 1.7
+ 1 10 1.7 2 . 0 1.8 0. 6 0.6 3.4
+ 2 10 3.3 5.3 4.2 1.3 2.4 8.2
+ 3 10 7.0 8.6 4.5 1.4 5.4 11.8
+4 9 14.3 13.8 2 . 0 0.7 12.2 15.4
+ 5 10 18.7 20.2 5.0 1 . 6 16.6 23.8
+ 6 10 24.4 24.2 5.0 1.6 20.6 27.8 b
+ 7 10 25.4 25.6 3.9 1.2 22 . 9 28.3 d
+ 8 10 24.8 22 . 7 5.2 1. 7 18.9 26.5 a
+ 9 9 25.5 23.3 3.7 1.2 20.5 26.1 c
+ 10 9 16.6 18.4 5.5 1.8 14.2 22.6 b
+ 11 9 18.4 16.7 6.8 2 . 3 11.4 22 . 0 d
+ 12 10 9.0 10.9 6.9 2.2 5.9 15.9 c
+ 13 9 5.2 4 . 3 2.5 0.8 2.5 6.1
+ 14 9 2 . 1 2 . 3 1.7 0.6 0.9 3.7
P
index
10 101.0 111.8 18.6 5.9 98.5 125.1
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05 a
p <0.02 b
p <0.01 c
p <0.001 d
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Table 5.1.26
All Cysts (low P index)
Plasma LH concentrations (IU/1)
Day Nos Median Me an SD SEM 95% low 95% high
-10 20 9.1 9 . 0 4.9 1 . 1 6.7 11.3
-9 22 7.8 8 . 3 5.2 1 . 1 6.0 10.6
-8 23 7.1 9.6 6.7 1.4 6.7 12 . 5
-7 24 7.4 8 . 3 4.8 1.0 6 . 2 10.4
-6 25 9.2 9.2 4.9 1 . 0 7.1 11.3
-5 27 7.7 8 . 6 4 . 8 0.9 6.7 10.5
-4 28 7.0 8.2 4.5 0.9 6.4 10.0
-3 27 8.9 9 . 5 6.2 1.2 7.0 12.0
-2 28 10.0 11.0 5.1 1.0 8.9 13.1
-1 27 19.0 23 . 6 13.8 2.7 18.0 29.2
0 30 67.5 60.0 19.3 3.5 52.8 67.2
+ 1 29 23.0 25.1 11.7 2 . 2 20.6 29.6
+ 2 30 12.0 12.8 6.9 1.3 10. 1 13.5
+ 3 30 14.0 14.0 7 . 1 1.3 11.3 16.7
+ 4 29 10.0 13.5 8.1 1.5 1 0. 4 16.6
+ 5 29 9.8 11.8 7 . 4 1.4 8.9 14.7
+ 6 26 9.6 10.3 6.8 1.3 7.6 13.0
+ 7 30 9.4 9 . 3 6.2 1 . 1 7 . 1 11.5
+ 8 28 5.5 8.1 6.0 1.1 5.8 10.4
+ 9 26 5.7 8.9 7 . 6 1.5 5.8 12.0
+ 10 26 7.0 7.4 5.2 1.0 5.3 9.5
+ 11 28 5.5 6.5 4.9 0.9 4.7 8.3
+ 12 23 7.6 7.2 4.5 0.9 5.3 9.1
+ 13 22 6.1 6 . 0 3.7 0.8 4.3 7.7
+ 14 19 6.9 6.7 3.4 0.8 5.0 8.4
No significant differences from controls and normal P index 
cycles.
(Wilcoxon Rank Sum Test)
Table 5.1.27
All Cysts (normal P index)
Plasma LH concentrations (IU/1)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 6 8.0 9.3 3.8 1.6 5.2 13.4
-9 8 6.4 9.4 6.5 2.3 4 . 0 14.8
-8 10 7 . 1 8.2 4.6 1.4 5.0 11.4
-7 9 11.0 11.5 6.3 2.1 6.7 16.3
-6 10 9.0 10.4 5.3 1.7 6.6 15.2
-5 10 9 . 0 9 . 7 4.6 1 . 5 6.3 13.1
-4 9 7.4 7 . 1 3.4 1 . 1 4.6 9.6
-3 9 7 . 5 8.1 2 . 3 0.8 6.3 9.9
-2 9 8.8 9.2 4.4 1 . 5 5.7 12.7
-1 9 13.0 15.7 6.3 2 . 1 10.9 20.5
0 9 50.0 49.7 22.7 7.6 32.2 67.2
+ 1 8 13.0 27 . 9 20.4 7 . 2 10.9 44. 9
+ 2 10 16.0 14.4 5.8 1.8 10.3 18.5
+ 3 10 10.5 10.5 4.7 1. 5 7 . 1 13.9
+4 9 12.0 16.2 13.9 4.6 5.6 26.8
+ 5 10 8 . 0 10.2 4.8 1 . 5 6.8 13.6
+ 6 9 10.0 10.1 5.9 2.0 5.5 14.7
+ 7 10 6.3 7.8 5.3 1 . 7 4.0 11.6
+ 8 8 4.7 6.3 3.9 1.2 3.5 9.1
+ 9 8 3 . 8 7.4 7 . 5 2.7 1.0 13.8
+ 10 9 4.5 6.9 5.8 1 .9 2.5 11.3
+ 11 8 7.4 8.3 5.5 1.9 3.8 12.8
+ 12 8 6.3 7.9 4.9 1.7 3.9 11.9
+ 13 9 8.7 8.7 2 . 3 0.8 6.9 10.5
+ 14 8 9.3 8.8 2.3 0.8 6.9 10.7
No significant differences from controls.
(Wilcoxon Rank Sura Test)
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Table 5.1.28
All Cysts (low P index)
Plasma FSH concentrations (IU/1)
Day Nos Median Mean SD SEM 95% low 95% high
-10 20 6.8 7.1 2.9 0.6 5.8 8.4 a
-9 22 6.3 6.6 2.5 0.5 5.6 7.6
-8 23 5.9 6.3 2.9 0.6 5.1 7.5
-7 24 5.5 5.8 2.2 0.5 4.8 6.8
-6 25 5.2 6.0 3.1 0.6 4.8 7.2
-5 27 5.5 5.4 2 . 6 0.5 4.4 6.4
-4 28 4.5 4.4 1 . 6 0.3 3.8 5.0
-3 26 3.9 3 . 9 1 . 4 0.3 3.3 4.5
-2 28 4.0 4.0 1.4 0.3 3.4 4.6
-1 27 5.1 5.4 2.5 0.5 4.4 6.4
0 30 13.0 13.0 6.1 1 . 1 10.8 15.2
+ 1 29 8.0 8.5 4.5 0.8 6.9 10.1
+2 * 27 5.7 6.3 3.8 0.7 4.9 7.7
+ 3 30 4.6 5.1 2 . 6 0.5 4.1 6.1
+ A 29 5.1 4 . 9 2.9 0.5 3.9 6.9
+ 5 30 3 . 8 4.4 3 . 0 0.5 3.4 5.4
+ 6 26 3.5 4 . 0 2.5 0.5 3.0 5.0 a
+ 7 30 3.5 3 . 7 2.8 0.5 2.7 4.7 a
+ 8 28 3.2 3.5 2.5 0.5 2.5 4.5 a
+ 9 27 3.2 3.6 2 . 6 0. 5 2.6 4.6 b
+ 10 26 2.8 3.3 2.5 0.5 2.3 4.3 a
+ 11 28 2.4 3 . 0 2.3 0.4 2.2 3.8
+ 12 24 2.7 3.2 2.3 0.5 2.2 4.2
+ 13 23 2 . 8 3.6 2.7 0.6 2.4 4.8
+ 14 19 3.6 4.4 3.0 0.7 2.9 5.9
Significance (Wilcoxon Rank Sum Test) in comparison with : 
Controls Normal P index
P <0.05
p <0.01
a
b
i
ii
Table 5.1.29
All Cysts (normal P index)
Plasma FSH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 6 8.1 8.4 4.0 1.6 4.3 12.5 a
-9 8 9.2 10.1 4.0 1.4 6.8 13.4 c
-8 10 9.1 8.5 4.8 1 . 5 5.1 11.9
-7 9 9.9 8.5 4.6 1 . 5 5.0 12.0 a
-6 10 7.6 7.3 2.6 0.8 5.5 9.1 b
-5 10 6.6 5.7 1 . 7 0.5 4.6 6.8
-4 10 4.9 4 . 5 2.0 0.6 3.1 5.9
-3 10 3.6 3.9 1 . 7 0.5 2.8 5.0
-2 10 3.8 3 . 8 1.3 0.4 2.9 4.7
-1 10 4.4 4.8 1 . 9 0.6 3.4 6.2
0 10 13.5 12.1 6.1 1.9 7.8 16.4
+ 1 10 9.8 9.4 5.0 1 . 6 5.8 13.0
+2 "9 6.9 6.4 3 . 0 1 . 0 4.1 8..7
+ 3 10 4.9 5.4 3.2 1 . 0 3.1 7.7
+4 9 4.3 4.7 3 . 0 1 . 0 2.4 7.0
+ 5 10 3.4 3.8 2.4 0.7 2.2 5.4
+ 6 9 3 . 3 3.7 1.7 0.6 2.3 5.1
+ 7 10 3.2 2 . 9 1 . 1 0.4 2.0 3.8
+ 8 10 3.0 2.6 0.9 0.3 1.9 4.3
+ 9 7 2.3 2 . 6 0.8 0.3 1.9 3.3
+ 10 9 2 . 7 3.4 2.9 1 . 0 1.1 5.7
+ 11 9 2 . 3 2 . 9 1 . 6 0. 5 1.7 4.1
+ 12 10 3.8 3 .1 1 . 6 0.5 2.0 4.2
+ 13 9 4.1 3.8 2.2 0.7 2.2 5.4
+ 14 8 4.5 5.6 3.4 1.2 2.8 8.4
Significance (Wilcoxo n Rank Sura Test) in comparison with :
Controls
p <0.02 a
P <0.01 b
P <0.001 c
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Table 5.1.30
All Cysts (low P index)
Follicular Diameters (ram)
Day Nos Med ian Mean SD SEM 95% low 95% high
-5 7 11.0 11.7 3.9 1 . 5 8.0 15.4
-4 11 13.0 13.5 2.3 0.7 11.9 15.1
-3 11 15.0 15.1 3.7 1 . 1 12 . 6 17.6
-2 12 16.3 16.9 2 . 9 0.8 15.1 18.7
-1 1 6 18.8 18.3 2.4 0.6 17.5 19.6 i i
0 21 20.0 19.9 3.3 0.7 18.4 21.4 i
+ 1 17 19.0 20.1 6.0 1.4 17.1 23.1
+ 2 18 21.0 22 . 4 5.0 1 . 2 19.9 24.9 a
+ 3 19 26.0 2 4.6 6.9 1 . 6 21.2 28.0 b
+ 4 1 9 23 . 0 23 . 7 7 . 6 1 . 7 20.1 27.3 b
+ 5 13 26.0 27.4 7 . 0 1 . 9 23.3 31.5
+ 6 17 21.0 24.2 10.2 2 . 5 18.9 29.5
+7 12 29.5 28.6 7 . 5 2.2 23 . 8 33.4
+ 8 13 27 . 5 29.4 12.0 3.3 22.2 36.6
Cyst 31 27.0 27.8 10.4 1 . 9 23.9 31.7
size
Significance (Wilcoxon Rank Sum Test) in comparison with : 
Controls Normal P index
p <0.05
p <0.01 
p <0.001
a
b
i
ii
Table 5.1.31
All Cysts (normal P i n d e x )
Follicular diameters (mm)
Day Nos Med ian Mean SD SEM 95% low 95% high
-5 3 12.5 13.5 2.2 1.3 7.9 19.1
-4 5 15.0 15.4 3.4 1 . 5 11.2 19.6
-3 4 13.5 14.5 1 .6 0.8 12.0 17.0
-2 7 17.0 17.2 4.0 1 . 5 13.5 20.9
-1 4 22.3 22 . 0 1.2 0.6 20.1 23.9
0 9 21.5 22.6 2 . 6 0.9 20.5 24.7
+ 1 8 22 . 0 20.9 3 . 8 1.4 17.6 24.2
+2 6 19.8 20.4 4 . 0 1. 6 16.3 24. 5
+3 7 20.5 21.5 3.4 1.3 18.3 24.7 a
+ 4 3 22 . 0 21.3 2 . 1 1.2 16.1 26.5 a
+ 5 7 21.0 23 . 1 4.9 1 .9 18.5 27.7
+ 6 3 20.0 22 . 3 6 . 8 3.9 5.5 39 .1
+7 3 22.5 23.0 4.8 2 . 8 11.0 35.0
+ 8 4 24.5 25.8 8.4 4.2 12.4 39.2
Cyst
size
10 20.5 23.0 5.4 1.7 19.2 26.8
Significance (Wilcoxon Rank Sum Test) in comparison with 
Controls 
p <0.001 a
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Table 5.1.32
Large Cysts (>20mm s h r i n k e r s )
Plasma E2 concentrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 7 65.0 72 . 9 2 0.2 7.6 54.2 91 . 6
-9 7 80.0 74.3 26.2 9.9 50.1 98. 5
-8 8 72.5 69 . 4 19.0 6.7 53.5 85.3
-7 8 87 .5 84.4 18.4 6.5 69.0 99.8
-6 8 95.0 92 .5 22.4 7.9 73.8 111.2
-5 9 120.0 118.9 22.6 7 . 5 101 . 5 136.3
-4 8 118.0 124.1 38.3 13.5 92 .1 156.1
-3 9 140.0 141.7 25.4 8.5 122.2 161.2
-2 8 185.0 185.6 46.2 16.4 146.9 224.3
-1 8 195.0 203 . 8 39 . 8 14.1 170.5 237 .1
0 10 198.0 198.3 39.9 12.6 169.8 226. 8
+ 1 9 13 5.0. 133.9 27.5 9 . 2 112.8 155.0
+ 2 1 0 126.5 119.3 19.6 6.2 105.3 133.3
+ 3 10 127.5 130.3 24 . 2 7 . 7 113.0 147.6
+ 4 10 130.0 148.5 39.7 12.5 120. 1 176.9
+ 5 10 130.0 139.3 31.7 10.0 116.6 1 62 . 0
+ 6 9 125.0 141.1 37.5 12.5 112.3 169.9
+ 7 10 127.5 152.0 48.0 15.2 117.6 186.4
+8 10 137.5 149.0 41 .4 13.1 119.4 178.6
+ 9 8 122.5 133.8 33 . 4 11.8 105. 9 161.7
+ 10 9 125.0 144.4 62.5 20.8 96 . 3 192 . 5
+ 11 9 120.0 123.9 37.0 12 . 3 95.5 1 52 .3
+ 12 7 110.0 111.4 44.5 16.8 70.2 152 . 6
+ 13 7 90.0 92 . 9 32 . 9 12.4 62.5 123.3
+ 14 6 90.0 90.0 29.8 12.2 58.7 121.3
No significant difference from controls and non shrinkers.
(Wilcoxon Rank Sum Test)
Table 5.1.33
Large cysts (>20mm n o n - s h r i n k e r s )
Plasma E2 concentrations (pg/ml)
Day Nos Median Mean SD SEM 95% low 95% high
-10 13 80.0 79.2 14.8 4.1 70.2 88.2
-9 14 77.5 78.3 13.0 3.5 70.8 85 . 8
-8 16 87.5 83 . 8 15.8 3.9 75.4 92 .2
-7 17 85.0 87 . 1 17.1 4.1 78.3 95. 9
-6 17 85.0 88. 1 20.5 5.0 77.5 98.7
-5 17 105.0 104.4 21.3 5.2 93.5 115.3
-4 20 115.0 123.2 39.9 8.9 104. 5 141. 9
-3 19 140.0 145.9 49.8 11.4 121.9 169.9
-2 20 168.0 179.6 52.7 11.8 154.9 204.3
-1 19 235.0 221.1 55.5 12.7 194.3 247 .9
0 20 191.5 195.2 61.2 13.7 166.6 223 . 8
+ 1 19 145.0 L41 . 6 48.8 11.2 118.1 165.1
+ 2 20 116.5 122.2 35.0 7 . 8 105. 8 138.6
+ 3 20 137.5 139.2 30.9 6.9 124.7 153.7
+ 4 19 140.0 144.2 47 . 9 11.0 121.1 167.3
+ 5 20 135.0 157.5 59 . 7 13.3 129.6 185.4
+ 6 19 150.0 1 52 . 6 54.4 12.5 136.8 168.4
+7 1 9 155.0 155.3 44.7 10.3 133.8 176.8
+ 8 18 142.5 156.3 51 . 1 12.0 130.9 181.7
+ 9 18 155.0 169.2 80.6 19.0 129.1 209 . 3
+ 10 16 140.0 148. 9 53 . 1 13.3 120.6 177.2
+ 11 18 136.5 1 53.2 63.6 15.0 121.6 184 .8
+ 12 1 9 130.0 133.1 54.3 12.5 106.9 159.3
+ 13 17 115.0 115.1 43.0 10.4 93.0 137.2
+ 14 16 97.5 99. 7 31.9 8.0 82.7 116.7
No significant difference from controls.
(Wilcoxon Rank Sum Test)
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Table 5.1.34
Large Cysts (>20mtn shrink e r s )
Plasma P concentrations (ng/ml)
Day Nos Med i an Me an SD SEM 95% low 95% high
0 7 0.8 1 . 1 0.9 0.3 0.3 1.9
+ 1 9 1.4 1 . 9 1 . 9 0.6 0.4 3.4
+ 2 10 3.2 4.7 4 .4 1.4 1 .6 7 . 8
+ 3 10 5.8 7.4 5.0 1 . 6 3.9 10.9 i
+ 4 10 11.1 11.1 3.7 1 .2 8.5 13.7 iii
+ 5 10 15.8 16.2 5.4 1 . 7 12.4 20.0 iii
+ 6 9 21.2 20.7 5.7 1 . 9 16.3 25.1 ii
+ 7 10 21.0 22 . 0 4.9 1 . 5 18.5 25.5 i
+8 10 18.4 19.3 5.7 1.8 15.2 23.4
+ 9 8 20. 5 19.6 7.4 2 . 6 13.4 25.8
+ 10 9 16.8 17.6 7.9 2.6 11.5 23.7
+ 11 9 15.4 15.6 8.2 2.7 9 . 3 21.9 b
+ 12 7 12.8 11 .‘1 5.2 2 . 0 6.3 15.9 b
+ 13 7 5.4 5.7 3.9 1. 5 2 . 1 9.3 a
+ 14 6 2.7 4 . 1 3.6 1.5 0.0 8.2
P
index
10 90.0 92 . 5 29.4 9.3 71.5 113.5 iii
Significance (Wilcoxon Rank Sura Test) in comparison with : 
Controls Non-shrinkers
p <0.05 a
p <0.01
p <0.001 b
i
ii
iii
Table 5.1.35
Large Cysts (>2Qmm n o n - s h r i n k e r s )
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 12 1.0 1 . 0 0.6 0.2 0.6 1.4
+1 18 1.2 1 . 4 0.7 0.2 1 . 0 1.8 b
+ 2 1 9 2 . 8 2 . 7 1 . 3 0.3 2 . 1 3.3 c
+ 3 20 4.1 4.4 2.4 0.5 3.3 5.5 d
+ 4 1 9 5.6 5 . 8 3.4 0.8 4.2 7.4 d
+ 5 20 8.2 8.8 4.1 0.9 6 . 9 10.7 d
+ 6 1 9 10.4 12 . 5 5.9 1.4 9 . 7 15.3 d
+7 19 14.4 15.6 7.8 1 . 8 11.8 19.4
+ 8 19 10.8 14.2 6.9 1 . 6 10.9 17.5 a
+ 9 18 13.2 14.3 7.0 1.6 10.8 17.8
+ 10 1 6 13.4 13.2 6.0 1 . 5 10.0 16.4
+ 11 18 11.1 11.6 - 6.5 1 . 5 8.4 14.8 c
+ 12 19 8.2 8.9 6.3 1 . 4 5.9 11.9 c
+ 13 17 4.0 5.7 5.3 1.3 3 . 0 8.4 a
+ 14 16 1 . 1 3 . 0 3.2 0.8 1 . 3 4.7
P
ind ex
20 53 . 5 54.8 24.1 5.4 43. 5 66.1 d
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05 a
P <0.02 b
p <0.01 c
p <0.001 d
i
EI
FIGURE 5.1.17
_  CVJ
CO
CD
CL
co
co
CD
>
CO
CD
-
COO
-  CM
E
o >
Table 5.1.36
Large Cysts (>20mm shrinkers)
Plasma LH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 6 7.0 8.2 4.4 1 .8 3.6 12.8
-9 7 6.5 8.5 6.8 2 . 6 2.2 14.7
-8 8 7.5 8 . 0 4.3 1 . 5 4.4 11.6
-7 8 6.2 10.1 7.6 2.7 3.7 16.5
-6 8 6.9 9.3 5.4 1 .9 4.8 13.8
-5 9 5.4 7 . 2 4.9 1.6 3.2 11.4
-4 7 4.9 5.7 2 . 1 0.8 3.8 7.6
-3 8 6.8 6.5 2 . 1 0.7 4.7 8.3
-2 7 8.1 9.2 3.3 1.3 6.1 12.3
-1 7 13.0 20.0 15.3 5.8 5.9 34.1
0 9 73.0 64.8 15.8 5.3 52 .7 76.9
+ 1 8 25.0 29.1 16.1 5.7 15.6 42.6
+ 2 9 12.0 12.4 6.£ 2 . 1 7.5 17.3
+ 3 10 15.0 14.7 6.8 2.2 9.8 19.6
+ 4 10 15.5 15.8 14.7 4.6 5.3 26.3
+ 5 10 8.8 10.3 6.5 2 .1 5.6 15.0
+ 6 8 8.0 8.2 5.9 2 . 1 3.3 13.1
+ 7 10 7.3 7 . 1 5.1 1 . 6 3.4 10.8
+ 8 8 4.1 4.9 4 .1 1.5 1 . 5 8.3
+ 9 7 3.8 8.7 8.7 3.3 0.7 16.7
+ 10 9 4.4 5.3 2.7 0.9 3.3 7.3
+ 11 8 5.8 6.8 6.4 2 . 3 1. 5 12.1
+ 12 5 4.9 5.0 3.2 1.4 1.0 9.0
+ 13 7 7.2 7.6 2 . 6 1.0 5.2 10.0
+ 14 5 7.2 8.4 2 . 5 1 .1 5.4 1 1.4
No significant differences from controls and non— s h r i n k e r s .
(Wilcoxon Rank Sum Test)
Table 5.1.37
Large Cysts (>20mm n o n - s h r i n k e r s )
Plasma LH concentrations (IU/1)
Day Nos Median Mean SD SEM 95% low 95% high
-10 12 9.9 9.3 4 . 0 1.2 6.8 11.8
-9 14 8.3 9.0 5.4 1.4 5.9 12.1
-8 1 6 7.4 9.4 6.2 1 . 5 6.1 12.7
-7 1 6 8.7 9.1 4.0 1.0 7.0 11.2
-6 17 9.7 9.5 4.1 1 . 0 7.4 11.6
-5 18 9.7 9.7 3.6 0.9 7.9 11.5
-4 20 7.0 8.3 3.9 0.9 6.5 10.1
-3 19 9.4 10.8 6.2 1.4 7 . 8 13.8
-2 20 10.0 11.2 5.1 1 . 1 8.8 13.6
-1 19 19.0 22 . 5 12.4 2.9 16.5 28.5
0 20 63.0 60.4 19.2 4.3 51. 5 69.3
+ 1 20 18.0 22 . 3 14.0 .3.1 15.8 28.8
+ 2 20 14.5 14.0 7 . 6 1.7 10. 5 17.5
+3 20 13 . 0 12.7 6.0 1.3 9.9 15.5
+ 4 1 8 11.0 14.1 7.7 1 . 8 10.3 17.9
+ 5 20 10.5 13.0 7.2 1. 6 9.6 16.4
+ 6 1 9 9.0 10.3 6.4 1 . 5 7 . 2 13.4
+ 7 20 8.4 10.1 6.3 1.4 7.2 13.0
+ 8 18 5.8 7 . 9 4.4 1 .0 5.7 10.1
+ 9 18 8.9 10.1 7.5 1.8 6.4 13.8
+ 10 1 6 8.7 9 . 1 5.3 1 . 3 6.3 11.9
+ 11 18 6.0 7 . 9 4.8 1 . 1 5.5 10.3
+ 12 18 7.8 8.5 4.6 1 . 1 6.2 10.8
+ 13 16 7.0 6.3 3.0 0.8 4.7 7 . 8
+ 14 14 7.2 7.3 2 . 6 0. 7 5.8 8.8
No significant differences from controls.
(Wilcoxon Rank Sum Test)
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Table 5.1.38
Large Cysts (>20mm shr i n k e r s )
Plasma FSH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 6 6.6 6.9 3 .1 1.3 3.6 10.2
-9 7 8.8 8.1 3.8 1.4 4.6 11.6 a
-8 8 6.3 7. 5 4.8 1.7 3 . 5 11.5
-7 8 6.3 7.5 3.6 1 . 3 4.5 10. 5 i
-6 8 6.1 7.0 2 .1 0.7 5.3 8.7 c
-5 9 5.5 5.1 1 . 3 0.4 4.1 6.1
-4 8 4.9 4.7 1 .4 0.5 3 . 5 5.9
-3 9 3.4 3.7 1. 2 0.4 2.7 4.7
-2 8 4.3 3.9 1.0 0.4 3.0 4.8
-1 8 5.1 5.0 2 . 0 0.7 3.3 6.7
0 10 13.0 12.3 4.5 1.4 9.1 15.5
+ 1 9 8.1 8.2 3 . 6 1.2 5.4 11.0
+2 9 4.8 5.3 2.6 0.9 “ 3 . 3 7.3
+ 3 10 4.7 5.2 3.3 1.0 2 . 8 7.6
+4 10 5.5 4.8 2.7 0 . 8 3.0 6.6
+ 5 10 3.6 4.0 2.2 0.7 2.4 5.6
+ 6 8 3.4 3.9 2 .1 0.7 2 . 1 5.8
+ 7 10 3.0 2.7 1.3 0.4 1 . 7 3.7
+8 10 3.1 2.9 1.5 0.5 1 .8 4.0
+ 9 6 3.4 3.4 1. 5 0.6 1.8 5.0 b
+ 10 9 3.2 3.3 3.0 1 . 0 1 . 0 5.6
+ 11 9 3.1 2.7 1 . 9 0.6 1.2 4.2
+ 12 7 3.9 3.4 1.8 0.7 1.7 5.1
+ 13 7 4.0 3.8 2.3 0.9 1.7 5.9
+ 14 5 4.2 5.4 3.7 1 .7 0.8 10.0
Significance (Wilcoxon Rank Sum Test) in comparison with : 
Controls Non— shrinkers
P <0.05
p <0.02
P <0.01
a
b
c
i
Table 5.1.39
Large Cysts (>20mm n o n - s h r i n k e r s )
Plasma FSH concentrations (IU/1)
Day No s Med ian Me an SD SEM 95% low 95% high
-10 12 7.2 7 . 5 2.2 0.6 6.1 8.9 c
-9 14 6.3 6.7 2 . 0 0.5 5.6 7.8
-8 1 6 6.0 6.3 2 . 7 0.7 4.8 7 . 8
-7 16 5.3 5.2 1.7 0.4 4.3 6 .1
-6 17 5.2 5.4 2.1 0.5 4.3 6.5
-5 18 5.5 4.9 1 .5 0.4 4.1 5.7
-4 20 4.2 4.1 0. 7 0.2 3.8 4.4
-3 19 3.9 3.8 1.3 0.3 3.2 4.4
-2 20 3.8 3.7 1.2 0.3 3.1 4.3
-1 19 4.5 5.0 2.2 0.5 4.0 6.0
0 20 14.0 14.2 6.7 1. 5 11.1 17.3 a
+ 1 20 7.0 7.8 4.7 1.0 5.6 10.0
+ 2 1 9 4.7 6.4 4.4 1.0 4.3 8.5
+ 3 20 4.1 5.1 2.9 0.7 3.7 6.5
+ 4 18 3.9 5 . 0 3.6 0.8 3.2 6.8
+ 5 20 4.0 4.6 3.6 0.8 2 . 9 6.3
+ 6 1 9 3.3 4 . 1 2 . 8 0.6 2.7 5.5 a
+ 7 20 3.6 4.2 3.3 0.7 2.7 5.7 b
+ 8 18. 3.0 3.7 2.9 0.7 2 . 3 5.1 a
+ 9 18 2.9 3.8 3.1 0.7 2.3 5.3 b
+ 10 16 3.0 3.8 3 . 0 0.8 2 . 2 5.4 b
+ 11 18 2.7 3.3 2.8 0.7 1.9 4.7
+ 12 19 2.6 3.2 2.5 0.6 2.0 4.4
+ 13 17 2.7 3.7 2.9 0.7 2.2 5.2
+ 14 14 3.7 4.8 3.2 0.8 3.0 6.6
Signif icance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05 
p <0.02 
p <0.01
a
b
c
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Table 5.1.40
Large Cysts (>20mm s h r inker s)
Follicular Diameters (ram)
Day Nos Med ian Me an SD SEM 95% low 95% high
-5 3 10.0 10.2 2.3 1.3 4.6 15.8
-4 3 15.0 16.3 4.2 2.4 6 . 0 26.6
-3 2 12.8 12.8 1 . 1 0.8 3.3 22 . 3
-2 4 15.0 16.9 5.4 2.7 8.3 25.5
-1 2 17.8 17.8 2.5 1.8 - -
0 9 20.5 21.2 2.8 0.9 19.0 23.4
+ 1 9 19.0 19.2 3.9 1.3 16.2 22.2
+ 2 6 20.5 21.3 2 . 8 1 .1 18.4 24.2 a
+3 8 23.5 24.2 5.1 1.8 19.9 28.5 b
+ 4 6 22.0 24 . 0 4.0 1.8 19.0 29.0 b
+ 5 6 23.5 23.3 2.9 1.2 20.3 26.3
+ 6 3 21.0 23 . 0 4.4 2.5 12 . 2 33 . 8
+ 7 4 24.3 23.4 4.8 2.4 15.7“ 31.1 i
+ 8 6 24.5 25.5 8.0 2 . 4 19.2 31.8 i
Cys t 
size
10 23.8 25.0 5.1 1 . 6 21.4 28.6 ii
Signif icanc e (Wilcoxoin Rank Sum 1Test) in comparison with :
Controls Non-shrinkers
p <0.05 i
p <0.02 a
p <0.01 ii
p <0.001 b
Table 5.1.41
Large Cysts (>20mm non -s h r i n k e r s )
Follicular Diameters (mra)^
Day Nos Med ian Mean SD SEM 95% low 95% high
-5 4 9.5 11.8 3.3 1 . 7 6.5 17.1
-4 8 13.8 13.3 1 .4 0.5 12 .1 14.5
-3 9 14.0 15.2 3.9 1.3 12.2 18.2
-2 8 16.3 17.3 3.1 1 . 1 14.7 19.6
-1 11 18.0 18.2 2 . 9 0.9 16.2 20.2
0 11 19.5 19.6 3.5 1. 1 17.2 23.0
+ 1 10 21.0 22 . 9 6.5 2.1 18.2 27.6 a
+ 2 11 25.5 24.9 4 .1 1.2 22.2 27.6 b
+ 3 13 26.0 2 6.6 5.4 1 . 5 23.4 29.8 b
+ 4 9 28.0 28.9 6.5 2.2 23.9 33.9 b
+ 5 12 31.0 28.8 6.4 1.9 24.7 32 . 9
+ 6 9 31.0 31.7 8.7 2.9 25.0 38.4
+ 7 9 33.0 31.6 5.4 1.8 27.4 35.8
+8 7 37.0 37.2 10.2 3.9 27.7 46.7
Cyst 20 
size
33.0 33.1 8.4 1.9 29.1 37 .1
Signif icance (Wilcoxon Rank Sum Test) in comparison with :
Controls
p <0.05 a
p <0.001 b
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Table 5.1.42
Large Cysts (>20mm low P index)
Plasma E2 concentrations (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 15 75.0 78.7 16.7 4.3 69.4 88.0
-9 1 6 77.5 78.2 16.8 4.2 69.3 87 . 1
-8 17 85 . 0 83 . 8 15.0 3.6 76.1 91.5 i
-7 19 90.0 88. 5 18.1 4.2 79.8 97.2
-6 18 85.0 90.7 22 . 5 5.3 79.5 101 . 9
-5 19 105.0 103 .2 33 . 5 7.7 87.0 119.4
-4 21 120.0 124.7 40.4 8.8 106. 3 143.1
-3 21 130.0 144.2 48.3 10.5 122.2 166.2
-2 21 1 68.0 176.2 49 . 0 10.7 153.9 1 98. 5
-1 20 225.0 218.6 56.2 12.6 192.3 244 . 9
0 23 191.5 200.4 49.5 10.3 179.0 221.8
+1 21 140.0 145.5 43.4 9.5 125.7 165.3 a
+ 2 23 130.0 126.2 31 . 5 6.6 112.6 “ 139.8
+ 3 23 145.0 140.8 29.8 6.2 127.9 1 53 . 7
+ 4 23 140.0 1 52 . 8 47.3 9.9 132.3 173.3
+ 5 23 135.0 156.7 56.1 11.7 132.4 181.0
+ 6 21 150.0 158.5 50. 4 11.0 135.5 181.5
+ 7 22 1 52 . 5 159.1 47.3 10.1 138.1 180.1
+ 8 21 145.0 160.4 49.9 10.9 137.7 183.1
+ 9 20 145.0 165.5 77.6 17.3 129.2 201 .8
+ 10 1 9 140.0 151.7 57 . 9 13.3 123.8 179.6
+ 11 21 140.0 149.0 6 0.3 13.2 121 .6 176.4
+ 12 19 135.0 133.3 53. 7 12.3 107 . 4 159.2
+ 13 18 115.0 116.8 42.3 10.0 95.7 137.9
+ 14 16 102 . 5 103.1 29.3 7.3 87 . 5 118.7
Significance (Wilcoxon Rank Sum Test) in comparison with 
Controls Normal P index
p <0.05 a i
Table 5.1.43
Large cysts (>20mm normal P index)
Plasma E2 concentrations (pg/ml)
Day Nos Median Mean SD SEM 95% low 95% high
-10 5 65.0 72 . 0 17.2 7 . 7 50. 7 93.3
-9 5 80.0 73.0 22 . 8 10.2 44.7 101.3
-8 7 65.0 67 . 1 20.0 7 . 5 48.6 85.6
-7 6 85.0 79.2 12.4 5.1 66.2 92.2
-6 7 85.0 86. 4 16.8 6 . 3 70.9 101.9
-5 7 110.0 113.6 14.4 5.4 100.3 126.9
-4 7 115.0 119.7 36.1 13 . 6 86. 3 153.1
-3 7 145.0 143.7 23.7 9.0 121.8 165.6
-2 7 210.0 196.4 54 . 8 20.7 145.8 247 . 0
-1 7 2 10.0 208.6 35.9 13.6 175.4 241 .8
0 7 185.0 182. 6 70.5 26.7 117.4 247.8
+ 1 7 135.0 120.0 37.0 14.0 85.8 15 4.2
+ 2 7 100.0 104.0 18.0 6.8 87.4 1 2 0 .“6
+ 3 7 120.0 121.1 19.8 7.5 102.8 139.4
+ 4 120.0 118.3 11.7 4.8 106 . 0 130.6
+ 5 7 125.0 134.0 33 . 6 12.7 103.0 165.0
+ 6 7 115.0 120.0 33 . 3 12 . 6 89.2 1 50. 8
+ 7 7 130.0 138.6 35.7 13.5 105. 6 171.6
+ 8 7 130.0 133.6 33 . 1 12.5 103 . 0 164.2
+9 6 120.0 134.2 35.6 14.5 96.9 171.5
+ 10 6 120.0 133.3 48.4 19.8 84. 9 181.7
+ 11 6 110.0 124.2 43.3 17.7 78.8 169.6
+ 12 7 110.0 110.7 46.3 17.5 67.9 153.5
+ 13 6 87.5 83.8 25.2 10.3 57.3 141.1
+ 14 6 77.5 80.8 31. 8 13.0 47.4 114.2
No significant differences from controls.
(Wilcoxon Rank Sum Test)
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Table 5.1.44
Large Cysts (>20mm low P index)
Plasma P concentrations (ng/ml)
Day Nos Med ian Me an SD SEM 95% low 95% high
0 13 0.9 0.9 0.5 0.2 0.6 1.2
+ 1 20 1.3 1 . 3 0.7 0.2 1.0 1.6 c
+2 22 2 . 7 2.5 0.9 0.2 2.1 2 . 9 d i
+3 23 3 . 6 4 . 1 1 . 7 0.4 3.3 4.9 d i i
+ 4 23 6.2 6 . 0 2.9 0.6 4.7 7.3 d i i
+ 5 23 9.2 8.9 3.7 0.8 7.3 10.5 d i i
+ 6 21 12.8 12.6 5.5 1.2 10.1 15.1 d ii
+ 7 22 15.5 15.3 6.6 1. 4 12.4 18.2 a i i
+ 8 22 14.4 13.8 5.7 1.2 11.3 16.3 b i
+ 9 20 13.2 13.3 6.1 1.4 10.4 16.2 ii
+ 10 19 13.2 13.4 6.6 1 . 5 10.2 16.6
+ 11 21 11.6 11.7 6.8 1.5 8.6 14.8 c
+ 12 19 8.2 8.6 5.2 1 . 2 6.1 11.1 c ►
+ 13 1 8 7.3 6.3 5.4 1.3 3.6 9.0 b
+ 14 16 3 . 5 3.7 3.7 0.9 1 . 8 5.6
P 23 63 .0 54 .4 20.0 4.2 45.7 63.1 d i i
index
Significance (Wilcoxon Rank Sum Test) in comparison with :
Controls Normal P index
p <0.05 a
P <0.02 b
P <0.01 c i
p <0.001 d ii
Table 5.1.45
Large Cysts (>20mm normal P index)
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 6 1.2 1.3 0.9 0.4 0.3 2.3
+ 1 7 1 . 5 2.3 2.1 0.8 0.2 4.4
+ 2 7 5.4 6 . 2 4.8 1. 8 1.7 10.7
+ 3 7 8.6 9.5 5.3 2.0 4.6 14.4
+4 6 13.6 13 . 8 2 . 5 1.0 11.2 16.4
+ 5 7 17.6 18.7 4.5 1 . 7 14.5 22 . 9
+ 6 7 22.4 22 . 8 4.9 1.9 18.3 27.3
+7 7 25.2 25.5 4.4 1.7 21.4 29.6 b
+ 8 7 25.2 22 . 8 5.7 2.1 17.6 28.0
+ 9 6 26.7 24 . 7 3.3 1.3 21.3 28.1 b
+ 10 6 16.7 19.1 6.6 2.7 12.2 26.0 a
+ 11 6 17.1 17.2 7 . 5 3.1 9.3 25.1 c
+ 12 7 12.2 12.1 7.6 2.9 5.1 19.1 b
+ 13 6 4.9 4 . 1 2.3 1.0 1. 6 6.6
+ 14 6 1 . 9 2.2 1.7 0.7 0.4 4.0
P
index
7 101 .0 109.9 22.4 8.5 89.1 130.7
Significance ' (Wilcoxon Rank Sum Test) in comparison with : 
Controls
p <0.05 a
p <0.01 b
p <0.001 c
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Table 5.1.46
Large Cysts (>2Qmm low P index)
Plasma LH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 14 9.9 8.8 4.2 1 . 1 6.4 11.2
-9 1 6 8.2 8.5 5.4 1.3 5.6 11.4
-8 17 7 .1 9.2 5.9 1 . 4 6.2 12 . 2
-7 18 7.6 8.4 4.4 1.0 6.2 10.6
-6 18 9.6 9.2 4 . 1 1 . 0 7.2 11.2
-5 20 8.4 8.6 4.0 0.9 6.7 10.5
-4 21 6.9 8.2 3.8 0.8 6.5 9.9
-3 21 9.3 10.1 6.3 1.4 7.3 12 . 9
-2 21 10.0 11.3 4.6 1.0 9.2 13.4
-1 20 25.0 23.5 14.0 3.1 17.0 30.0
0 23 70.0 63. 1 17.5 3.6 55.6 70.6
+ 1 22 22 . 0 24 . 5 12.4 2.6 19.0 30.0
+ 2 23 13.0 13.2 7.4 1 . 5 10.0 16.4
+ 3 23 15.0 15.0 6.4 1.3 12.2 17.8 a
+ 4 22 12 . 5 14.4 8.4 1 . 8 10.7 18.1
+ 5 23 12.0 13.0 7.5 1 . 6 9.8 16.2 b
+ 6 21 8 . 8 10.1 6.4 1.4 7.2 13.0
+ 7 23 9.5 9.7 8.4 1.3 7.1 12.3
+ 8 21 5.8 7 . 8 7 . 5 1 .1 5.6 10.0
+ 9 20 9.3 10.2 6.4 1.6 6.8 13.6 a
+ 10 19 7.3 7 . 5 6.1 1 .0 5.4 9 . 6
+ 11 21 6.0 7.2 4.8 1 .1 5.0 9.4
+ 12 18 7.8 8.1 4.4 1.0 5.9 10.3
+ 13 1 7 7.0 6.0 2.8 0.7 4.6 7.4
+ 14 14 7.2 7.5 2.6 0.7 6.0 9.0
Signif icance (Wilcoxon Rank Sum 'Test) in comparison with :
Controls
P <0.05 
P <0.02
a
b
Table 5.1.47
Large Cysts (>20mm normal P index)
Plasma LH concentrations (IU/1)
Day Nos Med i an Mean SD SEM 95% low 95% high
-10 4 7.0 9.5 3.8 1 . 9 3.5 15.5
-9 5 6.5 10.0 7.4 3 . 3 0.9 19.1
-8 7 7.4 8.2 4.9 1 . 8 3.7 12 . 7
-7 6 11.0 12.7 7.1 2.9 5.3 20.1
-6 7 8.6 10.1 5.5 2.1 5.0 15.2
-5 7 9.3 9.5 4.8 1 . 8 5.0 14.0
-4 6 5.7 5.7 2.5 1.0 3.1 8.3
-3 6 7.3 7.5 1 .3 0.5 6.2 8.8
-2 6 8.4 8.4 4.7 1 . 9 3.4 13.4
-1 6 13.5 16.3 7.4 3.0 8.5 24.1
0 6 57.0 56.7 21.1 8.6 34.6 78.8
+1 6 13.0 23.3 22.5 9.2 -0.4 47.0
+ 2 6 16.0 14.6 6.4 2 . 6 7.8 21.4
+3 7 8.9 11.0 5.4 2.1 6.0 16.0
+4 6 9.5 15.9 17.0 6.9 -1.9 33. 7
+ 5 7 9.2 9.1 3.9 1 .5 5.5 12.7
+ 6 6 6.7 8.1 6 . 1 2.5 1.7 14.5
+ 7 7 4.5 7 .1 5.6 2.1 1.9 12.3
+ 8 5 4.2 5.3 2 . 5 1 . 1 2.2 8.6
+9 . 5 3.7 7.6 9.7 4.4 -4.5 19.7
+ 10 6 4.5 7.0 7.3 2.8 -0.3 14.3
+ 11 5 7.9 8.9 7 .1 3.2 0.1 17.7
+ 12 5 4.9 6.7 5.2 2.3 0.7 13.2
+ 13 6 8.7 8.5 2.7 1.1 5.7 11.3
+ 14 5 7.2 8.0 2.7 1 . 2 4.7 11.3
No significant difference from controls.
(Wilcoxon Rank Sum Test)
Lar
ge 
Cys
t F
orm
ers
No
rm
al 
& A
bn
orm
al 
P I
nd
ex
FIGURE 5.1.23
Day
 r
elat
ive 
to 
LH 
pe
ak
Table 5.1.48
Large Cysts (>20mm low P index)
Plasma FSH concentrations (IU/1)
Day Nos Median Mean SD SEM 95% low 95% high
-10 14 6.6 7 . 3 2 .2 0.6 6.0 8.6 ' b
-9 1 6 6.3 6.5 2 . 0 0.5 5.5 7.5
-8 17 6 . 2 6.4 2.6 0.6 5.0 7 . 8
-7 18 5.6 5.4 1 . 5 0.4 4.6 6.2
-6 1 8 5.2 5.5 1 . 9 0.4 4.6 6.4
-5 20 5.1 4.8 1 .3 0.3 4.2 5.4
-4 21 4.3 4.0 0.9 0.2 3 . 6 4.4
-3 21 3.9 3.8 1 .2 0.3 3.2 4.4
-2 21 4 . 0 3 . 8 1 . 1 0.2 3.3 4.3
-1 20 5.1 5.1 2.2 0.5 4.1 6.1
0 23 13.0 13.7 6.2 1.3 11.0 16.4
+ L 22 7 . 0 7.8 4.5 1 .0 5.8 9.8
+ 2 22 4 . 8 6 . 2 4.2 0. 9 4.3 8.1
+ 3 23 4.3 5.2 2.8 0 . 6 4.0 6.4
+ 4 22 4.6 5.1 3.2 0.7 3.7 6.5
+ 5 23 4.1 4.6 3 . 3 0.7 3.2 6.0
+ 6 21 4 . 0 4.1 2.7 0.6 2.9 5.3 a
+ 7 23 3.5 3.9 3.2 0.7 2.5 5.3 a
+ 8 21 3.4 3.7 2 . 7 0.6 2.5 4.9 a
+9 20 3.2 3.9 2 . 9 0.7 2.5 5.3 c
+ 10 19 3.2 3.6 2.9 0.7 2.2 5.0 a
+ 11 21 2 . 9 3.2 2 . 6 0.6 2.0 4.4
+ 12 19 2.8 3.4 2.5 0.6 2.2 4.6
+ 13 18 2 . 8 3.7 2.8 0.7 2.3 5.1 •
+ 14 14 3.7 4.8 3.1 0.8 3.0 6.6
Significance (Wilcoxon Rank Sum Test) in comparison with : 
Controls
p <0.05 a
P <0.02 b
P <0.01 c
No significant difference from normal P index.
Table 5.1.49
Large Cysts (>20mm normal P index)
Plasma FSH concentrations (IU/1)
Day No s Median Mean SD SEM 95% low 95% high
-10 4 8.0 7.5 3.7 1.8 1 . 7 13.3
-9 5 9.0 6.6 3.5 1.6 2.2 11.0
-8 7 5.6 7.6 5.2 2.0 2 . 8 12 . 4
-7 6 7.1 7.5 4.5 1 .8 2.8 12.2
-6 7 7.0 6.9 2 . 6 1.0 4.5 9.3
-5 7 6.4 5.4 1.8 0.7 3.8 7.0
-4 7 4.5 4.6 1.4 0.5 3.3 5.9
-3 7 3.4 3 . 5 1 .5 0.6 2.1 4.9
-2 7 3.2 3.6 1 . 2 0.4 2.5 4.7
-1 7 3.8 4.7 1.9 0.7 2.9 6.5
0 7 14.0 13.0 5.8 2.2 7.6 18.4
+ 1 7 7.6 8.3 4.0 1.5 4.6 12 . 0
+ 2 - 6 5.7 5.5 3.1 1. 3 2.3 8.7
+ 3 7 4.5 5.1 3.9 1.5 1.5 8.7
+4 6 3.8 4.3 3.5 1. 4 0.7 7.9
+ 5 7 2.4 3.5 2.6 1 . 0 1 .1 5.9
+ 6 6 3.2 3.5 2.2 0.9 0.8 6.2
+7 7 3.2 2.9 1 .3 0.5 1 .7 4 .1
+ 8 7 2.7 2.6 1.1 0.4 1.5 3.7
+9 4 2.6 2.6 1.0 0.5 1.1 4.1
+ 10 6 2.6 3.7 3.6 1.5 -0.1 7.5
+ 11 6 3 . 1 3.2 2 . 0 0.8 1 . 1 5.3
+ 12 7 3.1 2.9 1.9 0.7 1.1 4.7
+ 13 6 4 .1 3.8 2.6 1.0 1.1 6.5
+ 14 5 4.3 5.2 4.0 1.8 0.3 10.1
No significant differences from controls.
(Wilcoxon Rank Sum Test)
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Table 5.1.50
Large Cysts (>20mm low P index)
Follicular Diameters (mm)
Day Nos Median Mean SD SEM 95% low 95% high
-5 4 9 . 0 9.3 1 . 5 0.8 6.9 11. 7 a i
-4 7 13.0 12.9 1 .4 0.6 11.4 14.4 i
-3 8 13.0 14.9 4.3 1 . 5 11.3 18.5
-2 6 16.0 17.0 3.5 1.4 13.3 20.7
-1 11 18.0 17.5 2 . 4 0.7 15.9 19.1 b i
0 13 19.0 18.9 2.7 0.7 17.3 20.5 ii
+ 1 13 20.0 21.2 6.3 1 . 7 17.4 25.0
+2 13 25.5 24.0 4.2 1 .2 21 .4 2 6.6 c
+ 3 1 6 26.0 2 6.6 5.5 1 . 4 23.6 29.6 c
+4 12 27.5 27.9 6.2 1.8 23.9 31.9 c
+ 5 12 27.5 28.4 6.4 1 . 8 24.4 32.4
+6 10 28.5 30.4 8.9 2 . 8 24 . 0 36.8
+ 7 io - 29.8 29.0 6.4 2 . 0 24.4 33.6
+8 9 30.0 30.4 9.6 3.2 23 . 0 37.8
Cyst 23 32 . 0 32 . 0 8.6 1.8 28.3 35.7
size
Significance (Wilcoxon Rank Sura Test) in comparison with : 
Controls Normal P Index
p <0.05 a
p <0.02 b
p <0.001 c
i
ii
Table 5.1.51
Large Cysts (>20mm normal P index)
Follicular Diameters (mm)
Day Nos Median Mean SD SEM 95% low 95% high
-5 3 12 . 5 13.5 2 . 2 1.3 8.1 18.9
-4 4 15.0 16.3 3.2 1.6 11.2 21.4
-3 3 13.5 14.3 1 . 9 1 . 1 9.6 19.0
-2 6 16.5 17.3 4.3 1 . 8 15.5 19.1
-1 2 21.8 21.8 1 . 8 1.3 5.9 37.7
0 6 21.5 22.6 2 . 7 1. 1 19.7 25.5
+ 1 6 22 . 5 21.0 4.4 1.8 16.4 25.6
+2 4 22 . 0 22.4 3.1 1.6 17.4 27.4 a
+3 5 23.0 22 . 8 3.2 1 . 4 18.8 26.8 b
+4 2 22 . 5 22 . 5 0.7 0.5 15.1 28.9 b
+ 5 6 23.0 24.2 4.5 1 . 9 19.4 29.0
+ 6 2 25.0 25.0 7.1 5.0 - -
+ 7 2 25.3 25.3 3.9 2 . 8 - -
+ 8 3 26.0 28.7 7 . 4 4.3 10.4 47.0
Cyst
size
7 24.5 25.2 4. 9 1 .8 20.8 29.6
Significance (Wilcoxon Rank Sura Test) in comparison with :
Controls
p <0.02 a
p <0.001 b
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Table 5.2.1
Poor Progesterone Surge
Patient/cycle characteristics
Nos Mean SD SEM Med ian Range
AGE (years)
51 30.0 4.0 0.6 30 22-40 a
FOLLICULAR PHASE (Days)
51 15.2 3.7 0.5 15 8-27
LUTEAL PHASE (Days)
51 15.1 1.7 0.3 15 11-18
CYCLE LENGTH (Days)
51 30.4 4.3 0.6 30 24-44
Significance (Wilcoxon rank sum test) in comparison with controls 
a = P <0.001
Table 5.2.2
Poor Progesterone Surge
Plasma E2 concentrations (pg/ml)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 37 73.0 72.3 16.3 2.7 66.8 77.8
-9 40 75.0 75.1 18.6 2 . 9 69.2 81 .0
-8 43 78.0 79.6 18.2 2 . 8 74.0 85.2
-7 45 84 . 0 83 . 6 16.9 2.5 78.5 88. 7
-6 47 90.0 92 . 1 19.6 2.9 86.3 97 . 9
-5 46 100.0 99 . 7 20.6 3 . 0 93. 6 105. 8 b
-4 50 112.5 115.3 34.3 4.9 105. 5 125.1 a
-3 50 133.0 131.8 39.8 5.6 120.4 143.2 b
-2 - 51 164.0 161.6 47.3 6.6 148.2 175.0 b
-1 49 205.0 199.6 56.7 8.1 183.2 216.0 a
0 50 18 5.0 188.1 42.5 6 . 0 176.0 200. 2
+ 1 50 135.0 134.1 40. 5 5.7 122. 5 145.7
+2 51 110.0 111.7 42.9 6 . 0 99.6 123.8
+3 50 125.0 125.1 37.5 5.3 114.4 135.8
+4 51 135.0 133.5 45.9 6.4 120.5 146.5
+ 5 51 140.0 141.7 50.2 7.0 127.5 155.9
+6 48 142.0 141.7 41.0 5.9 129.7 153.7
+ 7 49 1 50.0 150.4 45.3 6.5 137.3 163.5
+8 47 155.0 156.8 56 . 0 8.2 140.3 173.3
+ 9 48 165.0 165.1 73.9 10.7 143.6 186.6
+ 10 46 150.0 149.4 57.5 8.5 132.3 16 6.5
+ 11 48 150.0 152 . 6 75.7 10.9 130.5 174.7
+ 12 43 145.0 147 . 5 90.9 13.9 119.5 175.5
+ 13 38 130.0 125.7 57.6 9.3 106. 8 144. 6
+ 14 35 1 02 . 5 105.8 41 .2 7.0 91 .7 119.9
Significance (Wilcoxon Rank Sum Test) in comparison with controls
a = p <0.05 
b = p <0.01
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Table 5.2.3
Poor Progesterone Surge
Plasma P concentrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 27 0.9 0.8 0.4 0.1 0.6 1.0
+ 1 45 1.3 1 . 2 0.5 0.1 1.0 1.4 d
+2 50 2.5 2.3 0.8 0.1 2.1 2.5 d
+ 3 49 4.5 4.0 1 . 4 0.2 3.6 4.4 d
+4 50 6.8 6.3 2.5 0.4 5.6 7.0 d
+ 5 51 10.2 9.7 3.8 0.5 8.6 10.8 d
+ 6 48 13.1 12.7 5.4 0.8 11.1 14.3 d
+ 7 49 14.4 14.5 6.2 0.9 12.7 16.3 c
+8 47 14.8 14.6 6.5 0.9 12.7 16.5 b
+ 9 48 13.7 13.6 6.5 0.9 11.7 15.5
+ 10 45 13.0 12.6 7.0 1.0 10.5 14.7
+ 11 48 11.4 11.0 7.8 1 . 1 8.7 13.3 b
+ 12 43 8.5 8.5 6.2 0.9 6.6 10.4 c
+ 13 38 6 .1 6.2 5.7 0.9 4.3 8.1 a
+ 14 35 3.2 3.4 3.4 0.6 2.2 4.6
P 51 61.0 54.9 19.3 2.7 49.4 60.4 d
index
Significance (Wilcoxon Rank Sum Test) in comparison with controls
a = p <0.05 
b = p <0.02
c = p <0.01
d = p <0.001
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Table 5.2.4
Poor Pro gest erone Surge
Plasma LH c o nc entrat io ns (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 36 8.8 8.9 5.0 0.8 7.2 10.6
-9 40 8.8 8.9 6.1 1.0 7.0 10.8
-8 43 10.0 10.0 7.8 1.2 7.6 12.4
-7 44 10.3 10.3 9.3 1.4 7.5 13.1
-6 46 9.9 10.0 7.3 1 . 1 7.8 12.2
-5 47 9.6 9.5 6.6 1 . 0 7.6 11.4
-4 50 10.1 10.0 7.1 1 . 0 8.0 12.0
-3 49 11.5 11.5 9.0 1.3 8.9 14.1
-2 51 11.7 11.8 6.6 0.9 9.8 13.8
-1 49 " 23 . 0 23 . 0 14.9 2 . 1 18.7 27.3
0 50 60.0 58.3 23.0 3.3 51.7 64.9
+1 51 29 . 5 29.3 16.4 2 . 3 24.7 33 .9
+2 51 14.5 14.9 9.2 1 . 3 12.3 17.5
+3 50 12.7 13.5 7.8 1 . 1 11.3 15.7
+4 48 12.4 15.8 12.4 1 .8 12.2 y 19.4
+ 5 51 12.9 13.5 9.5 1.3 10.2 16.8 a
+6 48 10.8 11.5 8.9 1.3 8.9 14.1
+7 50 10.2 10. 1 7.4 1 .0 8.0 12.2 a
+8 47 9.1 9.1 6.9 1 . 0 7.1 11.1
+9 48 9.1 9.3 7 . 3 1. 1 7.2 11.4
+ 10 44 8.7 8.5 6.7 1 .0 6.5 10.5
+ 11 47 7.2 7.1 5.0 0.7 5.6 8.6
+12 42 8.0 8.1 6.0 0.9 6.2 10.0
+ 13 36 6.9 6.9 4.5 0.7 5.4 8.4
+14 33 7.0 7.3 5.0 0.9 5.5 9.1
Significance (Wilcoxon Rank Sum Test) in comparison with controls 
a = p <0.02
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Table 5.2.5
Poor Progeste rone Surge
Plasma FSH concentrations (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 36 6.8 6.7 2.5 0.4 6.0 7.6 a
-9 40 6. 5 6.5 2 . 1 0.3 5.8 7.2
-8 43 6.6 6.7 3 . 7 0 . 6 5.6 7.8
-7 44 6.3 6.3 3.4 0.5 5.3 7.3
-6 46 6.0 6.1 3 . 2 0.5 5.1 7.1 a
-5 47 5.4 5.4 2 . 7 0.4 4.6 6.2
-4 50 4.6 4.6 1 . 9 0.3 4 .1 5.1
-3 49 4.4 4.4 1 . 8 0.3 3 . 9 4.9 a
-2 51 4.5 4.5 2.1 0.3 3.9 5.1
-1 49 "6.4 6.3 4. 7 0.7 4.9 7.7
0 50 13.6 13.7 6.7 0.9 11.8 15.6
+ 1 51 9.6 9.4 5.0 0.7 8.0 10.8
+2 50 6.5 6.6 4.1 0.6 5.4 7.8
+3 51 5.5 5.5 3.4 0.5 4.5 6.5
+4 48 5.4 5.4 3.6 0.5 4.3 6.5 a
+ 5 51 4.8 4.9 3.1 0.4 4.0 5.8 b
+6 48 4.5 4.4 2 . 6 0.4 3.6 5.2 c
+7 50 3.9 3.9 2 . 5 0.3 3.2 4.6 c
+8 47 3.6 3.6 2 . 3 0.3 2.9 4.3 c
+9 48 3.8 3.7 2.7 0.4 2.9 4.5 c
+10 44 3.8 3.8 3 . 1 0.5 2.8 4.8 b
+ 11 47 3.3 3.3 2 . 6 0.4 2.5 4.1
+ 12 43 3.6 3.5 2 . 6 0.4 2.7 4.3
+ 13 37 3.7 3.7 2.3 0.4 2.9 4.5
+ 14 33 4.0 4.1 2.6 0.7 2.7 5.5
Signi f i canc e (Wilcoxon Rank Sura Test) in corapar ison with controls
a = p <0.05 
b - p <0.02 
c = p <0.01
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FIGURE 5.2.4
Table 5.2.6 
Poor Progesterone Surge 
Follicular Diameters (mm)
Day Nos Med ian Mean SD SEM 95% low 95% high
-5 10 11.5 11.5 2.5 0.8 9.7 13.3
-4 20 12.8 12.8 2 . 1 0.5 11.8 13 . 8
-3 19 14.5 14.5 3 . 1 0.7 13.0 16.0
-2 22 16.0 16.1 3.2 0.7 14.7 17.5
-1 28 18.0 17.8 2.5 0.5 16.8 18.8 a
0 30 19.0 18.7 3.0 0.5 17.6 19.8
+ 1 21 21.0 21.5 9.2 2.0 17.2 25.6
+2 22 22 . 0 21.9 8.9 1 . 9 18.0 25.8
+*3 16 26.5 27.3 9.4 2.4 22.3 32.3
+4 22 24.0 20.6 8.1 1 . 7 18.0 24.2
+ 5 9 28.0 28.4 7.2 2.4 22 . 9 33 . 9
+ 6 1 6 27.0 25.9 12.2 3.1 19.4 32.4
+7 11 30.0 30.6 9.1 2.7 24.5 36.7
+8 9 34.0 33 . 8 13.2 4.4 23.7 43.9
Significance (Wilcoxon Rank Sum Test) in comparison with controls 
a = 0.01
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Table 5.3.1
High LH
Patient/cycle characteristics
Nos Mean SD SEM Median Range
AGE (Years)
20 28.6 4.7 1.0 28 22-37
FOLLICULAR PHASE (Days)
20 17.7 5.3 1.2 15.5 12-30 a
LUTEAL PHASE (Days)
20 15.2 1 . 8 0.4 15.5 9-17
CYCLE LENGTH (Days)
20 32.8 5.7 1.3 31 26-44 a
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.01
Table 5.3.2
High LH
Plasma E2 concen trati on s (pg/ml)
Day No s Median Mean SD SEM 95% low 95% high
-10 15 85.0 78.3 16.9 4.4 68.9 87 .7
-9 1 6 80.0 78.4 17.3 4.3 69.2 87.6
-8 18 80.0 79.2 12.3 2.9 73. 1 85.3
-7 17 82.5 83 . 2 16.4 4 . 0 74.8 91.6
-6 17 95.0 91 . 4 18.0 4.4 82 . 1 100.7
-5 18 97.5 99.9 19.1 4.5 90.4 109 .4
-4 19 102 . 5 111.5 36.7 8.4 93 . 8 129.2 a
-3 18 129.0 130.1 36.3 8.6 112.0 148.2 c
-2 19 155.0 159.5 57.6 13.2 131.7 187.3 b
-1 1 9 210.0 192.4 53 . 1 12 . 2 166.8 218.0 a
0 20 192.5 183 . 2 38.6 8.6 165.1 201 .3
+ 1 1“9 125.0 129.5 42.3 9.7 109. 1 149.9
+2 20 103 . 0 113.5 30.2 6.8 99 . 4 127.6
+3 20 130.0 125.4 27 .1 6.1 112.7 138.1
+ 4 20 135.0 137.8 41 .5 9.3 118.4 157.2
+ 5 20 135.0 134.6 35.3 7 . 9 118.1 151.1
+6 20 150.0 143 . 0 39.2 8.8 124.7 161.3
+7 19 1 50.0 153.0 46.5 10.7 130.6 175.4
+8 17 152.5 160.2 42 . 3 10.3 138.5 181.9
+ 9 1 7 160.0 168.8 72 . 2 17.5 131.7 205. 9
+10 16 167.5 165.1 51 .4 12.9 152 .3 178.0
+ 11 16 152.5 157.1 45.6 11.4 132.8 181.4
+ 12 16 130.0 137.5 47.7 11.9 112.1 162 .9
+ 13 1 5 130.0 121.0 42 .1 10.9 97 . 7 144.3
+ 14 13 95.0 102 . 5 34.9 9.7 81 . 4 123.6
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.05 
b = p <0.02 
c = p <0.01
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Table 5.3.3
High LH
Plasma P conce ntrat ions (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 16 0.9 1.2 0.8 0.2 0.8 1.6
+ 1 20 1.4 1 . 9 1. 6 0.4 1 . 2 2 . 6
+2 19 3.3 4 . 0 3.7 0.8 2.2 5.8
+ 3 20 6.0 6.8 5.0 1.1 4.5 9.1
+4 20 8.6 9.3 5.0 1.1 7.0 11.6 a
+ 5 20 13.1 14.2 6.6 1 . 5 11.1 17.3
+6 20 17.8 16.9 6.4 1.4 13.9 19.9
+ 7 19 16.4 16.9 7.0 1.6 13.5 20.3
+8 17 17.3 17.3 5.8 1 .4 14.3 20.3
+9 17 19.0 18.0 6.4 1.6 14.7 21.3
+ 10 15 17.6 18.7 4.9 1 .3 16.0 21.4 a
+ 11 16 15.8 15.3 6.4 1.6 11.9 18.7 b
+ 12 16 10.4 11.2 5.6 1.4 8.2 14.2 b
+ 13 15 5.4 7.0 5.2 1.3 4.1 9.9 a
+14 13 3.1 3.9 3.7 1.0 1.7 6.1
P
index
20 71.5 80.4 36.3 8.1 63.4 97.4 a
Significance (Wilcoxon Rank Sum Test) in comparison with controls
a = p <0.01 
b = p <0.001
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Table 5.3.4
High LH
Plasma LH co ncentr at ions (IU/1)
Day Nos Med ian Me an SD SEM 95% low 95% high
-10 15 14.0 14.2 6.4 1 .7 10.7 17.7 b
-9 16 16.0 .16.2 6.9 1 . 7 12.5 19.9 b
-8 18 17.0 19.4 7.4 1.7 15.7 23.1 b
-7 1 7 18.0 20.4 11.3 2 . 7 14.6 26.2 b
-6 17 17.0 18.9 8.2 2 . 0 14.7 23.1 b
-5 1 8 17.0 17.6 6 . 4 1 . 5 14.4 20.8 b
-4 18 17.2 16.9 7.3 1.8 13.2 20.6 b
-3 17 17.0 19.5 10.4 2.5 14.2 24.8 b
-2 18 19.0 19.4 7.3 1 . 7 15.8 23.0 b
-1 18 35.0 36.8 16.1 3.8 28.8 44.8 b
0 19 75.0 64.6 17.8 4.1 56.0 73.2
+1 19 32 . 5 36.0 18.7 4.3 27.0 45.0
+2 19 2 1.0 22 . 3 13.4 3 . 1 15.8 28.8 b
+ 3 20 21 . 5 21.0 10.3 2 . 3 16.2 25.8 b
+4 20 24.0 24.2 15.5 3.5 16.9 31.5 b
+ 5 20 20.5 20.7 10.8 2 . 4 15.6 2.5.8 b
+6 19 15.0 18.0 10.9 2 . 5 12.7 23.3 b
+ 7 19 14.9 15.5 6 . 8 1 . 6 12.2 18.8 b
+8 15 15.0 15.4 7.3 1.9 11.4 19.4 b
+ 9 16 14.0 13.9 7 . 1 1 . 8 10. 1 17.7 b
+ 10 15 8.3 11.1 7 .1 1 .8 7.2 15.0 a
+ 11 15 8.4 11.6 6.8 1.8 7.8 15.4 b
+12 14 8.1 10.3 7.3 2 . 0 6.1 14.5
+ 13 14 8.1 9.4 5.8 1.6 6.1 12.7
+14 11 12.0 11.7 6.4 1 .9 7.4 16.0
Significance (Wilcoxon Rank Hum Test) in compari son with controls
a ** p <0.01 
b = p <0.001
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Table 5.3.5
High LH
Plasma FSH concentra tions (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 15 6.0 6.6 2.3 0.6 5.3 7.9
-9 1 6 6.8 7 . 1 2.9 0.7 5.6 8.6
-8 18 6.4 7.0 3.5 0.8 5.3 8.7
-7 17 5.4 6.4 2.7 0.7 5.0 7.8
-6 17 5.5 6 . 0 2.0 0.5 5.0 7.0
-5 18 5.3 5.5 2 .0 0. 5 4.5 6.5
-4 19 4.5 4 . 8 1.6 0.4 4.0 5.6
-3 18 3.8 4.3 1 . 6 0.4 3.5 5.1
-2 19 3.6 4 . 2 1.8 0.4 3.3 5.1
-1 19 5.5 5.5 2.4 0.6 4.3 6.7
0 20 9.9 10.8 4.5 1.0 8.7 12.9
+ f 20 6.1 7 . 0 3.9 0.9 5.2 8.8
+2 18 4.1 4.7 2.2 0.5 3.6 5.8
+3 20 4.0 4.3 2 . 0 0.4 3 . 4 5.2
+4 20 4.0 4.2 1.8 0.4 3.4 5.0
+ 5 20 3.6 3 . 9 1 . 9 0.4 3 . 0 4.8
+6 19 3.1 3.9 2.2 0.5 2.8 5.0
+ 7 19 2.7 3.4 2 . 0 0.5 2.4 4.4
+8 17 2.6 3.2 1.8 0.4 2.3 4.1
+ 9 15 2.9 3 . 0 1 . 7 0.4 2 . 1 3.9 a
+ 10 15 2.6 3 . 3 2.6 0.7 1 . 9 4.7
+ 11 16 2.7 2.9 1.8 0.5 1.9 3.9
+ 12 16 2.5 3.4 3.2 1.7 1.7 5.1
+ 13 15 2.8 2 . 9 1. 6 0.4 2.0 3.8
+ 14 11 3.1 3.2 1.3 0.4 2.3 4.1
Significance (Wilcoxon rank sum test) in comparison with controls 
a = p <0.05
FIGURE 5.3.4
CO
Table 5.3.6 
High LH 
Follicular Diameters (mm)
Day No s Med ian Mean SD SEM 95% low 95% high
-5 3 16.0 15.7 3.0 1.7 7.2 23.2
-4 6 15.5 15.6 2.9 1.2 12 . 6 18.6
-3 7 15.0 15.2 4.1 1.5 11.4 19.0
-2 8 16.0 15.0 3.7 1.3 11.9 18.1 a
-1 12 17.0 17.2 3.9 1 . 1 14.7 19.7 b
0 11 21.0 21.6 2.8 0.9 19.6 23.6
+ 1 10 20.0 21.0 7.4 2.3 15.7 26.3
+2 6 19.5 20.1 5.5 2.2 14.3 25.9
+3 5 26.0 23 . 8 10. 1 4.5 11.3 36.3
+4 8 20.0 21.6 10.0 3.5 13.2 30.0
+ 5 3 21.0 23.3 4.9 2.8 11.1 35.5
+ 6 4 22.0 25.3 15.1 7 . 6 1.3 49.3
+7 3 28.0 28 . 3 6.5 3.8 12.2 44.4
+ 8 4 33.5 36.0 13.3 6.7 14.8 57.2
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.05 
b = p <0.02
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Table 5.4.1
Poor Follicular M a t u r a t i o n
Pa ti ent /cy cle charac ter istic s
Nos Mean SD SEM Median Range
AGE (Years)
16 29.2 2.3 0.6 29 25-32 b
FOLLICULAR PHASE (Days)
16 17.0 3.9 1.0 15.5 10-27 c
LUTEAL PHASE (Days)
16 15.7 1.0 0.3 16 14-17 a
CYCLE LENGTH (Days)
16 31.2 4.5 1.1 31 25-44
Significance (Wilcoxon Rank Sum Test) in comparison with controls
a = p < 0 . 0 5  
b = p <0.02 
c = p <0.01
Table 5.4.2 
Poor Follicular Development (<17mm Day 0) 
Patient/cycle c h aracteristics
No s Mean SD SEM Median Range
AGE (Years)
12
FOLLICULAR PHASE (Day
32. 5 
s )
4.7 1.4 31.5 26-41 a
12 13.2 2.9 0.8 13 8-19
LUTEAL PHASE (Days)
12
CYCLE LENGTH (Days)
15.4 1 .4 0.4 1 6 13-17
/
12 29.4 3.1 0.9 29.5 25-36
Significance (Wilcoxon Rank Sum Test) in comparison with controls 
a = p <0.001
Table 5.4.3
Poor Fol l i c u l a r  Ma t u r a t i o n
Plasma E2 c o n c e n t r a t i o n s  (pg/ml)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 14 60.0 63.2 15.4 4 . 1 54.3 72 . 1 b
-9 15 65.0 63.2 14.1 3 . 6 55.4 71.0 d
-8 15 65.0 62 . 9 12.3 3.2 56.1 69.7 d
-7 14 65.0 69.6 11.5 3 . 1 63.0 76.2 d
-6 15 70.0 75.9 13.7 3.5 68.3 83.5 d
-5 14 82 . 5 82.5 13.0 3.5 75.0 90.0 d
-4 15 80.0 82 . 1 13.7 3 . 5 74.5 89.7 d
-3 1 6 1 05 . 0 101.4 14.2 3.6 93. 9 108. 9 d
-2 16 127.5 121.6 23.3 5.8 109.2 134.0 d
-1 16. 147.5 147.4 26.0 6 . 5 133.6 161.2 d
0 16 165.0 158.8 30.7 7 . 7 142.5 175.1 c
+ 1 1 5 115.0 12 0.5 31 . 3 8. 1 103.2 137.8
+2 16 76.5 84.6 26 . 9 6.7 70.3 98.9 c
+3 16 95.0 99.9 34. 6 8.7 81 .5 118.3 a
+4 16 110.0 107.2 33.3 8.3 89.5 124.9 b
+ 5 1 6 107 . 5 111.9 35.7 8.9 93.0 131.0 c
+6 16 112.5 115.8 29.4 7.4 100.1 131.5 c
+ 7 15 125.0 124.2 25.6 6.6 110.0 138.4 c
+8 1 4 120.0 123.4 34.1 9.1 1 03 . 7 143. 1 c
+9 13 12 5.0 131.9 32 . 9 9 . 1 112.0 151.8 a
+ 10 13 125.0 134.1 36.9 10.2 111.8 156.4
+ 11 13 140.0 142. 7 30.5 8.5 124.3 161.1
+12 13 110.0 121.4 50.9 14.1 90.6 152.2
+ 13 12 92 . 5 106 . 9 50. 9 14.7 74.6 139.2
+ 14 12 80.0 87 . 5 37.0 10.7 64.0 111.0
Significance (Wilcoxon Rank Sum Test) in comparison with controls
a = p <0.05 
b = p <0.02
c = p <0.01 
d = p <0.001
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Table 5.4.4
Poor Fol li cular Deve lopmen t (<17mm Day 0)
Plasma E2 c o nce nt rations  (pg/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 9 70.0 72.2 13.5 10.4 48.3 96.1
-9 9 70.0 73.1 26.1 8.7 53.0 93 .2
-8 9 75.0 74.8 14.0 4.7 64.0 85. 6
-7 11 85.0 84.2 18.5 5.6 71.8 96.6
-6 11 80.0 83.3 17.6 5.3 71.5 95.1 a
-5 11 95.0 98.7 22 . 1 6.7 83 . 9 113.5
-4 11 110.0 124.1 48.5 14.6 91 . 5 156.7
-3 12 137.5 151.4 55.8 16.1 115.9 186.9
-2 12 166.5 177.4 57 . 4 16.6 140.9 213.9
-1 11 "2 00.0 221.3 59.0 17.8 181 .7 260.9
0 12 195.0 184. 9 35.4 10.2 162.4 207.4
+1 12 107 . 5 108.2 34.2 9.9 86.5 129.9
+2 12 91.5 87.6 18.9 5.5 75.6 99.6 a
+3 12 102 . 5 1 03 . 9 15.2 4.4 94 .2 113.6
+4 12 120.0 124 . 3 26.4 7 . 6 107 . 5 141.1
+5 11 110.0 116.9 17.9 5.4 104.9 128.9 b
+ 6 1 1 115.0 117.1 27.6 8.3 98. 6 135.6 c
+7 12 122.5 121.3 29.8 8.6 102 .3 140.2 c
+8 12 122 . 5 118.7 37 . 7 10.9 94. 7 142.7 c
+9 12 137.5 128.8 37 . 0 10.7 105.3 152.3 a
+ 10 12 130.0 131.8 37.4 10.8 108. 0 155.6
+ 11 12 134.0 125.5 39.8 11.5 100.2 150.8
+ 12 11 110.0 120.4 58.4 17.6 81.2 159.6
+13 1 1 95.0 116.7 52.5 15.8 81 .4 152.0
+ 14 10 85.0 84.9 33.3 10.5 61.1 108.7
Significance (Wilcoxon rank sum test) in com pa rison w it h controls
a = p <0.05 
b = p <0.02
c = p <0.01
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Table 5.4.5
Poor Folli cular M a t u r a t i o n
Plasma P c o n c e n tration s (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 10 0.8 0.9 0.6 0.2 0.5 1.4
+ 1 15 1 . 0 1 . 2 0.8 0.2 0.8 1.6 b
+2 15 2.3 2.5 0.9 0.2 2.0 3.0 c
+3 16 4.6 5.2 2 . 0 0.5 4.1 6.3 b
+4 16 7.2 8.1 3.2 0.8 6.4 9.8 c
+ 5 16 12.5 13.0 6.1 1.5 9.8 16.2 a
+6 16 16.5 16.1 6.4 1.6 12.7 19.5
+ 7 15 17.2 17.8 7.3 1.9 13.8 21.8
+8 14 17.0 17.7 6.6 1 . 8 13.9 21.5
+ 9 13 16.4 15.6 4.0 1 . 1 13.2 18.0
+ 10 12 18/2 17.7 5.3 1 . 5 14.4 21.0 a
+ 11 13 16.0 17.1 7.2 2 . 0 12.7 21.5 c
+12 13 12.2 12.4 6.7 1 .9 8.4 16.4 c
+ 13 12 7.0 8.7 6.8 2 . 0 4.4 13.0 b
+ 14 12 3.5 4.2 3.4 1 . 0 2.0 6.4
P
index
16 67.0 70.4 24.9 6.2 57.1 83.7 c
Significance (Wilcoxon rank sum test) in comp arison with  controls
a = <0.02 
b = < 0 . 0 1  
c = <0.001
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Table 5. A . 6
Poor Fol lic ular De ve l o p m e n t  (<17mm Day 0)
Plasma P c o n c e ntra ti ons (ng/ml)
Day Nos Median Mean SD SEM 95% low 95% high
0 10 1.0 1 . 1 0.7 0.2 0. 6 1.6
+1 11 1 .7 2 . 1 2 . 0 0.6 0.8 3.4
+2 12 3 . 2 4.2 3.6 1 . 0 1 . 9 6.5
+3 12 5.7 7.1 5.2 1 . 5 3.8 10.4
+A 12 10.6 11.3 6.7 1 . 9 7.0 15.6
+ 5 11 14.4 14.1 4.7 1 .4 10.9 17.3
+ 6 11 16.4 17.1 7.0 2 . 1 12 . 4 21.8
+7 12 20.3 18.7 7.9 2.3 13.7 23.7
+ 8 12 19.6 18.7 7.2 2.1 14.1 23.3
+9 11 16.4 “16.2 6.4 1 . 9 11.9 20.5
+ 10 11 16.8 17.5 7.8 2.4 12.2 22.8 a
+ 11 11 12.8 14.9 7.3 2 . 2 10.0 19.8 c
+ 12 11 9.6 11.5 7 . 6 2.3 6.4 16.6 b
+13 11 6.6 7.8 6.3 1 . 9 3 . 6 12.0 b
+ 14 8 4.3 4.8 2.2 1 . 0 2 . 4 7.2 b
P
index
12 85.0 85.7 37.0 10.7 62 . 0 109.2
Significance (Wilcoxon rank sum test) in co mp ariso n with controls
a = p <0.05 
b = p <0.01 
c = p <0.001
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Table 5.4.7
Poor F o l l icular  Matu ra tion
Plasma FSH conce ntrations  (IU/1)
Day Nos M e d i a n  Mean SD SEM 95% low 95% high
-10 14 6.5 6.7
-9 15 6 .1 6.3
-8 15 6.1 6.2
-7 14 5.5 5.9
-6 15 5.2 5.6
-5 14 4.7 5.1
-4 15 4.4 4.5
-3 16 4.3 4.4
-2 16 3.6 4.1
-1 16 4.1 4.9
0 16 12.0 13“. 0
+ 1 16 8.6 9.7
+2 15 5.0 5.8
+ 3 16 4.8 5. 1
+4 16 4.7 4 . 8
+ 5 16 4.3 4.4
+6 16 3.7 4.1
+7 15 3.7 3.8
+8 14 2.8 2.9
+ 9 13 2 . 9 2 . 9
+10 13 2.6 2.8
+ 11 13 2.7 2.9
+ 12 13 2.8 2.8
+ 13 12 2.8 3.2
+14 10 3.5 3.3
2 . 1 0.6 5.5 7.9
1 . 9 0.5 5.2 7.4
2.2 0.6 5.0 7.4
2 . 1 0.6 4.7 7.1
2 . 0 0.5 4.5 6.7
2 . 4 0.6 3.7 6.5
1.9 0.5 3.4 5.6
1 . 8 0.5 3.4 5.4
1.8 0.5 3.1 5.1
2 . 3 0.6 3.7 6.1
6.8 1.7 9.4 16.6
5.3 1.3 6.9 12 . 5
2.8 0.7 4.2 7.4
2 . 2 0.6 3.9 6.3
1 .6 0.4 3.9 5.7
1 . 8 0.4 3.5 5.3
2.2 0.5 3 . 0 5.2
1 . 8 0.5 2 . 8 4.8
1 . 6 0.4 2 . 0 3.8
1. 6 0.5 1 . 9 3.9
1 .4 0.4 1 .9 3.7
1 . 6 0.4 2 . 0 3.8
1 .3 0.4 2 . 0 3.6
1 . 7 0.5 2 .1 4.3
1.4 0.4 2.3 4.3
Significance (W ilc oxo n rank sum test) in c o m p ar is on with controls
a a p <0.05 
b = p  <0.02
c « p < 0 . 0 0 1
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Table 5.4.8
Poor Fol lic ular D evelop me nt (<17mm Day 0)
Plasma FSH concen t r a t i o n s  (IU/1)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 9 6.7 6.6 3.2 1 . 1 4.2 9.0
-9 9 6.4 6.5 2 . 1 0.7 4.9 8.1
-8 9 6.1 6.4 2.9 0.9 4.2 8.6
-7 11 5.7 5.9 2.5 0.8 4.2 7.6
-6 11 6.5 6.4 2.4 0.7 4.8 8.0 a
-5 11 6.9 6.6 3.5 1 . 1 4.2 9.0 a
-4 11 4.7 5.9 4.4 1.3 3 . 0 8.8
-3 12 4.7 5.2 2.9 0.8 3.4 7.0 a
-2 12 4.4 4.7 Jl. 0 0. 6 3.4 6 . 0
-1 1 1 5.2 6.8 3.8 1 . 1 4.3 9.3
0 12 15.0 15.6 6.7 1. 9 11.2 19.8 b
+1 12 10.5 11.1 5.5 1 . 6 7.6 14.6 a
+2 12 7.2 8.1 4.9 1 . 4 5.0 11.2 a
+3 12 5.9 7.2 4.8 1 .4 4.1 10.3 a
+4 12 4.8 6.4 4.4 1.3 3.6 9.2 b
+5 11 4.4 5.9 4.7 1.4 2.8 9.0 b
+ 6 11 3.7 4.6 3.7 1 . 1 2 . 1 7.1 a
+7 12 3.4 4.3 3.9 1 .1 1.8 6.8 a
+8 12 2 . 7 3.6 3.5 1.0 1.4 5.8
+9 12 3.0 3.5 3.1 0.9 1 . 5 5.5
+ 10 12 3 . 0 3.6 3.2 0.9 1.6 5.6 a
+11 12 3 . 0 3.6 3 . 5 1.0 1.4 5.8
+12 12 3.2 3.6 3 . 0 0.9 1 . 7 5.5
+13 10 3.3 4.2 3.3 1 . 0 1.9 6.5
+14 10 3.1 5.0 4.5 1.4 1 . 8 8.2
Significance (Wilcoxon rank sura test) in comparison with controls
a = p <0.05
b = p <0.02
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Table 5.4.9
Poor Follicu lar  Matu ration
Plasma LH concentra tions (IU/1)
Day Nos Med ian Mean SD SEM 95% low 95% high
-10 14 9.0 8.5 4.2 1 . 1 6.1 10.9
-9 15 8.0 9.4 4.9 1.3 6.7 12.1
-8 15 8.1 10.4 5.0 1 .3 7.6 13.2
-7 14 9.6 11.3 6.4 1 . 7 7.6 15.0
-6 15 9.2 11.1 7.5 1 . 9 6.9 15.3
-5 15 8.0 9.8 5.1 1.3 7 . 0 12 . 6
-4 15 11.0 11.2 5.5 1 .4 8.2 14.2 b
-3 15 9.8 10.6 5.2 1.3 7.7 13.5
-2 16 10.5 11.7 4.9 1.2 9.1 14.3
-1 1 6 17.0 19.4 9.8 2 . 5 14.2 24.6
0 16 70.0 62.5 17. 0* 4.3 53.4 71.6
+ 1 1 6 39.0 38.7 17.9 4.5 29.2 48.2 a
+2 16 12.0 17.8 12.8 3 . 2 11.0 24.6
+3 1 6 11.0 14.0 8.8 2 . 2 9.3 18.7
+4 16 11.5 17.1 14.6 3 . 7 9.3 24.9
+ 5 16 9.7 14.6 11.1 2 . 8 10.7 20.5
+6 16 9.1 13.1 11.0 2.8 7.2 19.0
+ 7 15 8.2 11.0 6.9 1 . 8 7.2 14.8
+8 14 5.9 8.2 6.6 1.8 4.4 12.0
+ 9 13 6.2 8.6 7.4 2 . 1 4.1 13 . 1
+10 13 6.1 6.8 3.7 1 . 0 4.6 9.0
+ 11 13 6.1 8.2 6.0 1.7 4.6 11.8
+ 12 13 5.5 7.3 3.9 1 . 1 5.0 9.6
+ 13 12 5.8 7 . 5 5.6 1 . 6 3.9 11.1
+ 14 10 5.7 7.7 4.8 1 . 5 4.3 11.1
Significance (Wilcoxon rank sum test) in comparison with controls
a “ p <0.05 
b = p <0.01
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Table 5.4.10
Poor Follicular Development (<17mm Day 0)
Plasma LH co ncentrations (IU/1)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 9 9.0 7.8 3.1 1 . 0 5.4 10.2
-9 9 6.4 6.9 3.7 1.2 4.1 9.7
-8 9 6.9 7 . 2 3 . 2 1 . 1 4.7 9.7
-7 11 7.8 7.8 3.3 1 . 0 5.6 10.0
-6 11 7.9 9.2 3.5 1 . 1 6.8 11.6
-5 11 8.0 9.7 5.0 1 . 5 6.3 13.1
-4 11 6.6 7.8 3.4 1 . 0 5.5 10.1
-3 12 9.1 9.2 3.2 0.9 7.2 11.2
-2 12 11.0 12.6 6 . 7 1 . 9 8.3 16.9
-1 11 15.0 22 . 2 13.6 4\ 1 13.1 31.3
0 12 66.5 60.0 16.8 4.8 49.3 70.7
+ 1 12 27.5 26.4 13.1 3 . 8 16.1 34.7
+2 12 12.0 13.3 4.2 1 . 2 12 . 6 16.0
+3 12 10.5 10.9 3 . 1 0.9 9 . 0 13.0
+ 4 12 10.5 10.7 4.7 1.4 7 . 7 13.7
+ 5 11 8.3 8.3 2.7 0.8 6.5 10. 1
+ 6 11 7.5 7.4 2 . 7 0.8 5.6 9.2
+7 12 7.3 7.0 3 . 0 0.9 5 . 1 8.9
+8 12 6.4 6 . 6 3.5 1 . 0 4.4 8.8
+9 12 6.5 6.3 2.1 0.6 5.0 7.6
+ 10 12 4.9 5.0 2 . 7 0.8 3.3 6.7
+ 11 12 4.2 5.3 4.1 1.2 2.7 7.9
+ 12 11 5.2 7.0 3.8 1 . 1 4.4 9.6
+ 13 10 6.2 6.9 3.1 1 . 0 4.7 9.1
+ 14 10 6.0 6.5 3.3 1 . 0 4 .1 8.9
No significant differences in comparison with controls
(Wilcoxon rank sura test)
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Table 5.4.11 
Poor Follicular Maturation 
Follicular Diameters (mm)
Day Nos Median Mean SD SEM 95% low 95% high
-5 3 12.0 12.3 1 . 5 0.9 8.5 16.1
-4 3 12 . 0 12.0 4 . 0 2.3 2 . 1 21.9
-3 5 16.5 16.7 4.6 2 . 0 11.1 22 . 3
-2 5 14.0 12 . 7 2 . 9 1.3 9 . 1 16.3 b
-1 8 16.8 16.5 3.2 1 . 1 13.9 19.1 b
0 7 16.0 16.7 3.6 1. 4 13.4 20.0 a
+ 1 8 17.5 20.0 8.6 3.0 12.8 27.2
+2 5 17.0 16.2 3.2 1.4 12.2 20.2
Significance (Wilcoxon rank sum test) in comparison with controls
a = p < 0 . 0 5  
b = p <0.01
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Table 5.4.12 
Poor Follicular Development (<17mm Day 0) 
Follicular diameters (mm)
Day Nos Median Mean SD SEM 95% low 95% high
-4 3 12.0 11.3 3.1 1 . 8 3.6 19.0
-3 5 15.0 14.4 2 . 0 0.9 12.0 16.8
-2 4 14.8 15.5 3 . 0 1 . 5 10.8 20.2
-1 2 18.0 18.0 2.8 2 . 0 - -
0 12 15.0 14.3 2.1 0.6 13.0 15.6 a
+ 1 8 14.5 14.9 3.5 1.2 12.0 17.8
+2 2 14.5 14.5 3.5 2.5 - -
+3 5 16.5 15.4 4.6 2.0 9.7 21.1
Significance (Wilcoxon rank sum test) in comparison with controls 
a = p <0.001
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Table 5.5.1
Short Luteal Phase
Patient/cycle char acter istics
Nos Mean SD SEM Med ian Range
AGE (Years)
6 33.0 3.5 1.4 33 28-37 b
FOLLICULAR PHASE (Days)
6 1.4.5 2.9 1.2 13.5 11-18
LUTEAL PHASE (Days) 
6 10.5 0.8 0.3 11 9-11 b
CYCLE LENGTH (Days) 
6 2 5\0 2.2 0.9 2 4.5 22-28 a
Significance (Wilcoxon rank sum test) in comparison with controls
a = p < 0 . 0 1  
b = p <0.001
Table 5.5.2
Short Luteal Phase
Plasma E2 co nce ntr ations (pg/ml)
Day Nos Mean SD SEM Med ian Range
-10 3 81 .7 20.2 11.7 85.0 60-100
-9 4 85. 8 28 . 0 14.0 86.5 55-115
-8 4 70.0 14.7 7.4 70.0 55-85
-7 4 84. 5 19.8 9.9 85. 0 65-103
-6 6 110.5 19.7 8.1 115.0 80-130
-5 6 120.0 26.1 10.6 115.0 90-155
-4 6 148.0 40.7 16.6 130.0 110-200
-3 6 158. 3 54 . 9 22.4 147 . 5 115-235
-2 6 217.2 65.3 26.7 222 . 5 130-308
-1 5 264. 6 51 . 2 22 . 9 283 .0 210-330
0 6 206. 7 72 . 1 “ 29.4 192.5 130-340
+ 1 6 140.8 39.4 16.1 142.5 100-210
+2 6 115.0 30.7 12.5 110.0 90-175
+ 3 6 143.3 40.6 16.6 137.5 105-215
+4 6 159.2 44.3 18.1 1 50.0 115-245
+ 5 6 163 . 0 58.7 24.0 142.5 125-280
+ 6 6 163.3 60.3 24.6 142.5 130-285
+ 7 6 163.8 49.6 20.3 156.5 120-250
+8 6 154.7 40.7 16.6 147.5 110-230
+ 9 6 136.7 54.5 22 . 2 125.0 90-235
+10 5 107.0 42 . 7 19.1 110.0 65-170
+ 11 4 98. 8 68.4 34.2 70.0 55-200
No sign ificant differences in comparison with controls
(Wilcoxon rank sum test)
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Table 5.5.3
Short Luteal Phase
Plasma P con centratio ns (ng/ml)
Day No s Mean SD SEM Median Range
0 5 1.3 0.6 0.2 1.3 0.7- 1.8
+ 1 5 2.7 1 . 5 0.7 3.2 0.9- 4.2
+2 6 4.9 3.3 1.4 5.1 0.7- 9.0
+ 3 6 8.3 5.8 2.4 6.7 5.2-18.6
+4 6 11.9 6.8 2.8 11.6 3.4-23.4
+ 5 6 14.8 6.5 2.6 13.6 7.5-26.6
+ 6 6 13.3 7.5 3.1 10.7 5.9-23.0 a
+ 7 6 10.8 2.8 1 . 1 11.4 7.4-13.4 c
+8 6 9.6 5.5 2.2 7.5 5.2-20.4 b
+ 9 6 5.2 2 . 6 1 . 1 5.2 2.4- 9.4 c
+ 10 5 1.9 1 . 9 0.9 1.7 0.5- 5.0 b
+ 11 3 0.9 0.6 0.4 0.5 0.5- 1.6 a
P
Index
6 79.8 41 . 2 16.8 77.5 30.0-151.0
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.05 
b = p <0.01 
c = p <0.001
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Table 5.5.4
Short Luteal Phase
Plasma LH concentration s (IU/1)
Day Nos Mean SD SEM Median Range
-10 3 10.3 7.7 4.4 7.5 4.5-19.0
-9 4 9.3 7.7 3.9 7.1 3.0-20.0
-8 4 8.1 6.1 3 . 0 4.2 4.1-17.0
-7 4 9.6 7 . 8 3.9 6.5 4.3-21.0
-6 6 7.2 7.3 3.0 4.4 2.8-22.0
-5 6 6.6 5.2 2.1 4.9 1.7-16.0
-4 6 6.3 3.9 1 .6 5.0 3.8-14.0
-3 5 6.7 3.8 1. 7 6.3 2.8-13 . 0
-2 6 7.5 2 . 3 0.9 6.6 6.1-12.0
-1 6 16.7 10.6 4.3 15.0 5.0-33 . 0
0 5 51.6 25.4 11.4 45.0 20.0-80.0
+1 6 26.1 18.4 7.5 22 . 0 8.7-60.0
+2 6 11.5 7.8 3.2 8.6 5.9-27.0
+ 3 6 10.0 8.6 3.5 7 . 7 3.9-27.0
+4 5 9.8 7.0 3.1 6.5 4.1-21.0
+ 5 6 13.5 8.4 3.4 13.2 4.6-23.0
+6 6 8.2 5.7 2.3 8.7 2.3-17.0
+ 7 6 9.1 8.0 3.3 5.7 2.2-24.0
+8 6 6.6 5.9 2.4 4.9 0.9-16.0
+ 9 6 5.3 6.1 2.5 2 . 9 0.9-17.0
+10 5 2.9 1 . 5 0.7 3.0 0.9- 4.4
+ 11 4 4.6 0.5 0.3 4.7 4.0- 5.1
No sig nificant differences in comparison with controls
(Wilcoxon rank sum test)
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Table 5.5.5
Short Luteal Phase
Plasma FSH concentrations (IU/1)
Day Nos Mean SD SEM Med ian Range
-10 3 11.2 7.7 4.4 7.5 6.0-20.0
-9 4 7.4 5.1 2.5 5.0 4.7-15.0
-8 4 6.8 3.5 1 .8 5.6 4.1-12.0
-7 4 6.6 2.9 1 . 5 5.4 4.8-11.0
-6 6 6.0 2.7 1 . 1 4.5 4.0-10.0
-5 6 5.2 3.6 1 . 5 3.3 3.0-12.0
-4 6 4.9 3.2 1.3 3.8 2.0-11 .0
-3 5 3.3 1 .1 0.4 3.2 1.8- 4.5
-2 6 4.1 1.8 0.7 4.2 1.6- 7.0
-1 6 5.9 4.0 1 . 6 4.0 2.0-11.0
0 5 12.4 6.7 3.0 “10.0 6.4-21.0
+ 1 6 9.1 3.1 1 . 3 9 .1 5.6-13. 0
+ 2 6 5.9 2.7 1 . 1 5.6 3.0- 9.4
+3 6 4.7 1 . 6 0.7 4.8 2.8- 6.4
+ 4 5 4.2 2.2 1 .0 3.9 1.8- 7.4
+ 5 6 3. 1 1.0 . 0.4 2.9 1.8- 4.7
+6 6 2 . 7 1 .4 0.6 2.4 1.0- 5.1
+ 7 6 2 . 5 1 . 5 0.6 2.2 0.4- 4.6
+8 6 2.5 1 . 6 0.7 1 . 9 0.8- 4.9
+ 9 6 1 . 9 0.8 0.3 1 . 7 0.8- 3.1
+ 10 5 1 . 7 0.7 0.3 2.0 0.6- 2.0
+ 11 4 2.6 1. 5 0.7 2 . 5 1.0- 4.6
No significant differences in compari son  with controls
(Wilcoxon rank sum test)
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Table 5.5.6
Short Luteal Phase
Follicular Diameters (mm)
Day Nos .Mean SD SEM Med i an Range
-4 4 15.6 4.3 2.2 15.0 12.0-20.5
-3 3 16.8 2.6 1.5 17.5 14.0-19.0
-2 2 19.5 0.7 0.5 19.5 19.0-20.0
-1 4 20.8 2.2 1 .1 20.0 19.0-24.0
0 5 22 .2 1.9 0.9 22.0 20.0-25.0
+1 4 18.8 3.0 1 . 5 19.0 15.0-22.0
No significant differences in comparison with controls 
(Wilcoxon rank sum test)
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Table 5.5.7
Long Foll icular Phase (20 days +)
P at ie nt/ cycle ch ar acter istics
Nos Mean SD SEM Med ian Range
AGE (Years)
9 27.1 3.9 1 .3 27 22-34
FOLLICULAR PHASE (Days)
9 24.8 3.7 1.2 25 20-30 a
LUTEAL PHASE (Days) 
9 14.8 1 .7 0.6 15 12-17
CYCLE LENGTH (Days) 
9 39.7 4.7 1 .6 41 33-44 a
Significance (Wilcoxon rank sum test) in comparison with controls 
a = p <0.001
Table 5.5.8
Long Follicular Phase (20 days +)
Plasma E2 concentra tions (pg/ml)
Day No s Med ian Mean SD SEM 95% low 95% high
-10 8 82 . 5 81 . 9 19.1 6.7 66.0 97.8
-9 8 85.0 80.0 22 . 0 7.8 61.6 98.4
-8 8 80.0 84.4 21.8 7.7 66.2 1 02 . 6
-7 7 80.0 85.0 16.3 6.2 69.9 1 00.1
-6 8 1 02 . 5 103.8 22.3 7.9 85.1 122 . 5
-5 9 100.0 120.0 50.7 16.9 81 . 0 159.0
-4 8 130.0 123.8 31.7 11.2 97.3 150.3
-3 8 147 . 5 150.0 45.6 16.1 111.9 188.1
-2 8 175.0 188.1 78.0 27.6 122.9 253 .3
-1 7 215.0 208 . 6 61.6 23.3 151.7 265.5
0 8 220.0 202 . 5 61 . 8 21.8 150.9 254. 1
+ 1 9 120.0 136.1 58.5 19.5 91 . 1 181.1
+2 9 110.0 112.8 36.8 12.3 84. 6 141.0
+3 9 120.0 119.4 31 . 2 10.4 95 . 4 143.4
+ 4 9 130.0 123.9 39.1 13.0 93 . 8 154.0
+5 8 142.5 13 7.5 4 0.2 14.2 103 . 9 171.1
+6 7 150.0 143.6 55.5 21.0 92 .3 194.9
+ 7 9 135.0 139.4 44. 0 14.7 105.6 173.2
+8 8 147.5 144.4 60.1 21.3 94 .1 194.7
+ 9 9 150.0 155.6 72.7 24.2 98.3 212.9
+ 10 7 160.0 1 50.7 41.5 15.7 112.3 189.1
+ 11 9 160.0 141.1 78.9 26.3 80.5 201 . 7
+ 12 8 165.0 155.0 60.7 21.5 104.2 205.8 a
+ 13 6 120.0 135.8 69.4 28.3 63 . 0 208. 6
+ 14 5 60.0 83 . 0 56.0 25.0 13.5 152 .5
Signif ic ance (Wilcoxon rank sum test) in comparison with controls
a = p <0.05
Lon
g 
Fol
lic
ula
r 
Ph
as
e
FIGURE 5.5.6
_ o
-  LO
LO
L U  CM
Day
 r
elat
ive 
to 
LH 
pe
ak
Table 5.5.9
Long Follicular Phase (20 days + )
Plasma P con centrations (ng/ml)
Day Nos Med ian Mean SD SEM 95% low 95% high
0 8 0.9 1 .1 0.7 0.3 0.5 1 . 7
+ 1 9 1. 7 2.2 2.2 0.7 0.5 3.9
+2 9 2.3 4 . 1 4.2 1 . 4 0.9 7.3
+3 9 6 . 1 7 . 8 6.2 2 . 1 3.0 12 . 6
+4 9 9.6 11.2 7.0 2.3 5.8 16.6
+ 5 7 13.5 14.6 7.2 2 . 7 8.0 21.2
+ 6 6 14.4 15.8 6.4 2 . 6 9.1 22.5
+ 7 9 15.2 16.8 9.4 3 . 1 9.6 24.0
+8 7 16.8 16.6 5.3 2 . 0 11.7 21 . 5
+ 9 8 18.0 16.6 8.5 3 . 0 9.5 23.7
+ 10 “ 5 18.8 17.8 8.7 3.9 7.0 28.6
+ 11 8 13.1 14.2 7.9 2 . 8 7 . 6 20.8 b
+ 12 8 9.3 10.1 4.6 1 . 6 6.2 14.0 b
+ 13 6 6.4 7.9 6.3 2 . 6 1.2 14.6 a
+ 14 3 1 . 8 1 . 9 1.8 1 . 0 - -
P 9 
index
73.0 83.9 44.5 14.8 49.7 118.1
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.02 
b = p <0.01
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Table 5.5.10
Long Follicular Phase (20 days +)
Plasma LH concent rations (IU/1)
Day Nos Median Mean SD SEM 95% low 95% high
-10 8 12.0 9.8 6.7 2.4 4.2 15.4
-9 7 14.0 13.1 5.8 2.2 7 . 7 18.5 b
-8 8 18.7 15.2 7.9 2.8 8.6 21 .8 b
-7 7 14.0 14.4 4.4 1 . 7 10.3 18.5 c
-6 8 10.9 13.3 6.3 2.2 8.0 18.6 b
-5 9 13.0 12 . 3 5.3 1 . 8 8.2 16.4 b
-4 9 11.0 12.2 4.7 1 . 6 8.6 15.8 c
-3 9 12.0 11.8 4.3 1 . 4 8.5 15.1
-2 9 15.0 15.9 8.6 2 . 9 9.3 22 . 5 a
-1 8 28.5 28.6 10.8 3.8 19.6 37 . 6 a
0 9‘ 75.0 61.3 23.0 7.7 43.6 79.0
+ 1 9 13 . 0 28 . 0 28.8 9.6 5.9 50.1
+2 9 12.4 11.6 6.2 2.1 6.8 16.4
+ 3 9 12.0 11.1 4.7 1 . 6 7 . 5 14.7
+4 9 7 . 5 8.8 4.5 1 . 5 5.4 12.2
+ 5 8 10.0 10.9 7.3 2.6 4.8 17.0
+6 7 8.6 9.8 6.6 2 . 5 4.0 15.6
+ 7 9 7 .1 7 . 8 5.8 1 . 9 3.3 12.3
+ 8 8 7.9 9.0 7.1 2.5 3.1 14.9
+ 9 8 4.7 6.9 7.2 2 . 5 0.9 12.9
+ 10 7 9.7 10.0 6.9 2.6 3.7 16.3
+ 11 8 5.8 7 .1 4.1 1 . 5 3.6 10.6
+ 12 7 4.7 6.5 4.3 1.6 2.5 10.5
+ 13 5 7 .1 6.6 2.3 1 . 1 3.7 9.5
+ 14 5 4.5 6.6 4.1 1.8 1 .5 11.7
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.02 
b = p <0.01 
c = p <0.001
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Table 5.5.11
Long Follicular Phase (20 days +)
Plasma FSH concentr ati ons (IU/1)
Day Nos Med i an Mean SD SEM 95% low 95% high
-10 8 5.3 5.3 1.9 0.7 3.7 6.9
-9 8 4.7 5.5 2.3 0.8 3.6 7.4
-8 8 4.1 5.2 2.6 0.9 3.0 7.4
-7 7 4.6 4.7 1 . 1 0.4 3.7 5.7
-6 8 3.9 4.2 1.2 0.4 3.2 5.2
-5 9 3.6 3.9 1 . 1 0.4 3 .1 4.7
-4 9 3.8 3.7 0.8 0.3 3.1 4.3
-3 8 3.2 3.2 1 .1 0.4 2 . 3 4.1
-2 9 3.2 3.2 1.2 0.4 2.3 4.1
-1 8 4.1 4.3 1.2 0.4 3 . 3 5.3
0 9 8.3 9.2 3.8 1.3 6.3 12.1
+ 1 9 5.0 6.2 4.9 1.6 2.4 10.0
+ 2 9 3.1 3.6 1 .9 0.6 2 . 1 5.1
+3 9 2 . 7 2 . 9 1.0 0.3 2 . 1 3.7
+4 9 2.3 2 . 7 1 .1 0.4 1 . 9 3.5
+5 8 2.6 2.6 1 . 0 0.3 1 . 8 3.4
+6 7 2.5 2.7 1 .4 0.5 1 . 4 4.0
+7 9 1.7 2 . 1 1 . 0 0.3 1.3 2.9
+8 8 1 .6 2.0 1.4 0.5 0.9 3.1
+ 9 9 1.2 1.8 1.0 0.3 1 . 1 2.5
+ 10 7 2.2 2.3 1.4 0.5 1.1 3.5
+ 11 9 1.2 1.5 0.7 0.2 0.9 2.1
+ 12 9 1 .6 1.6 0.8 0.3 1.0 2.2
+ 13 6 1 . 7 1.8 1 .1 0.4 0.6 3.0
+ 14 5 2.3 2.5 1 . 2 0.5 0.6 4.4
No significant differences in comparison with controls
(Wilcoxon rank sura test)
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Table 5.5.12
Long Follicular Phase (20 days +)
Follicular Diameters (mm)
Day Nos Med ian Me an SD SEM 95% low 95% high
-5 3 13.0 12.3 4.0 2 . 3 2.4 22.2
-4 2 13.8 13.8 3.2 2.3 - -
-3 3 14.5 13.8 1 . 6 0.9 9.8 17.8
-2 7 16.0 16.6 3.2 1.2 13.6 19.6
-1 4 18.5 19.8 1 . 9 0.9 16.8 22 .8
0 5 21. 0 20.5 3.9 1.7 15.8 25.2
+ 1 4 20.0 20.0 1 . 6 0.8 17.4 22 . 6
No significant differences in comparison with controls 
(Wilcoxon rank sum test)
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Table 5.5.13
Short Follicu lar Phase (10 days or less)
Patient/cycl e characteristi cs
Nos Mean SD SEM Median Range
AGE (Years)
6 32 .3 4.8 1.9 32 26-38 a
FOLLICULAR PHASE (Days) 
6 8.0 1 .8 0.7 8 6-10 b
LUTEAL PHASE (Days)
6 15.3 2 . 0
00.o 16 12-17
CYCLE LENGTH (Days)
6 23.3 3.3 1.4 23.5 18-27 b
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.01 
b = p <0.001
Table 5.5.14
Short Follicular Phase (10 days or less)
Plasma E2 concentra tions (pg/ml)
Da Nos Mean SD SEM Med ian Range
-9 2 86. 5 44. 5 31.5 86.5 55-118
-8 2 65.0 21.2 15.0 65.0 50- 80
-7 3 85.0 20.0 11.5 85.0 65-105
-6 3 84.3 12.5 7.2 90.0 70-93
-5 4 91.3 21.7 10.9 97.5 60-110
-4 5 149.0 64.8 29.0 145.0 70-250
-3 6 183.8 69.3 28.3 175.0 105-308
-2 6 224.7 69.8 28.5 245.0 135-325
-1 6 227 .7 53 . 7 21 . 9 209.0 160-313
0 6 1 84 . 7 . 4 4 . 8 18.3 186.5 130-245
1 6 109.7 33 . 5 13.7 100.0 80-175
+2 6 96.3 29.8 12.2 87.0 65-140
+3 6 113.0 33.3 13.6 112.0 75-150
+4 6 109.7 27.3 11.1 112.0 80-155
+ 5 5 124.6 27.2 12.2 110.0 105-170
+6 6 116.2 30.3 12.4 133.0 84-160
+ 7 5 137.0 13.5 6.0 135.0 120-155
+8 6 137.7 36.8 15.0 127.5 98-195
+ 9 6 141.3 33. 0 13.5 141.5 95-195
+ 10 6 122.2 19.8 8.1 120.0 100-150
+ 11 6 127.2 19.5 8.0 131.5 100-155
+ 12 6 118.8 19.5 8.0 111.5 100-150
+ 13 6 117.7 41.4 16.9 121.5 60-160
+ 14 5 87.6 31.0 13.9 93.0 50-135
No significant differences in comparison with controls
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Table 5.5.15
Short Follicular Phase (10 days or less)
Plasma P co ncentrations (ng/ml)
Day , Nos Mean SD SEM Med ian Range
0 5 0.9 0.2 0.1 1.0 0.5- 1.0
+ 1 6 1 .4 0.6 0.2 1 . 5 0.5- 2.0
+ 2 6 3.3 1.0 0.4 3 . 6 2.0- 4.4
+ 3 6 5.8 2.6 1 .1 5.2 3.1- 9.4
+ 4 6 8.8 3.9 1.6 8.9 3.5-13.7 a
+ 5 5 13.7 8.4 3.7 12.6 3.4-26.8
+ 6 6 19.1 9.0 3.7 19.9 3.6-28.0
+ 7 5 16.2 7.4 3.3 18.4 3.3-22.4
+ 8 6 17.4 8.1 3.3 18.4 3.5-26.8
+9 6 15.9 6.3 2.6 18.4 4.9-21.0
+ 10 6 13.8 8. 1 - 3.3 17.2 2.7-20.8
+ 11 6 13.5 8.0 3.3 13.4 3.0-22.8 b
+ 1-2 6 8.7 6.1 2.5 8.9 0.7-16.0
+ 13 5 7.9 4.9 2.2 8.6 1.0-14.0 b
+ 14 5 3.4 2.1 1. 5 3.6 0.5- 6.3
P
index
6 76.5 31 . 9 13.0 79 . 0 25-120
Significance (Wilcoxon rank sura test) in comparison with controls
a = p <0.0 5 
b = p <0.01
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Table 5.5.16
Short Follicular Phase (10 days or less)
Plasma LH concentrations (IU/1)
Day Nos Mean SD SEM Median Range
-9 2 4.8 4.5 3.2 4.8 1.6- 8.0
-8 2 4.7 5.4 3.8 4.7 0.9- 8.5
-7 3 4.6 2 . 5 1. 4 4.0 2.4- 7.3 a
-6 3 5.9 4.1 2.3 5.8 1.9-10.0
-5 4 7.9 4.5 2.3 6.8 3.9-14.0
-4 5 4.7 2.8 1.2 4.7 1.0- 8.4 a
-3 6 5.1 3.7 1 . 5 3.8 0.9-11.0 a
-2 6 7.3 3.3 1.4 8.3 1.7-11.0
-1 6 13.5 6.5 2.7 15.5 3.0-20.0
0 6 39.1 17.1 7.0 37.8 20.0-68.0 b
+ 1 6 16.5 12 . 5 5\ 1 11.5 3.6-34.0
+2 6 8.3 4.6 1.9 8.8 3.2-13.0
+ 3 6 8.3 5.5 2.2 9.3 1.8-13.0
+4 6 7 . 6 3.5 1 .4 8.3 2.7-11.0
+ 5 5 8.5 5.5 2.5 9.8 1.4-16.0
+ 6 6 8.1 6.4 2.6 6.4 2.2-20.0
+ 7 5 9.2 11.0 4.9 5.6 1.2-28.0
+8 6 7.5 3.1 1.3 7.8 3.7-11.0
+ 9 6 5.3 2.2 0.9 5.1 2.9- 9.0
+ 10 6 5.2 3.7 1 . 5 4.3 1.6-10.0
+ 11 6 4.7 3.5 1 . 4 3.8 0.9- 9.9
+ 12 6 4.9 4.4 1.8 3.9 0.9-12.0
+ 13 5 6.3 4.5 2.0 7 . 1 0.9-11.0
+ 14 5 5.3 4.8 2 . 1 4.8 0.9-12.0
Significance (Wilcoxon rank sum test) in comparison with controls
a = p <0.05 
b = p <0.001
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Table 5.5.17
Short Follicular Phase (10 days or less)
Plasma FSH concentrations (IU/1)
Day Nos Mean SD SEM Med ian Range
-9 2 4.5 1.6 1 .1 4.5 3.4- 5.6
-8 2 4.5 0.4 0.3 4.5 4.2- 4.7
-7 3 4.9 0.7 0.4 4.5 4.4- 5.7
-6 3 5.6 2 .1 1.2 5.0 3.8- 7.9
-5 4 6.0 2 . 2 1 .1 6.0 4.0- 7.9
-4 5 5.0 1 . 6 0.7 4.6 3.2- 7.4
-3 6 4.2 1.4 0.6 3.6 2.9- 6.5
-2 6 4.6 1 .5 0.6 4.2 2.9- 6.8
-1 6 6.6 2.4 1.0 6.6 3.4- 9.9
0 6 12.8 2.7 0.9 13.0 10.0-17.0
+ 1 6 10.9 3.3 1. 3“ 10.3 6.6-16.0
+ 2 6 9.6 4.9 2 . 0 10.3 2.4-15.0 c
+3 6 8.7 5.5 2.2 8.3 2.8-16.0 b
+4 6 9.2 5.2 2 .1 9.0 3.4-16.0 d
+ 5 5 8.5 6.3 2.8 7.2 3.0-18.0 b
+6 6 5.8 4.4 1.8 6.6 3.4-14.0 b
+ 7 5 6.9 5.2 2.3 5.3 3.6-16.0 d
+8 6 5.8 4.4 1.8 4.0 2.6-14.0 d
+ 9 6 4.8 4.1 1 . 7 3.3 1.8-13.0 c
+ 10 6 5.0 4.0 1.6 4.1 2.4-13.0 c
+ 11 6 4.6 4.2 1 . 7 3.2 2.0-13.0 a
+ 12 6 4.8 3.6 1 . 5 3.4 2.8-12.0
+ 13 5 5.8 3.6 1.6 4.9 2.8-12.0
+ 14 5 6.5 3.8 1 .7 6.8 2.7-12.0
Significance (Wilcoxon rank sum test) in comparison with controls 
a = p <0.05
b = p <0.02 
c = p <0.01 
d = p <0.001
Sho
rt 
Fol
licu
lar 
Ph
ase
FIGURE 5.5.14
C\ l  O  CO CO CNJ CO
L1 . 0 ) 1
Day
 r
elat
ive 
to 
LH 
pe
ak
Table 5.5.18
Short Follicular Phase (10 days or less)
Fol licular Diameters (mm)
Day Nos Mean SD SEM Median Range
-2 2 13.8 1.1 0.8 13.8 13.0-14.5
-1 3 18.8 2.6 1.5 19.5 16.0-21.0
0 4 19.3 3.0 1.5 19.0 16.0-23.0
+ 1 3 18.5 0.5 0.3 18.5 18.0-19.0
+ 2 2 14.5 3.5 2.5 14.5 12.0-17.0
No  s i g n i f i c a n t  d i f f e r e n c e s  i n  c o m p a r i s o n  w i t h  c o n t r o l s  
( W i l c o x o n  r a n k  s u m  t e s t )
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Table 6.1 
Paired Cycle Data 
Patient Characteristics
Nos Mean SD M e dian Range
AGE (Years)
26 30.4 4.4 30.5 21-39
DU R A T I O N  INFERTILITY (Years)
26 4.8 1.7 4.0 3-10
INTERVAL BETWEEN CYCLES (Months)
26 3.6 2.4 3.0 1-9
Table 6.2 
Paired Cycle Data 
Cycle Characteristics
1 2
Foil Lut Tot Foil Lut Tot
Nos 23 21 24 23 21 24
Mean 14.0 15.1 29.0 14.0 14.1 28.1
SD 4.1 1.8 4.8 3.1 1.8 4.3
Med 13.0 15.0 28.0 14.0 14.0 28.0
Ran 8-29 10-19 22-43 9-22 10-17 18-37
No significant differences between cycles 
(Paired Student's t-test, Wilcoxon Rank Sum Test)
Table 6.3
Paired Cycle Data
Biochemical Indices
1 2
E2 Index P Index E2 Index P Index
Nos 23 23 23 23
Mean 195.3 74.6 192.7 87.8
SD 37.1 24.0 41 .1 30. 9
Med 200.0 70.0 188.0 90.0
Range 128-284 32-150 133-277 30-162
No significant difference between cycles 
(Paired Student's t-test, Wilcoxon rank sum test)
Table 6.4
Paired Cycle Data
Biochemical Profiles
Cycle 2
Normal Abnormal Total
Normal 1 0 1
Cycle 1 Abnormal 11 14 25
Total 12 14 26
Table 6.5
Paired Cycle Data
Biochemical Abn orm alities
1 2
PPS 17 10
PPS-N 14 6
PPS-S 3 4
PFM 7 4
High  LH 5 3
An ovu lation 3 2
SLP 1 0
SFP 0 1
LFP 1 1
High PRL 1 0
E2 plateau 1 0
Table 6.6
Paired Cycle Data
Patients with biochemical abnormalitie s in both cycles
1 2
1* ( PFM 
(PPS-N 
(High LH
(PFM
(High LH
2* * (PFM 
(PPS-N 
(High LH
(PFM 
(PPS-N 
(High LH
3« High PRL PPS-N
A, PPS-N PPS-S
3* * PPS-S PPP-S
6 . * PPS-N PPS-N
7. * PFM PFM
8- An ovulat ion Short follic
* (PFM
(High LH 
(Anovul ation
(PFM
(High LH 
(Anov ul ation
10. * Anovulation Anovulation
11. (PFM 
(PPS-S
PPS-S
12 . * PPS-N PPS-N
13. * PPS-N PPS-N
14. * PPS-S PPS-S
: - Patients where abnorm ality in second cycle was the same 
that which occurred in the first.
as
Table 6.7
Paired Cycle Data
Biochemical Abnormal it ies : Recurrence Rates
Ab no r m a l i t y  No in 1 Total Abn 2 Same Abn 2 % Chance same
PPS 17 9 (52.9%) 8 88.9
PFM 7 5 (71.4%) 4 80.0
Hi gh  LH 5 3 (60.0%) 3 100.0
A n o v u l a t i o n  3 2 (66.7%) 2 100.0
Table 6.8
Paired Cycle Data
Ultrasonic Profiles
CYCLE 2
Normal Abnormal Total
Normal 6 3 9
CYCLE 1 Abn or mal 9 8 17
T o tal 15 11 2 6
Table 6.9
Paired Cycle Data
Ultrasonic Abnorma lities
Cycle 1 Cycle 2
Luteal cysts 10 6
PFD 3 2
Ano vul ation 3 2
Twin ovulation 0 1
Non-funct. foil. 1 0
Table 6.10
Paired Cycle Data
Patients with ultrasonic abnorm ali ties in both cycles
1 2
1. * Luteal cyst Luteal cyst
2. Luteal cyst PFD
3. * Luteal cys t Luteal cyst
4. Luteal cys t Twin ovulation
5. * PFD PFD
6. * A nov ulation Anovulat ion
7. * Anovula tion An ovu lation
8. * Luteal cys t Luteal jcyst
Table 6.11
Paired Cycle Data
Ultrasonic Abnormalitie s : Recu rrenc e Rates
A b n o r m a l i t y  No in 1 Total Abn 2 Same Abn 2 % same
Luteal cyst 10 5 (50.0%) 3 60.0
Poor foil. dev. 3 1 (33.3%) 1 100.0
A n o v u l a t i o n  3 2 (66.7%) 2 100.0
Table 6.12
Paired Cycle Data
Ultrasonic and Biochemical Abnormali ties Combined
U/S Bio chemis try
Cycle 1 17 25
Cycle 2 11 14
Chi-square significant only for bio chem istry  
(Chi-square = 10.3, p <0.001)
Table 6.13
Paired Cycle Data
patients with abnormalities in both cycles
U/S in both 1
Bio ch em istry in both 7
Combined abnormalities in both 7
Bi oc hemi st ry in 1, U/S in 2 1
Total 16
Table 6.14 
Paired Cycle Data 
Maximum follicular diamet er (Day 0)
1 2
N o s . 10 10
Mean 21.2 20.9
SD 3.3 1.8
Med ian 21. 5 21.3
Range 16-26.5 17-22.5
C o r r e l a t i o n  1 & 2 : Pearson's cor relation co- efficient r = 0.45
p = 0.19
“Paired Student's t-test : No significant difference between 1 & 2
t = 0.32 
p = 0.76
Right 
Lef t 
Right 
Lef t
Table 6.15 
Paired Cycle Data 
Side of follicular dev elo pm ent
Right U  (42.3%)
Left 5 (19.2%)
Left 4 (15.4%)
Right 6 (23.1%)
No sign if icant  difference (Chi-square = 5.95, p = 0.11)
Table 7.1 
Peritoneal Fluid Study 
CYCLE ANALYSIS
B I OCHE MI STRY
ULTRASOUND
Normal Abnormal
Normal 16(72.7%) 4(18.2%)
Abnormal 1 (4.5%) 1 (4.5%)
Table 7.2 
Peritoneal Fluid Study 
ABN ORM AL CYCLES
U L T R A S O U N D BIOCHEMIST RY DAY OF LAP.
Small luteal cyst (16mm) Normal + 12
Contralate ral cyst (21mm) Normal + 5
Poor follicular developme nt PPS-S + 2
Poor follicular development Normal +6
Large ovulatory FD (30ram) Normal + 5
No rmal PPS-N +8
Poor Follicu la r Development - Pre -ovu latory follicle <99.9% 
confidence limit of normal mean.
PPS-S - Subnormal progesterone profile throughout the luteal 
p h a s e .
PPS-N - Subnormal progesterone profile in the early luteal phase 
(Days +2 - +6). Value s normal thereafter.
Table 7.3 
Peritoneal Fluid Study 
Day of L a p a ro scopy
GROUP LAPARO SCOPY DAY NUMBER OF PATIENTS
Pune turn +2 2
+4 2
+5 3
+ 6 1
+7 5
+ 8 2
+ 12 1
E q u ivocal punctum + 3 1
+ 12 2
LUF + 5 
+6 
+ 9
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Table 7.4 
Peritoneal Fluid Study 
STEROID LEVELS (pg/ml) IN CL SUB-GROUPS
No. of patients 
PF E2
median
range
PF P
median
range
E2 ratio
median
range
P ratio
median
range
PUNCTUM EQ UIVOCAL LUF
16
307.5 130 140
70-1700 100-1300 125-145
28.9 7.5 30.0
8.5-131.0 6.0- 350.0  23.8-30.4
1.83 0.87 1.28
0.75-17.0 0.83-14.4 1.26-1.23
1.85 1.58 1.19
0.39-40.0 0.58-58.3 1.15-1.48
Table 7.5 
Pe ritoneal Fluid Study 
STEROID LEVELS (pg/ml) & E N D O M E T R I O S I S
Number of patients 
PF E2
Med ian 
Range
PF P
Med ian 
Range
E2 ratio
Median
Range
P ratio
Med ian 
Range
NO ENDOMET RI OSIS EN DOMETRIOSIS
12
370
100-1700
33 . 0
6.0-350.0
1 .99
0. 75- 17.0
2.16
0.58-58.3
10
206.5
70-820
25.8
8.5-89.5
1 .43
0.87-8.81
1.39
0.39-40.7
Table 7.6 
Peritoneal Fluid Study 
PATIENTS WHO CONCEIVED  S U B S E Q U E N T L Y
Patient Pregs. Punctum Endometr. U/S Biochemistry
1 1 Yes No Normal Normal
2 1 LUF No Normal Normal
3 1 Yes No No rraal Normal
4 2 Yes Yes Normal No rmal
5 1 Yes Yes No rmal PPS-N
6 2 Equiv No No rmal Normal
Table 7.7
Peritoneal Fluid Study
STEROID CONCENTRATIONS IN PATIENT WITH 
GREATEST CYCLE A B N O R MALITY
E2 ( p g / m l ) P (ng/ml)
Plasma 95 2.2
Peritoneal fluid 820 90
Corpus luteum 7800 1000
1 cm cyst 2100 20.5
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